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Timothy Allen Barshinger 
INTERPRETATIONS OF COMMUNICATION EXPERIENCES OF  
PHARMACEUTICAL-SPONSORED CLINICAL EDUCATORS 
This qualitative study explored the communication experiences of clinical 
educators who provide patient education on behalf of pharmaceutical company sponsors.  
It investigated how these educators navigate a medical encounter within the domain of 
three regulatory drivers—on-label compliance, fair-balance presentation, and adverse 
event reporting.  The study used the ecological model of communication in medical 
encounters and the theory of Communication Privacy Management (CPM) as the lenses 
for interpreting the data. The main data were telephonic interviews with twenty-six 
clinical educators who delivered education services for pharmaceutical companies. 
Member checking, in the form of three post-interview focus groups, was also used.   
Seven themes emerged: (a) political/legal contexts factors greatly influenced 
clinical educators’ communication with patients; (b) the influence of factors within this 
contexts would frequently force educators to experience ethical dilemmas; (c) a new 
context, the disease and treatment context, emerged from the interviews as having 
significant influence in the conversation dynamics;  (d) educators employed 
communication strategies to better navigate within the political/legal and disease and 
treatment context ecological factors; (e) educators believed they needed to establish and 
maintain trust throughout the engagement process for them to successfully solicit 
meaningful patient disclosures; (f) educators managed the information disclosed to them 
by patients using routinized rules as well as changing rules; and (g) educators managed 
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multiple types of confidant roles with patients including stakeholder, deliberate, and 
reluctant.   
A main implication for this study is that educators feel ethically and morally 
bound to do whatever was necessary to avoid breaching the trust they established with 
patients.  For some, this attitude prevailed over their obligation to deliver a compliant 
educational engagement.  Hence, pharmaceutical companies need to recognize that for 
many of their clinical educators, the question of whether to be compliant is not a legal or 
policy matter.  It is a moral and ethical issue.   
That being said, educators were also skilled at using communication strategies to 
navigate through the compliance and disease and treatment barriers that functioned as 
self-management barriers.  Many of those skills often served to influence the way 
educators created privacy rules and managed privacy decisions related to their patient 
engagements. 
Jennifer J. Bute, PhD, Chair 
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Chapter 1: Introduction  
 A recently published white paper from eyeforpharma, a popular pharmaceutical 
business and trends magazine, proclaimed that the pharmaceutical industry is at the start 
of a revolution in patient support programs (PSPs) that is about to transform their 
business model (eyeforpharma Ltd. & S3 Connected Health, 2018).  A PSP is an 
umbrella term that can refer to any type of disease or therapeutic support service or 
program provided by a health-related organization (e.g. hospital, clinic, physicians’ 
group, disease advocacy group) or industry (e.g. pharmaceutical company, medical 
device manufacturer, health insurance provider, retail pharmacy chain) (Ganguli et al., 
2016).  Within the context of pharmaceutical and biotech companies, PSPs assist patients 
and caregivers in accessing and understanding their prescribed drugs, medical devices, 
and the diseases for which they are indicated.  These programs are frequently viewed 
within the pharmaceutical and biotech industry as a means for promoting patient 
engagement and centricity (eyeforpharma Ltd. & S3 Connected Health, 2018) while also 
helping to increase medication adherence and adoption of other necessary disease self-
management behaviors (Ganguli et al., 2016).  Examples of the types of services 
available through PSPs include insurance benefits investigations, copay card 
reimbursements, product and disease-state education programs, clinical assistance 
services (i.e. nurse help lines), adherence reminder and tracking tools, and peer and 
caregiver counseling and support groups (Ganguli et al., 2016; Ocvirk, 2016).  The 
“revolution,” as explained by eyeforpharma, is that such programs are evolving beyond 
small-scale product-specific engagements to be highly customized holistic experiences 
delivered in collaboration with payers, health systems, and tech companies that support 
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patients across their entire lives,  not just when patients are taking the company’s 
medication (eyeforpharma Ltd. & S3 Connected Health, 2018).  In essence, the white 
paper predicts that pharmaceutical-sponsored clinical and non-clinical support services 
will play an increased and fundamental role in patients’ daily healthcare management. 
 The present study examines one component of pharmaceutical-sponsored PSPs—
product and disease-state education delivered by clinical educators.  The literature review 
that follows explains how these education programs originated as a strategy to combat 
medication adherence issues, particularly for products with a complex administration 
process, such as self-injected or self-infused biologics.  The role of the pharmaceutical-
sponsored clinical educator, as noted in the literature, is defined along with three 
regulatory factors that impact how those educators deliver educational programs.  Two 
theoretical frameworks are reviewed, the ecological model of communication in medical 
encounters (Street, 2003) and communication privacy management (CPM) theory 
(Petronio, 2002).  These theories serve as the lens through which the findings were 
interpreted.  Lastly, the research questions that drove the study are identified.   
The methods section that follows the literature review explains how and why a 
qualitative methodology was used to explore the research questions.  This section 
includes a description of the participants, their recruitment and sampling, an overview of 
the researcher role, an explanation of the data collection process, and a discussion of how 
the data were analyzed and interpreted within the constructs of the theoretical 
frameworks. 
 There are two findings chapters, each one interpreting the data within the context 
of one of the two theoretical frameworks.  The first findings chapter explores the data 
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using Street’s (2003) ecological model of communication in medical encounters.  Four 
themes arose from that interpretation.  These were: (1) Political/legal contexts factors, 
manifested in pharmaceutical industries’ compliance regulations, greatly influenced 
clinical educators’ communication with patients; (2) The influence of ecological factors, 
particularly within the political/legal context, would frequently force educators to 
experience ethical dilemmas; (3) A sixth context, the disease and treatment context, not 
previously identified in the ecological model literature, emerged from the interviews as 
having significant influence in the conversation dynamics between the educator and 
patient; and (4) Educators employed communication strategies to better navigate within 
the political/legal and disease and treatment context ecological factors.  The second 
findings chapter explores the data using Petronio’s (2002) CPM theory.  Three themes 
arose from that interpretation.  These were: (1) Educators believed they needed to 
establish and maintain trust throughout the engagement process for them to successfully 
solicit meaningful patient disclosures; (2) Educators managed the information disclosed 
to them by patients using routinized rules based on core privacy rule decision criteria as 
well as changing rules based on catalyst privacy rule decision criteria; and (3) Educators 
managed multiple types of confidant roles with patients including stakeholder, deliberate, 
and reluctant. 
 The last chapter is a discussion of the findings as they relate to the theoretical 
models and the implications they present for the pharmaceutical industry.  One of the 
major constructs that arose from the interpretation of the data was that three ecological 
factors inherent and unique to the educators’ role greatly affected their communication 
dynamic with patients.  Those factors—staying on-label, fair-balance presentation, and 
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adverse event reporting—were three of the most influential types of industry and 
government-imposed compliance regulations that shaped educators’ beliefs about how 
they could engage and educate patients.  As such, educators often struggled with their 
need to reconcile the regulatory obligations to the industry that employed them with the 
professional and ethical orientations that guided their beliefs about patients care.  The 
chapter closes with an explanation of the study’s limitations and suggestions for future 
research.   
In summary, pharmaceutical companies are increasing their participation in the 
public health environment via the expanding role of PSPs.  Additionally, as Cegala 
(2011) notes, the changing social and economic landscape of the country is moving to a 
model in which patients are assuming greater responsibility for their own care.  This 
means that patients’ ability to be active participants in their interpersonal engagements 
with healthcare providers (HCPs) is of increased importance if they are to be successful 
in their health management.  The increased role that both patients and pharmaceutical-
sponsored clinical educators are taking within the larger healthcare domain has 
implications for both groups.  Patients will find themselves needing to engage with a 
broader and more diverse range of healthcare professionals and resources beyond the 
traditional healthcare team.  This would include clinical educators.  As such, there is an 
increased responsibility and need for understanding how the educators who are 
facilitating these programs are maintaining equivalent standards of care as traditional 
healthcare providers.  This is especially important given the unique regulatory and 
sociological factors that impact these educators—factors that are not faced by a patient’s 
formal healthcare team. A goal of the current study is to interpret within the context of 
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the two theoretical frameworks how pharmaceutical-sponsored clinical educators 
navigate the communication complexities that are at the heart of those regulatory and 
sociological factors.  The outcomes of this study can inform the pharmaceutical industry 
of the perceived impact of regulatory factors on clinical educators’ dialogue with 
patients.  In addition, this study will increase pharmaceutical companies’ and policy 
makers’ understanding of the communication strategies that are deployed by clinical 
educators to navigate successfully and compliantly within those factors.  
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Chapter 2: Review of the Literature 
Medication Self-Management Behaviors 
 Improper self-management behaviors for prescription medication is an endemic 
problem that impacts the physical, mental, and financial well-being of the individual and 
society at large.  Recent studies has placed non-adherence rates between 25% to 50% for 
those who take medication (Brixner et al., 2019; Zhou et al., 2018). A far-reaching 2013 
survey conducted by the National Community Pharmacists Association (NCPA) 
estimates that almost one-half of all adults age 40 or over are taking at least one 
prescription medication for a chronic condition such as hypertension, hyperlipidemia, 
diabetes, heart problems, or asthma. Of those patients, almost 60% have missed doses 
while approximately 30% forgot whether they took their medication.  Slightly less than 
30% did not refill a prescription in time while more than 20% took a lower dose of 
medication than prescribed.  Finally, 15% stopped taking a medication before consulting 
their healthcare provider (HCP) (National Community Pharmacists Association, 2013). 
Reasons for non-adherence varied with some of the most popular responses being: 42% 
said they forgot, 34% ran out of the medication, 27% were away from home, 22% were 
trying to save money, 21% had problems with side effects, 17% were too busy, 17% felt 
the prescription was not working, 16% did not think the prescription was needed, and 
12% did not like taking the medication.   
 Adherence rates for common chronic afflictions such as diabetes, osteoporosis, 
rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD), to which 
there are a wide range of different medications, have similar figures.  One study noted 
that adherence for a popular self-injected medication indicated for treating the 
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autoimmune conditions of RA, psoriasis, and IBD was approximately 40%  (Brixner et 
al., 2019).  Various studies on patients prescribed osteoporosis medications have seen one 
year discontinuation rates reach between 50% to 75% (Hiligsmann et al., 2013).  This is 
problematic as poor adherence can significantly reduce the bone health gains attributed to 
these medications while also stifling the cost-effectiveness of proper disease 
management.  Lastly, poor medication adherence is a noted as the primary factor for why 
50% of people with diabetes in the United States do not achieve an appropriate A1C 
level, the metric by which physicians measure average blood glucose levels (Zhou et al., 
2018). 
The impact of non-adherence can have far-reaching clinical and financial 
repercussions for the patient and society at large  (Brixner et al., 2019; Ganguli et al., 
2016).  For instance, studies have estimated that non-adherence adds anywhere from an 
additional $117 to $290 billion annually to U.S. healthcare costs (National Community 
Pharmacists Association, 2013; National Council on Patient Information and Education, 
2007).  Equally disturbing is a study that noted that more than 30% of the patients 
readmitted to a hospital for a chronic condition were there because of non-adherence to 
their medication (Lam & Fresco, 2015).   Reasons for non-adherence are numerous but 
can be grouped by variable types to include: patient variables such as education, health 
beliefs, comorbidities, and ability to pay; treatment variables such as medication types, 
frequencies, side effects, and administration modalities; and variables related to the 
dynamics of interaction between the patient and the HCP (Briot et al., 2009; Hammond, 
1995; Shu et al., 2009).  As such, studies have shown that when adherence increases, 
overall healthcare costs can be lowered (Brixner et al., 2019).  Similarly, studies of 
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patients with diabetes have shown that when adherence rates improve, so too do A1C 
levels while diabetes-related complications tend to go down (Zhou et al., 2018). 
Biologics and self-injection barriers.  Adding to the complexity of adherence 
challenges is that an increasing number of healthcare therapeutic areas are relying on 
treatments that use large-molecule biologics derived from living cells instead of small-
molecule drugs synthesized through a chemical process (Cohen et al., 2006).  Most 
biologics cannot be taken orally and therefore require more invasive and complex 
procedures for administration, such as self-injection.  Self-injected biologics are used to 
treat a range of some of the most common chronic conditions including diabetes, multiple 
sclerosis, and inflammatory autoimmune conditions such as ulcerative colitis, Crohn’s 
disease, rheumatoid arthritis, and psoriasis.   In fact, since 2010, half or more of the top 
ten biologics (in sales) are indicated to treat these conditions (Radar, 2011; Stone, 2019; 
Ubel, 2014).   
Unfortunately, issues related to confidence and self-efficacy toward self-injection 
of biologics are some of the most common patient barriers for adhering to this type of 
therapy (Brixner et al., 2019).  Self-injections create a higher patient burden due to the 
additional complexity and lifestyle adaptations they require (Lorenzi et al., 2011).  These 
include understanding the correct and safe injection administration protocol, overcoming 
needle phobias, following special storage, travel, and disposal requirements, and 
navigating a frequently difficult insurance approval and reimbursement process.  Such 
impediments decrease patients’ motivation to speak with their provider regarding self-
injectable treatments or seek the educational services that their HCP may provide 
(Colwell et al., 2005; Lorenzi et al., 2011; Stockl et al., 2010).  Finally, insufficient self-
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injection training, coaching, and follow-up delivered by HCPs can produce challenges 
that exacerbate a patient’s inability to be adherent (Hicks et al., 2011).  However, as with 
all medications, improvements in biologic adherence can have long-term positive 
healthcare cost benefits (Brixner et al., 2019). 
The Clinical Educator and Patient Support Programs 
 A popular strategy for helping patients overcome adherence and other barriers to 
treatment and build self-efficacy toward new therapies is though structured interventions 
delivered by clinicians specially-trained in patient education  Patient-centered educational 
engagements have been shown to increase initiation of and adherence to a range of 
treatments, including those that involve self-injection medications for osteoporosis, 
diabetes, and rheumatoid arthritis (Briot et al., 2009; Lorenzi et al., 2011; Stockl et al., 
2010).  Through a structured dialogue, a shared understanding between patient and 
provider can be developed regarding the expectations, limitations, and projected 
outcomes of treatment (Lindeman, 1995).  Most importantly, it is during these 
conversations that a patient can gain acceptance of their condition and understand the 
rationale of the required therapy.  Only after a patient has accepted the “why” for 
treatment can behaviors change and the barriers that may slow or impede progress be 
addressed (Street et al., 2009).  Additionally, patient satisfaction with the way a clinician 
communicates is related to adherence—improved communication leads to better 
adherence (Duggan & Thompson, 2011). 
 One format for these educational interventions is patient education delivered by a 
certified or licensed clinician such as a physician, registered nurse (RN), physician 
assistant (PA), pharmacist, registered dietitian (RD), clinical therapist, or licensed clinical 
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social worker (LCSW).   These patient education services are frequently cited in the 
literature as a type or subset of “patient navigation.”  Individuals who deliver such 
services are referred to as “patient navigators,” “nurse educators,” or “clinical educators.” 
Patient navigation has been defined by the National Cancer Institute as “the logistic and 
emotional support needed to achieve the completion of diagnostic and treatment care” 
(Freund et al., 2008).  
 A patient support program (PSP) is a term used to describe a structured disease 
and therapy self-management support intervention delivered by a clinical educator.  
These educational programs can be broadly defined though most include individualized 
medication counseling, training, support, and medication reminders (Ganguli et al., 
2016). PSPs can include many different objectives, but most tend to focus on helping 
patients better manage their diseases and therapies while improving adherence and 
reducing complications and healthcare costs (Ganguli et al., 2016).  Studies have 
identified PSP programs being implemented by healthcare providers (HCPs), healthcare 
systems, insurance companies, pharmacy benefits managers (PBMs), and pharmaceutical 
companies (Brixner et al., 2019; Ganguli et al., 2016).  These studies also reported that 
multiple delivery methods have been employed for PSPs to include individual and group 
face-to-face interventions as well as telephonic and online engagements. 
 Much of the literature on clinical educators and PSPs consists of quantitative 
research that looks at outcomes such as adherence or persistency rates and feasibility 
analytics (Ganguli et al., 2016; Kelly et al., 2015; McVay et al., 2014).  Such programs 
were found to promote adherence and reduce hospital readmittance, as well as positively 
support humanistic outcomes, such as improved quality of life and functional status 
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(Ganguli et al., 2016; Hiligsmann et al., 2013; Zhou et al., 2018).  In fact, those programs 
that included multiple interventions beyond a single session, such as those that included 
additional education sessions or follow-up medication reminders, were found to be even 
more effective (Ganguli et al., 2016). 
 Another frequently measured outcome for PSPs is patient satisfaction scores 
(Ganguli et al., 2016).  However, the way patients define a satisfactory educational 
interaction can vary.   Many patients perceive the quality of time spent teaching to be as 
important to their satisfaction as the quantity of time in the interpersonal engagement 
(Alexander et al., 2012; Bartlett et al., 1984; Braddock & Snyder, 2005).   Additionally, 
many patients with chronic conditions feel dissatisfied with how disease and lifestyle 
information is delivered, particularly in those situations in which a patient perceives the 
HCP to be rushing through the process.  Such frustration often stems from education that 
consists of an overwhelming amount of information presented in infrequent occurrences.  
This is at odds with most patients who prefer, and tend to benefit more when, their 
providers deliver smaller chunks of information over time as part of a continuous process 
(Hashim, 2017; Wikblad, 1991). 
In addition to delivering informational content related to a medication’s efficacy 
and risks, a common goal of PSPs is to empower patients to take ownership of their 
disease and therapy.  This means coaching and motivating them to adopt the sort of self-
care behaviors that lead to positive therapeutic outcomes (eyeforpharma Ltd. & S3 
Connected Health, 2018; Wolever et al., 2010).  The literature has described the process 
of patient empowerment in varying terms.  For example, one frequently used term in the 
literature is patient activation (Hibbard & Cunningham, 2008; Tolve, 2012; Wolever et 
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al., 2010).  The term is generally understood to refer to individuals’ ability and 
willingness to take on the role of managing their health and healthcare (Hibbard & 
Cunningham, 2008).  Studies have shown that patients’ ability to be activated is a result 
of many factors that may directly or indirectly affect their healthcare experiences.  This 
includes demographic factors such as age, race, ethnicity, education level, and 
socioeconomic status as well health-related characteristics such as presence of a chronic 
condition, comorbidities, health insurance type, body mass index (BMI), and self-
perceptions of overall health status (Hibbard & Cunningham, 2008).   For instance, 
studies that measure activation have shown that people with chronic conditions are more 
likely to have lower levels of activation compared to those without.  However, those with 
multiple chronic conditions tend to be more activated than those with only one.  High 
patient activation has been linked to behaviors such as use of preventative care, engaging 
in healthy behaviors, having clinical indicators within normal ranges, and costing less to 
insure (Greene & Hibbard, 2012).  
 Many studies have examined the impact of these PSPs within the context of 
specific chronic diseases.  Some have found conflicting evidence regarding their impact 
on adherence such as Higligsmann’s et al. (2013) review of osteoporosis PSPs, which 
determined some patients had positive outcomes while others did not.  However, most 
studies related to disease-specific PSPs have documented primarily positive gains.  For 
instance, in a quantitative study of hypertensive patients who were on a long-term drug 
treatment, researchers found that those who received training about the risks associated 
with not taking their medication, coupled with multiple follow up visits from a clinical 
educator, had a longer adherence than those who did not receive the follow-up visits with 
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training (Saounatsou et al., 2001).   Such findings were supportive of a meta-analysis in 
that same therapeutic area, which determined that education interventions were 
successful in improving health-related quality of life (HRQoL) for patients with coronary 
heart disease (Brown et al., 2013).  A secondary outcome noted by those researchers was 
that such interventions reduce subsequent healthcare utilization, which may reduce 
healthcare costs. Similar positive outcomes were demonstrated for educational 
interventions in patients with diabetes.  One study found that patient education 
interventions were not only successful in increasing adherence for diabetes treatment, 
they were a means for strengthening the patient-provider relationship (Rubin, 2005). 
These stronger bonds led to more regular follow-up visits, that have been shown to be a 
strong predictor of treatment adherence.  Additional findings from that study noted that 
the educational interventions helped improve diabetes patients’ understanding, 
confidence, and level of self-care toward their disease.  Other studies have found that 
educational interventions were most effective for increasing patients’ understanding of 
the diabetes disease state as well as their adherence rate for dietary regimens and 
metabolic control (van Dulmen et al., 2007).  
 Clinical education is particularly impactful for patients who are required to self-
inject biologics.  One study explained that compliance and discontinuation rates trended 
toward better outcomes for patients who participated in an extended education program 
for an injectable diabetes medication (Lorenzi et al., 2011).  Similarly, patients who 
participated in a supplemental disease therapy management (DTM) educational program 
for an injectable rheumatoid arthritis medication showed significantly higher rates of 
adherence than those who participated in a routine pharmacy benefits management 
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(PBM) service.  The DTM program included the standard components of the PBM 
service—welcome brochure, mail-service delivery, refill reminders, and 24-hour 
pharmacist access.  However, the DTM program also provided more robust patient-
centric education strategies that included regular consultations with a care coordinator 
(Stockl et al., 2010). 
 These studies have clearly shown that patient education programs at the start of 
treatment are an important step toward adherence.  Yet, research also suggests there is a 
need for ongoing support and even refresher trainings to make sure proper injection 
techniques are followed.  One study noted that because of poor retention of proper 
injection technique information, many patients incorrectly self-injected.  This resulted in 
adverse outcomes such as lack of site rotation, inaccurate needle depth or angle, improper 
skin fold technique, insufficient delivery timing, and the formation of fatty lumps that 
appear at insulin injection sites (Hicks et al., 2011). 
The commonality among most studies conducted around medication education is 
that they have followed a quantitative methodology that examined outcomes related to 
the patient. Very few studies have approached the concept of pharmaceutical education 
utilizing a qualitative perspective that explores the role of the clinical educator.  This type 
of interpretive research is best for discovering constructs such as clinical educator 
engagement, activation, and motivation as well as understanding the nature of the patient-
provider relationship from the educator’s vantage point.  Additionally, pharmaceutical-
sponsored clinical educators have a unique role within the healthcare system and are 
bound by certain regulatory factors that impact how they communicate with patients 
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during education.  While qualitative studies would be appropriate for exploring the 
relationship between that role and those factors, such studies currently do not exist.   
 Pharmaceutical-sponsored clinical educators.  Many pharmaceutical 
companies are utilizing clinical educators to provide product and lifestyle education via 
PSPs (eyeforpharma Ltd. & S3 Connected Health, 2018; Newmark & Blackburn, 2018).  
Such education programs are especially popular among those companies who 
manufacture biologics used to treat chronic conditions and those who produce oral 
medications that have severe side-effect profiles, such as oncolytics, which are self-
administered cancer medications (Arrington et al., 2018; Rossheim, 2016).   For these 
programs, patient education is provided by a clinician who is paid by a pharmaceutical or 
biotech company.  Like other PSPs, industry-sponsored programs include product and 
safety information as well as injection training for self-administered biologics.  Program 
content can be delivered via a range of different formats, including web-conference, 
telephonic support, and face-to-face engagements. (AbbVie, 2013; Amgen, 2019; Biogen, 
2020; NovoNordisk, 2019; Sanofi-Aventis, 2019; UCB, Inc, 2020).  In addition to 
product training, some manufacturers also underwrite or sponsor lifestyle and disease-
state management programs that focus on topics such as diet, physical activity, and 
mental health (NovoNordisk, 2019; UCB, Inc, 2020). 
A primary reason pharmaceutical-sponsored education programs are growing in 
popularity is an outcome of the dissatisfaction some patients feel regarding the length and 
type of communication they receive from their primary healthcare team regarding their 
prescribed therapies (Alexander et al., 2012; Bartlett et al., 1984; Ganguli et al., 2016; 
National Council on Patient Information and Education, 2007).  However, there are only 
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a few studies in the peer-reviewed literature that have examined the outcomes of 
industry-sponsored PSPs.  Most were large-scale and utilized real-time prescription 
databases that tracked actual fills and refills instead of relying on patient self-reports. One 
such study examined the impact of a multiple touchpoint PSP delivered by a team of 
clinical nurse educators for over 2,200 U.S. patients prescribed a popular biologic used to 
treat chronic autoimmune conditions like RA, psoriasis, and IBD.  It used a national 
claims database to track de-identified prescriptions and found that the participants 
enrolled in the PSP had a 29% higher adherence rate than those not enrolled and a 22% 
lower discontinuation rate.  Additionally, it noted that disease related medical costs and 
all-cause medical costs were lower by 35% (Brixner et al., 2019).  A study for that same 
medication was conducted on a telephonic-based version of the PSP in Canada using 
prescription data from over 10,000 patients.  Participants in the PSP were found to have a 
72% decreased risk for therapy discontinuation and a greater likelihood for adherence 
compared to those prescribed the medication but not enrolled in the program (Marshall et 
al., 2018).  Lastly, a 12-month retrospective of patients with Type 2 diabetes looked at 
outcomes for those enrolled in a PSP for insulin.  It found that adherence and persistency 
increased for patients new to insulin as well as those switching from another brand 
compared to those not enrolled (Zhou et al., 2018).  
Regulatory Factors  
 There is a difference in a formal patient education program conducted on behalf 
of a pharmaceutical company compared to one delivered by a patient’s primary 
healthcare team.  The former is held to a level of government scrutiny imposed by U.S. 
Food and Drug Administration (FDA) mandates that limit the scope and way content can 
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be addressed.  Specifically, there are three regulatory-related factors that shape the 
content and delivery of pharmaceutical-based clinical educators program—staying on-
label, fair-balance presentation, and adverse event reporting.   
 Staying on-label.  The primary purpose of an FDA-mandated prescription 
medication label, also known as the prescribing information or package insert, is to give 
HCPs the information they need to properly prescribe drugs and biologics (Kremzner & 
Osborne, 2007).  Drug labeling requirements are regulated by Title 21 of U.S. Code of 
Federal Regulations (CFR) section 201.56 “Requirements on Content and Format of 
Labeling for Human Prescription Drug and Biological Products” which state that labels 
must (a) provide a summary of the safe and effective use of the drug, (b) be informative 
and accurate, (c) be non-promotional and not false or misleading, (d) not imply claims or 
suggestions for use if evidence of safety or effectiveness is lacking, and (e) when 
possible, be based on data derived from human experience (U.S. Government Printing 
Office, 2014).  Pharmaceutical companies who violate drug labeling and promotional 
regulations are subject to a range of penalties.  Additionally, violators may be forced into 
lengthy and expensive Corporate Integrity Agreements (CIA) with the government that 
require increased scrutiny measures, additional reporting, and regular training (U.S. 
Office of Inspector General, 2015). 
 An FDA approved label drives all decisions regarding how a pharmaceutical 
company markets and promotes a product.  All messaging must be supportive of, and 
verifiable to, the label.   Sales representatives, clinical educators, promotional materials, 
and media may only speak to claims, indications, side effects, safety information, and 
clinical trial data as noted in the label.  As agents of these companies, pharmaceutical-
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sponsored clinical educators are therefore held to the same guardrails as sales 
representatives.  They cannot discuss medication-related content outside the scope of the 
label.   
 Fair balance presentation.  In addition to overseeing the content of the label, the 
FDA also regulates the way drug and biologic product information is marketed to the 
public and delivered to potential prescribers.  The concept of fair balance is a term used 
to explain the governmental requirement that product promotions must balance claims of 
benefits and efficacy with information regarding risks and side effects.  Content must be 
presented in a way that does not diminish risks through such techniques as obscured or 
overly small font size, unrealistic imagery of the target patient populations, or rushed 
explanations of common side effects tacked onto the end of a physician presentation 
(U.S. Food & Drug Administration, 2015, 2017b).   
 Additionally, the FDA requires that all subject deaths that occurred during or 
immediately following clinical trials be included as part of a drug’s New Drug 
Application (NDA) regardless if there was any evidence that directly linked the drug to 
the cause of death (U.S. Government Printing Office, 2019).  Thus, this could result in 
death being included as a possible serious side effect as part of the Important Safety 
Information in promotional material.  
 Adverse event reporting.  From clinical trials to post-market launch, adverse 
event data is collected throughout the lifecycle of a drug.  The FDA defines an adverse 
event as “any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related” (U.S. Government Printing Office, 2019).  
Adverse events can include mild to severe side effects, product use errors, product quality 
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problems, and therapeutic failures (U.S. Food & Drug Administration, 2017c).  As part of 
the drug’s post-marketing safety surveillance program, the FDA requires drug companies 
to document and track all adverse events each time they are observed or reported through 
the FDA Adverse Event Reporting System (FAERS) (U.S. Food & Drug Administration, 
2017a).  In some instances, adverse event data gathered after clinical trials can affect a 
drug’s post-market safety profile.  This can result in such consequences as changes to a 
product’s label, FDA-issued safety alerts, or in extreme cases, removal of the product 
from the market (U.S. Food & Drug Administration, 2014).   
 Understanding the relationships and influences of these regulatory factors on 
those responsible for educating patients on medications can best be understood when 
examined with the context of interpersonal and health communication theories.  The 
following section examines two theoretical frameworks well-suited for this task. 
Theoretical Frameworks 
 Many communication theories that explore the concept of interpersonal 
engagement in the health environment do so within the context of the individual as a 
patient and/or caregiver interacting with an HCP (Street & Epstein, 2008).  Such is the 
case of the present study that investigated interpersonal engagements between patients 
and pharmaceutical-sponsored clinical educators.   While these clinical educators are 
typically not considered part of a patient’s primary or “formal” healthcare team, the 
education, coaching, and psychosocial support they provide is akin to those same services 
the patient would receive from his or her doctors, nurses, pharmacists, and therapists.  
Therefore, theories that explore the nature of patient-HCP interpersonal health 
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communication can provide suitable frameworks for examining the communication 
complexities clinical educators face when they are engaged in medical encounters.    
 Two widely used communication frameworks that are relevant to the current 
study are Street’s (2003) ecological model of communication in the medical encounter 
and Petronio’s (2002) Communication Privacy Management (CPM) theory.  Street’s 
model is specific to interpersonal health communication while Petronio’s theory has been 
applied within the broader context of interpersonal communication.  However, both offer 
a means for interpreting the way regulatory factors influence clinical educator 
communication engagements and the manner in which educators respond to those 
dynamics.  For instance, Street’s ecological model’s emphasis on the role of socio-
political and demographic contexts in interpersonal health communication provides a 
suitable lens to explore how industry and government regulations related to staying on-
label, fair balance presentation, and adverse event reporting function as influencing 
factors within a political/legal context.  Secondly, CPM describes how confidant role 
types impact the communication boundaries between a health information discloser and 
recipient.  This serves as an appropriate framework for exploring how patients and 
clinical educators co-create communication rules and boundaries based on those 
perceived confidant roles as well as the regulatory factors that impact those boundaries.  
The following sections describe each theory in greater detail and their relevance to the 
present study.  
Ecological model of communication in medical encounters.  Ecological models 
of communication have been used by health communication researchers to understand the 
relationship between people and their health.  At the heart of an ecological perspective is 
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the notion that health behaviors cannot be interpreted in isolation of the environmental 
and policy contexts in which they occur (Sallis et al., 2008).  Such perspectives consider 
that these influences happen simultaneously within multiple levels to include 
intrapersonal, interpersonal, organizational, community, and public policy (Street, 2003).  
Street (2003) examined the variety of ecological factors and influences that can 
impact the interpersonal patient-provider dialogue within a medical encounter. This is an 
important consideration as such factors can determine the nature and scope of 
interpersonal communication.   Street separates these factors into four contexts of socio-
political and demographic factors that impact and influence both the patient and the HCP 
and the way their interactions unfold.  The culture context is comprised of factors that are 
descriptive of one’s culture, such as race, gender, ethnicity, religion, and socioeconomic 
status.  Street noted that the ecological factors of race and ethnicity are often of high 
interest for study as they can help understand and alleviate the well documented impact 
of those types of disparities in healthcare.   Additionally, the use of this context as a study 
lens can serve as means for designing the sort of training programs that improve HCP 
cultural competencies.  The media context includes factors related to the modalities by 
which communication occurs, such as access to or use of Internet, telemedicine, and mass 
media exposure.  Street specifically highlighted the way the Internet has transformed the 
interpersonal dynamic between patients and HCPs because of the way it has enabled 
patients to seek out and come to an interpersonal encounter armed with their own 
information.  He credits this medium as a primary reason for a shift from the traditional 
physician-centered approach to healthcare communication to one that is oriented around a 
shared decision-making partnership with patients.  The political-legal context is inclusive 
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of factors that are tied to legislative and judicial actions pertinent to healthcare, such as 
the Affordable Care Act (ACA) and government-funded healthcare programs (e.g. 
Medicare, Medicaid), malpractice litigation, and patients’ bill of rights.  Street posited 
that because this context was understudied, there is a lack of clarity as to how it could 
impact patient-provider communication.  He asserted that two outcomes were possible, 
one being that the constant threat of litigation would pressure HCPs to adopt a more 
cautious and guarded style of interaction with patients.  The converse possibility was that 
HCPs might engage in more patient-centered communication as such behavior styles are 
thought to lower malpractice risks. 
The fourth socio-political context identified by Street (2003) was the 
organizational context.  It includes the influence of structures such as managed cared, the 
medical services available, and the standards of care that drive those services.  When 
explaining the organizational context, Street (2003) pointed out how factors within a 
context can function as healthcare barriers by impeding the patient-provider 
communication dynamic.  For example, he examined the impact of the managed care 
healthcare system, an influencing factor within the organizational context of his model, 
on patient-provider dialogue.  He contended that the frequently diminished trust that is 
created by the cost-controlled foundation of managed care can inadvertently lead to a 
more physician-centered communication framework described as paternalistic dialogue.  
In fact, he questioned whether the ecological influence of health regulations, coupled 
with the fear of litigation imposed by health payors and insurers, have pressured 
clinicians to adopt a cautious and guarded style of communication with patients.  Such a 
question is relevant when exploring any theoretical constructs of patient-HCP dialogue as 
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related to the role of clinical educators.  If cost-control and government policy factors of 
the managed care system has the potential to erode trust and impact a physician’s 
communication dynamics, similar consequences may be possible regarding FDA-
mandated regulatory factors on pharmaceutical-sponsored clinical education programs. 
Many ecological perspective models used in social science research are similar to 
Street’s (2003) in that they use a framework of socio-political and demographic contexts 
to explain behavior.  However, Street’s ecological model of communication in the 
medical encounter is unique in that it narrows its focus to the interpersonal 
communication behaviors that exist between an HCP and patient as part of a health-
related engagement.  As such, Street explains that, in addition to the four socio-political 
contexts, an interpersonal communication context exists that further impacts how patients 
and HCPs talk to each other.   That context contains two types of influences— 
cognitive/affective and predispositional.   
Street (2003) explains that within any interpersonal interaction, participants create 
a cognitive representation of the encounter that incorporates their goals, perceptions, 
appropriate behaviors and the way the engagement will unfold.  He characterizes these 
elements as cognitive/affective influences.  These influences account for the situational 
factors which spur patients and HCPs to adapt their communication for strategic goals 
and purposes.  They also encompass attributional factors, (e.g. perceptions, stereotypes, 
impressions), relational constructs (e.g. trust, familiarity), and emotional considerations 
(e.g. fear, anxiety).  For example, as Street explained, an HCP who is gregarious and 
typically engages with patients using shared decision-making tactics, may change that 
style to a more directive or didactic approach when discussing a difficult prognosis.  
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Similarly, an individual who typically prefers a collaborative form of engagement with 
HPCs may seek out a more paternalistic approach from a physician if that individual is 
serving in the role of a decision maker for an incapacitated friend or family member.  
Street stresses that such contexts needs further study.  He acknowledges that though 
scholars have a firm understanding of the relationship of socio-political and demographic 
factors influence on interpersonal communication, they know less about how the 
interactants’ goals, expectations, and perceptions affect what occurs in consultations. 
The other factors within Street’s (2003) interpersonal context are what he refers to 
as predispositional influences.  These are factors that provide for consistency of 
communication such as communication style (e.g. expressive, dominant, open, attentive), 
individual self-concept (e.g. attitudes, beliefs, personality), and access to linguistic 
resources.  For instance, predispositional influences are what a communication scholar 
might use to describe whether a physician has a patient-centered style of communication 
(e.g. using open-ended questions, seeking patient input, incorporating counseling 
behaviors) or a physician-centered style of communication (e.g. using close-ended 
questions, being directive to patients, focusing strictly on a patient’s physical condition). 
Like cognitive/affective factors, these influences can also drive how patients interact with 
their HCPs, such as choosing a collaborative style of engagement or seeking a more 
paternalistic HCP approach in which the provider is more directive.   
Other scholars have similarly noted how different types of HCP communication 
styles can influence the relationship and type of engagement that develops between the 
HCP and patient.  For instance, Emanuel and Emanuel’s (1992) four models of the 
physician-patient relationship categorized the interpersonal health communication 
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process as it relates to medical decision-making.  The paternalistic model is one in which 
the HCP assumes leadership and management of the dynamic and thereby makes 
decisions based on what he or she feels is in the best interest of the patient.   The inverse 
of that style is the informative model in which the HCP simply provides information 
while the patient assumes leadership and management of decisions.  The interpretive 
model, like the informative model, recognizes the need for the physician to provide 
technical information.  However, while the patient is still the decision maker, he or she 
allows the provider to elucidate their values and assist in the guidance of therapies and 
medical decisions.  Lastly, there is the deliberative model, which is when the patient not 
only requires technical advice from the HCP, but also help in determining what values 
are necessary to guide the decision-making process.  The provider empowers the patient 
with both technical knowledge and values, and through dialogue, helps the patient make 
medical decisions. 
 The ecological model and ethics.  The predispositional influence of 
communication styles has served as an explanatory lens within multiple studies that 
examine the ecological model of interpersonal communication within a healthcare 
context.  Many of these studies examined communication style and how its intersection 
with the medical ethic of autonomy influenced patient preferences and participation in the 
medical encounter (Cegala, 2011; Street, 2003; Street et al., 2005, 2012).  For instance, 
Street, et al. (2012) explain that patient preferences related to their healthcare “are 
dynamic and embedded within multiple, interconnected layers of context” (p. 170).  As 
an example, they note that if an HCP has a predispositional communication style in 
which they always frame a prognosis message for treatment in the context of its efficacy 
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or positive outcomes (e.g. lives saved), a patient will be more likely to prefer that 
treatment.  Conversely, if the message is framed in the context of the treatment’s risks or 
negative outcomes (e.g. lives lost), the patient will be less likely to prefer it.  As the 
authors also point out, accounting for patients’ preferences for care is endemic of good 
clinical practice as it honors the medical ethic of autonomy.  Patient autonomy is critical 
to three of Emanuel and Emanuel’s (1992) four models of models of patient-physician 
relationships—informative, interpretive, and deliberative.  Hence, when an HCP’s 
predispositional communication style is such that it encourages patients to adopt full or 
shared autonomy in the decision-making process, patients are more likely to articulate 
their preferences regarding treatment and disease management. 
 That notion has been the subject of studies by others, including Cegala (2011) and 
Street et al. (2005).  Findings from Cegala’s study asserted that physicians’ patient-
centric communication style significantly predicted active patient participation in the 
medical encounter.  In other words, those physicians who placed value on communication 
styles that nurtured patient autonomy found that their patients were more actively 
engaged in discussions, asked more questions, and provided more details about their 
disease and treatment.  Such outcomes were supportive of an earlier study by Street et al., 
that found patients were more likely to be an active participant in their consultations with 
physicians when those physicians used partnership-building and other types of supportive 
communication. They described partnership-building to include such behaviors as asking 
for a patient’s opinion, using open-ended questions, and engaging in reassuring and 
encouraging dialogue.  Conversely, they noted that physicians who utilized a paternalistic 
style of communication that focused on control would discourage patient participation. 
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Lastly, scholars have hypothesized that there is an interpersonal health 
communication context that occurs outside the scope of the patient-provider dyad, which 
later influences the communication within that dyad.  This is the everyday talk that 
patients have with family, friends, co-workers, strangers, and third-party healthcare-
related professionals—those outside the formal healthcare team (Cline, 2011).  Casual 
health dialogue with such “others” has the power to both enable and constrain formal 
patient-provider conversations (Head & Bute, 2017).  This is an important consideration 
for pharmaceutical-sponsored clinical educators as their role is a nebulous one—
straddling the boundary between a formal or primary healthcare team member and an 
external third-party other.  Head and Bute describe multiple ways in which everyday 
interpersonal health communication serves as an influential ecological factor that impacts 
the formal conversations patients have with providers. Some of these influences are 
relevant to the pharmaceutical-sponsored clinical educator’s role.   For instance, Head 
and Bute shared that everyday conversations can later influence the dialogue in formal 
medical encounters by encouraging patients to ask certain questions or seek specific 
information. Such would be the case for clinical educators who may further catalyze a 
patient’s information-seeking behaviors with a physician because of the educators’ 
inability to broach off-label topics.  In fact, the authors specifically cite that an area of 
necessary future research would be studies that explore the role third parties (i.e. 
pharmaceutical-sponsored clinical educators) play as ecological factors in the formal 
patient-provider medical encounter.  
 Ecological models in chronic disease management.  As previously noted, 
clinical educators are frequently employed by pharmaceutical companies that 
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manufacture drugs and biologics to treat chronic conditions such as diabetes, arthritis, 
psoriasis, inflammatory bowel disease, and multiple sclerosis (AbbVie, 2013; Amgen, 
2019; Biogen, 2020; NovoNordisk, 2019).  Not surprisingly, ecological models are 
frequently used as a means for understanding the communication dynamics between 
HCPs and patients with chronic conditions.  Ecological perspectives have been employed 
as road maps for interpreting how patients and HCPs understand, prevent, and manage 
diseases such as diabetes, HIV, cardiovascular disease, chronic pain, asthma, and 
dementia (Fisher et al., 2005; Hruschak & Cochran, 2017; McKenzie et al., 2012; Mudd-
Martin et al., 2014; Rose & Garwick, 2003; Tan et al., 2014).   Such research serves to 
inform HCPs of the role ecological factors play in patient understanding and management 
of their disease.   Additionally, intervention-based studies have explored the impact and 
outcomes of education-based strategies that address ecological factors.  One example is 
the Resources and Supports for Self-Management (RSSM) approach developed by The 
Diabetes Initiative of the Robert Wood Johnson Foundation.  RSSM is grounded in the 
context of social and environmental influences and recognizes that self-management of 
diabetes is influenced by many layers and dimensions that are ecologically framed within 
a set of processes and behaviors (Fisher et al., 2005).  The authors explain that ecological 
influences initiated through policy and community factors may filter down to influence 
family factors which in turn influence individuals within the family (Fisher et al., 2007). 
 Moreover, demographic characteristics such as gender, race, ethnicity, and 
community types are frequently examined in conjunction with specific disease types to 
provide further understanding of the impact of layered ecological domains on 
interpersonal health communication.  For instance, an ecological model has been used to 
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explain how HIV positive and negative men who have sex with men of color leverage the 
ecological domains in which they had high power against the ecological domains in 
which they had low power (Tan et al., 2014).   The authors contend that the model helps 
health professionals understand why an HIV positive individual from a disadvantaged 
population would leverage sexuality in order to gain access to financial benefits.  In other 
studies of layered ecological domains, rural community life was examined as a factor for 
helping health professionals understand how that community type impact patients’ 
responses to chronic conditions such as cardiovascular disease and dementia (McKenzie 
et al., 2012; Mudd-Martin et al., 2014,).  Similarly, the role of urban life on American 
Indian caregivers has been investigated to describe how the interplay of those ecological 
domains impacted barriers to the management of childhood asthma (Rose & Garwick, 
2003).  Finally, gender differences in patient-provider communication have been 
explored within an ecological framework as has the role of adolescence in such 
conditions as sickle cell disease and sexually transmitted diseases (DiClemente et al., 
2005; Hauser & Dorn, 1999; Street, 2002).   
 Communication Privacy Management (CPM) theory.  The four context 
categories of Street’s (2003) ecological model, along with the extension of the model 
posed by Head and Bute (2017), provide a suitable framework for examining how 
regulatory factors impact the patient-educator interpersonal dialogue.  However, 
recognizing how the impact happens is just one part of understanding the process by 
which clinical educators navigate the communication complexities of a medical 
encounter.  As noted previously, the ecological influence of regulatory factors has the 
potential to erode the trust established during a medical encounter (Street, 2003). CPM 
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theory provides a means for understanding how educators are able to establish and 
maintain trust, in light of those communication complexities, by focusing on how 
relationship boundaries are defined and how privacy rules are created (Petronio, 2002). 
CPM posits that a person has a sense of ownership over their private information that 
directs how, when, what, and to whom that information will be shared (Petronio, 2002).  
Thus, that individual will create privacy rules in order to manage and control the sharing 
of information.  Such rules manifest themselves in figurative boundaries of varying 
thickness. “Thickness” is a metaphor akin to the concept of boundary permeability that 
describes the degree of comfort and trust an individual is willing to provide to another 
person regarding the type and amount of disclosed private information.  Someone who 
has high levels of restriction to their information would therefore have thick or 
impermeable boundaries.  Conversely, a person with fewer constraints for information 
sharing would have thin boundaries and greater permeability (Petronio & Durham, 2008).   
 CPM theory also accounts for the sharing of information by noting that once an 
individual discloses information to another, that information is now co-owned (Petronio, 
2002).  As part of that co-ownership, the discloser and recipient establish privacy rules 
that govern how that information in managed and subsequently shared with others.  The 
recipient maintains responsibility for upholding the established rules.  However, should 
that person violate the rules, whether purposefully or because of misinterpretation, a 
condition referred to as privacy turbulence occurs.  This means that boundary 
permeability has changed and, as a result, new rules might need to be established between 
the discloser and recipient.  For instance, if the violation was intentional, such as in a case 
of deception or betrayal, communication may be disrupted and thin boundaries may 
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become thick as the discloser limits or stops communication.  If the violation was due to 
miscommunication or misinterpretation of the rules, those rules may be clarified or 
renegotiated and thin boundary permeability may remain intact going forward (Petronio, 
2002; Petronio & Durham, 2008). 
 Privacy rules.  Boundary coordination is the process by which the information 
discloser and recipient together negotiate rules and establish boundary parameters 
(Petronio, 2002).  Privacy rules, as a concept, are agreements that help both parties 
understand how the information is managed and to whom is permitted access.  Privacy 
rules are derived from decision criteria related to the individuals’ culture, gender, 
motivations, context, and risk-benefit ratio (Petronio, 2002; 2013).  CPM identifies two 
main types of rule criteria—core criteria and catalyst criteria. Core criteria are described 
as durable or stable and tend to function in the background with little deliberation or 
consideration. These criteria are typically influenced or created from outgrowths of 
cultural expectations, gendered tendencies, personality characteristics, or socializing 
privacy orientation (Petronio & Durham, 2008).   Cultural expectations are privacy values 
related to an individual’s culture whereas gendered tendencies are values resulting from 
societal expectations of gender identity (Petronio, 2002; 2013).  Personality 
characteristics, as the term would imply, are privacy values related to various tolerances 
or propensities inherent to an individual’s personality.  This might include such 
internalized constructs such as self-efficacy, self-monitoring, or tolerances for ambiguity.  
Socializing privacy orientations are values that are generated by group affiliations or 
other socialized experiences (Petronio, 2002; 2013).  As such, core criteria are viewed as 
predictable meaning that the privacy rules a discloser co-creates with one recipient can be 
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assumed to be similar to another recipient who shares similar criteria attributes (Petronio, 
2013).  As an example, studies have shown that cultural influences within the African 
American community impact the manner in which family medical histories are shared 
that are different compared to white communities (Ashida et al., 2012; Lin et al., 2018; T. 
Thompson et al., 2013).  Therefore, a healthcare provider would be inclined to solicit 
medical histories for all African American clients using the same privacy rules; such 
rules may differ from those used to collect medical histories from white patients.   
 Over time, most core criteria become representative of routinized properties.  
Hence, routinized rules are describe within the CPM context as the types of rules that 
develop when rule criteria become stable and manifest themselves into routine privacy 
behaviors (Petronio 2002).  These sort of rules can be thought of as pre-established 
guides that inform and direct the way a discloser will typically go about managing their 
private information with individuals.  With long-term repeated use, routinized rules can 
become so engrained in an individual’s privacy behavior, they function as a concretized 
orientation, and therefore, difficult to change (Petronio, 2002). 
 While core criteria address that which is stable, catalyst criteria account for the 
triggers that lead to rule changes (Petronio & Durham, 2008).  Additionally, just as core 
criteria typify routinized rules, catalyzed criteria are exemplary of what CPM theory 
refers to as changing rules (Petronio, 2002).  CPM theory explains that catalysts are 
inclusive of factors such as motivational goals, risk-benefit goals, situational conditions, 
and emotional needs.  An individual’s motivation can influence him or her to change 
established rules, such as in the case of a discloser who has a physical attraction to the 
recipient or if there is the potential to receive some sort of reward as a result of disclosing 
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(Petronio, 2002).  Rule change can be catalyzed when the discloser performs a mental 
risk/benefit analysis that weighs the advantages of granting access to private information 
(or the advantages of concealing information) against the degree of vulnerability 
(Petronio, 2002; Petronio & Durham, 2008).  Situational conditions can provoke privacy 
rule changes such as in the case of a traumatic event, a new life circumstance, or when 
the discloser engages in a therapeutic session in which openness is an expectation 
(Petronio, 2002).  Lastly, an intense emotional experience, such as rage, passion, or 
extreme glee, may prompt a disclosure which, in a typical staid emotional state, would 
remain concealed.   
 While core and catalyst criteria help describe how privacy rule decisions are 
made, they are not the only guiding CPM factors for determining the nature of the 
communication relationship among two (or more) individuals.  The next section 
examines the CPM construct of confidant roles which are varying roles that disclosers 
and recipients co-create for the recipient.  These roles are characterized by the varying 
expectations and methods by which information is shared and managed.   
 Confidant roles.  Petronio (2002) explains that recipients of private information 
often take on the role of one of four types of confidants—deliberate confidant, inferential 
confidant, reluctant confidant, or stakeholder confidant.   Role assignment can change 
based on such things as setting, type of experienced relationship, and the nature of the 
boundary permeability.  Three of these roles—deliberate, stakeholder, and reluctant—are 
relevant to the current study.  
 The deliberate confidant is one who receives a disclosure because it has been 
solicited in the context of providing advice, counsel, or coaching.  By nature of their role, 
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a clinical educator can be perceived by their patients as a deliberate confidant in that they 
actively solicit private information for coaching and counseling purpose.  Petronio (2002) 
points out though that such a role can lead to dilemmas if there are expectations of 
reciprocity.   This is referred to as the norm for reciprocity which can be understood as a 
type of quid pro quo, i.e. in exchange for providing a disclosure, one is expected in return 
(Bradac et al., 1978).    
 The reluctant confidant is an individual who receives private information, 
intentionally or inadvertently, but did not have an expectation for such (Petronio, 2002).  
A passenger on a bus who is disclosed information from a stranger is a reluctant 
confidant.  In this case, privacy boundaries are unwillingly linked as, in most instances, 
the recipient has no desire to own the information.  Petronio (2002) explains though that 
in some situations, deliberate confidants, who are typically trained to handle disclosures, 
end up finding out more than they want to know.  Thus, a paradoxical situation arises in 
which the deliberate confidant becomes a reluctant one.   In fact, Petronio noted that 
certain occupations, such as nurses, bartenders, and hair stylists, are predisposed for 
receiving extraneous or irrelevant information simply due to the nature of their 
profession.  She refers to this subset of reluctant confidants as occupational confidants. 
 Finally, within the realm of healthcare services, there are those who function as 
stakeholder confidants.  These are individuals such as doctors, nurses, and other patient-
facing health professional who, by nature of their healthcare role, receive patients’ private 
health information  (Petronio & Sargent, 2011).  In other words, a stakeholder confidant 
is an individual who co-owns an individual’s health information because he or she is a 
stakeholder in the individual’s medical care (Petronio & Sargent, 2011).  This role 
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includes an expectation and appreciation for the co-ownership of confidential patient 
information (Brann & Mattson, 2004).  
 Stakeholder confidant roles between an HCP and patient are created for two 
primary purposes.  One reason is that patients have an emotional need to disclose to the 
provider their feelings about their health situation.  The other reason is that patients 
understand that providing private information is a condition for receiving medical and 
therapeutic care (Petronio & Sargent, 2011).   
 Street’s (2003) ecological model and Petronio’s (2003) CPM theory together offer 
the requisite frameworks for interpreting the current study that explores the nature of the 
pharmaceutical-sponsored clinical educator role and the challenges posed by the 
regulatory factors that influence it.  The remainder of this chapter summarizes the 
rationale for this study and the questions that guided its approach. 
Research Questions 
 The scarcity of existing research on pharmaceutical-sponsored clinical educators, 
along with the complexities of government regulations that impact such services, have 
revealed a gap in the understanding of the relationship between the patient and a 
pharmaceutical-sponsored clinical educator.  This gap exposes the need for research that 
explores concepts such as how pharmaceutical-sponsored clinical educators perceive 
their role, how those educators perceive the impact of their communication with patients, 
how the educators adapt communication engagements to fit patient or therapeutic needs, 
how regulatory factors impact the educators’ communication with patients, and how 
educator-patient relationships grow or change over time.   
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 Additionally, as more pharmaceutical companies enlist the assistance of clinical 
educators for patient education services, and a growing number of patients are utilizing 
them to receive health information and make healthcare decisions, studies such as this 
one are necessary for multiple reasons.  As noted, there is a relationship between the type 
and perceived quality of communication patients receive from their healthcare providers 
and health behavior outcomes, such as adherence rates (Colwell et al., 2005; Lorenzi et 
al., 2011; Stockl et al., 2010).  Similarly, ecological factors can also influence such 
behavioral outcomes (Fisher et al., 2005; McKenzie et al., 2012; Mudd-Martin et al., 
2014; Street, 2003).   
 This study will help the pharmaceutical industry understand that the regulatory 
requirements that function as ecological drivers for these programs can influence the 
programs’ adherence goals.  Further, the ongoing success of these programs is contingent 
on knowing how educators effectively and compliantly navigate within those ecological 
drivers.  Additionally, this study can assist the industry by identifying other strengths and 
weaknesses of the pharmaceutical-sponsored clinical educator model and by providing 
recommendations to address them.  Outcomes from this study can be shared with new 
and tenured clinical educators through professional development in-services and 
onboarding programs which, in turn, can lead to improved job performance and fewer 
compliance violations.   Finally, this study is valuable to the policy makers who create 
the guardrails that regulate these programs.  While the primary intent of the regulatory 
requirements is patient safety, this study will show that, in some instances, their 
ecological influence may undermine the educational integrity of clinical educator 
programs.  This study will aid in the development or refinement of regulatory policies 
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that account for their ecological influence while still maintaining requisite safety 
standards.  In order to address these needs and fulfill these goals, the following research 
questions guided this study: 
• RQ 1. What role do ecological factors, such as regulatory requirements, play in 
pharmaceutical-sponsored clinical educators’ communication with patient? 
• RQ2:  How do those ecological factors influence the way pharmaceutical-
sponsored clinical educators establish and manage communication privacy 
boundaries with patients? 
The next chapter will describe the methods that were used to explore these questions. 
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Chapter 3: Methods 
 A qualitative approach was selected as the methodology for examining the 
research questions.  Qualitative methodologies for understanding the patient education 
experience have grown in acceptance by health intervention researchers and are finding 
their way into publications that have traditionally only printed quantitative studies 
(Finset, 2008).  The rationale for such growth is that qualitative studies in this area are 
best suited for interpreting the how, why, and what in regard to patient coaching and 
counseling (Tracy, 2013; Whaley, 2014). Hence, the most appropriate way to address the 
proposed research questions was through a qualitative approach that provides the 
educators opportunity to elucidate on their experiences and interpret the meaning they 
bring to their work.  
 In this chapter, I will describe the methods I used to conduct this study.  I will 
first describe the recruitment site and provide an explanation of the profession of 
pharmaceutical-sponsored clinical educator and the duties and expectations of that role.  
Next, I will explain the sampling methodology used to include defining the inclusion and 
exclusion criteria as well as describing the sampling rationale and sample size.  The 
participant recruitment and selection process will be reviewed and followed by a 
summary profile of the participant group.  Then, I will describe the data collection 
process to include an overview of the data sources.  Following that description, I will 
review how the data was analyzed and interpreted.  Lastly, I will explain my role in the 
process and the relationship I had to the phenomenon of study. 
 39 
Recruitment Site 
The participants for this study are pharmaceutical-sponsored clinical educators 
who provide education and coaching to patients.  “Pharmaceutical-sponsored” means the 
educators work on behalf of a pharmaceutical company, or a patient education services 
company contracted by a pharmaceutical company, to deliver educational information 
and support services regarding the company’s medication and, in some instances, its 
indicated disease state.  For the purposes of this study, all participants delivered 
education for medications that needed to be prescribed by a licensed healthcare provider 
(HCP).  In most instances, these educators engaged with patients only after the decision 
was made by an HCP to prescribe the medication.  Additionally, as required by law, these 
clinical educator services were funded by the companies that manufacture the medication. 
HCPs are not allowed to bill for these services nor do patients or insurance companies 
pay for them.  Depending on the company, educators can be hired as full or part-time 
employees or as independent contractors. 
The participants for this study were recruited with the assistance of VMS 
BioMarketing, an Indianapolis-based company who contracts with pharmaceutical 
companies to deliver patient and healthcare provider education and coaching services 
through nationwide networks of clinical educators.  An individual VMS network is 
funded by a single medication, typically referred to as a “brand,” and consists of a few to 
hundreds of educators depending on the brand’s scope and budget.  All VMS patient 
education networks are for biologic medications that required parenteral administration 
(i.e. routes other than the alimentary canal) to include self-injection with a syringe or 
pen/autoinjector device, subcutaneous self-infusion, ambulatory infusion pumps (such as 
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with insulin), inhalation, or intravenous (IV) infusion or injection in the physician’s 
office or infusion center.    
Different VMS networks function in different ways.  For instance, most networks 
use either contractors or employees, though some have used a combination of both.  
Communication modalities and number of engagements with patients also vary by 
network.  Some networks are structured to be a single face-to-face or group education 
session, often referred to as a “one-and-done,” while others have coupled this initial 
training with follow-up phone calls.  Other networks may be strictly telephonic, or web-
conference based, and may include multiple education or coaching calls that extend over 
numerous weeks or months.  For instance, educators for one VMS network engage with 
patients monthly, either in-person or telephonically, over the course of an entire year.  All 
networks educate the patient on the safety and efficacy of the medication.  These types of 
education sessions are called “branded programs” as the content is guided by the 
regulatory requirements established by the brand and approved by regulating agencies.  
All branded program content consists of the medication’s indication and efficacy 
information, safety and side effects profile, and administration instructions.  Most 
branded programs also include information about support services, such as manufacturer 
co-pay cards and financial assistance programs, syringe disposal programs, and disease-
related advocacy or support groups.  In addition to branded educational sessions, some 
networks also offer disease-state and lifestyle education sessions that are referred to as 
unbranded programs.  These programs tend to be offered as a separate engagement from 
branded programs.  Unbranded program content focuses on the nature of the disease itself 
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as well as disease-related self-management strategies on topics such as diet, physical 
activity, and mental/emotional well-being. 
VMS clinical educators are different than home health nurses.  VMS educators 
are only allowed to educate on a product and/or disease-state and coach toward self-
management skills; they are not allowed to provide medical advice, a term typically 
meant to encompass any clinical recommendation.  Additionally, while some networks 
allowed for patients to self-inject or self-infuse the medication while the educator is 
present, educators are prohibited from administering the medication themselves.  
Educators are only allowed to provide verbal coaching and corrections during the 
injection or infusion process.   
All study participants were clinical educators who were current or former 
employees or contractors for VMS.  Full-time employee educators are salaried and tend 
to deliver a large and consistent volume of programs on behalf of a specific 
pharmaceutical client or brand.  Conversely, contracted “on demand” educators typically 
have fulltime employment elsewhere in the field (e.g. physician office, hospital, 
pharmacy) and provide education services for VMS based on their availability and 
schedule flexibility throughout the week.  These educators are paid on a per program 
basis and represent most of the total number of VMS clinical educators. Contractors 
would include those considered “active”—currently assigned and working for a VMS 
program network—as well as “inactive”—those not currently assigned or working for a 
program network but able and interested in being deployed should a suitable network 
become available.  Some contracted educators simultaneously serve on multiple VMS 
brand networks as well as other clinical educator networks not affiliated with VMS. 
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All participants had a connection to VMS as either an employee or contractor.  
However, most of the interviewed participants also had additional experiences as a 
clinical educator hired directly by a pharmaceutical company or by a VMS competitor.  
These other clinical educator networks tend to be organized and operated in a similar 
manner as a VMS network.  Like VMS, these other networks employ different 
engagement modalities, such as face-to-face, telephonic, or web-conference, may include 
more than one engagement or touchpoint with a patient, and may cover disease-state 
information in addition to product information. Therefore, during interviews and focus 
groups, participants were asked to reflect on the totality of their experiences as a 
pharmaceutical-sponsored clinical educator, including experiences working for 
companies other than VMS. 
Sampling 
Inclusion and exclusion criteria.  Participants were required to have a post-
secondary degree in a clinically relevant field such as medicine, nursing, dietetics, 
pharmacy science, or clinical social work.  Participants needed to have provided 
pharmaceutical-sponsored education services to patients for at least one year, though that 
time did not have to have been strictly in service as a VMS clinical educator.  This was to 
ensure that the educators possessed sufficient experience to adequately address the 
interview questions. As the focus of this study was communication between educators 
and patients, an educator’s patient education experience needed to have been through 
synchronous communication modalities such as face-to-face, telephonic, or two-way web 
conferencing.   Experiences in asynchronous patient education delivery, such as via text 
messaging, email, one-way broadcast, or online course instruction were permitted 
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provided they had also included some form of synchronous delivery.   Educators needed 
to be able to describe how their prior experiences of providing direct patient care in the 
field (e.g. hospital, physician office, clinic) influenced and compared to their role as a 
pharmaceutical educator.  Therefore, they were excluded if they did not have any prior 
clinical field experience.   Lastly, per a request from VMS and approved by the 
university’s Institutional Review Board (IRB), an educator was excluded if he or she was 
involved in a legal dispute or action related to patient or healthcare provider education 
with VMS, a pharmaceutical company, a biotech company, or any company who offered 
similar services as VMS.  Participants were asked to verify they were not involved in any 
such dispute at the start of their interview. 
Sampling method.  The goal of sampling in qualitative research studies is not to 
collect a representative sample, but rather to collect a sample of individuals who provide 
the targeted and pertinent information related to the research question (Grove et al., 2013; 
Morse, 1994; Sandelowski, 1995).  In other words, participants are selected because they 
all have experienced the phenomenon being studied and are therefore considered to be 
information-rich.  For this project, that shared experience is the delivery of patient 
education sponsored by a pharmaceutical company.    
My intent for this study was to examine the research questions beyond the domain 
of a specific communication delivery modality, disease state, or employment type.  This 
included understanding the themes and concepts that are present across the breadth of 
clinical educators and synthesizing those concepts within the constructs of the two 
theoretical frameworks.  Once identified, those concepts can guide future research, such 
as comparative studies or investigations that examine the experiences of more narrowly 
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defined clinical educator groups, to see if they held up in those situations.   Given the 
variation of program delivery modalities, disease states, and employment types, I chose a 
maximum variation sampling strategy.  Tracy (2013) defines this as a form of purposeful 
sampling in which participants represent wide variations of the phenomena under study.  
For instance, educators from varying combinations of delivery modalities, disease states, 
and employment types were recruited.  Some examples included a telephonic fulltime 
chronic autoimmune disease educator, a face-to-face fulltime educator for a terminal 
neurodegenerative condition, and an on-demand (contracted) face-to-face diabetes 
educator. 
Sample size.  Unlike quantitative research in which sample size is related to the 
number of variables measured and determined by a statistical power analysis, the sample 
size for qualitative studies is less easily defined  (Creswell, 2014; Grove et al., 2013).   
The goal for a qualitative study sample is having enough participants to reach saturation 
of information—or when no new information is provided and there is repetition of the 
data (Tracy, 2013).  This number can vary from study to study based on the heterogeneity 
of the participants and the quality of the data provided by them (Grove et al., 2013; 
Tracy, 2013).   The profession of pharmaceutical-sponsored clinical educator consists of 
a homogenous group of individuals.  This was also true of the pool of educators from 
which participants for this study were recruited.  The reason for this homogeneity is that 
pharmaceutical companies tend to prefer to hire nurses with specialized certifications or 
credentials and multiple years of experience in the therapeutic area for which they will be 
providing services.  In general, most clinical educators are registered nurses (RNs) who 
have advanced degrees and/or professional certifications.  Most are middle-class white 
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females in the mid-to-late stage of their career with at least 10 years of experience in the 
field, and who have primarily worked within the United States.  There is heterogeneity, 
however, in geography and the types of populations they have educated, as well as 
diversity in disease states and program brands for which they served.  Still, many of the 
drugs these educators represent are targeted to a demographic that includes primarily 
older patients with common chronic conditions who all face similar barriers and concerns 
regarding their disease and medications.  Therefore, based on the recommendation 
provided by qualitative methods scholars and the relative homogeneity of the clinical 
educator population, the sample size goal established prior to starting was 25-30 
participants. 
Participant Recruitment and Selection Methods 
I submitted this study’s proposal to the Indiana University (IU) IRB as an exempt 
review application in November of 2018.  Once it was approved a month later, I began 
recruitment.  I was provided an electronic spreadsheet by VMS that listed the names and 
contact information of all their current and past clinical educators (employee and 
contracted) segmented by brand network.  The networks with the largest number of 
names were for brands that treated diabetes.  In fact, more than two-thirds of all VMS 
educators had provided education for a diabetes medication.  Many educators’ names 
were on multiple lists because they had served on multiple networks.  Therefore, I 
removed duplicates from the list in a systematic manner.  If an educator had served on 
both a diabetes brand network and a non-diabetes brand network, their name was 
removed from the diabetes brand network list/s.  If an educator’s name was on two or 
more non-diabetes brand lists, I kept it on the first brand list in which it appeared and 
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removed it from all subsequent lists.  Similarly, if an educator name was on multiple 
diabetes brand network lists, it was kept on the first list in which it appeared.  This 
cleaning left two sets of lists, a diabetes brand network set that included 773 unique 
names and a non-diabetes brand network set that included 354 unique names for a total of 
1,127 educators. 
I recruited and interviewed participants in two waves.  The first wave occurred 
from December of 2018 through February of 2019 and was followed by the second wave 
in May and June of 2019.  The first recruitment wave included all the names from the 
non-diabetes brand network set as well as all the male and all the multilingual educators 
from both sets, a total of 412 individuals.  The remaining 715 diabetes-only educators, 
who were female and delivered education only in English, were recruited and interviewed 
during the second wave.  The reason educators were recruited in this fashion was a 
strategic effort to help promote the maximum variation of the sample as noted above.   
Prior to initial recruitment, I set a sampling goal for securing at least 50-75% of 
the total number of participants from the first wave of educators because this group was 
more diverse and supportive of the maximum variation strategy.   I achieved this goal 
with 17 of the 26 interviewed participants coming from the first wave. At that point, I 
conducted preliminary data analysis which, as explained in the data analysis section of 
this chapter, led to the support of early sensitizing concepts and the development of initial 
themes.  Then, I explored those concepts and themes further with the more homogenous 
group of the second wave, as well as during focus groups, to determine if they were 
substantiated or refuted.   
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I recruited participants primarily via email.  An invitation email was sent out at 
the beginning of each wave and included a short explanation of the study’s purpose and 
instructions for next steps for those that were interested in learning more (see Appendix 
A: Recruitment and Participation Communication).  All diabetes-only educators and most 
non-diabetes educators were sent the same initial recruitment email inviting them to 
participate. However, in order to maximize sample variation, I first sent four customized 
versions of that recruitment email to small subsets of the non-diabetes educators’ set.  
These four customized emails included a different email subject heading and a modified 
introductory paragraph that targeted specific clinical educator characteristics.  For 
instance, one email was targeted to the twenty-four fulltime employee educators who 
represented a brand for the only medication used to treat a non-chronic condition.  That 
network provided education and coaching for patients afflicted with a terminal 
neurodegenerative disease.  Additionally, that network was also unique in that it had the 
longest timespan of patient/educator intervention; educators would engage with patients 
monthly over the course of a year, more than twice as long as the next longest network 
intervention.  The email was customized to stress the importance of having the “voice” of 
those unique educator characteristics represented in the study.  That email was successful 
as seven educators responded, of which four were eventually interviewed.   
The second customized email was sent to thirteen current or prior fulltime 
educators of a network that delivered a series of telephonic-only medication and disease-
state education engagements with patients.  In addition to the fact that this was one of the 
few VMS telephonic-only networks that also included multiple engagements with a 
patient over the course of many months, the educators were unique in that they were 
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versed in three very different therapeutic areas.  This network was for a single medication 
indicated to treat five chronic autoimmune conditions in the therapeutic specialties of 
rheumatology, dermatology, and gastroenterology.  This email was tailored to emphasize 
the desire to hear both the voices of telephonic-based educators and those who served a 
diversity of disease types.  Of the seven educators who responded to this initial 
recruitment email, five were interviewed. 
Male clinical educators represented less than four percent of all the educators on 
the full list, therefore a customized version of the initial recruitment email was distributed 
to them.  That email requested their perspective since their gender made them a minority 
in their field.  Lastly, another minority group of educators, who represented less than six 
percent of all VMS educators, received a tailored email.  That group included educators 
who provided pharmaceutical-sponsored education to patients in another language in 
addition to English.  The response rate for these last two specialized emails was not as 
successful as the first two.  Only three male educators responded to the customized email 
with one eventually participating.  However, another male educator had responded to one 
of the earlier specialized emails giving a total of two male participants.  Only one 
individual responded to the multi-lingual educator request, though she did not end up 
participating.  However, a total of three multilingual educators were participants as they 
had replied to other email solicitations.  
After an educator expressed an interest in the study, I responded with two types of 
follow-up communication.  The first was a phone call in which I re-introduced myself, 
thanked the individual for their interest, and clarified my role as a fellow VMS employee 
who was conducting the study as part of my requirement for a PhD in Health 
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Communication at Indiana University Purdue University Indianapolis (IUPUI).  The 
second follow-up communication was an email that contained detailed information about 
the study along with three attachments (see Appendix A: Recruitment and Participation 
Communication).  One of the three attachments was an IRB-approved Study Information 
Sheet (SIS). It explained the study’s purpose, participation criteria, risks, benefits, 
confidentiality expectations, and protection measures (See Appendix B: Study 
Information Sheet).  The second attachment was a Letter of Support from VMS 
BioMarketing that outlined the company’s awareness of, and support for, the study (See 
Appendix C: VMS Letter of Support). 
The third attachment was a Participant Information Form (PIF).  The purpose of 
this form was to capture general demographic and professional experience information 
from prospective participants that would assist me in meeting the maximum variation 
sampling goal.  I used this form as the primary tool for determining whether a respondent 
was eventually invited to participate.  Respondents whose characteristics were identical 
or similar to those already selected for interviews were declined.  The form was 
published in an editable PDF format that allowed respondents to type information into 
blank text fields and select clickable check boxes from listed options (See Appendix D: 
Participant Information Form).  
 The final tactic I used to help maximize participant variation was snowball 
sampling.  At the end of each one-on-one interview, I asked willing participants to 
actively encourage their peers to participate in the study.  Specifically, I requested that 
participants reach out and provide my contact information to other educators who they 
felt would have differing thoughts, attitudes, or perspectives regarding the discussed 
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topics.  This strategy was not successful as only one participant disclosed during her 
interview that a previously interviewed educator reached out and encouraged her to 
participate.  That same educator had also received a recruitment emails, so she was 
already familiar with the study. 
Participant selection. A total of 142 educators responded to the initial 
recruitment email invitation and requested additional information about the study. I 
documented their names, email addresses, phone numbers, brands, and time zones on a 
participant tracking spreadsheet upon receipt.  Of the 142 educators who replied to that 
invitation and were sent the follow-up communication, thirty-six returned a completed 
PIF and indicated a continued interest in participating.  The remainder either declined to 
participate or never responded to the follow-up and reminder communications.   The PIF 
for each of the thirty-six positive responses was vetted against the inclusion/exclusion 
criteria.  PIFs were then compared against each other as a means for maximizing 
variation in the characteristics of disease state, medication administration type, program 
delivery modality, and employment status.  Any educator who desired to participate and 
was representative of any of the special characteristics noted in the four customized 
recruitment categories was accepted for interview.  This included sixteen of the twenty-
six participants, of which, fifteen were selected from the first recruitment wave.  I 
selected the remaining ten participants based on their diversity of demographic factors 
such as region of the country, age-range, and number of years delivering programs. 
Participants  
As noted, I achieved maximum variation of the participant group through the use 
of the PIF that captured both demographic and professional experience information.  The 
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following is a summary profile of the participant group derived from the Participant 
Characteristics Table, an amalgamation of all PIFs, located in the Appendices.  
The group was geographically dispersed with nine from the Midwest, eight from 
the South, six from the West, and three from the Northeast.  Participants were in diverse 
stages of their career with half in a mid-to-late stage (46-60 age range), five in early-to-
mid stage (30-45), and eight in late stage (>60).  Educators were nearly evenly divided 
among those who were VMS employees (thirteen), and those who were contractors 
(fourteen).   One participant had served in both capacities.  All but three of the educators 
were Registered Nurses (RNs).  Two were Registered Dietitians (RDs) and one indicated 
her primary credential as Master’s in Health Education.  Eleven educators indicated 
multiple credentials or added a credential, the most common of which was Certified 
Diabetes Educator (CDE).  Twelve educators had been delivering pharmaceutical-
sponsored education between three to five years while six had been delivering between 
six to ten years and eight for more than ten years.  All but two educators had experience 
in delivering face-to-face education either to an individual or a group.  Nineteen 
educators also had experience providing some type of telephonic education while nine 
had used web conferencing and eight had used texting/instant messaging.  All educators 
had experience providing education for products that were administered via self-
injection, although three had not instructed on a self-injection syringe, while another 
three had not instructed on a self-injection pen/autoinjector.  Ten had delivered education 
for oral medications while nine delivered instruction for self-infused products and twelve 
taught on products administered in the physician office/infusion center.  Diabetes and 
common chronic autoimmune conditions were the most represented disease types with 
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fifteen and thirteen educators providing those disease services respectively.  Eleven 
educators trained patients with osteoporosis while six had experience working with those 
afflicted by neurodegenerative conditions.  Four educators were experienced in patient 
education for hyperlipidemia and five for rare/other diseases.  Only one educator 
provided education services for patients with psychiatric conditions (See Table 1: 
Participant Characteristics by Pseudonym).  
When grouped by recruitment and interview waves, educators from the first wave 
were a heterogenous group as represented by their demographic characteristics and the 
type of education programs they provided.   For instance, educators from the non-
diabetes set represented medications for over thirteen different disease types.   In fact, 
one of the networks in that first wave was for a medication used to treat a terminal 
condition, the only non-chronic disease represented.  Additionally, educators in the non-
diabetes set included a mix of both VMS employees and contractors as well as educators 
who served on networks in which all engagements occurred telephonically or via web-
conference.  Conversely, the second wave of educators was a homogenous group.  In 
addition to only educating patients who had Type 1 or Type 2 diabetes, these educators 
were all contractors, all female, and delivered programs only in English.  Additionally, 
while some diabetes networks did include short check-in follow-up phone calls, for the 
most part, the second set of educators delivered the bulk of their interventions via face-to-
face engagements. 
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Table 1: Participant Characteristics by Pseudonym  
 Location*  Age Range  Employment Type** 
 NE SO MW WE  30-45 46-60 >60  CE FE AC IC 
Antonia   x     x  x    
Bonnie    x  x    x    
Cora   x    x   x    
Deandra   x    x      x 
Evelyn x      x   x    
Felicia  x     x     x  
Gabi    x    x    x  
Hanna  x     x     x  
Iris x       x  x    
Janelle   x   x    x    
Karl    x  x    x    
Lois   x    x   x    
Martin   x     x      x 
Nadine   x   x    x    
Olivia   x    x   x    
Penny  x    x    x    
Quinn    x    x     x  
Reba    x    x   x  x 
Sophie   x    x      x 
Tabitha    x    x     x 
Ursula  x      x     x 
Vivian  x     x      x 
Whitney x      x      x 
Xoe    x    x    x  
Yvonne  x      x   x   
Zara  x     x      x 
TOTAL 3 8 9 6  5 13 8  11 2 5 9 
* Educator’s state aligned to one of the four U.S. Census Bureau Regions (2010) of NE: Northeast, SO: South, MW: Midwest, or WE: West 
** CE: current employee, FE: former employee, AC: active contractor, IC: inactive contractor 
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* RN: Registered Nurse, RD: Registered Dietitian, NP: Nurse Practitioner, OT: other 
**1:1: one-on-one face-to-face, GRP: group face-to-face, TEL: telephonic, WEB: web-conferencing, TEX: texting/instant messaging 
Table 1:  Participant Characteristics by Pseudonym (continued) 
 Credentials*  Years Educating  Patient Engagement Modality** 
 RN RD NP OT  3-5 6-10 >10  1:1  GRP TEL WEB TEX 
Antonia x     x    x x x x  
Bonnie x x  x   x   x x x   
Cora x  x x   x   x x x x x 
Deandra x      x   x x  x  
Evelyn x      x   x x x   
Felicia x     x    x x   x 
Gabi x     x    x x x  x 
Hanna    x  x    x x x x  
Iris x   x    x  x x x x x 
Janelle x     x    x x x x  
Karl x     x    x  x   
Lois x     x      x   
Martin  x  x x    x  x x x  x 
Nadine x     x      x   
Olivia x       x  x x x x  
Penny x     x    x x x x  
Quinn  x      x   x x x  x 
Reba x     x    x x    
Sophie x   x  x    x x    
Tabitha x   x    x  x x   x 
Ursula x   x    x  x x x   
Vivian x   x    x  x x    
Whitney x       x  x x    
Xoe x       x  x x x x x 
Yvonne    x   x   x x x   
Zara  x  x  x    x x x   
TOTAL 23 2 2 11  12 6 8  24 23 19 9 8 
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Table 1:  Participant Characteristics by Pseudonym (continued) 
 Medication Administration Route*  Disease Type Experience** 
 ORA S-IS  S-IP S-IN HCP  DIA CAI OST NEU PSY HYP R/OD 
Antonia x x x x x     x    
Bonnie x x x x x  x x x     
Cora x x x x   x x x    x 
Deandra  x x x x   x     x 
Evelyn  x x  x     x  x  
Felicia   x  x    x     
Gabi  x x  x   x x    x 
Hanna x x x    x  x     
Iris  x x     x x x    
Janelle  x  x x   x     x 
Karl  x x     x      
Lois  x      x      
Martin  x x x x x  x       
Nadine  x x  x   x      
Olivia  x x  x   x  x    
Penny   x x x  x x  x x x  
Quinn   x x    x x x    x 
Reba x x x    x       
Sophie  x x  x  x       
Tabitha x x x x   x  x     
Ursula x x x    x x x     
Vivian  x x    x  x     
Whitney   x    x  x     
Xoe x x x x   x   x  x  
Yvonne x x x    x       
Zara  x x    x     x  
TOTAL 10 23 23 9 12  15 13 11 6 1 4 5 
* ORA: oral, S-IS: self-injected syringe, S-IP: self-injected pen/autoinjector, S-IN: self-infused, HCP: healthcare provider administered 
** DIA: diabetes, CAI: chronic autoimmune, OST: osteoporosis, NEU: neurodegenerative, PSY: psychiatric, HYP: hyperlipidemia, R/OD: rare/other diseases 
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Data Collection 
 I collected data for this study from four sources.  The main data source was single 
one-on-one interviews with each of the twenty-six participants.  A second source was 
three follow-up focus group interviews with sixteen of the twenty-six interviewed 
participants.  Interviews and focus groups were conducted telephonically since this study 
was unfunded and participants were geographically dispersed.  While the previously 
described PIF functioned primarily as a recruitment and sampling resource, it also served 
as a data source.  The information from the PIFs was used to customize questions during 
educator interviews.  Additionally, PIF data was included as part of the data analysis and 
findings related to the first research question.   The final data source was the field notes I 
documented throughout the data collection process.  I began collecting data in December 
of 2018 and continued through August of 2019.  The following section describes the 
interviews, focus groups, and field notes. 
Interviews.  I conducted a single one-on-one telephonic interview with each 
participant during the two previously described waves.  The first wave of interviews, 
which included seventeen participants, occurred in January and February of 2019.  The 
remaining nine participants were interviewed as part of the second wave in May and June 
of that same year.  The length of the interviews ran from 45-75 minutes with most lasting 
approximately one hour.  Each interview was scheduled for a mutually-agreed-upon date 
and time.  Scheduling correspondences were done via email and phone.  In order to avoid 
interfering with our regular workday duties, I suggested, and made available, interview 
timeslots outside the typical workweek hours to include evenings, weekends, and lunch 
hour breaks.  Most interviews took place during one of those timeslots, though I had 
 57 
flexibility with my own schedule to accommodate interviews from different time zones 
during workday hours.  I documented and tracked all interview dates and times using the 
electronic participant tracking spreadsheet. 
I recorded all interviews with two recording devices.  The primary device was a 
recording app called TapeACallPro that was on my mobile phone.   This app recorded 
and stored a call as an audio file to my personal passcode-protected Google Drive 
account. Each audio file was then immediately deleted from the Drive account once it 
was downloaded and stored to my local and backup drives.  I also used a handheld digital 
voice recorder as a backup recording device by engaging the phone’s speaker function 
during each interview.  To protect participant confidentiality, I conducted interviews at 
my home office or in a private room at my company’s office.  I then removed the 
irrelevant portions of the conversation from the front end and back end of each audio file 
before uploading them to my Rev.com transcription service account.  Once transcribed, 
each transcription was corrected for accuracy and had identifiable information removed.  
The cleaned file was downloaded and a copy imported into the qualitative data analysis 
software called Quirkos (2019).  Each step of this transcription process was documented 
in the participant tracking spreadsheet. 
For the interviews, I used two versions of a semi-structured interview guide, one 
for each wave (see Appendix E: Interview Guides).   The first guide consisted of 
approximately twenty questions that solicited the bulk of data for each interview.   Some 
questions included additional and optional prompts that were designed to probe for more 
information, when needed.  I made three minor revisions of the first guide early in the 
interviewing process to adjust for learned insights.  These revisions included such things 
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as rewording questions, changing the order of certain questions, and adding questions 
related to topics not accounted for during the guide’s initial development.  While the 
guide served as a general roadmap, I conducted all interviews using a participant-
centered approach that allowed questions to be tailored based on educators’ responses.  
The semi-structured interview guide used during the second wave was similar in format 
and scope as the first guide.  Many of the same questions were included in the second 
version, though they may have been modified or reworded to account for learnings from 
the first wave.  The main difference in the second version was the inclusion of additional 
questions written specifically to address sensitizing concepts and ideas that were 
emerging from the preliminary data analysis that occurred between the two interview 
waves. 
Focus groups.  I conducted focus groups with educators as a form of member 
checking—a process by which emerging themes and ideas were validated or refuted by 
those who participated in the interviews (Creswell, 2014).  These focus groups occurred 
in August of 2019 after the completion of all one-on-one interviews and following a 
portion of the data analysis process that led to the development of preliminary themes.  I 
invited educators via email to attend one of three telephonic focus groups sessions (See 
Appendix A: Recruitment and Participation Communication). Each email invitation was 
sent individually as it informed the educator of their pseudonym, which they were 
requested to use during the focus group discussion.  A copy of the Study Information 
Sheet (SIS) was attached to the email to remind participants of the purpose, benefits, and 
risks of the study.   
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Sixteen of the twenty-six educators participated in a focus group; seven in the first 
group, four in the second group, and five in the third group.  I placed educators in a 
specific focus group based on their availability and to create as equal-sized groups as 
possible.   Educators who did not respond to the initial focus group email invitation were 
sent a reminder email a week later. Reasons for non-participation included unavailability 
for any of the three dates, lack of response to the focus group invitations, and no-
show/forgetting to attend.  All focus group correspondences, responses, and educator 
availability dates were documented in the participant tracking spreadsheet.  Each of the 
three focus groups were scheduled to last one hour. 
A few days prior to their focus group, participants were emailed a telephonic dial-
in number. I used VMS’ audio bridging service called Zoom to connect all participants in 
a multipoint call format.  All participants could speak freely at any point of time during 
the focus group and each participant could hear one another.   Along with the dial-in 
number, I also included in the email a focus group discussion guide (see Appendix F: 
Focus Group Discussion Guide).  This was done in advance to give the educators time to 
review the guide’s content and to prepare themselves for the discussion.  Educators were 
encouraged to have the guide accessible during the meeting.  The content of the guide 
included an abstract of the study, the two research questions, a brief review of the one-
on-one interview process, a summary of participants and their characteristics, a brief 
explanation of the two guiding theories, and a list of seven preliminary themes that were 
emerging from the interview data.  Each theme included two to four bulleted sub-themes 
listed below it.  I also included discussion questions for four of the themes that were of 
greatest interest at that point in the data analysis process.  
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I provided explanations of the two study theories, the ecological model of 
communication in the medical encounter and communication privacy management 
(CPM) theory, in the discussion guide for two reasons.  First, the explanations helped 
provide background for some of the preliminary themes and sub-themes.  Secondly, most 
educators were clinicians with advanced degrees and certifications who had training and 
experiences in both the theoretical and practical tenets of patient-provider 
communication.  Therefore, asking educators to reflect on the themes, in the context of 
those theories, and engage in relevant conversation, was not beyond the scope of their 
capabilities. 
During the focus groups, I facilitated the discussion using the themes as 
conversational prompts.  To accommodate the limitation of only having an hour for each 
call, I focused first on themes in which I found a diversity of responses in interview 
transcripts or those that were requiring more in-depth clarification and supporting data.  
These were the themes that included discussion questions printed in the guide.  Themes 
that had little disparity of responses or that were sufficiently supported by existing 
interview data were discussed toward the end of the meeting when time allowed for it.  
All three focus groups were recorded, transcribed, and checked for accuracy and 
confidentiality using the same services, tools, and protocols outlined in the one-on-one 
interviews. 
Field notes.  In addition to the participant tracking spreadsheet, I kept field notes 
throughout the data collection process.  The most extensive notes were those that 
followed each one-on-one interview.  Shortly after the completion of an interview, I 
documented my personal reflections of the event to include such components as 
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summations and highlights of what was discussed, insights related to the interview 
process and educator responses, a self-assessment of my interviewing acumen and 
suggestions for improvement, potential changes to the interview guide, topics or concepts 
for further defining or additional exploration, and emotions that were prevalent during the 
discussion.  I then reviewed each interview’s notes immediately prior to the initial coding 
of the interview transcript and then later throughout the data analysis process.  In addition 
to the interview field notes, I also documented ideas and reflections during the early 
stages of the data analysis process prior to the second wave of interviews. These notes 
outlined emerging concepts and ideas with sample quotes to support them, discrepancies 
in the data, and ideas for how to explore new topics in the second wave of interviews. 
The next section explains the constant comparative approach that was employed 
for data analysis.  This is a methodology in which analysis occurs in iterative stages with 
frequent revisits to guiding theories (Glaser & Strauss, 2009). 
Data Analysis 
 Data analysis was an iterative process that started while data were being collected 
in early 2019 and continued through the fall of that same year.  For the purposes of this 
study, Tracy’s (2013) conception of “iterative analysis” best represents the methods by 
which I examined and made sense of the data. Tracy explains this term as the way in 
which analysis continuously alternates between emergent readings of the data and active 
reflections of existing models and theories.  The constant revisiting of theories while 
immersed in the data enabled me to progressively refine emerging themes while 
expanding the knowledge gleaned from them (Tracy, 2013).   For instance, though 
structured first-level coding of data for this study did not begin until completion of the 
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first wave of seventeen interviews, I engaged in unstructured iterative analysis as early as 
completion of the first few interviews.  As described previously, I adjusted the interview 
guide during the first wave based on insights gained shortly after completing a handful of 
interviews.  The purpose of those adjustments was to promote a more focused exploration 
of the theoretical tenets and relevant “lenses”—or what Tracy referred to as sensitizing 
concepts—that were guiding the study. 
Sensitizing concepts.  Qualitative scholars have described sensitizing concepts as 
interpretive devices that serve as starting points or lenses for guiding inquiry (Charmaz, 
2014; Tracy, 2013).  Charmaz (2014) goes on to explain how a qualitative researcher will 
frequently begin with existing empirical interests and a loose framework for how they 
will look at them.  Those interests initiate the sensitizing concepts that serve as points of 
departure for forming interview questions, listening to interviews, and analyzing data.  In 
the context of this study, one example of a sensitizing concept was the construct of dual 
loyalties, the notion that clinical educators felt a sense of obligation to both the patients 
they educated and the pharmaceutical company that sponsored them.  As is often the case 
in a client-employee-employer relationship, the needs the employee is expected to fulfill 
for the betterment of the client may conflict with the needs the employee is expected to 
fulfill for the betterment of the employer.  As I approached this study, I believed that this 
notion served as the crux for how and why regulatory drivers such as on-label 
compliance, fair-balance presentation, and adverse event reporting created tension in the 
interpersonal communication that occurs between the educator and the patient.  Educators 
must constantly make communication decisions that weigh the value of the outcome of 
the patient against the value of the outcome for the pharmaceutical company.  During 
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data collection, my role was to ask the type of questions and listen for the types of 
answers that explored the inherent tension at the heart of that sensitizing concept.  Then, 
during the early stages of the iterative analysis process, I identified parts of the data that 
supported or rejected the sensitizing concepts in the context of the two guiding theories.  
When necessary, questions for second-wave interviews were adjusted to account for data 
discrepancies regarding the concepts.  Finally, during late stage iterative analysis, those 
concepts were either accepted or modified to fit within the primary assertions of the 
theoretical model or were rejected outright.    
The next section describes the beginning stages of this iterative data analysis, a 
process called first-level coding (Tracy, 2013).  It is during this phase that descriptive 
terms, or codes, were applied to interview transcripts.  These codes were then mapped to 
new concepts or to those sensitizing concepts that have been previously derived from the 
two theoretical frameworks. 
First-level coding.  First-level coding, or descriptive coding, was the first form of 
structured qualitative analysis that I conducted.  This is a type of coding in which 
descriptive words or phrases are assigned to recurring ideas or concepts identified in the 
transcript data (Tracy, 2013).  First-level coding began in April of 2019 after all 
seventeen first-wave interviews were transcribed and checked for accuracy.  I created an 
electronic codebook in a spreadsheet to document first-level codes to include each code’s 
abbreviated short-form name, the full long-form name, and a definition.  The spreadsheet 
also included a column that cross-referenced each code to similar or related codes (See 
Appendix G: Codebook).   Definitions and cross-referenced codes were useful because 
they allowed me greater efficiency when coding sections of transcripts.  
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Initially, I coded transcripts manually in the order in which the interviews 
occurred.  I read a printed version of the transcript and wrote in the margin a term or 
phrase that captured the essence of a sentence, phrase, or short passage.  That short-form 
version of the term was then documented on a notepad.  I continued this process by 
adding or editing codes for each new concept as it appeared.  Upon completion, I entered 
the handwritten list of codes into the spreadsheet where it was alphabetized, translated to 
long-form terms, defined, and cross-referenced to related codes.  The first interview 
transcript generated approximately sixty first-level codes.  This procedure was duplicated 
with the second transcript during which the codebook was used to refer to existing codes 
while new codes were handwritten on the notepad.  I then added the new codes into the 
codebook spreadsheet, defined them, and cross-referenced them.  This process continued 
until new codes were exhausted by the fifth interview.  At that point, I had generated a 
total of 169 first-level codes.  I continued coding six more interviews with first-level 
codes.  By the eleventh interview, I understood the patterns that were emerging and 
recognized how frequently coded terms were starting to group together in the framework 
of sensitizing concepts related to the guiding theories.  At this point, second-level coding 
could begin. 
Second-level coding.  This level of coding is the organization, synthesis, and 
categorization of first-level codes into interpretive concepts (Tracy, 2013).  Many of the 
second-level codes were representative of, or akin to, sensitizing concepts that were 
derived from the two theoretical frameworks prior to beginning or that emerged during 
data analysis.  For the purpose of this study, I grouped all second-level codes within a 
parent group category.  These groupings were organized by primary constructs of the 
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guiding theories or as sensitizing concepts that shared a common theme (See Appendix 
G: Codebook).  Most of the parent group categories served as a precursor to a preliminary 
theme developed during the latter stages of data analysis.  An example of a parent group 
that was organized by the sensitizing concepts from a guiding theory was the one titled 
“CPM Confidant Roles to Patients.”  It was inclusive of secondary-level codes that 
represented three types of confidant roles noted in the communication privacy 
management theory (Petronio, 2002).  Those codes were “RolePTDelib” (deliberate), 
“RolePTReluct” (reluctant), and “RolePTStake” (stakeholder).  Each was coded to 
transcription data that exemplified a clinical educator’s interpretation of a patient relating 
to, or interacting with, them as a deliberate, reluctant, or stakeholder confidant.  An 
example of a parent group organized by sensitizing concepts that shared a common theme 
was the group titled “Dual Loyalty.”  It was inclusive of second-level codes that 
represented a type of dual loyalty dilemma experienced by educators.  This group 
consisted of the secondary level codes “DLPtVPharm” (dual loyalty—patient vs. 
pharma), “DLPtVHcp” (dual loyalty—patient vs. healthcare provider), and “DLPtVFam” 
(dual loyalty—patient vs. family).  Each was coded to transcription data that exemplified 
a clinical educator’s interpretation of a sense of conflicting loyalty between their patient 
and an “other” (i.e. pharmaceutical company, HCP, or family member).   
I began the next phase of data analysis by creating a list of second-level codes on 
a notepad while referencing the list of first-level codes.  Some first-level codes migrated 
to second-level codes as supporting data revealed them to be representative of larger 
interpretive concepts.  I entered all second-level codes in a separate tab in the codebook 
spreadsheet, assigned a short-form name, and defined.  Codes were organized and 
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assigned to parent groups which were also defined.  I approached the coding process for 
this level in a similar fashion to first-level coding, starting with Interview A, and using 
printed transcripts while handwriting codes in the margins.  Because some first-level 
descriptive codes were indicative of the larger second-level interpretive concepts, I 
frequently referred to the first-level coded transcripts to assist in assessing transcript data 
and assigning second-level codes.  Additionally, I also frequently referred to code 
definitions to ensure consistency.  As the first few transcripts were reviewed, I made edits 
and additions to the second-level codebook to account for concepts not identified in the 
initial version.  By the third interview, all second-level codes were solidified to include 
fifty-nine unique codes organized within fourteen parent groups. 
I performed second-level coding with eight of the seventeen first-wave interviews 
by hand.  At that point, I felt comfortable with the process and migrated to coding using 
the Quirkos (2019) qualitative data analysis software.  Once I imported each electronic 
transcript (Interviews A through Q) into the software, I dragged and dropped selected 
portions of text data into the hierarchical code fields.  I created parent group and second-
level code fields within the software that mimicked those developed in the codebook 
spreadsheet.  The eight hand-coded transcripts were migrated first and recoded into the 
electronic fields using the handwritten margin codes as a guide.  The remaining nine 
transcripts were coded directly in the software. 
The second wave of nine interviews (Interviews R through Z) took place at the 
same time as the electronic coding of first-wave transcripts.  Those interviews used the 
revised interview guide that included new questions related to second-level interpretive 
concepts such as the various types of dual loyalty ethical dilemmas.  Once those 
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interviews were completed, they were electronically coded using the same second-level 
code fields as the first wave.  Lastly, focus group transcripts were electronically coded 
shortly after those events occurred using the same process as the interview transcripts. 
Throughout the second-level coding process, I copied sentences and passages of 
transcript data that stood out as exemplary representations of second-level interpretive 
concepts to a separate tab in the codebook spreadsheet.  Such passages were referenced 
as quotes during the construction of the Findings and Discussion chapters.   
The qualitative software contained other functions that allowed me to manipulate 
and manage the transcript data in ways that assisted in the latter steps of analysis.  For 
instance, I was able to click on each individual code field to view all the text segments 
across transcripts that were assigned to that code.  This was a useful tool for selecting the 
most relevant or salient examples for inclusion in the Findings and Discussion chapters.  
This function also helped me organize the structure and layout of the core components of 
each theme as it was developed.  That process, called thematic development, was the last 
step in data analysis. 
Thematic development.  The a priori sensitizing concepts, along with the field 
notes and new interpretative concepts that were revealed as part of the second-level 
coding of data, began to evolve into themes that guided the explanation of the Findings 
and subsequent Discussion chapters.  I began documenting preliminary themes following 
second-level coding of interview transcripts and prior to the focus group meetings.  Those 
themes were included in the focus group discussion guide sent to educators and served as 
catalysts for discussion.  Each theme contained component sub-themes that further 
defined and explained the main assertion of the parent theme.  One example was a 
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preliminary theme related to the ecological model of communication (Street, 2003) that 
emerged from the data but was not an a priori sensitizing concept.  That theme was 
defined in the discussion guide as, “A context, not previously identified in the ecological 
model literature, emerged from the interviews as having significant influence in the 
conversation dynamics between the educator and patient.  This is the disease context.”  
One of the sub-themes for that theme stated, “The types of factors educators identified 
that could fit within a disease context include chronic or terminal prognosis, disease side 
effects, treatment side effects, pregnancy status, drug administration modality, prevalence 
of disability or comorbidity, and where the patient was on their disease journey.” This 
theme was affirmed during the focus group discussion and continued to be supported by 
on-going data synthesis.  Therefore, I included a revised version of it as part of the 
Chapter 4 Findings.  However, I also added, deleted, or refined other sub-themes, or 
components of sub-themes, to align with a deeper analysis of the data and guiding theory.  
For instance, I determined the segment of the sub-theme that states “…and where the 
patient was on their disease journey” was not a component of the newly identified disease 
context.  Rather, upon reflection, the concept of a “disease journey” had already been 
accounted for in the literature as part of Street’s ecological model.  
Other preliminary themes noted in the discussion guide went through a similar 
process of constant comparative analysis to the data collected in later stages of the study 
with reflection back to the guiding theoretical frameworks.  Most of the preliminary 
themes were affirmed and carried through, albeit with similar revision and refinement, to 
the Findings chapters.  A few themes were rejected outright or underwent significant 
change, not because the preliminary versions were erroneous in their assertions, but 
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rather they were not in full alignment with the current research questions.  Those themes 
could serve as starting points for research questions of future studies that utilize this data 
or other sets of data related to the pharmaceutical-sponsored clinical educator experience. 
The final section of this chapter examines the unique relationship of my role as a 
researcher to the phenomenon of study.  Further, it describes how that affiliation 
influenced my interpretation of the Findings. 
Researcher Role 
My role in this study was that of the “participant observer.”  In that regard, my 
experiences, reflections, and interpretations influenced the data collection and analysis 
process due to my immersion with the participants and the data collected from them 
(Grove et al., 2013).  Additionally, my relationship to the study topic and to study 
participants was different than most research projects in that I worked with the 
participants being researched.  Hence, I could bring a unique perspective to the studied 
phenomenon.  Some of those insights were brought forth in the Discussion chapter.  
Tracy (2013) explained how the participant observer role is analogous to Victor Turner’s 
concept of liminality—the notion that “people are neither here nor there; they are betwixt 
and between the positions assigned and arrayed by law, custom, convention, and 
ceremony” (p.76).  In other words, a participant observer must be close enough to the 
studied population to understand them, yet simultaneously far enough away to maintain 
an outsider perspective.  My role and experiences at VMS had afforded me the necessary 
closeness to understand the participants and the phenomenon of interest.  However, there 
were also two ways in which I was able to mitigate influence of my VMS role during 
data collection and analysis.   
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Though I was studying clinical educators, I had never served in that role.  
Therefore, I was an outsider to the group having never had a shared experience.  
Additionally, except for a small number of direct observations previously completed as 
part of an internal auditing process, my understanding of the pharmaceutical-sponsored 
clinical educator experience was mostly based on anecdotal data along with some limited 
insights gleaned from the few studies that are in the literature.  The anecdotal data 
included information garnered from my interactions with educators when they 
periodically visited the corporate office or from my daily casual conversations with VMS 
office staff members who worked closely with the educators and managed their networks.  
While my role as a clinical educator trainer did frequently allow interaction with the 
educators, most of those engagements typically occurred as part of their new-hire 
onboarding, prior to the delivery of programs.   There was no regular on-going contact 
with educators once they were trained and released to the field.   
Secondly, I addressed the potential influence of my role through the data analysis 
methodology.  This included the member checking strategy during which participants 
were asked to review, reflect on, and provide confirmation of findings.  Such a process 
can occur at any stage, but frequently happens during later stages of analysis following 
the emergence of themes and assertions (Charmaz, 2014).   Additionally, as Creswell 
(2014) explains, member checking is a suitable device for helping ensure a study’s 
qualitative validity and reliability—or the degree by which the findings are deemed 
trustworthy, authentic and credible.   
The next two chapters explore the final themes, and their component sub-themes, 
that emerged from the completion of the data analysis.  Each theme is supportive of one 
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of the two research questions.  Chapter 4 Findings examines those themes that align to 
the first research question which focuses on Street’s (2003) ecological model of 
communication in the medical encounter. That question states, “How do ecological 
factors, such as regulatory requirements, function within pharmaceutical-sponsored 
clinical educators’ communication with patients?”  Chapter 5 Findings looks at those 
themes supportive of the second research question.  That question narrows how some of 
those ecological factors act within the context of Petronio’s (2002) communication 
privacy management theory.  That question states, “How do those ecological factors 
influence the way pharmaceutical-sponsored clinical educators establish and manage 
communication privacy boundaries with patients?” 
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  Chapter 4: Findings—Ecological Model of Communication in Medical Encounters 
 The findings for this chapter are examined within the context of Street’s (2003) 
ecological model of communication in medical encounters and address the first research 
question: “What role do ecological factors, such as regulatory requirements, play in 
pharmaceutical-sponsored clinical educators’ communication with patient?”  Street’s 
model posits that ecological factors influence the nature and scope of interpersonal 
patient-provider dialogue in medical encounters. These factors are segmented into four 
socio-political and demographic contexts, as well as one interpersonal context, that 
impact both the patient and the healthcare provider (HCP) and the way their interactions 
unfold.  For instance, the cultural context is comprised of factors such as race, gender, 
ethnicity, religion, geography, education, and socioeconomic status.  The media context 
includes factors such mass media exposure as well as access to and use of the Internet 
and telemedicine.  The organizational context includes the influence of structures such as 
managed care, available medical services, and the standards of care that drive those 
services.  The political/legal context includes factors that are tied to governments’ 
influence such as the Affordable Care Act (ACA), the Health Insurance Portability and 
Accountability Act (HIPAA), and government-funded healthcare programs like Medicare 
and Medicaid.  While these four contexts are representative of the external factors that 
impact communication, Street also explains that there are internal forces of influences 
that comprise the interpersonal context.  This context is divided into cognitive/affective 
influences, which are factors that incorporate an individual’s goals, perceptions, and 
emotions, as well as predispositional influences, which are factors related to 
communication style, individual self-concepts, and access to linguistic resources.  Lastly, 
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Head and Bute (2017) identified an additional context, everyday talk, to account for the 
influence of conversations that occur outside the medical encounter, such as with family 
and friends, that later impacts patient-provider communication.   
 Data from the interviews revealed that factors from all five contexts influenced 
the communication dynamics between the clinical educators and their patients.  However, 
for the purposes of this study, only Street’s fourth context, the political/legal, is applied in 
these findings.  The rationale for focusing on this context is four-fold and includes: (a) 
educators described how the factors from this context influence the way they 
communicated with patients, whereas for the other three contexts, educators tended to 
focus on the reverse dynamic (i.e. the way those factors influenced how patients 
communicated with them), (b) most of the insights educators provided regarding the 
other four contexts reinforced and supported known assertions and findings from prior 
studies related to this model, (c) the regulatory environment in which these factors 
operated made this context particularly relevant, and (d) the richness of the data related to 
this context was the most appropriate for addressing the research question. 
 While only one of Street’s and Head and Bute’s five contexts is explored here, a 
new context emerged in the data.  This context, the disease and treatment context, 
potentially reveals a wealth of insights related to how disease and treatment-related 
ecological factors influenced the communication dynamic between the clinical educators 
and their patients.  The interviews highlighted that a range of communication challenges 
arose from the disease and treatment context, as well as the political/legal context, which 
in turn, created barriers that impeded patient self-management behaviors.  Educators, 
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therefore, provided insights into the many types of verbal and nonverbal strategies they 
employed to help navigate patients through those challenges. 
 This chapter is organized around four themes that represent the major findings as 
related to the ecological model and the first research question.  Those themes are: 
1. Political/legal contexts factors, manifested in pharmaceutical industries’ compliance 
regulations, greatly influenced clinical educators’ communication with patients. 
2. The influence of ecological factors, particularly within the political/legal context, 
would frequently force educators to experience ethical dilemmas. 
3. A sixth context, the disease and treatment context, not previously identified in the 
ecological model literature, emerged from the interviews as having significant influence 
in the conversation dynamics between the educator and patient.   
4. Educators employed communication strategies to better navigate within the 
political/legal and disease and treatment context ecological factors. 
Compliance Regulations in the Political/Legal Context 
Theme 1. Political/legal contexts factors, manifested in pharmaceutical industries’ 
compliance regulations, greatly influenced clinical educators’ communication with 
patients. 
When educators discussed factors related to a political/legal context, specifically 
industry and government mandated compliance regulations, they expressed in broad and 
varied opinions how those factors impacted the way they communicated with patients. 
This theme explores those discussions starting first with educators’ beliefs about the 
necessity of the regulations for protecting their patients’ well-being and mitigating their 
employers’ liability.  Here, educators explained how they understood the intense legal 
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pressure their companies constantly faced; however, they also expressed disappointment 
with how liability seemed to be prioritized above all other things.  Next, the educators’ 
criticisms toward compliance regulations are examined, specifically their views regarding 
the influence of the three regulatory factors of fair-balance presentation, staying on-label, 
and adverse event reporting.  It is here that educators shared their frustration with the 
regulations as factors that would often stifle communication and inhibit patients’ 
comprehension of information.  Lastly, as a result of their frustrations and beliefs that 
some compliance regulations were counterproductive, educators admitted to engaging in 
purposeful non-compliant communication behaviors.  
 Compliance necessity.   When educators spoke about the necessity for 
compliance measures, they would typically frame their beliefs in a pragmatic context, 
such as the regulations offered guidance that prevented errors and provided protection.  
Felicia, a registered nurse (RN) and educator for an osteoporosis medication said, “It’s a 
plan to follow…So you never have a patient that says, ‘[Felicia] said I could do that.’ 
And then the doctor tells the [sales] rep and the rep is like, ‘I can’t believe she did that 
kind of thing.’”  Ursula, an RN and a diabetes and osteoporosis educator, thought the 
regulations were important for those who see themselves as rule-followers, “I think they 
make it easier, because they’re expectations that you’re...This is what you should do. And 
I’m kind of a rule follower, so it was nice to have that very clear definition of this is what 
you do.” A similar sentiment was offered by Evelyn, an RN who had experience 
educating patients with neurodegenerative conditions.  She even went as far as to imagine 
government regulators as part of every program she delivered when she stated, “I’m a 
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rule follower. I just always pretended that the FDA was somebody that I was teaching or 
they were in the room.”   
Hanna, a dietitian and educator for both diabetes and osteoporosis products, 
appreciated how compliance regulations gave her succinctness and little room for error.  
She stated, “Because the expectations are already set. What you can do, what you can say 
is all very concise. There is no gray area to it.”  She also credited her prior experience as 
a pharmaceutical sales representative as creating a compliance-oriented mindset, “Well, I 
think it’s probably easier for somebody who has come out of a pharma sales position to 
understand all of that than it is probably maybe for someone who has not had that 
experience.”  Penny, an RN who also had prior experience as a pharmaceutical sales rep 
echoed the protection-related language while simultaneously highlighting that regulations 
can create limits, “It definitely limits modes and ways of clinical education, but they exist 
for a reason, to protect everyone.” 
Finally, there were some educators who simply understood the regulations to be 
part of their job and a valid expectation of their employer.  Therefore, whether they 
agreed with the regulations was irrelevant. Martin, a nurse practitioner and certified 
diabetes educator (CDE) summarized it this way, “It doesn’t matter what I think should 
be done. I’m there representing the company. They have told me how they want it done. 
And it’s my responsibility to deliver the message like they want it delivered.”  
 Compliance and liability.  Educators recognized that adhering to compliance 
regulations was more than just an expectation of the companies that employed them.  
Most understood the high degree of scrutiny and vigilance the industry faces from 
government agencies.  Tabitha, an RN and CDE who has worked with many diabetes 
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drug manufacturers stated, “The pharma companies are so highly regulated, and the 
government will go after them like vipers if it’s perceived that they’re not toeing the 
line.”  Educators also recognized that non-compliance offenses can lead to costly fines or 
multimillion-dollar court settlements against pharmaceutical companies by state and 
federal governments.  Penny, an RN and former pharmaceutical sales rep who also has 
provided education for multiple disease types, shared, “…because liability wise, one slip 
costs millions and millions of dollars and billions of dollars too.  So that’s why 
[compliance regulations] exist.” 
 While many of the large lawsuits against the industry have focused on the 
behaviors of the companies’ sales representatives and marketing team (Harris, 2009; U.S. 
Department of Justice, 2013), a few educators were aware that federal investigations have 
been launched against the companies because of their patient support programs (PSPs) 
(Loftus, 2018).  These court cases accused educators of functioning as a type of “white 
coat marketing”, an industry term that describes the use of healthcare professionals for 
marketing products to patients.  Deandra, an RN who has trained patients on products for 
autoimmune conditions, stated during her focus group, “There have been some recent 
lawsuits going on with the pharma educators.  Department of Justice is claiming that 
educators are really just doing whitewashed selling or white coat selling. That they’re not 
really educating.”  During her focus group, Tabitha shared her realization that she may 
have unknowingly served as a white coat marketer because her program was in violation 
of parts of the Sunshine Act.  This federal legislation, which is part of the Affordable 
Care Act, seeks to track and control payments and “items of value” provided to HCPs by 
pharmaceutical companies (Richardson, 2014).  In some of their court cases against the 
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companies, the government has interpreted items of value to include clinical educators 
(Loftus, 2018).  As Tabitha explained, “The doctors were thrilled and once they realize 
this was a great deal, they continued to write prescriptions for [pharmaceutical company] 
insulin, which I guess is what put an end to this entire program…this was considered 
some sort of bribery.”  
 For many of the educators, liability concerns directly influence how and what 
they say to the point they warned patients of the regulations’ impact.  Deandra shared, “I 
always say to my patients, not only do we practice medicine, but we practice law.  There 
are certain things you had to be careful in how you respond because legally, you could be 
stepping in some hot water.”  Gabi, an RN with pharmaceutical education experience in 
multiple therapeutic areas, implied that the constant compliance vigilance pushed by 
some companies caused her to feel paranoid.  She said, “There’s one pharmaceutical 
company that seems to be so concerned...very litigiously minded and to the point where 
we feel like I just say the wrong thing and the FDA is going to show up at the door.”  
Antonia, an educator who engages with patients on a monthly basis, reflected on how 
liability concerns limited her ability to document information about her patients, “In this 
job, data entry, most companies are afraid of being sued, so you’re not really allowed to 
enter much. Just that I was there.” 
 Educators lamented that the focus on liability protection had made them question 
the pharmaceutical companies’ commitment to proper and authentic patient education.  
Lois, a telephonic educator for a drug used to treat multiple indications, summarized it 
this way, “I think that they’re so tied down by legal matters and legal...the legalities of 
everything, that I don’t know that [patient education] is that important to them, honestly.”  
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Reba, an RN and diabetes educator, went as far as to question the legitimacy of the 
industry’s liability concerns because they were counterintuitive to the goals and purpose 
of patient education.  She said, “I never truly understood the comments that they made 
about having to meet all these federal regulations for exactly what you’re going to say. 
To me, that’s not education. Education isn’t forcing something down a patient’s throat.”  
A similar sentiment was offered by Iris, who provided education for patients with chronic 
autoimmune diseases, when she stated “…you always have to think around the issue so 
that you can remain an advocate to your patient because a lot of the regulations, they’re 
legal and they’re made by people who really don’t understand patient interaction at all.”    
Educators frequently expressed that the companies’ intense focus on liability 
concerns constrained their ability to properly deliver a program. Antonia explained, “I 
feel like the pharmaceutical company we work for are compliance maniacs. I don’t know, 
I could be wrong about that. But we have so many restrictions regarding compliance it’s 
hard sometimes to do our job.”   Lois, a telephonic educator for a drug used to treat 
autoimmune conditions similarly complained, “You always have to have in the back of 
your mind the rules and restrictions that you need to follow when you’re talking. So, you 
just can’t be as free in your conversation as you would like to be.”  Gabi, an RN and 
former pharmaceutical sales representative, believed that the strict focus on compliance 
by some companies took away from the naturalness or authenticity of the patient-provider 
experience.  She stated, “There’s this one company that’s to the point where you’re afraid 
to say anything. It makes if difficult because you’re so concerned that you might say the 
wrong thing instead of being natural...it impedes our care for the patient.” 
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Reba, an RN and diabetes educator, echoed a similar notion as she compared the 
pharmaceutical role to her previous responsibilities working in the field, “You’re always 
looking at maintaining and following all the rules and regulations. Sometimes you don’t 
say as much or go into as much detail as you would in say my work setting where I didn’t 
have to worry about that.” Sophie, another diabetes educator, also appreciated how her 
field roles provided her more autonomy to adapt educational materials as she felt 
necessary.  She explained, 
So, the differences in the hospital, for me, are much more elaborate on how I 
would explain something to the patient. I’d draw things out for them…whatever 
angle I need to change my words up, maybe to have them understand it. I had a 
lot more flexibility in the hospital and autonomy than doing pharmaceutical 
programs. Like I said, it was really strict…just present what was on the flip chart. 
So, you really couldn’t draw anything different. Everything had to be 
pharmaceutical approved…So I felt it was very, it was stringent, everyone doesn’t 
learn that same way. 
Many of the liability reduction measures that provoked educators’ feelings of 
restrictiveness were outgrowths of the industries’ response to the government-mandated 
regulations created to protect the public.  Three of these regulations drove compliance 
policies and served as factors that were the object of educators’ ire.  The next section 
examines these three political/legal factors and their influences on the educator/patient 
communication dyad.  These factors contributed to most of the criticism educators had 
regarding compliance regulations. 
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Compliance factors that influenced communication.  Educators highlighted 
three government and industry mandated compliance policies that were foundational to 
the way they engaged with patients.  These influencing factors not only drove how they 
spoke with patients, they also dictated much of what they could say as well as how they 
could respond to patients’ questions and concerns.  The factors of fair-balance 
presentation, staying on-label, and adverse event reporting are policies mandated by the 
government and enforced by the industry to help protect the consumers of prescription 
medications.  While educators understood the rationale for such protective measures, and 
even supported their necessity, they also bore the brunt of many of their unintended 
consequences. 
Fair-balance presentation.  Fair-balance presentation is an industry guideline 
that requires an equal balance of product benefits with product risks as part of any 
promotional activity (U.S. Food & Drug Administration, 2015).  Deandra, an RN and 
educator for autoimmune disease products, had a more whimsical interpretation.  When 
asked what the term meant to her, she replied, “You give them the good, the bad, and the 
ugly.”  Yvonne, a diabetes educator, used the same euphemism while clarifying the 
necessity of fair-balance presentation.  She shared, “I’m going to tell them the good, the 
bad, and the ugly…I just want them to make an informed decision, because like I said, I 
go home at the end of the day. [The patients] do too.”  Part of the “ugly” that Yvonne 
referred to would include the requirement to discuss “black box warnings”.  These are 
warning instructions that are enclosed in a black box on the printed prescribing 
information of drugs that pose special problems, such as that those that might lead to 
death or serious injury (U.S. Food & Drug Administration, 2015).  She described it this 
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way, “If it’s got a black box warning, you’ve got to say it and you’ve got to say it the way 
the FDA wants it said. If it scares the patient, I’m sorry. It’s still there. You’ve got to tell 
them.” 
One way pharmaceutical companies help ensure fair-balance presentation in 
clinical educator programs is by using program scripts, instructional guides, and pre-
produced educational materials.   Bonnie, an educator who delivered programs for many 
different products and therapeutic areas, explained their rationale this way, “Again, it’s 
just so critical that we maintain that everyone’s saying the same thing, that it’s what’s 
approved, that it’s accurate information.”   While Bonnie was correct that all materials 
and scripts contained the approved and accurate information to which educators were to 
follow, the complexities of the scripts varied from network to network.  Some networks’ 
program materials and scripts contained near-verbatim language to which educators were 
expected to follow.  Other networks preferred to give the educators more leeway by 
providing talking points instead of exact verbiage, though the expectation was still that 
educators not deviate from the key concepts or “spirit” of the message.  Vivian, an RN 
and diabetes and osteoporosis educator described it this way, “Some of the programs 
were extremely scripted. You could only say what was on the board and on the flip chart. 
You couldn’t elaborate, couldn’t answer a lot of questions. Others were a little more 
liberal and you could elaborate.”  Cora, a nurse practitioner who provided product 
education programs for diabetes and autoimmune conditions had a similar interpretation, 
“It will vary from one company to the next. Some will just give discussion topics and 
then you’re allowed to have more liberty and freedom. And then other companies really 
don’t want to leave anything up to chance.”  
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 Script restrictiveness was viewed as troublesome by educators as it impeded 
proper assessment of the patient. Vivian felt this was especially problematic for those 
patients who were newly diagnosed or who had little understanding of their disease.  She 
lamented, “It makes it difficult to stay on a scripted program when you know the patient 
has never heard a word about diabetes…to find where your patient’s at, if you don’t have 
that wiggle room, to get that assessment part in.”  Interestingly, Bonnie noted that the 
inflexibility of scripted programs could be equally detrimental to well-informed patients 
when she stated, “If a patient has done their own research…they may have their hopes up 
that they’re going to get more information or more personalized information, and then 
they may be disappointed because of those standards and that compliance.”  Penny, an 
educator for patients with neurodegenerative and autoimmune conditions, explained that 
because scripted programs tended to create an unnatural presentation style, they could be 
off-putting to the point patients would stop participating.  She stated, “I think when 
clients or patients are in an overly robotic consultation or discussion, they’re more likely 
to opt out of the services.”  Similarly, the expectation to never deviate from the script 
frustrated educators.  Sylvia admitted it was the reason she stopped delivering programs.  
She shared, “I think that was what ultimately led to me stopping doing the programs, 
because it wasn’t fun anymore…it had gotten to the point that if it wasn’t on the paper, 
you couldn’t open your mouth and say anything about it.” 
Educators who delivered their programs over the phone shared many of the same 
arguments against highly scripted materials, though they also pointed out some concerns 
that were unique to their program delivery modality.  For instance, Cora, a telephonic 
educator who supported medications for multiple diseases, noted that the inability to see 
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her patients exacerbated the weaknesses of scripted programs.  She explained, “It’s a 
little challenging when you’re so scripted and you’re on the telephone. That’s a little 
more challenging too versus when you’re doing webinars where people can see you on 
camera and you can do a little bit more explaining.”  Another expectation that seemed to 
frustrate telephonic educators was some companies’ requirement to read verbatim the 
Important Safety Information (ISI) at the end of the program or even every time the drug 
name is mentioned.  The ISI a summary of a drug’s risks that the Food and Drug 
Administration (FDA) requires to be included within every promotional artifact or 
presentation (O’Donoghue et al., 2014).  Lois explained, “And then part of the script is 
reading the Important Safety Information message that is a requirement if the name of 
drug is mentioned…it was a huge adjustment, coming from where I didn’t even have to 
worry about that.”  Bonnie provided further clarification by noting how the ISI was a 
redundant document that, by reading verbatim, added a lot of unnecessary time to the 
call.  She stated, “Sometimes it’s time consuming or we’re keeping someone on the 
phone who’s already been on the line for a long time so that we can read them another 
five or seven minutes of information that they have access to.”  
Staying on-label. “Prescribing information, prescribing information, prescribing 
information! You cannot talk off of prescribing information!”  Janelle, a telephonic 
educator who provided education for patients with rare autoimmune and blood disorders, 
made this declaration to emphasize the requirement that clinical educators must always 
stay “on-label” when discussing a product.  The prescribing information, which is also 
referred to as the package insert, PI, product label, or simply “label”, is the FDA-
mandated document that gives HCPs the information they need to properly prescribe 
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drugs and biologics (Kremzner & Osborne, 2007).  It must accompany every prescription 
and is found on the product’s website.  Educators are well versed on the importance of 
not providing “off-label” information or personal opinions regarding their products.  
Examples of off-label topics would include an experienced side effect not listed in the PI, 
whether a medication can be taken with certain foods or other drugs not specifically 
noted in the label, or how the efficacy of the prescribed medication compares to another 
similar medication.   As Yvonne, a diabetes educator, explained, “We are not supposed to 
give that product credit for anything that the FDA has not signed off on…It may do 
wonderful things…but if the FDA has not okayed it, doesn’t matter. I cannot speak to it.”  
Zara, another diabetes educator, explained how educators had to be particularly careful 
when talking about the efficacy of the drug to only make claims that are supported by the 
label.  She stated, “Well, I guess you have to be careful what you say as far as what it will 
do. You have to be very careful about not making false claims.”   
  Most educators found the inability to address off-label questions, especially those 
to which they knew the answer, to be demoralizing for themselves as well as the patients.  
Bonnie, a diabetes educator, bemoaned this fact as she reflected on the greater freedom 
she had working in the field.  For example, as an office clinician, she could easily address 
a patient’s request to compare the efficacy and side effects of two different brands of 
insulin.  She would be limited or unable to do this as a pharmaceutical educator unless 
the drug she represented included that information in the label as part of a head-to-head 
comparison done during the clinical trials.  She stated, “A person may have a question 
and we may be able to answer, but we may not be allowed to answer…I feel like I can’t 
help the person as much as if I were working independent of a pharmaceutical company.”  
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For others, the frustration was a result of the way compliance regulations would cast 
doubts in patients’ minds towards the educator’s skills or capabilities.  Evelyn, an 
educator for multiple neurodegenerative conditions stated,  “I perfectly know the answer 
and it’s basic nursing knowledge or basic human knowledge, but you can’t share it, so 
you sort of think, ‘Oh God, I’m really sort of looking stupid,’ but you just can’t say it.”  
Lois, a telephonic educator who has multiple calls with her patients over the 
course of four to six months, described how repeated deferrals to the HCP caused 
frustration for her patients.  She explained, “Sometimes they’ll say, ‘Well, why am I even 
talking to you? I should’ve just called the doctor’s office.’ That type of thing. ‘You said, 
you can’t give me your opinion. I want your opinion!’ So that can be frustrating.”  Evelyn 
articulated a similar refrain, “You’d have to just review over and over that, ‘I am 
permitted to talk about stuff on label and I can’t go off.’  You sound like a broken record, 
but I just was very careful about doing it.”   
Vivian, a diabetes educator, reflected on how patients would come to understand 
why she was not able to address some question, but would still leave the program 
discouraged.  She explained, “They understood the necessity of why I was or wasn’t 
allowed to answer questions, but they missed the learning, teaching moment, because 
they wanted to know now how things would work…I think it was kind of almost 
disheartening for them.”  Later in her interview, Evelyn recalled the experiences of 
patients for whom she provided multiple sclerosis (MS) drug education.  In those 
instances, her deferral to a physician was problematic as patients would get caught in a 
cycle in which their concerns could not be addressed by either their clinical educator or 
their HCP.  She shared, “It was like, ‘Call your physician about it.’ The really sad thing is 
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that most of the MS physicians didn’t know anything about injections. The patients 
would call back and say, ‘They don’t know. They said to call you.’”  
Adverse event reporting. The FDA requires that pharmaceutical companies 
document any reported adverse event (AE) or product complaint (PC) related to their 
medication (U.S. Food & Drug Administration, 2017a).  In addition to product use errors, 
therapeutic failures, and the known side effects included in the product label, adverse 
events also include any untoward medical occurrence suspected to be related to the use of 
the medication (U.S. Food & Drug Administration, 2017c)  As Antonia, an educator for 
neurology medications, simplified it, “And we report absolutely anything. If they tell us 
their nose itched on Tuesday, unfortunately we have to report it. I’m not exaggerating.”  
As agents of the pharmaceutical company, clinical educators are required by law to 
document an AE whenever it is shared with them.   Quinn, a diabetes educator, described 
the process by which she would document an AE, such as a patient presenting with 
headaches while taking a medication.   
Okay, well I’ll sit down and ask them, “Tell me exactly how you’re feeling.  How 
long does this last? Is there anything that you do that decreases the feeling or this 
pain?”  I’m writing everything down and then of course I’m going to call that in. 
And the more description, the more you can describe it, the better off it is to 
pinpoint what’s going on, because that could be another drug, it could be a flu, it 
could be anything.  
While educators are trained on the AE documentation process, and many of them 
admitted it was a common expectation of their role, it was not always an easy or 
straightforward process.  The educators noted multiple challenges about AE reporting 
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that impacted their communication with patients. One difficulty as described by Antonia, 
an educator for patients with a terminal neurodegenerative disease, is that some 
companies encourage the patient to self-assess whether they believe the AE was related 
to the drug.  She stated, “One of the questions you ask is ‘Do you feel like this was 
caused by the drug?’…Sometimes they do, sometimes they don’t…I get the information 
in their words, and we don’t make a judgment…if they report it, I report it.”  A related 
problem, also described by Antonia, is that reporting AEs is a time-consuming process.  
She stated, “So, the reporting of adverse events I can tell you, takes about an hour. From 
the time you get the information to reporting it.”  She went on to explain how the process 
is especially problematic due to the progressive nature of the terminal disease her 
medication treats and that she engages her patients on a monthly basis.  She stated, “If 
you have an in-depth discussion with a patient every month, I would say at least 70% of 
them have progressed…so if you were to be 100% compliant, seven out of ten calls 
would include a 15-minute adverse event report.”  
 Another common concern articulated by some of the educators is the challenge of 
collecting the adverse event information without alarming the patient to the point they 
overreact.  Janelle, an educator for multiple medications that treat autoimmune 
conditions, put it this way, “They also call in with adverse events.  You know, ‘This is 
happening, this is happening. Is this quote-unquote normal?’ Patients always want to 
know if they’re normal.”  Martin, a nurse practitioner and diabetes educator, elaborated 
more on this concept as he explained the challenge of collecting AE information from a 
patient in a face-to-face situation.  He shared, “What do I tell the patient? You have to 
address the issue, but you have to think about their ability to understand this was 
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abnormal. It may not have been harmful, but it was not an expected outcome.”  Finally, 
Iris shared that a concern for her was that the requirement for clinical educators to collect 
AEs can create dilemmas even in the seemingly innocuous conversational pleasantry of 
asking a patient how they are feeling today.  She described, “Even if the patient has a 
cold and they’re taking your drug, that’s a reportable AE.  You can’t say, ‘How are you 
feeling?’ And they’re like, ‘I didn’t have a good night’s sleep’…so everything is 
reportable according to the FDA.”  
The frustration with compliance regulations related to AEs, fair-balance 
presentation, and staying on-label sometimes boiled over to the point that educators 
pushed back against them, or simply ignored them.  This typically was a result of 
educators’ belief that the regulations’ influence was having too great an impact on patient 
care.  The next section examines these behaviors in detail. 
Purposeful non-compliant communication.   During interviews, some educators 
freely admitted to engaging in purposeful non-compliant communication behaviors, 
though not without deliberation.  During a focus group, Tabitha lamented that the nature 
of the regulations presented educators with a “Sophie’s choice”—a situation in which 
they must choose between two equally difficult alternatives.  She said, “You walk away 
with one or two beliefs. Either ‘I got it across to the patient, I succeeded in my 
mission’…or ‘I didn’t use any other words…and I was compliant. But I’m not sure the 
patient really got it.’” Vivian, a diabetes educator, reinforced this sentiment and noted 
that the goal of these education programs—promoting adherence behaviors that leads to 
treatment success—was at risk. 
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You know you either fail your patient or you fail the compliance. With the 
regulations as strict as they are, often, when I knew I had to be careful, I left the 
session feeling like the patient really didn’t get what they needed out of the class. 
But my [sales] rep was happy because I did everything by the book and dotted 
every ‘I’ and ‘T’ and didn’t stray in any direction off script. But at the same time, 
I think that’s the kind of patients that eventually fail treatment because they 
weren’t going to be compliant because they didn’t understand. 
Vivian’s qualifier of “when I knew I had to be careful” was reflective of her 
earlier one-on-one interview in which she felt that her need to completely uphold 
compliance regulation was often dictated by the presence of her pharmaceutical 
company’s sales representative.  She begrudgingly explained that, in those instances she 
felt inclined to follow compliance guardrails, even though doing so devalued her skills as 
an educator.  She said, “Some classes, I was on my own. I never saw a rep. I would 
answer stuff that I was probably not supposed to.” Iris was much more forceful in her 
criticism.  She believed that the expectation to use a program script not only devalued and 
disrespected her and her ability as a nurse, it disrespected the patient as well.  She stated, 
“You could just have an answering machine to do that…Tell me what it is that you need, 
what information you need. Give me the respect that I know how to get proper 
information, an answer you want from your patient.” 
Later in her focus group, Deandra shared that a decision whether to go off script 
would sometimes be dictated by the type of program she was presenting.  She explained 
that she felt more comfortable deviating from the approved materials of her 
pharmaceutical-sponsored disease-state programs—those in which the topics were 
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disease pathology and lifestyle management—as opposed to product programs in which 
she was instructing on the safe usage of a company’s medication. She explained, “[The 
pharmaceutical company] is not going to jump down my throat if I present it as, ‘This is 
like an army and this a sergeant’ or whatever…But when it comes to product discussion, 
way more watching out what I’m doing.”   
During the focus groups, educators were asked directly if they felt the educational 
scripts and materials provided to them were written beyond the comprehension level of a 
patient, whether it was acceptable to “go off script” and bring it down to a level the 
patient would understand.  Educators who supported going off script provided 
rationalizations related to the necessity of trying to provide education at the learner’s 
level.  Sophie, a diabetes educator, was supportive of going off-script if the situation 
merited it, “If the whole purpose is to educate the person, then you may need to bring it 
down to their level…Again whether that’s through a drawing or rewording something to 
help them understand that. I do think that’s appropriate.” 
As a follow-up to that question, educators were asked whether they thought 
pharmaceuticals company give tacit approval to go off-script in situations in which an 
educator deemed it necessary.  Sophie believed that the companies would give that tacit 
support if their goal is to have their patients be compliant with their medication.  She 
noted, “I would say if they as a pharmaceutical company would like the patient to 
successfully continue to use their medication, I do think that they would give a nod to 
that.”  Others, however, were not as optimistic and noted the discord between the 
companies’ public promotions of patient-centricity and the private legal ramifications that 
drove much of their decision making.  Iris stated, “I don’t think the company gives 
 92 
approval because they constantly say we couldn’t…Their top concern is the legal 
ramifications of everything we do… though they say that they are interested in the patient 
and it’s patient directed…it’s to sell drugs.”  Tabitha sympathized with a belief that while 
the companies would ultimately like to give educators discretion to adapt programs to 
patient needs, ultimately their liability concerns would always take precedent.  She 
reasoned, “I don’t think they can give tacit approval for something like that. They 
probably would want to. But I don’t think they really can. Their job is to tell us what our 
role is and what being compliant is.”   
 While multiple educators admitted to a history of breaching compliant 
communication guardrails, or a willingness to do so in the future, three of them—
Antonia, Iris, and Tabitha—provided passion-driven rationales that extended beyond 
mere frustration or annoyance with the regulations.  Their justifications for non-
compliance were driven by personal philosophies that put unfettered patient care as the 
primacy of their role.  These educators fully understood the logic of compliance 
regulations and the liability implications for violating them.  However, they struggled 
when those regulations hampered patient care.  Additionally, while all three admitted to 
violations, they did not blithely disregard all compliance regulations.  In fact, as was 
evident in their interviews, they had a profound and deep respect for them.  Their 
decision to be non-compliant was not a reaction based on disrespect for the institutions 
they served, rather it appeared to come from what drives rebellions—a passion for 
change.   
   The remainder of this theme explores the non-compliant communication 
behaviors as illustrated through the experiences of Antonia, Iris, and Tabitha.  These 
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stories exemplify how factors within the political/legal context (i.e. compliance 
regulations) can influence communication behaviors that are opposite of their intent.  The 
goals of compliance policies and regulations are to provide structure and guidance for the 
educators while also promoting clarity and preventing errors during their interpersonal 
engagements with patients.  However, these three educators felt they provoked confusion 
and eroded trust.  As such, the resultant frustration and confusion compelled the 
educators to respond with actions that were counter to the regulations’ goals.  
Additionally, as will be explored in the next theme, as well as in the Chapter 6 
Discussion, the ability of these ecological factors to simultaneously promote and impede 
compliant communication behaviors forced many of the educators to experience ethical 
dilemmas regarding their role.  Antonia’s, Iris’, and Tabitha’s stories help provide a 
foundation for understanding why those ethical dilemmas were pervasive and 
troublesome. 
Antonia was one of the four participating educators who provides full-time 
coaching and education services on behalf of a single client, a pharmaceutical company 
that manufactures one of the few drugs that treats a rare and terminal neurodegenerative 
condition.  The drug, which is administered in the physician’s office or at an infusion 
center, is not curative, it only slows the progression of the disease.  The condition is not 
easily diagnosed and tends to progress quickly once identified; most patients die within 
two years of starting the medication.  Antonia’s role is educating patients on the 
medication as well as serving an on-going navigator who provides support in the form of 
infusion coordination, side-effect management, payor services connections, and disease 
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management strategies. Antonia engages with her patients either in-person or over the 
phone approximately once a month.   
Antonia started her healthcare career as an RN in neurology before spending 
many years as a pharmaceutical sales representative.  During her interview, Antonia 
shared two catalysts that spurred her change from pharmaceutical sales to clinical 
education.  The first catalyst was the personal experience of caring for a relative’s child 
with a terminal disease.  The second facilitator of her role change was the uneasiness she 
felt while watching healthcare professionals, whom she sold medications to as part of her 
sales role, send patients home improperly trained on those medications.  She explained, “I 
was uncomfortable if healthcare professionals were basically going to send the patient 
home even though I knew they weren’t qualified. I didn’t feel like they were safe, or they 
could do it in a sterile environment.” 
 For Antonia, “time” was the enemy of her patients for reasons beyond the mortal 
nature of their disease.  She believed that it was often something many patients were 
denied in their educational interventions.  She stated, “…the biggest obstacle always in 
education is time, because some patients, you could teach them how to give themselves 
an IV medication in a half an hour and other patients take three hours.  But you don’t 
really have three hours.”  She felt that before even broaching the technical components of 
training patients, “you need to get a baseline relationship with them, and they need to 
develop trust in you and that takes time.”  She went on to explain why establishing a 
baseline relationship is important.  She noted, “You really have to say, ‘Tell me about 
your journey. What are your struggles?’ So, if you have a half an hour, you still need to 
spend ten minutes on that or they’re not going to hear the final twenty.”  Antonia 
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confessed that she allots time for patients beyond her company’s expectations because 
she values its importance to the relationship.  She shared, “I tell my patients, ‘I’m here 
until we both are comfortable that you understand.’ So, having that kind of trust. ‘I’m not 
leaving.  I’m not in a hurry. I’m here until we’re both comfortable with what you need.’” 
Antonia explained that there is an emotional element to her role that is not typical 
of clinical educators who work with chronic disease patients.   She clarified, “So in this 
job, first of all, I’m working with people who have or have recently been diagnosed with 
a terminal disease.  So that adds a whole emotional element throughout the theme of 
every visit.”  In fact, during another point in her interview, she estimated the amount of 
time she spends dealing with the emotional components of her role.  She stated, “So, it’s 
frustrating because I believe 80% of what we do in terminal diseases is emotional 
support.”  She went on to suggest that the trust that she builds with patients throughout 
the tenure of her support service is what ultimately cements an emotional relationship 
with them.  She explained, “They invite their family, they invite their church people over, 
so I’m a part of their lives. I really feel that keeping the trust... Because I need to keep—
this is a long-term relationship—I need to earn their trust, long-term.” 
Interestingly, it was only after the interview had ended, and without prodding, that 
Antonia felt compelled to fully reflect on her experiences of working with dying patients 
and how that impacted her emotional health.  She mused, 
One piece of this which I didn’t really talk about is that there’s a lot of loss. We’re 
trying to help our patients and they die. And when you have a relationship with 
someone—sometimes I’ll lose two patients a week—dealing with the grief is 
hard. We’re advised not to go to funerals. We’re advised not to send cards. But 
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that’s a big portion for us…And I have to tell you, people ask me, I would say out 
of a five-day work week I cry three days…I mean you get choked up. You don’t 
start balling. But you hang up the phone and you think “Shit. Shit.” 
Like Antonia, Iris felt there was an emotional element to her role, though in her 
case, it was passion.  In fact, during her one-on-one interview, Iris jokingly responded to 
a comment regarding the passionate way she spoke of her work and her role by saying, 
“Oh, that has gotten me in so much trouble. I’m Italian, that’s my background. It’s gotten 
me in a lot of trouble many times. But I’m so glad that you say that it’s passion and not 
anything other than that.”  Iris is a clinical educator who has spent more than ten years 
training patients on medications in many different therapeutic areas including neurology, 
rheumatology, gastroenterology, and geriatrics.  She was an introspective individual who 
lives her professional life centered around a core belief that, like Antonia, was grounded 
in trust.  As she explained it, “You learn something that becomes the center core of how 
you go, you always come back to that one thing… ‘be in the place where your patient is’. 
You’re not going to reach a patient if you can’t do [that].” Later in her interview, Iris 
elaborated on this core belief and how it was refined by a simple Buddhist principle.   She 
stated, 
[Trust] is a lacking thing in our society and more and more, it becomes so 
important…Do you know the Buddhist concept of loving kindness? ...It is being 
able to recognize and consider, to look at that person and truly in your heart 
consider what their need is. That’s that nonjudgmental thing. It’s that going in 
where the patient is and being able to truly have their interest at heart. 
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Iris was similar to Antonia in other ways.  She was also in her sixties and had a 
long career that included hospice care and working with patients who were dying.  Her 
experiences in treating patients nearing the end of their lives influenced how she 
approached her clinical educator role, particularly regarding the older patients with whom 
she frequently worked.  She described how older patients, especially those who recently 
lost a loved one, were at increased risk for health issues such as hypertension and the 
onset of other diseases. Therefore, she believed part of her role was to broaden her 
educational engagements beyond the approved management strategies of her company’s 
medication to include a broader scale of coaching and lifestyle-management tactics.  She 
described it this way. “Working with them, encouraging them. ‘Make sure you make this 
doctors’ appointment.’ Then working with them with their side effects, telling them who 
to report to and that’s important, or ‘Let’s think a more about this. What can we do?’”  
Like her two peers, Tabitha has a long and diverse career that included time 
serving patients at the end of their lives. After working as a nurse overseas, she settled 
back in the U.S. as a diabetes educator.  Tabitha was never employed full-time on behalf 
of a pharmaceutical company.  Instead, she served as a contracted educator who was paid 
on a per-program basis.  Tabitha had beliefs similar to Iris and Antonia about the nature 
of trust in her clinical educator role.   When asked what she had learned throughout her 
career about the way to communicate with patients, Tabitha reflected on her time as a 
hospice nurse.  She had learned that trust was at the foundation of her relationship with 
all types of patients, and that keeping that trust was contingent on open and honest 
communication—even when patients were nearing the end of their lives.  She explained it 
this way, “Those patients need to trust you. Even as a hospice nurse, the level of intensity 
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and emotion between the patients and you instantly is established…You have to be able 
to tap into that very early on in the relationship.”  
Tabitha worked primarily with patients who had diabetes and osteoporosis during 
the latter part of her career.  However, it was evident that her earlier experiences in 
hospice and nursing abroad influenced her views about how to engage patients with 
common chronic conditions. She explained how she took advantage of working in multi-
practice offices with shared waiting rooms.  She would often address her chronic 
patients’ “fatalistic” views about their disease by reminding them that, unlike patients 
with a terminal disease, there were options.  She stated, “For chronic disease…people get 
fatalistic.  Often, I’d say, ‘There’s more things life can hand you than diabetes…Did you 
sit in that waiting room next to anybody with a bandana on because they’re going for 
chemo? …We’ve got options for you.’” Tabitha concluded her thoughts by expressing a 
sentiment that seemed to be at the core of her personal belief system regarding patient 
education.  Her notion of “you still have control” not only served as a message of 
empowerment to her patients, it mimicked the medical ethics’ principle of autonomy and 
spoke to the role such ethics played in how she communicated.  She reflected, “You have 
to let people know they have control over what’s happening to them. That dying patient 
may die in 72 hours, but in those 72 hours they have control…You have diabetes, it’s not 
curable, but you still have control.” 
For these three educators, the need to build and maintain trust, as well as the need 
to respect patients, their time, mortality, and autonomy, served as primary rationales for 
purposeful non-compliant communication. The high value Antonia placed on both time 
and a trust-based relationship with patients were reasons why she chose to occasionally 
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defy the rules. For example, Antonia rationalized her and her colleagues’ willingness to 
keep hand-written notes about patients and their families, a compliance violation, was 
necessary to avoid breaching trust with individuals she viewed as already emotionally 
fragile from the desperateness of their situation. 
Patients that are terminal are desperate and they’re desperate for someone to 
understand them…Nowhere are we allowed to write down the fact that John and 
Lisa have two children and their daughter got breast cancer and the wife was 
diagnosed with Parkinson’s the week she was diagnosed with [neurodegenerative 
disease] and all those facts.  We have to just remember that…[But], this is the part 
that no one talks about…I personally have a hundred patients approximately. 
There’s no way I can remember all these things. And they’re important to the 
patient…So most of us, myself included, keep notes…Otherwise I look like an 
idiot every time I call them…I literally have a patient that was diagnosed with 
breast cancer the week she was diagnosed with this terminal disease.  If I forgot 
that when she called me, how dumb would that be? 
 Antonia used the justification that she was preventing a trust breach when 
admitting to actions she took in another situation that bordered on being non-compliant.  
Antonia explained that she often struggles when her patients asked her questions about 
the availability of an oral version of the medication she supports that currently can only 
be administered as an intravenous (IV) infusion.  She grumbled,  
Everything I do I think about compliance. For example, there’s stuff online about 
my drug that I can’t say. And patients ask us questions all the time. My drug is 
IV. It’s common knowledge that they’re researching an oral version. When the 
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patients ask me about that I have to say, “I’m not allowed to respond to that.” I 
feel like it damages their trust in me. Because I know full well that they’re 
researching oral, that my drug is being researched. It goes out in the newspaper; 
anybody can Google it. So why do I have to pretend like I don’t know about it? 
She went on to describe how she responds to patients when faced with this 
inquiry.  She explained, “I don’t know if this is compliant, I tell them every IV drug 
launched is studied as an oral, because it’s the easiest and safest. So, it’s a matter of time. 
That’s as much as I say because I’m restricted.”  Antonia defended her actions by 
describing a strategy she uses that she felt was a reasonable workaround and one that 
avoided further non-compliant behaviors.  She explained what she says when she does a 
periodic follow-up call with her patients’ physicians. She said, “I’ll say, ‘[Patient] is 
really excited about the concept of oral medication. If you have the ability to look that up, 
I’m not allowed to address that.’ The clinics like when I tell them that because they trust 
me more.” While Antonia did feel hamstrung by these compliance limitations, she also 
made sure that her patients understand their rationale, so as to not cast a negative light on 
her company.  She shared, “I tell them, ‘The reason that I’m limited to what I can say is 
patients diagnosed with this disease are vulnerable. And companies can’t walk around 
saying what they want. They can only say what the FDA approves.’” 
 Like Antonia, Tabitha knowingly violated compliance rules because she was able 
to justify doing so.  As an example, she rationalized that providing her personal phone 
number to patients was a reasonable, albeit non-compliant action, because doing so 
promoted patient autonomy.  She felt that her medication’s self-injection process was not 
always something that patients could master during a single training intervention and 
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therefore, wanted to provide an additional means of support.  She explained, “I would do 
something that was totally against the rules. I would give patients my home number and 
they would call me. [Pharmaceutical company] would have went crazy, but I did do 
that… Because I knew how lonely you feel.”  
 Even though Tabitha initially stated that giving out her phone number was her 
only violation, she would admit later in the interview and in her focus group to more non-
compliant actions.  Each time she was able to defend her behavior. For instance, she 
described how physicians would occasionally send patients that were not prescribed the 
insulin she represented to one of her insulin group education classes.  She was expected 
to turn those patients away.  However, she rationalized that allowing them to attend was 
in their best interest.  She stated, “Sometimes there were ten patients on [company] 
insulin and two on [different company] insulin. I was to turn [the two] away but couldn’t 
do it. I’d let them sit in. That’s another non-compliance thing, but they were always so 
happy.” 
Iris’ primary justification for her non-compliant actions were centered on her 
respect for patients.  This meant providing them with the information they needed in 
ways they could understand it.  She stated, “The best teachers give you what you need, 
respect you and your opinion and decision, be non-judgmental…That’s part of loving 
kindness, you’re going in to offer them information you have. That doesn’t make them 
less than you in any way.”  However, just as important as her respect for her patients was 
her respect for herself.  For Iris, the question of whether to be compliant would always 
come down to a sense of personal integrity.  That integrity would not allow her to bend to 
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what she felt were indefensible compliance regulations out of blind allegiance to a 
pharmaceutical company.  She shared that belief in the following way, 
I don’t believe I can change a whole lot. I can only change one thing, and 
that’s…that patient and the job that I have with that patient.  I can’t change the 
world, but maybe I can do one little thing one day at a time. That’s all I can do 
because I don’t have the power to do anything else. But it’s my integrity. You see 
what I’m saying? I can’t walk away from a patient’s house and say, “Oh, that 
damn drug company made me teach her that way,” because that’s my integrity. 
 Iris and Tabitha both expressed their greatest compliance grievances toward the 
expectation that educators were not to deviate from, or adjust, approved language and 
materials, even if they felt doing so was necessary to meet patients’ perceived 
comprehension level.  In fact, Tabitha believed that if she delivered the program using the 
language and materials exactly as they were to be presented, she would never be 
successful.  She explained that once she was alone with the patient, her primary goal was 
to get the patient to understand the information and be comfortable in administering their 
medication—by any means necessary.  She stated, “If we held to the letter of the 
compliance law, we’d never be able to do what we did…But once the door closed, I had 
one goal—to get you to understand…Any way I could do that, I would.” 
Tabitha criticized regulations that prevented her from adapting program materials 
because she felt they failed to account for patients with limited health literacy or poor 
language skills. Thus, she believed being compliant put a patient’s safety at risk. She 
explained it this way, “Frequently, [material] was written to high school levels. I have 
somebody that barely speaks English and they have to know how to titrate insulin. What 
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am I to do? I’m going to read this to them!? Are you kidding me!” Iris shared a similar 
experience of patient safety needing to come before compliance.  In her case, she 
believed that the instructional materials provided by her client were poorly written and 
unsafe.  Therefore, patients were at risk for giving themselves an unsterile injection.  She 
explained,  
I’m working in a program now where they always tell you, “You can’t cross 
anything off, you can’t change any of the material, blah, blah, blah. Don’t write 
on the material.” Well, the way that they outline for the patients who take an 
injection, if the patient washes their hands and then goes through 15 steps before 
and they now have a needle and a syringe up in the air that’s open, and now they 
have to take down their clothes and prepare their belly.  That’s nuts! You know 
what? Fine me! Do whatever, fire me.  I’m not going to have an 80-year-old lady 
lay down the open needle she was holding in order to pull down her panties. I’m 
trying to teach her how to give a sterile injection. Come on, she’s got to pull down 
her panties in the beginning. Everything’s got to be ready!  
At the heart of Iris’ frustration was that she perceived the programs to have been 
designed by individuals without expertise in adult learning, health literacy, or behavior 
change principles. For her, pharmacologists and marketers were not education experts.  
Or, as she stated, “‘Hey, listen to me, do you want an architect or a chef to design your 
kitchen?’ That’s what these companies have to realize…engage nurses in the way you’re 
addressing patients because we’re the ones who are delivering it.”   
 While Iris’ frustration left little sympathy toward her employers, Tabitha was 
more supportive.  In fact, among all twenty-six educators, she was the most vocal in a 
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defense of the pharmaceutical industry.  Tabitha would use phrases like “skirted the 
compliance thing” or “almost compliant” to downplay the severity of her non-compliant 
behavior and even imply that, though her companies’ sales representatives would never 
publicly acknowledge such, they understood and supported her actions. The following 
statement highlights this belief, “They understood, but did their due diligence as we took 
classes ad nauseam about compliance…The reps understood these regulations were hard 
to follow and didn’t benefit the patient…So we were close to compliant. Kind of like 
almost pregnant, almost compliant.” In fact, Tabitha believed that while she did choose to 
engage in non-compliant communication behaviors, her actions were not egregious 
enough that they would warrant severe discipline.  She explained, “I had a loyalty to 
[pharmaceutical company]. They were very good to me for many years. Anytime I kind 
of skirted the compliance thing, it was never something that a thinking person would 
really want to totally crucify me for.” 
Tabitha, like Antonia and Iris, often assessed her compliance dilemmas within the 
medical ethic of autonomy and her responsibility to provide information that allows 
patients to take control of their condition.  She had brought this notion with her from her 
prior experiences working in hospice.  She would often remind those patients that, even 
in the final stages of life, she was there to support their wishes.  As she stated, “You’re 
dying, but you still have control.”  Antonia, whose network served patients with a 
terminal condition, similarly spoke of the importance of maintaining trust and autonomy 
over all other things when she said, “I’m a part of their lives now…this is a long-term 
relationship, I need to earn their trust, long-term.”  Iris reflected on an ethical situation in 
which she was needing to provide product training for a patient who had previously 
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received a radiation treatment that was contraindicated to the use of the drug she 
represented.  Though Iris expressed discomfort with the patient’s decision to proceed, she 
explained that she ultimately needed to respect the patient’s autonomy given the patient’s 
awareness of the potential risks.  She described the experience this way, “It made me feel 
really uncomfortable, but I had to respect her decision…I wasn't going to say, ‘I'm not 
going to train you,’ because she made a conscious decision knowing…She understood it 
and she wanted to take that risk.” 
Tabitha’s, Iris’, and Antonia’s actions demonstrated how the influential nature of 
political/legal context factors can sometimes result in outcomes that are opposite of their 
intent.  The rigidity and complexity of government and industry regulations generated 
backlash when held up against these educators’ deep-seated beliefs about the nature of 
their role.  In fact, throughout her interview, Iris did not hold back from admitting that 
she would freely deviate from compliance regulations when they conflicted with her 
professional ethics.  She shared an example of a catalyzing situation she faced when she 
perceived the risks of the multiple sclerosis medication she represented began to 
outweigh its benefits for some of her patients.  She confessed, 
I worked with MS patients on lifetime long-term injections. These patients are 
diagnosed in their 20s and they may take [these] drugs. They’re now in their 70s 
and they might have been taking them all that time…I would go out and see these 
patients that had huge necrotic wounds, wheelchair bound from no muscle, no fat 
left. Areas of big wounds from this drug. At what point when you’re 70 years old 
or 80 years old should you still be continuing this drug?  So, risk versus benefit 
has changed and here I am representing and trying to tell them how to manage 
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taking this drug when I believe that they shouldn’t be taking it. So that raises a 
real question because I want the patient to trust me and I want that patient to know 
that I care about them because what I do is not worth anything if I don’t care 
about the person that I’m serving.   
Tabitha’s described a similar tension that existed as she felt equally duty-bound to 
protect her patients and the pharmaceutical companies.  She was able to reconcile this 
dissonance by rationalizing her non-compliant actions; she thought that she was never 
endangering the safety of her patients. She stated, “I think the pendulum has swung so far 
that, I never believed I endangered really, giving my home phone number was the most 
radical thing. Many patients utilized that, and I felt so good and they were so grateful.”  
The loyalty these three educators felt to both their patients and their employer was a 
common ethical dilemma experienced by many educators. In fact, this sense of “dual 
loyalty” was pervasive enough throughout the interviews that it rose to be one of the 
primary topics of the next theme in this chapter.  That theme examines how the influence 
of political/legal context factors forced educators to deliberate the ethics of their role. 
Ecological Factors and Ethical Dilemmas 
Theme 2: The influence of ecological factors, particularly within the 
political/legal context, would frequently force educators to experience ethical dilemmas. 
 For the most part, influential factors within the political/legal contexts provoked 
challenges and barriers that, though frustrating, were frequently resolved by the educators 
with little ethical deliberation.  However, that was not always the case as evident from the 
insights and experiences of Iris, Tabitha, and Antonia, who often struggled with moral 
predicaments.  The rationales they used to resolve those conflicts were rooted in 
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constructs such as professional integrity, respect for autonomy, and trust maintenance.  
This theme explores other examples of the relationship between ecological factors and 
ethical dilemmas and how similar logical and moral constructs were used in many 
clinical educators’ deliberations.  The ethical dilemmas presented here are organized 
within the framework of three dual loyalty contexts—situations in which educators 
needed to choose between two equally deserving alternatives.  Those dual loyalty dyads 
include patient versus the pharmaceutical company, patient versus their HCP, and patient 
versus their family. 
Dual loyalties: patients versus pharmaceutical companies.  Deandra, an 
educator for autoimmune disease products, used an analogy to emphasis a common 
tension of her role.  She stated that she felt like a puppet of the pharmaceutical company 
when she was expected to parrot their approved message at the expense of patient 
comprehension of the materials.  She asked rhetorically, “…do I step outside the 
regulations and get my job done and make sure my audience understands it or do I just 
stand there like a puppet and recite what the regulations tell me to say and walk away?”  
Her concern exemplified a dual loyalty deliberation described by many of the 
educators—a competing sense of loyalty and duty between the interests of the 
pharmaceutical companies that employed them and the patients for whom they served.   
Educators were disheartened by what they believed were misplaced priorities by 
the pharmaceutical companies regarding the educational programs and their intent.  
Multiple educators decried the companies’ focus on the quantity of delivered programs 
over their quality.  Bonnie, a telephonic educator for many different products, expressed a 
frustration in that regard.  She lamented, “It's more about numbers, it's more about, 
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unfortunately, quantity than quality and a lot of cases…At the end of the day, the email I 
get is, ‘This is how many calls you need per hour.’” A similar criticism was voiced by 
Cora, another telephonic educator for many different products, who believed that her 
companies’ emphasis on volume was shortsighted and counterproductive.  She felt that 
the amount of time necessary to accurately assess a patient’s barriers was at odds with the 
companies’ numbers-based focus.   Hence, long-term adherence to the medication was at 
risk.  She explained it this way, “We’re moving into a whole different spectrum of just 
looking at how many calls per hour…it's getting away from the holistic style where we're 
spending time with the patient and assessing their strengths and barriers, what they need 
to learn.”    
Adherence to compliance regulations was often implicated as one of the most 
common causes of moral distress.  In Iris’ view, the companies’ expectations for strict 
adherence to those regulations was an outcome of their fears of legal culpability.  She 
stated, “…pharmaceutical companies try to prevent, their first view, their absolute top 
concern is the legal ramifications of everything we do. And that's the way I feel.”  
Antonia described how those regulations eclipsed her duty to a patient who she felt was 
at risk for harm because of unsafe HCP practices.  As she explained it, “I feel like there's 
some disparity in our roles because I'm so limited to talking about…I had someone talk 
about some very unsafe port practices from their infusion clinic and I'm really not 
allowed to do anything about that.”  Iris shared a series of rhetorical questions to 
emphasize the internal struggle she faced with her patients who were prescribed the MS 
medication to which she believed the risk/benefit balance had changed “There is no little 
pharma bird on the wall listening to everything we say. So, it becomes an ethical 
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question. What do I do ethically? Where is my first responsibility? Is it to this patient or 
to this drug company?”   
Dual loyalties: patients versus healthcare providers.  While educators 
frequently struggled with competing loyalties between their patients and their 
pharmaceutical companies, it was not the only dual loyalty dilemma they faced.  At 
times, educators found themselves at crossroads that put patients against the providers 
who treat them.  In some cases, educators felt obligated to support the HCP even if they 
believed the HCP was providing inappropriate care or not acting completely in the 
patients’ best interests.  Martin, a diabetes educator, stated it succinctly, “…even if we 
recognize that a healthcare provider was not treating the patient correctly, we could not 
relay that to the patient.”  Antonia articulated a similar refrain.  She stated, “I have to be 
very careful. I never ever talk negatively about a doctor, never. A patient needs to have 
trust in their doctor. It would have to be pretty dang bad for me to.”  Olivia, an educator 
for terminal neurodegenerative disease patients, explained that she frequently felt obliged 
“to make nice” to patients on behalf of their doctors even when she believed the 
physicians were not providing the best care.  She lamented, “[Patients] will cuss out their 
doctor to you…and you're thinking all the same things that [patients are] saying but 
you're just telling them ‘It's us. We're asking so much of [physicians].’ We're always 
making nice on behalf of their offices.” 
 While educators often found themselves in a position of defending the physician 
to a patient, the reverse was also true.  Cora, a telephonic educator for numerous 
conditions, discussed having to advocate to physicians that providing educational 
services and materials to patients was not a futile endeavor.  She had encountered HCPs 
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who felt some patients were unreachable. She stated, “You have some [physicians] that 
champion what you do and are very thankful…then you have some that are not, that just 
see it as…some people are just unreachable…that's sad because I think everyone is 
reachable. It's just figuring out how.” 
Zara, a diabetes educator, shared a similar frustration when encountering patients 
whose physicians had not informed them of their diagnosis or provided any preliminary 
disease education.  Unfortunately, as she was unable to offer medical advice, she was 
limited in the response she could provide.  She believed those patients were frequently 
the ones whose diabetes would get out of control.  She shared, “I get patients whose 
doctors don't even tell them they're diabetic…just given the insulin and don't give any 
education…then you wonder why people are out of control because they're not taking 
their insulin because they're afraid of it.”  She continued by voicing additional annoyance 
with what she believed was physician laziness.  She felt that some HCPs resorted too 
quickly to prescribing medication instead of allowing time for patients to try lifestyle 
changes for diabetes control.  She also felt some of her physicians were lax in their 
responsibilities by not referring their diabetes patients to endocrinologists, opting instead 
to treat them themselves.  She begrudgingly noted, “[Physicians] may push, let's start 
medication without really encouraging the patients to try lifestyle change. They don't 
even refer patients because they don't want to take the time to do it, and that's really 
sickening…They're lazy.” 
Dual loyalties: patients versus families.  Clinical educators often trained 
patients in the presence of family members who served a range of supportive roles—from 
a simple emotional advocate to full-time assistive caregiver.  Not surprisingly, disease 
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and therapy related stress would sometimes give rise to situations that pitted educators’ 
loyalty to their patients against the family members who were supporting and caring for 
them long-term. 
Olivia explained how her role as an educator who met over the course of a year 
with patients with a terminal neurodegenerative condition sometimes included serving as 
a mediator between the patient and family members.  She shared an example that 
illustrated how her intervention served a larger purpose beyond helping families make a 
healthcare decision.  She believed her mediation was actually part of her larger 
responsibility to provide the requisite empathetic and emotional support necessary for 
families facing the impending death of a loved one.  She explained it this way, 
I've gone into homes where there'll be a patient and her sister. You're trying to go 
through the welcome kit with them, and all of a sudden the sister will be like 
“And she doesn't want a feeding tube”. The patient's looking at you, and she's 
like, “I don't HAVE to have a feeding tube.” You're like, “They want me to 
mediate this discussion for them.” You're thinking, “And this feeding tube has not 
a darn thing with what I'm here for.” But you're in that position, and they're both 
looking at you, and they're expecting you to be on their side, right?…That is the 
kind of stuff that this is about. It's not always just about [drug name] …They don't 
care about that. They want you there for other emotional things, so it's very 
interesting dynamics. 
 Other educators found themselves in even more tenuous family situations that 
forced ethical deliberations.  Quinn, a diabetes educator, described an experience she had 
of training a young girl who she suspected was being abused by her father.  She 
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explained how she felt mandated by her role as a healthcare professional to report her 
suspicions and therefore actively engaged her sponsoring company’s assistance in doing 
so.  She stated, “One girl had ligature marks around her wrist...When I walked out of 
there, I called the [pharmaceutical] company…And they said ‘You're a nurse, you have to 
do what you have to do.’ So, I did it. I called and reported it.”  Antonia was similarly 
faced with an ethical situation.  A patient’s family member disclosed to Antonia that she 
was thinking about committing suicide.  Antonia felt morally and professionally 
obligated to intervene in such a situation, even though the family member was not her 
actual patient.  She believed part of her role as a health service provider for patients 
included taking care of their family.  She shared, “When you take care of a patient, their 
family is really your patient too…So that was a real difficult one for me because she 
wasn't my patient. But some things we are, as healthcare professionals, required to 
divulge.” 
 Iris reflected on a similar moral dilemma related to patients’ mental health.   She 
explained that when suicidal ideation was disclosed to her by a patient, it was an easy 
ethical situation to resolve.  She was legally and professionally obligated to report such 
an event, even when serving in the capacity of a pharmaceutical-sponsored clinical 
educator.  However, she felt there was less clarity regarding her responsibility to a 
patient’s family if a patient exhibited mental instability that was less imminent or clearly 
life-threatening.   She struggled with the limitations of her role as a pharmaceutical 
educator that stymied her, both legally and ethically, from intervening, regardless if she 
believed it was in the best interest of the patient.  She explained, “Here’s the ethical 
question. If I have an older patient and I question their judgment and their mental status, 
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do I have a right to call their child and say, ‘Something's going on here.’ No, I don't. That 
is difficult.” 
 Educators believed the political/legal context was one of the most influential, if 
not the most influential, factor for determining how they communicated with patients.  
Those factors were integrally related to the ethical dilemmas educators would sometimes 
face as part of their role.  However, transcript data revealed another set of factors that had 
a compelling impact on patient engagements that did not fit within any of the other 
contexts noted in the literature.  The next theme examines a proposed context called 
“disease and treatment” that seeks to account for those factors. 
The Disease and Treatment Context and the Clinical Educator 
Theme 3: A sixth context, the disease and treatment context, not previously 
identified in the ecological model literature, emerged from the interviews as having 
significant influence in the conversation dynamics between the educator and patient.   
Throughout their interviews, the clinical educators frequently reflected on how 
the nature of the disease itself, as well as its treatments, were influential in the way they 
would communicate with patients.  Educators used an analogy of the disease journey to 
illustrate how they and their patients viewed disease in the context of an ongoing series of 
experiences that were traversed.  Some disease journeys had clearly demarcated 
progression benchmarks while other were less well defined.  As most of the educators 
worked with patients afflicted with treatable and manageable chronic conditions, those 
journeys tended to not have a clear end-point destination such as “cured.”  Rather the 
goal of the journey was to reach confidence and comfort in the self-management of the 
disease.  The disease journey was characterized with factors that influenced the way 
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patients would communicate with educators.  However, some of these factors did not fit 
within any of the parameters of the five existing contexts noted by Street (2003) and 
Head and Bute (2017).  Therefore, a sixth context, the disease and treatment context, is 
proposed for this study.  The remainder of this section examines five factors identified in 
the data that comprise this context and how they impacted patient-educator 
communication.  They include disease type, disease-related side effects, treatment-related 
side effects, prevalence of comorbidities or disabilities, and drug administration 
modalities. 
Disease type.  Most of the participants had experience working across multiple 
therapeutic areas both as a field educator and a pharmaceutical-sponsored clinical 
educator.   All the educators, at one point in time, provided pharmaceutical education for 
products indicated for common chronic conditions including the four educators who were 
employed full-time to provide services for a medication that treated a rare terminal 
neurodegenerative disease.  Additionally, most of the educators had prior field 
experiences working in areas beyond chronic disease management such as in acute or 
trauma-related conditions, surgery, oncology, rare diseases, and palliative/hospice care.  
Throughout their interviews, these educators would frame their beliefs and experiences 
about interpersonal communication with patients within a comparative context of 
common chronic versus non-common or non-chronic disease. 
Janelle was an educator for both in-market and clinical trial medications that 
treated a range of ailments, from common chronic conditions to rare and potentially 
terminal diseases such as primary immunodeficiency (PI), hemophilia, and 
phenylketonuria (PKU).  She explained how educating a patient with a rare disease 
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required a “higher touch” type of engagement than for those who were a common chronic 
disease patient.  She noted, “[Rare disease] patient populations need much more high-
touch…because it’s so rare, it seems like you’re the only person on the planet that has 
it…there’s a lot of hand-holding and a lot of therapeutic listening that goes in with those 
patients.”  Janelle continued by explaining that one of the differences of helping patients 
with rare diseases is that they tend to feel more secluded.  In fact, she described how 
some of her patients would share with her their belief that their physicians did not even 
understand the disease.  She said patients would make statements to her such as “Well, I 
don’t think the doctor understands this because it’s so rare, and I’m their only patient 
that’s even on this medication, and I don’t think they understand it!”  Adding to those 
patients’ struggles was that the medication administration process for some rare diseases 
involved complex and invasive procedures like self-infusion.  She described it this way, 
“You were educating patients constantly and their families on these really rare disease 
states; hematologic disease states that they didn’t understand…And the infusion process 
to teach patients or caregivers how to give these infusions was quite the uphill battle.” 
Similarly, educators would engage with patients who had a terminal prognosis 
differently than their patients with treatable chronic conditions. Iris, an educator who 
trained patients on a medication for autoimmune conditions but had prior experience 
working in hospice and palliative care, acknowledged as much when she asked the 
rhetorical question, “So am I going to talk to…someone who’s just been given a horrible 
terminal diagnosis compared to someone who is really engaged and says, ‘Okay, I’m 
ready. This is an issue…I know I can fight this.’”  Penny considered the depth of 
conversations she had with terminal disease patients to be much greater because they 
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tended to focus more on the value of life.  She explained, “So, education…you still tailor 
it based on their needs…But if there’s a terminal thing involved, you tend to focus on 
what matters and really question life. And then the conversation becomes deeper.” 
 Evelyn lamented that the rare terminal neurodegenerative disease for which she 
provides medication education had unique challenges that changed her instructional 
approach.  One issue was that, because of the rareness of her patients’ disease, it often 
took a long time to diagnose or was frequently misdiagnosed.  She remarked, “It’s a 
diagnosis of exclusion. Frequently patients have gone months or years getting 
misdiagnosed…It’s not like when you have a strep throat… you get a test, you get the 
medicine, you’re done, your test is fine, you’re feeling better.”  Adding to the frustration 
was that, unlike other neurological conditions such as multiple sclerosis, there was no 
way to verify that the medication she represented was working.  She stated, “You can’t 
test how the medication is working…With MS, you can follow the imaging and you can 
see changes in the imaging or no changes. With [neurodegenerative disease], you’re 
following the progression of the disease. It’s a little bit different.”  Evelyn admitted that 
these issues provided a greater conversational challenge for the neurodegenerative 
disease medication than the hypercholesterolemia (high cholesterol) drugs on which she 
once trained.  She described it this way, “It’s a little bit different than the 
hypercholesterolemia medicines. They take the medicine, then they look at their LDL 
level. That kind of reinforcement…It’s easier, and that’s something very specific. When 
you’re teaching them, it’s a much easier situation.” 
Olivia, one of Evelyn’s teammates for the medication that treated the 
neurodegenerative condition, came to her role having previously working in palliative 
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care.  She shared how she learned through her hospice role of the value of engaging the 
family in the emotional experiences of terminal diseases.  She carried that belief with her 
to her pharmaceutical role.  She shared, “With hospice you’re incorporating the entire 
family because you have this extended group around folks because they’re dying…It’s 
always very, very emotional and volatile, so you’re always trying to center things about a 
lot of emotional support with the education.” Interestingly, unlike any of her peers who 
worked with dying patients, Olivia was the only educator who shared an introspection of 
the way she believed patients sometimes adapted their communication to fit her 
emotional needs.  She described how this behavior was unique to her patients with the 
terminal neurodegenerative condition as she had not experienced it from other patients 
with whom she had previously worked.  She mused, 
For whatever reason, with [terminal neurodegenerative disease] these people now 
have this life sentence, and they know what the outcome is, and they’re all like 
happy and grateful. I have never in my life worked with a population of people 
that are so kind and so gracious and so lovely. Like they come to this acceptance, 
and they have this joy and this peace and this sense of wonder, and it is 
unbelievable to me…So, in some ways you almost would want to be like kinder 
and gentler…they don’t require any extra handling because they’re handling you 
like that…They’re like, “Thank you so much, and you’re such a joy and such a 
gift, and God bless you.” And you’re like, “Are you even kidding me!?” They are 
so good to me.  They fill my bucket.  
Disease side effects.  The way a disease progressed would sometimes result in 
side effects that educators would need to account for when interacting with patients.  For 
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example, in some instances, a side effect was simply the silent nature of a disease that 
would present issues.  A silent disease means the condition progresses asymptomatically 
until the later, more damaging stages.  The educators noted that even after a diagnosis, if 
a patient did not experience some direct or physical manifestations of their disease, they 
could be lax about taking self-care actions.  Felicia, an educator for a self-injectable 
medication for osteoporosis, noted that this was often the case with her patients.  She 
stated, “I think the main thing is that, with osteoporosis it’s a silent disease. They don’t 
even know that they have it, they don’t believe that they’ve had it.”  Adding to Felicia’s 
challenge was that the daily self-injectable biologic on which she trained, though 
efficacious, would not produce outcomes that were physically perceivable by the patient 
or easily measurable by the HCP.  She reflected on her prior role as a wound care nurse 
to highlight this difference.  She stated, “A wound was so simple, you measure it once a 
week…With a lot of these [osteoporosis] women, you don’t even know you have the 
disease, but now you’ve got to commit to two years of treating something…it’s a hard 
commitment.”  
 Quinn, a diabetes educator who also had experience delivering education for a 
multiple sclerosis medication, noticed that a lack of perceivable progression of a disease 
would often encourage patients to take a gamble by delaying treatment.  Unfortunately, in 
the case of MS, once it progressed, the damage was irreversible.  She would tell her 
patients, “You can let it go and take the risk of your MS not progressing, but once it does, 
you’re going to start to slow down from that point versus from where you could’ve 
started it where you were doing well.”  Vivian bemoaned a similar attitude among some 
of her diabetes patients.  She believed that a perceived lack of disease-associated pain 
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forced patients to sometimes deny the presence of diabetes, even when other indicators 
verified its presence. She vexed, “Diabetes doesn’t hurt. It’s easy to ignore it. It’s not like 
people walking around and going, ‘My left upper quadrant’s hurting…It must be the 
sugars out of control.’ If that were the problem, everybody would take care of it.” 
A loss of verbal communication skills was another example of an impactful 
disease side effect that was common among patients who suffered from a terminal 
neurodegenerative disease.  Though patients lost the ability to speak as a result of the 
condition, they still maintained full cognitive functions.  This was referred to as the 
bulbar phase of the disease and could occur at any time during the disease timeline.  
Since the educators interacted with patients monthly over the course of a year, it proved 
to be highly problematic, especially as many of their monthly engagements were 
delivered telephonically.  Evelyn summarized it this way, “But the nonverbal thing is 
pretty big and is pretty frequent and it’s a big issue with the [neurodegenerative disease] 
population.”  Penny explained that when patients would reach the bulbar phase, she 
would shift her verbal communication strategies by engaging more with the patient’s 
caregiver.  She emphasized that this presented a new set of issues in that caregivers 
sometimes had limited availability.  Even more troubling though was that she felt that by 
shifting focus to the caregiver, she was degrading the relationship she established with 
the patient.  She put it this way, “Communication is very important. It does impact it a 
lot…when they’re bulbar onset and they can’t talk, I always reach out for a caregiver. But 
then again, that limits my connection with the patient.”  
 Treatment side effects.  In addition to side effects caused by the disease, side 
effects of treatments were also an influencing factor in the educator-patient 
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communication dynamic.  Educators found that treatment side effects can have a direct 
impact on their ability to engage with patients because they may curtail or degrade 
conversations.  Lois pointed out how a medication’s lack of efficacy, which the FDA 
recognizes as an adverse event, will frequently discourage patients from continuing in the 
multi-touchpoint telephonic program she supports.  She lamented, “Sometimes I think 
they don’t pick up the phone if they feel like the product isn’t working, and they don’t 
want to tell me that. Or they’re just discouraged, and they don’t wanna talk about it.”  
Sadly, even when patients have not yet experienced a side effect with a medication, prior 
experiences can still create communication barriers.  For instance, Iris described a 
situation in which a patient’s experience of side effects from previous medications 
dissuaded that individual from actively engaging with her and from being adherent to her 
medication.  She explained, “[The patient] told me she had side effects with every single 
drug…She wasn’t going to take the drug while I was there…she just couldn’t move past 
her psychological knowledge that she was going to have side effects to this drug.” 
A patient’s disclosure of a pregnancy, or desire to become pregnant, while taking 
the medication is another situation that can change the dynamic of how an educator may 
engage with a patient in a discussion about side effects.  Xoe, a diabetes educator, 
explained that if a pregnancy is unknown prior to the start of engagement, but is disclosed 
during it, educators are ethically and morally obligated to take appropriate action.  This 
would include reviewing the prescribing information section on the use of the medication 
by pregnant women as well informing the patient’s physician.  She stated, “And all of a 
sudden they tell you they are [pregnant], then I think we’re morally and ethically 
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obligated to stop and say whatever the verbiage we use is, “You need to discuss this with 
your physician.’”   
Cora, a nurse practitioner with pharmaceutical education experience in many 
therapeutic areas, explained that even when a pregnant woman is made aware of a 
medication’s risks and decides to still move forward, communication is impacted.  She 
shared, “…[pregnancy] is pretty overwhelming. A lot of tears rolled down cheeks, but 
you just had to continue to hold their hand, build that trust, and explain to them 
[injections are] helping the baby, [they’re] going to grow a healthy-sized baby.”  Cora 
later went on to explain that, while pregnancy can be a catalyst for anxiety, it can also 
prove to be a motivational factor for some patients.  She described how some pregnant 
patients are more easily coached to self-management behaviors as they view doing so to 
be beneficial for the baby.  She stated, “You find that thing that’s going to motivate 
them…Especially for pregnant women, the majority of them, that one is an easier sell 
because they will do whatever they have to do to take care of that baby.” 
Disease-related comorbidities and disabilities.  The presence of disease 
comorbidities or pre-existing physical or developmental disabilities frequently presented 
communication challenges for clinical educators.  Often, these conditions were unknown 
to the educator prior to a scheduled engagement, thereby forcing them to react and adapt 
quickly.     
Comorbidities.  Diabetes educators were quick to note the impact of comorbid 
conditions when providing education or engaging patients in conversations about self-
care behaviors.  Hanna explained that, while her role as a CDE was always to address the 
primary disease, she often had to take into consideration conditions like hypertension and 
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obesity and adjust her information delivery appropriately.  She noted, “There was always 
looking at different disease comorbidities, such as hypertension, weight 
loss…Information that had to be shared with [patients] for devices…it was always a 
component that something else a patient would present with that had to be dealt with.”  
Vivian, also a diabetes educator, expanded on Hanna’s notion as she reflected on how she 
would adjust her interaction for a patient recovering from a stroke.  In that instance, she 
had to account for mobility and dexterity issues.  She expressed,   
Having to come up for the diabetic population, with some exercise regimen that 
they can do after they had a stroke, rather than just say, “Go and walk 15 minutes 
every day,” and you’re in a wheelchair.  Yeah, adjusting whatever 
recommendations are made or how, what utensils and gadgets we used based on 
what limitations they had.  
Physical comorbidities were not the only additional health issues with which 
educators had to contend. The stress and anxiety associated with patients’ diseases would 
often give rise to mental health comorbidities that could exacerbate the primary disease.  
Martin, a nurse practitioner and diabetes educator, believed that a comorbid condition 
like depression could severely impact a patient’s ability to self-manage their diabetes, 
particularly if it involved the use of a complex insulin pump.  He expressed such a 
sentiment in the following way, “It’s like insulin pumps. Some people think insulin 
pumps is an automatic fix-all. Well then, you’ve got a patient that is depressed, and not 
with it. It’s, ‘You know, I’m not sure you’re ready for an insulin pump.’”  
 Lois, an educator who supported patients with autoimmune conditions like 
Crohn’s disease, reflected on the way stress could serve as a flare-triggering factor for 
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that disease.  She shared that a frequent self-management strategy she used was to engage 
patients in a conversation about their perceived level of stress.  This gave her insight to 
the patient’s lifestyle and allowed her to focus her engagements on stress management 
tactics.  She stated, “[Patients] may not realize the stress they’re under until they start 
talking and you say, “Well, that must be very stressful.” And then they realize, “Well 
yeah, I guess it is stressful.” Sometimes they just think that’s their everyday life.” 
Physical and developmental disabilities.  Separate from comorbid conditions 
are physical and developmental disabilities that sometime function like comorbidities in 
that they require the educator to adjust their communication dynamics with patients.  
Many of the educators offered examples or shared stories of experiences in which they 
have adapted their educational engagement, sometimes without warning, because of a 
disability.  Martin discussed one such example, “There’s physical barriers. Went in one 
morning to teach insulin to a guy who had lost his right arm and had a prosthesis. I had 
not been alerted to that. It’s, like ‘Okay. How am I gonna deal with this?’”   
Felicia, an osteoporosis educator whose medication was also administered via 
self-injection, shared similar examples of needing to adapt to physical disabilities such as 
visual impairments or muscle weakness in the hand caused by stroke or other diseases.  
She stated, “The medication, even with glasses, or they have to take their glasses off to be 
able to see it up close. Some other women will have weakness in one hand…So, it’s just 
kind of working through little things like that.”   Xoe, a diabetes educator, noted that 
disabilities like vision or dexterity issues were sometimes not accounted for by the 
prescribing physician.  She shared how she has advocated on behalf of a patient to both 
the physician and the insurance provider to get an appropriate insulin delivery device.  
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She explained, “…when somebody was prescribed a medication and they simply could 
not mechanically, technically do it. You go… ‘Doc, he can’t do this. He can’t see well 
enough. We need to get him a pen [injector] so he can hear it.’”  
 Visual and dexterity issues were the most mentioned disabilities noted by 
educators.  However, Martin provided an amusing anecdote of a hearing disability that 
exemplified the way clinical educators must often think on their feet to accommodate a 
patient’s communication limitations.  He recounted,  
Whenever I worked with the inhaled insulin, they’d have to do a breathing 
test…They had to blow through this device to determine if they could inhale the 
insulin well enough. This drug rep calls me to teach this patient. I get there to 
realize the patient was deaf. I’m like, “Okay. Well, we have to do this breathing 
test.” …And I sat there making all these motions, sucking in, and blowing out 
with my hands. The rep and the doctor literally were in the hallway rolling…I 
showed the patient the device, and hand it to him. He blows the insulin out. I said, 
“No, no.” Then I start sucking up again and they’re again rolling…Then I look, 
and I say, “Is there a family member here with him?” “Oh yeah, his mom’s with 
him.” They bring her in, and I’m showing her. I go through the whole process, she 
looks at me and says, “Sir, I’m not gonna be able to remember this. I’ve had a 
stroke.” I said, “Do you have someone that drove y’all?” “Yeah. My son’s ex-
wife’s here.” I said, “Get her in here.  I don’t care who she is or how long she’s 
been out of the family, bring her back.” 
While many educators noted examples of adapting to physical disabilities, Hanna, 
a diabetes educator, had experience working with patients with developmental 
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disabilities.  She shared some of the key considerations and tactics she would use when 
engaging those patients.  She explained, “With someone with developmental 
disabilities…each step that you had to go through had to be practiced and repeated 
multiple times before moving on. With the same goal in mind, the timeframe in which it 
was to be accomplished was greatly extended.” 
Treatment administration modalities.  All twenty-six clinical educators had 
extensive experience training patients how to self-administer medications via parenteral 
methods such as injection, infusion, or inhalation.  In fact, most of the products the 
educators represented were large-molecule biologics that could not be manufactured for 
oral delivery.  The most common administration method among the group was self-
injection, usually through a pre-measured autoinjector or injection “pen”, though some 
educators also trained patients to inject via a vial and syringe.  For medications that 
required intravenous (IV) infusion, educators would typically just provide information 
about the drug during a formal training session.  The actual administration would be 
performed later by a healthcare provider in a physician’s office or infusion center. A few 
of the educators trained patients to self-administer sub-cutaneous (SQ) infusion 
medications, a more involved process than self-injection as it required multiple steps and 
pieces.  According to the educators, these administration methods presented a degree of 
complexity beyond what they were accustomed to with oral medications.  Not 
surprisingly, that complexity would give rise to barriers that impacted educators’ 
communication.   
Injecting or infusing biologic medications requires numerous steps for both 
preparation and delivery. They often involve multiple component pieces and supplies and 
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can include devices that look complex or fragile.  Even the autoinjectors, which are 
frequently marketed as easier-to-use alternatives to traditional syringes, were perplexing 
to some patients.  Many autoinjectors, such as those used for insulin delivery, come from 
the pharmacy preloaded with a multi-day supply of the medication.  Those autoinjectors 
include a dosage mechanism, such as a dial, that allows the user to adjust the amount of 
medication delivered with each injection.  As Tabitha, an educator who trained patients 
on both injectable diabetes and osteoporosis medication pointed out, this was problematic 
to many of her older patients with visual and dexterity limitations or who feared what 
would happen if they administered the wrong dose.  She shared, “I probably did a 
thousand [osteoporosis medication] trainings, and same with diabetes. People are so 
frightened of, ‘Oh my gosh, you mean I have to change the amount that I take every time 
and what if I do it wrong?’”   
Lois, an educator who trained patients how to use a syringe for a medication that 
treated multiple chronic autoimmune disorders, often had to address concerns about her 
drug not being available as an autoinjector.  She would draw from personal experience to 
explain why a syringe could sometimes be preferable to an injection pen.  She stated, “I 
could talk about an injector pen, how it might sting with the injection…As opposed to a 
syringe…I could use my past experience and education to tell them they may end up 
liking it because it may not do this.” 
Janelle highlighted that some of the administration devices for the rare disease 
medications on which she trained were more complex than those for a common disease 
like diabetes.  She remarked that she therefore had more talking points and checkpoints to 
review.  She clarified, “Depending on which injectable, it’s not just like a simple...you 
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know, ‘diabetes: click, click, click, inject, go.’ Some things are gonna have a little bit 
more talking points to it and a little bit more check points to it.”  Evelyn, who trained on 
injectable medications for multiple conditions, explained how she now never makes 
assumptions about an individual’s ability to easily master the steps for self-administering 
a medication, particularly if it involves a complex device.  She reflected on the difficulty 
a physician, who was her patient, had in assembling the injection device on which she 
was training and the implications for those without medical training.  She noted, “[The 
patient] did get it, but all I was thinking of...and this was somebody that worked in 
critical care with a lot of devices…Just because somebody’s educational background 
indicates that they should know about it, they might not.” 
 In some instances, the mechanical complexity of self-injecting was less of 
concern to educators than the computational complexity that was required.  Quinn, an 
educator for self-injectable diabetes and osteoporosis medications, hypothesized that the 
reason one of her diabetes medications struggled in the marketplace was because it 
required patients to calculate, or titrate, their dose before administering.  She felt titration 
was difficult for her patients because the dosage could change from day to day based on 
factors such as a blood glucose reading.  She lamented, “It was a powdered insulin that 
was titrated. That was really hard. Especially when they’re older to explain how to titrate 
medication. They want to know exactly what am I supposed to take at what time and how 
much.”  Xoe shared similar thoughts about a powered insulin product on which she 
trained that needed to be mixed before injecting.  In fact, she explained how she would 
encourage patients to delay picking up their prescription until after they were trained lest 
the task be too difficult, and they would end up paying for medication they couldn’t use.  
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She shared, “There were some people who could not do it…We would tell them, ‘Don’t 
fill your prescription. Come let us teach you how to do it’…We wanted to make sure they 
could do it before they spent money on a prescription.” 
Like political/legal context factors, the disease and treatment context factors 
served not just to influence patient/educator communication, but also to constrain it.  In 
many instances, these factors functioned as barriers that impeded educators’ ability to 
engage patients in the types of communication that could provoke behavior change.  In 
turn, patients’ ability to better self-manage their disease and treatments were at risk.  The 
next theme examines the communication strategies clinical educators used to address 
these factors and thereby overcome such barriers. 
Using Communication Strategies to Address Ecological Factors 
Theme 4: Educators employed communication strategies to better navigate within 
the political/legal and disease and treatment context ecological factors.  
Pharmaceutical-sponsored clinical educators spoke frequently of the importance 
of quickly establishing and maintaining trust in their patient relationships.  Doing so was 
viewed as a necessary precursor for working within the ecological factors that frequently 
functioned as barriers to disease management.  Educators also understood that the 
components of the disease and treatment context needed to be accommodated as part of 
any communication strategy they deployed.  Hence, educators would frequently try to 
make a personal connection with the patient in hopes of “meeting the patient where they 
are at”.  When faced with political/legal barriers, a common strategy for addressing the 
staying on-label and fair/balance presentation factors was “deferring”—redirecting 
patient questions or concerns they were not allowed to answer, back to the patient’s HCP.  
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Though educators noted that deferring could sometimes frustrate patients, they learned 
that they could leverage the trust they had built in their relationship to help abate that 
frustration.   The educators would employ verbal tactics during deferring, beyond a 
simple “You’ll need to talk to your doctor about that”, that kept the conversation opened 
and the patient engaged.  Lastly, as the communication medium could cause barriers to 
arise, particularly in the instance of telephonic engagements, educators developed 
linguistic skills that proved useful to navigate such barriers.  This section explores the 
strategies educators would use to address some of the barriers posed by the political/legal 
and disease and treatment context factors.   These include pragmatic “stick to the rules” 
approaches, as well as conversational and carefully worded linguistic nuances that could 
sustain trust while maintaining compliance. 
Communication strategies to address political/legal context factors.  Clinical 
educators and their patients needed to traverse political/legal context factors that were 
manifested in government and industry-imposed compliance regulations.  Specifically, 
the regulatory factors of staying on-label, fair-balance presentation, and adverse event 
reporting were the main factors within that context that were examined in this study.  
However, other compliance-related concerns were also discussed by participants.  
Though political/legal context factors did present challenges and barriers to patient and 
clinical educator interpersonal engagement, the educators had established a range of 
communication strategies to address them. 
 Some of the educators expressed a pragmatic sentiment that navigating 
compliance regulations was best accomplished by just “sticking to the rules,” particularly 
when it was related to using company-provided educational language and materials.  
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Unlike educators who had expressed reluctance to never deviate from program directives, 
these educators thought the best course of action was strict adherence.  Gabi, an educator 
who trained patients on medications for osteoporosis and chronic autoimmune conditions 
articulated this view when she said, “What you can do is stick to the package insert and 
training material and point out these are possible side effects and if they have questions, 
we refer them to their physician or pharmacy or back to the medical department.” Sophie, 
a diabetes educator, reinforced the same concepts as Gabi when she stated, “We would do 
really everything by the book…And then there were some things we could hand people, 
some [pharmaceutical company]-provided care sheets or educational material. Those 
things we could provide to patients. But that was it.”   For most educators, this strategy of 
sticking to the rules was rooted in a fear of non-compliance repercussions.  That belief 
was evident in the way educators articulated their disagreement with some compliance 
regulations in principle, but still demonstrated compliant communication and actions in 
order to avoid potential legal or disciplinary actions.   Hanna, a diabetes and osteoporosis 
educator, articulated this very notion when discussing why she would not address off-
label questions.  She stated, “It's hard to walk both lines, because you want to be able to 
say something, but it's not within your scope of practice. While you still have to know 
that your license allows you to do this, you carry liability.”  Fear of credential loss was 
also a motivating factor for Quinn, an educator who trained patients with diabetes, 
osteoporosis, and autoimmune conditions, who noted, “So I keep their stuff all private 
and I'm very compliant because I don't want to get in trouble. And I don't want to lose my 
nursing license. That would not be good.”    
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 Regardless of liability threats, most educators found creative ways to navigate 
within the compliance factors of staying on-label, fair-balance presentation, and adverse 
event reporting, while avoiding regulatory violations.  The next three sections explore 
some of the popular strategies and tactics educators used to accomplish this feat.   
 Strategies for staying on-label.  While sticking to the rules was the pragmatic 
and default approach many educators strove for to ensure compliant communication and 
content presentation, it was also something that seemed easier said than done.  Educators 
were quick to point out that patients could be assertive and persistent in their search for 
answers, often to questions to which educators were unable to compliantly reply.  Janelle, 
who provided training on products for patients with rare diseases, was an educator who 
spoke at length about this dilemma.  She shared the following example of how she would 
defer a patient back to their physician while also providing a rationale for why she was 
unable to fully address their concern. 
The way I frame it too, if they're having these side effects, they're like, “What 
should I do?” And I say, “Unfortunately, in our clinical trials when our patients 
did report headache or nausea or itching, we didn't give them any medication 
before, during, or after their infusions because we didn't want to suppress this 
data…” But I say, “Your doctor can recommend adjustments to your plan of care 
surrounding your infusion to potentially mitigate those side effects. Did you ask 
your doctor what they could do about these headaches or whatever?” “Oh, no, I 
didn't.” “You need to go back and ask them, because if you're not talking to them, 
they don't know this is occurring and they can't adjust your infusion plan orders 
and your plan of care.”  
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Janelle went on to explain that another reason she believes it’s important to stay 
compliant with her conversations, particularly when she is providing telephonic 
education, is to avoid creating disruptions or conflicts with a patient’s HCP.  She felt that 
in those circumstances in which she creates confusion, her actions could reflect badly on 
her pharmaceutical employer.  She stated, “What doctor wants to hear their patient say, 
‘Some lady on an 800-number told me this.’ That doesn't bode well if you are with a 
pharmaceutical company. As long as I stay on PI, that's a good cover.” 
 Felicia, an osteoporosis educator, also reflected on the nature of compliant 
communication and physician relationships.  However, as she pointed out, in some 
instances, the healthcare provider can create the confusion when they provide patients 
with information or instructions that conflict with the product label.  For instance, in one 
example, Felicia explained how a physician told a female patient to inject the medication 
in her thigh instead of the label-prescribed method of injecting in the stomach area.  
Felicia understood that the physician may have had a therapeutic reason for changing the 
injection location for that patient, however, she was not allowed to deviate from the label 
in her presentation.  She was able to work around the discrepancy through body language 
gestures and by verbally over-emphasizing the phrases “I must tell you” and “why it is 
pictured here.”  These tactics served as visual and linguistic signals to the patient to 
continue following the physician’s instructions even though Felicia was stating and 
presenting something different.  This is how she described it.  
I follow the deck and I followed the handout, the leave behind material… 
sometimes it's funny, physicians will give directions to the patients that are not 
compliant to what we are teaching. Like the injection site...To be compliant, you 
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inject in the belly. The physician told the patient your thighs, and I said, “No, I 
must tell you, you have to inject in your belly, which is why it is pictured here on 
our information.”  
Felicia continued by providing another example in which physicians would correctly 
instruct patients that they did not need to refrigerate the medication once it was opened.  
However, the physicians often did not take into consideration that many of her south 
Florida patients did not always use their air conditioning.  Hence, the temperature in their 
homes would exceed the allowable room temperature storage requirements noted in the 
product label.  Once again, she would use signaling body language and verbally emphasis 
key phrases such as “as stated right here” to clarify the physician’s instructions.   She 
explained, “They're like, ‘My doctor said, I don't have to refrigerate it,’ as I'm in their 
home sweating. I'll say, ‘That’s true. However, if it’s warmer than 77 degrees, as stated 
right here, you need to keep it in the fridge.’” 
Resources such as scripts, presentation outlines, discussion guides, and frequently 
asked question (FAQ) documents provided the guidance for delivery of compliant and 
on-label programs.  However, patients would still continue to ask questions beyond the 
scope of those materials.   Fortunately, educators employed many different 
communication strategies to contend with these instances when they were unable to 
address a question or concern.  Most educators expressed that it was important to explain 
to patients why they were unable to address off-label questions.  For instance, Penny, an 
educator for a terminal neurodegenerative condition, would point out to patients that she 
was only allowed to speak to the information in the package insert (i.e. label).  She said, 
“Well, I just redirect them to the package insert and say that... ‘I cannot talk about that 
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information because it's not in the package insert and it wasn't within the study 
guideline.’”  Deandra, an educator for autoimmune conditions, shared a similar refrain 
though she placed the onus on her company while also noting that her patients tended to 
accept her reasoning.  She stated, “…I'm very honest. I say, ‘I'd like to answer that 
question…But in my present position, my employer won't let me.’ They respect that…So 
they usually don't have a problem with that.”  Martin, a diabetes educator, articulated that 
patients were generally accepting of the compliance restriction when provided a rationale, 
though he was quick to point out that he avoided the use of the term “off-label”.  He felt 
some patients would not comprehend its meaning.  He shared this response about how he 
addressed a patient’s question regarding a different product than the one he represented.  
“I don't use the term ‘off-label’. [Patients] don't understand. I’d say, ‘This medicine isn’t 
meant to be used by this person. While they may get some benefit, it’s not 
recommended.’ Whenever you say it that way, most people get it.”  Reba, a diabetes 
educator, explained that she would address that situation by reminding the patient of her 
limitation to speak only to her product and deferring the choice to the physician’s 
therapeutic assessment.  She said, “I’d say, ‘I'm here because I'm being sponsored by this 
company, and I can’t discuss other medications.” …Although [patients] might say, “Well 
I take [insulin] instead of [another insulin].’ I’d say, ‘That’s a choice that you and your 
physician make.’” 
 Olivia, an educator for a product for a terminal neurodegenerative disease, took a 
proactive approach to handling off-label questions.  She explained that she would set 
expectations at the beginning of her patient engagements regarding the scope of questions 
she could address.  When patients would start to get “out into the weeds” with off-label 
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questions, she would remind them of the expectations she set at the start and refer them 
back to their physician.  She felt this made those situations easier on both her and her 
patients.  She described it this way, “I tell them, ‘We’re nurses, but we're never going to 
give you any medical advice.’ I set that expectation up front. If they start getting out in 
the weeds, I’ll say, “Remember when we talked about this?  I need to send you back.’”    
 While most educators discussed the importance of providing a rationale for their 
inability to address off-label questions or concerns, that tactic was typically just a first 
step.  Educators would often follow with additional conversational or linguistic strategies 
they found effective for maintaining their interpersonal connection with patients.  For 
instance, Deandra, a chronic autoimmune disease educator, believed a good strategy was 
to seek out the motivation for a question.  Doing so provided her additional insight into 
the patient’s disease experience or to the barriers that could be impeding comprehension.  
She described it this way,  
First, acknowledge their concern. They're obviously asking that for a reason, 
either they experienced it, they heard it from somebody or...You say, “Hey, can 
you tell me what's going on? Why is it that you're asking that question?  I realize I 
can't answer it fully but maybe I should understand a little better why you’re 
asking it and perhaps I can address the motivation behind it” … But, hopefully 
and asking a little bit more about their motivation or where that question is 
coming from, I can still have a conversation with them and perhaps talk about 
something else that's going on in the background that they don't understand, 
something about their disease process or something like that.  
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 Bonnie, an educator for multiple chronic conditions, felt an effective strategy was 
to encouraged patients to write down the questions she was unable to address and then 
share them with their HCP.  She believed this helped reinforce the validity of their 
question and averted an impression that she was being dismissive.  She stated, “A lot of 
times I start a list for their provider or encourage them to keep a general list of 
questions…But I'll give them another way to get that information or validate that it is an 
important question or concept.”  According to Cora, an educator for numerous chronic 
conditions, this tactic worked well in her multiple-engagement telephonic programs in 
which patients were sent a resource guide ahead of time.   At the end of the first call, she 
encouraged patients to write down questions in the back of that guide they would like 
answered the next time she connected with them on the phone.  She felt that this action 
not only better prepared patients for their program, it helped nurture the sort of trust that 
improved care.  She stated, “We tell them up front, ‘We're going to send you information. 
When you read through it, write all your questions down so when your educator 
calls…you can go through and get them answered.’ Right away, that builds the trusting 
relationship.” 
 Lois, another telephonic educator, supported a medication indicated for multiple 
common chronic autoimmune diseases for which there were competitor products.  As she 
explained, some of these other medications were in the same drug class as her medication 
as they had comparable pharmacological mechanisms of action, meaning they worked in 
the body in a similar way.  She highlighted how she would tell patients that, though she 
could not speak to the specifics of competing products, she was able to talk about the 
drug class.  She found this strategy helpful when patients would ask comparative 
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questions related to medications’ side effects.  She stated, “I say, ‘That product is in the 
same pharmaceutical drug class as my product, but they’re made differently and act 
differently.  I can't speak to that product, but I can tell you that this is what this product 
does.’” 
 Another option educators could utilize to handle off-label questions was to refer 
patients to the company’s medical information phoneline.  This is a telephonic support 
service staffed by physicians, pharmacists, or advanced practice clinicians who are 
authorized by the companies to provide detailed scientific and therapeutic product 
information to HCPs and, in some cases, to patients.  These support lines are generally 
not held to the same stringent compliance regulations as the marketing divisions of the 
company.  Gabi, an educator for common chronic autoimmune diseases, shared she 
would sometimes use this strategy.  She stated, “I'll just say I can't discuss that, that's 
something not my role. I don't make it like ‘…this company won't let me’… I'll say, ‘But 
here's the number to our medical department’. I just refer them back to medical.”   
 Referring patients forward to a companies’ medical department was a noted 
option, though educators spoke more frequently of deferring patients back to their HCP to 
answer off-label questions.  This strategy was also encouraged by the pharmaceutical 
companies.  However, educators recognized that there was a risk of upsetting or annoying 
patients by deferring them, especially as patients tended to view the educator role as that 
of an information provider.  Hence, they described the deferring process as a delicate 
situation that required communication nuancing, or as Cora, a telephonic educator for 
numerous products, described it, “tap dancing”.  She put it this way, “You can always 
refer them back to their healthcare provider…I think most of the time people understand. 
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But every once in a while you will have a disgruntled patient…You have to learn a little 
bit of tap dancing at times.”  Whitney, a diabetes and osteoporosis product educator, used 
a similarly analogy by referring to the deferring process as “steering”.  She stated, “The 
biggest trouble I had with patients is, ‘What do I do about dosing, or if I want to change 
this?’ or more like clinical kind of things…You just have to steer them back to the family 
doctor.” 
 Educators described multiple communication techniques they used for easing the 
deferring process.  One such strategy was to remind patients that their physicians 
possessed the requisite scientific knowledge about the drug to properly address certain 
questions.   Felicia, an osteoporosis product educator, explained how she used that 
approach in the following way, “Questions like that I've just refer back to the physician. 
‘Your physician understands all the molecular capabilities of this medication that I 
honestly can't explain to you. But he’s been educated and that's why he's ordering this 
over anything else.’” Ursula, a diabetes product educator, described how she used similar 
language in instances in which patients would ask her questions about other drugs in the 
same medication class as the one on which she trained.  She shared, “If somebody was on 
a GLP1, there's like five companies that make them, if somebody asked about another 
brand, I’d refer back to the physician, ‘[He] had this in mind for you and this is why he 
chose this one.’” 
 In addition to reminding patients of their physicians’ scientific expertise regarding 
the medication’s mechanism of action, educators would also reiterate that the doctors 
possessed a detailed understanding of patients’ specific medical histories.  Those histories 
influenced the decisions the doctors would make about prescribed medications.  Quinn, a 
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diabetes educator, shared the following response she would give patients, “You need to 
call your doctor and I'm sure the nurse or doctor would love to answer this for you. Or 
could answer it for you. I really don't know the depths of what's going on and can't 
answer that.”  Janelle, an educator on multiple products for patients with rare diseases, 
reinforced this same message by also informing the patient of the potential harm she 
could cause because she did not know patients’ medical histories.  She felt it was 
important to reframe the message so that patients understood that her rationale for 
deferring was for their protection.  She said, “Sometimes they'll press me on it and I'm 
like, ‘If I told you three medications to take, but you were allergic to two of the three of 
them, am I helping you at all by that? Because I don't have your medical chart.’” Later in 
her interview, she discussed how using this same tactic for off-label information requests 
worked well with her telephonic patients.  She shared this sample response as an 
example, “Unfortunately, I can't respond to that because I don't have your medical 
chart’...And so [they understand], ‘Oh, she's not doing it because she doesn't want to talk 
to me, she legit doesn't have enough information to make that decision.’”  
In some instances, educators would go beyond just deferring to also take on 
intermediary responsibilities between the patients and their physicians.  Penny, an 
educator who engaged with terminal neurodegenerative disease patients on a monthly 
basis, was allowed by her pharmaceutical sponsor to periodically contact her patients’ 
HCPs to provide progress updates.  This was a unique feature of her program and not 
typical of most others.  She explained that when she would defer an off-label question to 
the physician, she would also offer to contact the physician’s office ahead of time to let 
them know the patient would be calling with a concern.  She felt this helped reinforce her 
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commitment to the patient’s needs considering her limitation to address their question.  
She shared this response she gave patients as an example, “It seems like a very important 
question…What I can do is also connect with the office and let them know, if you'd like 
me to, that you're gonna call and you do have a question.”   
Deandra, an educator who often trained her patients in rooms at their physicians’ 
offices, took a slightly different intermediary approach.  She felt that sometimes patients 
were intimidated to ask their doctors questions.  Therefore, she would offer to pull the 
physician into the room on the spot so she could assist the patient in asking the question.  
She described it this way, “I'll say, ‘Maybe we can pull the doctor in here and have you 
pose that question to him,’ because sometimes patients are a little bit afraid to question 
the physicians…The physician's like ‘the all-knowing’ and you never question him.”  
Strategies for fair-balance presentation.  Fair balance presentation is the 
requirement that pharmaceutical companies balance information about a medication’s 
benefits with equal emphasis on its risks and side effects.  Bonnie, a telephonic educator 
for many different types of products, summarized it this way, “You want to make sure 
that if you say something that's positive about a medication, that it's explained in context, 
but you also share what risks there may be and what potential side effects there could 
be.”  The pharmaceutical companies typically relied on program resources such as 
scripts, presentation decks and guides, and other support materials used by the educators 
as the main strategy for ensuring compliance with this regulation.  Educators also 
understood that there were potential liability consequences were they not to comply with 
those guidelines.  However, a few educators thought compliance with this regulation was 
also a moral obligation and therefore reflected that belief in their communication with 
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patients.   For instance, Deandra, believed that fair-balance presentation ensured a 
perception of honesty and promoted a stronger relationship and rapport with patients.  
She noted, “Honesty is the best policy. Don't sugar coat too much, tell them what it is.  
They may not like it, but they will respect you and eventually come back to you and say, 
‘You know, you were right.’” Deandra was not the only educator to use the phrase “not 
sugar-coating” to describe how she strove to maintain trust with patients.  Lois, a 
telephonic educator for a product that treats multiple chronic autoimmune conditions, 
expressed the same sentiment.  She stated, “And I'm doing what I'm supposed to be 
doing, and I'm not sugar-coating anything when I read the safety information to them. So, 
that is a way to earn trust. They don't feel like I'm selling something to them.”  
Strategies for adverse event reporting.  When patients share with educators an 
adverse event (AE) or side effect they have experienced, the educators are required to 
document and report it to the pharmaceutical company.  The company, in turn, reports all 
AEs to the FDA who tracks them.  While AEs are typically not desired responses to a 
medication, many of them are common or expected reactions that do not affect the 
efficacy of the medication or cause long-term harm.  Educators explained that part of 
their responsibility when receiving AEs is to simultaneously impress upon patients the 
importance of sharing that information with their physician while also not unduly 
alarming them.  Reba, a diabetes product educator, summarized this approach in the 
following way, “I would probably say  ‘With any medication, even over the counter 
medicines like aspirin, there can be undesirable side effects…Certainly, if you have 
symptoms, you need to be discussing those with your physician or your care provider.’”  
Cora, an educator for many different products and disease states, noted how an adverse 
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event could even present an opportunity for a teachable moment that helped the patient 
understand more about their disease.  She talked about an example of a diabetes 
medication in the following way, “We're well-trained in being able to recognize and 
capture [AEs]. I know for some [patients], they've had complications that they had no 
idea were even related to the medication or it was a sign their blood sugars were off 
kilter.” Yvonne, a diabetes educator, also thought there was value in using a reported AE 
to further educate a patient, particularly on the process by which a physician determines 
how and why to prescribe a medication.  She provided the following sample explanation 
she gives to patients to iterate this point.  She said, “When a doctor makes a decision to 
put you on a product, they’re weighing the individual's indications, the contraindications, 
and with knowledge of the patient's medical history, makes a decision, this would be the 
most favorable thing for this patient.” 
 Janelle, a telephonic educator for patients with rare diseases, pointed out how an 
AE could be troublesome for a patient if it was not a common side effect noted in the 
product label.  When this happened, she would educate patients on how side effects are 
captured during clinical trials and why it is difficult to document all of them during the 
product’s research phase.  She provided the following example to highlight her approach, 
“If something is not what the side effect profile said was in clinical trials, I say, ‘You 
have other diagnoses, other medications that could be potentially causing an issue that we 
didn't capture in our clinical trials,’…Give them extra information.” 
 When educators explained their communications strategies for handling reported 
side effects, they often provided a description of the way they instructed patients to share 
the AE information with their doctor.  Felicia, an osteoporosis educator, stated such in the 
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following manner, “What I'll tell them is that I report it…and then I tell them, ‘You've 
got to call your doctor, he has to be aware of this. Thank you for telling me, but you've 
got to let him know as well.’” Gabi felt that it was important for patients to follow-up 
with their physicians regarding an AE as doing so promoted medication adherence 
behaviors.  She used the example of the osteoporosis product on which she trained to 
illustrate this belief.  She said, “So making sure they're aware of those side effects...to 
expect them. So, they don’t stop taking their medication as soon as they have one…that 
it's important to stay in contact with their doctor because those side effects reduce over 
time.”  
 Much like the deferral strategy for an off-label question, educators would 
sometimes serve as intermediaries by assisting patients in the sharing of an AE with their 
physician.  Yvonne, who often trained patients in the physician office, described how she 
would use that location to her benefit when patients presented a side effect.  She stated, 
“The offices I worked in, the doctors were usually right there. And they would stick their 
head in and I would say, ‘Mrs. Jones has an issue with such and such. Do you have a 
moment that you can talk?’” 
 Telephonic educators contended with AEs as well, though they had to adjust their 
communication tactics to fit the modality.  Janelle described strategies she would use 
when confronted by an AE to which she was unable to visually inspect.  Like other 
clinical educators, she strove to assess and address the AE within the limitations of her 
compliance capabilities and would then defer patients back to their HCP for appropriate 
care.  She provided the following example to illustrate how she would handle a patient 
who had an injection site reaction.  She explained, “I ask them clinical questions, but at 
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the end I always refer back... ‘You need to let your doctor know because I can't see it. If 
it’s hot, red, inflamed and hard, we didn’t see that in the clinical trials.’”  Janelle even 
shared that if she believed an AE to be severe enough, based on the patient’s description, 
she could recommend that the patient seek emergency assistance.   She said, “I’ll ask 
questions to see the severity. Do you need to call the doctor tomorrow or call today? Do 
you need to go to the ER in the next 30 minutes? I can say, ‘You need to seek emergency 
assistance.’”  
 Lastly, educators came to understand that side effects could sometimes be severe 
or onerous enough that patients would decide to discontinue the medication.  Iris, an 
educator for multiple common chronic disease conditions, explained that, in those 
instances, it was important to respect the patient’s decision and not pressure them to 
continue with the medication.  She said, “When a patient tells me, ‘I don't want to take 
this drug anymore.’ That’s [their] choice. I respect that…I explain to them about AEs and 
wish them good luck. ‘Hope that you're able to find something that works for you.’”     
Communication strategies for disease and treatment context factors.   Like 
the political/legal context, disease and treatment factors produced a range of barriers that 
directly influenced patients’ willingness and ability to engage in interpersonal 
communication with clinical educators.  Fortunately, the clinical educators mastered 
many types of communication strategies for addressing those factors.  One technique that 
educators relied on was engaging the patient in a conversation that centered on a personal 
connection.  For instance, Yvonne, a diabetes educator, explained how she would try to 
relate the patient’s disease experience to a topic like auto mechanics or electronics if she 
knew those were relevant to her patient.  She described it this way, “If they work on cars, 
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I can relate healthcare to an engine...technology is a little bit more tricky…but it's just 
electricity meeting with a number of obstacles…When you start talking to people about 
that, you can talk to those people.”  Vivian also stressed the importance of making a 
personal connection that centered on a partnership between her and the patient.  She 
would use the pronoun “we” to emphasize the joint nature of creating a disease self-
management plan.  She expressed it this way,  
If I walk in, I tell them, “I'm [Vivian]. I work with the diabetes team. We need to 
talk, because your sugars are up, way out of control.” Then that's it. I'm already 
out the door. Nobody's listening. But I found that if I go in and say, “Your doctors 
are concerned about your sugars and wanted us to get together and see what we 
can do to make things better. Tell me what you're doing at home. How's it 
working?” Then all of a sudden, they open up…so just establishing this little 
factor of I'm willing to listen to you. Tell me what you're doing and why is it 
working or not working, and then we develop a plan. 
Another part of establishing that personal connection according to Evelyn, an 
educator who treated patients with a terminal neurodegenerative condition, was helping 
them understand the uniqueness of their experience.  She discussed how she sometimes 
discouraged patients from focusing on how others handled their disease because it drew 
energy away from their own battle.  She clarified, “[Patients will] say, ‘Well, how are 
other people doing on it?’…I always go back to ‘Everybody's disease process is different, 
everybody's response to the medication is different, so talking about other people isn't 
important. What's important is talking about you.’” 
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While educators mostly referenced communication strategies they used with 
patients at the start, or at transitions points, of the disease journey, Janelle highlighted the 
importance of appropriately engaging seasoned travelers.  She worked with patients who 
frequently changed therapies, so she approached conversations in a way that avoided 
assumptions about experience or comprehension.  She stated, “I don't want to jump in 
with someone who's already had seven injectables for psoriasis…and they're like, ‘I've 
been doing this for eight years,’…I'm not gonna jump in and start yammering; I care 
more about meeting them where they're at.”  Later in her interview, Janelle also reflected 
on how the nature of the diseases and medications to which she treated occasionally 
forced her to take a more hard-nosed approach in her conversations.  She provided the 
example of how she mandated patients complete their first injection of an anticoagulant 
while she was present to avoid serious and life-threatening outcomes that could result 
from non-adherence.  She described it this way,  
It could be life or death if they didn't give themselves these shots…So, explaining 
the severity of if they didn't do it...you can't do that in a nice way. Sometimes you 
had to get a little bit firmer with some patients who kind of wanted to play it off 
like, “Oh, I'll do it when I get home.” “No, you won't. If you won't do it here, you 
won't do it at home once no one's staring you down.”  
 When addressing barriers related to injection and infusion administration 
modalities, multiple educators discussed the importance of correcting injection 
misconceptions, particularly about such as things as the needle’s size and associated 
degree of pain.  Deandra described the language and process she would use to walk a 
patient through their first injection.  Her first step was to understand any barriers while 
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also providing verbal reassurance.  She explained it this way, “Perhaps they think it's 
some two-inch long needle. So, show them that it's really small…Assure them I will be 
there to do this each and every time until they're comfortable with it. ‘I will help you with 
this.’”  Sophie shared a similar understanding and described her preferred tactic of doing 
an injection demonstration to address the barrier.  She stated, “It is not uncommon for 
myself to just do a dry injection, show them what it is like to do with a sterile syringe…if 
they can see somebody do it and actually have them do…they can start to learn.” 
 Telephonic educators also used communication workarounds for handling similar 
technical issues that would arise related to proper self-injection or self-infusion 
techniques.  One tactic was to create a visual analogy to which a patient could more 
easily relate.  For instance, Lois provided an example of the way she would verbally 
assist a patient needing assistance with the proper way to hold a syringe.  She shared, 
“Like for instance, how to hold a syringe. I'll say, ‘Well hold it like you're getting ready 
to throw a dart, or holding a pencil’, things like that. And then they'll say, ‘Oh, okay, 
that's how you do it.’”  Janelle, on the other hand, noted that she would sometimes refer a 
patient to the company’s website while she was on the phone with them, to walk the 
patient through the steps of a complex self-infusion process.  She explained, “If I'm not 
getting them, I ask… ‘Do you have access to the Internet? We've got a video online that 
the nurse walks through the process.’ So, they'll pull that up and be like, ‘Oh, I was 
totally missing this.’”  
Patient misconceptions were also pervasive barriers when discussing disease and 
treatment side effects.  For instance, Xoe noted that many of her patients had erroneous 
beliefs about insulin.  She explained how she often had to address a common 
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misperception that insulin was a therapy of last resort necessary for patients who failed to 
effectively manage their disease.  She shared, “We tried to take the mystery out of stuff, 
even when we did classes, to show them that… ‘Insulin isn't because you failed, it was 
because you had a change in your condition.’  I think new education does that.” 
 Another language strategy that educators would use was framing disease and 
treatment context messages in the format of a preventative measure.  Felicia used this 
approach for her osteoporosis patients who were at risk for a fall-related fracture and 
were prescribed a daily self-injectable biologic that stimulated bone growth. When asked 
by patients why they needed to take the medication for two years, she would say to them, 
“Because your option is a fracture, vertebral fracture, hip fracture, and then that alters 
your life forever.  Once you fracture your hip, you’re looking at hospitalization, surgery, 
physical therapy, medications, it changes everything.”  Like Felicia, Janelle found that 
reframing the injection message in the context of a preventative measure was necessary 
for rare disease patients.  In her case, those individuals were sometimes parents who were 
needing to administer an injection or infusion to their young child.  She shared this 
example of how she would speak to them, “We're doing this because we want them to not 
have a bleed’…retooling the idea of ‘I've gotta stick a needle in my kid.’ ‘You're doing 
this to help them.’ Reframing that whole idea…to get them in a comfortable spot.” 
 Martin, a Type 1 diabetes educator who worked with children, discussed other 
recommendations he felt were effective when speaking with parents and youth afflicted 
with disease.  He stressed how the foundation of that communication was based on 
establishing trust, which included both a need for honesty as well as opportunities for 
children to make some decisions about their treatment.  He explained it this way. 
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Telling a young child, “This is not going to hurt,” is not a way to build trust. 
Because, we know giving insulin may hurt. We have to kind of build that trust 
and say, “We've got to do this.” And offer options. That's what I used to do with 
them. And I'd tell the parents, “Let them choose where they want the insulin 
injected, but it's not a question of, ‘Do you want to take this insulin?’ or ‘Do you 
want to check your blood sugar?’, it's ‘Which finger do you want to use?’ But 
yeah, trust, especially in diabetes, because this is lifelong. And if you breach that 
trust it could make it very difficult in the future. 
Summary of Findings 
 Ecological factors were influential in the educator-patient communication 
dynamic.  However, the political/legal context had the greatest communication impact for 
interviewed participants as it was the only one interpreted primarily in the direction of 
educator to patient.   Industry and government-imposed compliance regulations were the 
most discussed political/legal context factors, particularly as they related to the factors of 
fair-balance presentation, staying on-label, and adverse event reporting.  Unfortunately, 
while educators reluctantly understood the rationale for these regulations, they were still 
frustrated in the way they impeded communication and jeopardized patients’ 
comprehension of information.  The inflexibility for adapting language and materials to 
specific patient learning needs was viewed as particularly problematic.  Not surprisingly, 
that frustration would sometimes lead to purposeful non-compliant behaviors as 
educators weighed the expectations of their role against their duty to provide the best care 
possible to their patients. 
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  Educators also struggled with other ethical situations that pitted their professional 
integrity and altruistic nature against the expectations of their role.  The experiences of 
Antonia, Iris, and Tabitha, who engaged in purposeful non-compliant behaviors, 
illuminated the complex deliberations these educators faced when confronted with 
morally conflicting situations.  However, while those three educators were most articulate 
in expressing their rationales for non-compliant behaviors, they were not alone in their 
feelings.  Most educators reflected, at least in some part, of the ethical implications of 
their role.  In many instances, educators interpretations were presented within a dual-
loyalty context—situations in which they must choose between two equally deserving 
alternatives.  The most noted type of dual-loyalty conflict was between their patient and 
their employer.  However, educators also shared examples of conflicting loyalties of 
patient versus their HCP and patient versus their family. 
 Though the political/legal context was the only one of Street’s (2003) four 
original contexts that was examined, it was not the sole influential domain in 
educator/patient interpersonal communication noted in this study.  Data analysis revealed 
a new context that educators interpreted as being highly impactful in the way patients and 
educators engaged each other.  The disease and treatment context included the varied 
components of a patient’s disease experience that would frequently necessitate that 
educators change the way they interacted with patients.  Factors that were part of this 
context included such things as disease type (e.g., chronic, terminal, rare), disease-related 
side effects, treatment-related side effects, the prevalence of comorbidities or disabilities, 
and drug administration modality (e.g., oral, self-injectable, self-infusion). 
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 The role of ecological factors within the political/legal and disease and treatment 
contexts did more than impact how communication occurred between educator and 
patient.  In many instances, those factors manifested themselves as behavioral barriers 
that impeded appropriate disease and treatment management.  Hence, educators 
employed a variety of communication and behavioral-management strategies to help 
them and their patients navigate through those barriers.  Educators also learned the value 
of establishing trusting relationships early in the engagement since they could leverage 
that rapport when faced with the limitations imposed by compliance regulations.  The 
next chapter examines findings related to this concept of trust relationships within the 
context of how educators managed privacy with their patients.  It explores in detail the 
type of confidant roles that educators take on as part of that process while also addressing 
how educators work to avoid breaches of trust. 
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Chapter 5: Findings—Communication Privacy Management (CPM) Theory 
The findings for this chapter are examined within the context of Petronio’s (2002) 
communication privacy management (CPM) theory and address the second research 
question: “How do those ecological factors influence the way pharmaceutical-sponsored 
clinical educators establish and manage communication privacy boundaries with 
patients?”  As discussed in Chapter 4, the ecological influence of political/legal context 
factors has the potential to erode the trust that is established between clinical educators 
and patients during educational encounters.  Yet, the ongoing success of clinical 
educators’ networks suggests educators can retain the requisite level of trustworthiness to 
coach and counsel patients to effective disease self-management behaviors 
(eyeforpharma Ltd. & S3 Connected Health, 2018; Newmark & Blackburn, 2018).  The 
process by which educators maintain trust and navigate within communication 
complexities can best be explored through the lens of CPM theory (Petronio, 2002) and 
its focus on the relationship between patients’ disclosure of private information and 
educators’ confidant role types.  
The nature of the pharmaceutical-sponsored clinical educator role as secondary or 
tangential to the primary healthcare team presents a unique challenge for both the 
educator and the patient regarding how the patient’s health information is shared and 
managed.  For instance, educators noted that patients changed the way they sometimes 
confided with a clinical educator because of perceived role differences from the primary 
care team.  Similarly, educators have provided insights regarding how they interpreted 
their role as a healthcare confidant in a different way than a primary care team member 
due to the health information limitations that are placed upon them.  CPM theory is used 
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here to help interpret this discourse.  This chapter presents evidence of how both 
disclosers and recipients of private information create privacy rules that help them 
manage that information.  Specifically, the findings presented here interpret (a) how the 
establishment of trust is foundational to educators’ ability to solicit disclosures, (b) how 
educators and patients established rules for managing private information, and (c) how 
educators were representative of three CPM theory confidant roles.  The chapter is 
organized around three themes that represent the major findings as related to CPM theory 
and the second research question.  Those themes are: 
1. Educators believed they needed to establish and maintain trust throughout the 
engagement process for them to successfully solicit meaningful patient disclosures. 
2. Educators managed the information disclosed to them by patients using routinized 
rules based on core privacy rule decision criteria as well as changing rules based on 
catalyst privacy rule decision criteria. 
3. Educators managed multiple types of confidant roles with patients including 
stakeholder, deliberate, and reluctant.   
Trust and Privacy 
Theme 5: Educators believed they needed to establish and maintain trust 
throughout the engagement process for them to successfully solicit meaningful patient 
disclosures. 
 Trust is a hallmark of CPM theory.  When it has been examined within the 
context of healthcare and medicine, the theory asserts that as a patient decides to disclose 
private information to a healthcare professional, such as a clinical educator, the action is 
predicated on the notion that the educator’s professional status and credentials carries an 
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inherent level of trust that the information will be protected (Petronio & Sargent, 2011).  
Additionally, while patients’ need for obtaining healthcare services is the primary 
motivational factor for revealing health information about themselves, patients might still 
perform a risk/benefit analysis about when, what, and how much to disclose to an HCP.  
A relationship grounded in trust, therefore, helps mitigate risk, which in turn, promotes 
greater comfort for disclosure (Petronio et al., 2012).  
This theme examines educators’ interpretations of trust and its necessity in 
soliciting the types of patient disclosures that help educators coach patients to successful 
disease self-management.  This examination begins with a discussion of how educators’ 
defined the nature of trust as it relates to privacy management behaviors.  Next, 
educators’ descriptions of how trust is established with patients is explored, followed by 
an explanation of how trust is strengthened and maintained throughout the engagement 
process.  Lastly, the concept of loss of trust is explored and its impact on patients’ 
privacy disclosures. 
 Defining trust.  The clinical educators were unanimous in their belief that a 
relationship built on trust was a requisite for soliciting meaningful disclosures from 
patients.  The way the educators interpreted or “defined” the concept of trust, however, 
did vary.  For instance, Antonia, an educator for patients with a terminal 
neurodegenerative disease, felt that trust was predicated on patients feeling respected by 
the educators.  She stated, “If I think of trust, do I trust you that you won’t steal my 
money? Not that kind of trust. But do I trust you to treat me with respect? ...In that 
respect, I think it’s very important.”  Cora, an educator for numerous medications and 
disease types, felt that trust was investing in the vulnerable nature of the patient status 
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and allowing them to feel comfortable in “exposing” their fears and concerns.  She put it 
this way, “When you develop a trusting relationship with a patient, then they’re able to 
really expose their inner self and all their fears and concerns, and that’s where you’re 
really able to build the bridge to help them accept the diagnosis.”  Reba, a diabetes 
educator, interpreted trust in a similar manner stating “I think [trust] plays a really 
important role, because especially with diabetes, people are putting their faith and trust in 
you to lead them in an appropriate direction. So, I feel it’s extremely important.”   
Finally, Karl, a telephonic educator for chronic autoimmune conditions, summarized 
succinctly its importance in the educator-patient dynamic when he stated, “Trust is 
everything. If you cannot develop trust, you’re not going to get anywhere.” 
When discussing the concept of trust, many of the educators spoke of it in 
conjunction with the concept of “rapport,” though there was often discrepancy regarding 
its interpretation.  Some educators considered the terms to be similarly defined, or even 
synonyms for each other.  Bonnie, a telephonic educator for multiple products that treat 
numerous conditions, articulated as much when she stated,  “Trust is one of the most 
important factors, you can call it rapport or connection…and it’s about [the patient], that 
you’re truly here to help that person and not yourself and not for some other reason.”  
Gabi, an educator for osteoporosis and chronic autoimmune condition drugs, implied a 
similar understanding of the synonymous nature of the two terms.  She used them 
interchangeably while discussing their importance at the start of her patient education 
programs.  She stated, “…that the patient has that trust in [educators] before they start the 
training. That’s why I think it’s important to...take the time to develop a relationship or a 
rapport with them before you start the training. So they feel comfortable.” 
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Conversely, Hanna, a diabetes and osteoporosis educator, felt trust and rapport 
were distinct components of the educator-patient relationship.  However, she was unsure 
as to which one served as the catalyst for the other.  She explained, “You can’t have trust 
without building rapport, and so I don’t know which comes first, the chicken or the egg 
kind of thing. I mean, you have to have one to be able to have the other.”  Penny, an 
educator for patients with a terminal neurodegenerative condition, however, was clear in 
her understanding of the two.  She believed that rapport was a precursor and requirement 
for the development of trust, as trust could only be earned once rapport was established.  
She put it this way, “If you develop rapport with them, that leads to trust over time. The 
most important thing is being able to connect with them immediately, so that connection 
and rapport building is a bridge to developing trust.”  
Establishing, maintaining, and losing trust.  While all the educators agreed that 
trust was a requisite for successful interactions with patients, there were differing views 
regarding how patient trust was earned or established.  Some educators believed that their 
credentials or status as a nurse automatically afforded them trust.  Others believed trust 
was not something that was imbued, but rather needed to be worked towards.  Nadine, a 
telephonic educator for chronic autoimmune conditions, hypothesized it was a 
combination of both when she explained,  
Nurses have that reputation of being trustworthy so that definitely helps. But I 
think each nurse has to really strive for that trust relationship. If we want to reach 
that patient, where they are and help them to understand their disease process or 
why it’s important to eliminate certain food items or change behaviors and such. 
And that’s all on that foundation of the nurse-patient trust relationship.  
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 Tabitha articulated a common sentiment that nurses are afforded a high level of 
trust as part of their healthcare role when she stated, “I think right from the get-go, we are 
trusted. I really do believe that. Even in hospitals, doctors, they’ll save your life, but 
who’s going to keep you alive? It’s the nurse who can keep you alive.”  However, she 
went on to clarify her beliefs when she stated, “I think we start out on top and if we screw 
up, that’s when we’re going to kind of fall down on the scale.”  She continued further by 
explaining how this implicit trust contrasted with what patients would grant physicians, 
whom she felt were perceived by patients as less altruistically oriented.  She speculated, 
“We’re [trusted] over doctors, we’re often on par with pharmacists. It’s a shame because 
patients have come to maybe not trust their doctors because there’s kind of this 
perception that they’re greedy, and ordering tests and things you don’t need.” 
Interestingly, a telephonic approach for patient engagement did not seem to be a 
limiting factor in educators’ perception of automatically receiving trust.  Olivia, a 
telephonic educator for patients with a terminal neurodegenerative condition, believed 
imbued trust was an innate part of her role. However, she also pointed out that patients’ 
perceptions of honesty and transparency were also important.  She described it this way, 
“I think people innately trust and respect us overall. But I think when you’re honest, 
genuine and transparent with people, it goes a long way. Even telephonically, you can get 
that across to people. They know when you’re being honest.”  Lois, another telephonic 
educator for a drug that treats chronic autoimmune conditions, shared how leveraging 
implicit trust was an important asset for helping her patients gain confidence in her 
abilities even though they were only connecting over the phone.  She noted, “If they 
don’t believe you know what you’re talking about, they may not listen or learn. So, even 
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if it’s saying, ‘Yes, I’m a nurse. I work with this particular drug’ …Anything to give 
them confidence in me is important.” 
 Not all educators were convinced though that trust was something automatically 
afforded them simply because of their role.  When asked a question about this 
phenomenon, Evelyn, an educator for a terminal neurodegenerative disease, stated, “No, I 
think you have to earn it. Well, I’d say maybe it could be implicit, but you really do have 
to earn it.”  Ursula, a diabetes and osteoporosis product educator, held similar beliefs.  
She explained how the “white coat” that may have promoted implicit trust in other 
geographies, would not work with her rural Southwest patients.  She put it this way, “I 
don’t think because you’ve got a white coat on…I’m not sure people relate to that, at 
least my rural people. Just because you’re a healthcare professional, I don’t think that 
comes with trust necessarily.  You have to earn it.”  
Establishing trust.  When educators spoke of earning patient trust, many of them 
discussed the importance of establishing it quickly at the start of their relationship with 
patients.  Janelle, who trained patients with many different types of rare conditions, 
framed it in the context of letting patients know from the get-go that she would always be 
there for them.  She stated,  “Yeah, I mean, you have to go in and try to sell that, but I 
had to display confidence and to instill that trust in them that yes, I will be available; yes, 
I will have your best interest at heart.”  Evelyn, an educator for patients with a terminal 
neurodegenerative condition, believed that a good way to instill patient trust was to 
immediately try to understand each patient’s personal disease journey.  She explained, “I 
always start with the beginning because I think it’s important to know, how did you get 
where you are today. What led up to your diagnosis? And I think they just start talking 
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and establish that sort of trust.”  Reba, a diabetes educator, shared that her goal was to 
develop a sense of trust with patients before even beginning to deliver her program 
content.  She believed she could accomplish this by being outgoing, welcoming, and 
reinforcing her willingness to address any questions or concerns patients may have about 
their disease or therapy.  She put it this way, “I tried to establish trust before I started the 
dialogue or program…I always tried to be real outgoing, welcoming, and letting people 
know there wasn’t any question too insignificant...It was sort of like setting up rapport 
before the program started.” 
Penny, another educator for patients with a terminal neurodegenerative condition, 
felt she was often able to immediately initiate a trust bond with patients by sharing 
personal anecdotes regarding her life and why she became a clinical educator.  She 
shared, “I explain to them why clinical education is important and why I became a 
clinical educator based on my personal experience as a caregiver…They want to know 
you’re a person who cares, not just somebody from the [pharmaceutical] industry.” 
Deandra, an educator of products for patients with rare diseases, however, summarized 
the overall importance of immediately establishing trust for succeeding with patients.  
She said, “It all happens with that first visit. It’s either sink or swim. You’re going to 
either make that treatment successful or you’re going to kill it by the way you present it 
to the patient and that trust is huge.” 
Maintaining trust.  Most of the clinical educators engaged with patients through 
multiple interventions over an extended time period.  Therefore, they recognized that 
while initiating trust at the start of the relationship was imperative, it had to be 
continuously maintained throughout their tenure with patients.  Antonia was an educator 
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for patients with a terminal neurodegenerative condition with whom she would meet 
monthly over the course of the year.  She felt that one of the primary reasons her patients 
found it difficult to establish trust relationships with healthcare providers (HCPs) was 
because they did not take the necessary time to try to establish one.   Therefore, she 
strove to make sure patients understood that she would provide them the time they were 
seeking.  She stated, “I tell my patients, ‘I’m here until we both are comfortable that you 
understand.’ So, having that kind of trust. ‘I’m not leaving, I’m not in a hurry, I’m here 
until we’re both comfortable with what you need.’”  Nadine, a telephonic educator for a 
program that included multiple engagements with patients with chronic autoimmune 
diseases, shared similar views that her role as a nurse, both in the field and as an 
educator, afforded her more time with patients.  That extra time therefore correlated to a 
stronger trust relationship with patients than they may have experienced with their 
physicians.  She explained, “Some patients feel that nurses have more time to spend and 
can invest more and listen than the doctor…A lot of times the patients will ask questions 
they don’t feel they can ask the doctor for those reasons.” 
Antonia also recognized her time with patients did not mean that she was 
responsible for dominating the conversations.  Patients needed the ability, opportunity, 
and encouragement to share their journey and its struggles, lest they not fully engage in 
the relationship.  She said, “To be effective, [patients] need to develop trust in you and 
that takes time…It has to be about them. You really have to say, ‘Tell me about yourself, 
tell me about your journey. What are your struggles?’ That takes time.”   
By far though, “open and honest” interpersonal communication was a frequently 
noted strategy that educators stressed was necessary for earning and later maintaining 
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trust.  In fact, multiple educators used that phrase to describe its relationship to trust.  
Ursula, a diabetes educator, posited, “I think just talking to people and being open and 
honest and caring, then hopefully you've got that trust.”  Olivia, an educator for a 
terminal neurodegenerative condition similarly noted, “But I think that when you're just 
open and honest and genuine and transparent with people, that it goes a really long way.”   
Others, such as Sophie, a diabetes educator, framed this notion in the context of a 
partnership with the patient based on two-way dialogue and decision making.  She 
shared, “I will find out, ‘What are your barriers, your fears?’ And go from there…If they 
had experience with insulin, what dose did they remember being problematic? Just gives 
them a say in it…and then you build that trust that way.”  Other educators supported 
Sophie’s belief that conversations needed to include active listening on the educators’ 
behalf to nurture and sustain trust.  Nadine, a telephonic educator for patients with 
chronic autoimmune diseases, explained the importance of non-judgmental and engaged 
listening for helping build a sense of connectedness between herself and the patient.  She 
shared, “Part of gaining trust is asking them about themselves, being nonjudgmental, 
letting them speak, not speaking over them, being a good listener...paraphrasing what 
they said…it helps them to trust, ‘This person is listening, they do understand, they do get 
me.’” Karl, a colleague of Nadine’s, articulated a similar vision of the role of active 
listening, as well as two other component that he felt were an important part of the 
formula for maintaining trust, honesty and keeping his word.  As he explained it, “I’m 
always being honest…I keep my promises.  If I tell my patient I’m going to be at their 
home at 2:30 PM, I will be there…The other thing is active listening…those are the 
things paramount to developing trust with somebody.”  Zara believed that the rapidly 
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evolving nature of chronic diseases like diabetes, along with the complexity of their 
therapies, required her to continuously educate and solicited questions from patients in 
order to maintain their trust.  As she described, “I explain why their doctor prescribed 
them, what makes them diabetic, what does diabetes mean. I’ll go over their labs and help 
them to understand…Just taking the time to answer questions...I think that’s what helps 
people to have trust.” 
 While the highly regulated nature of the clinical educator role did present 
communication challenges, many educators believed that a strong trust bond with patients 
mitigated the impact of compliance factors.  For instance, Deandra, an educator for 
autoimmune and rare diseases, spoke of how trust was maintained when she was required 
to share a product’s risk profile as part of her obligation to fair/balance presentation.  She 
explained, “I think that’s important if you’re to develop trust and credibility. If they think 
you’re pulling the wool over their eyes or trying to sugarcoat something, they’re going to 
shut you off and their mind is going to go elsewhere.” Additionally, Evelyn, an educator 
for patients with a terminal neurodegenerative disease, noted that trust was maintained 
when she disclosed to patients the limitations she faced regarding on-label compliance 
and her need to sometimes defer patients’ questions to their healthcare provider.  She 
stated, “I think I actually get more trust when they understand that you’re doing whatever 
you can within the parameters of how you can do it to do what you’re going to do.”  A 
similar sentiment was expressed by Bonnie, a telephonic educator for numerous chronic 
conditions.  In fact, she believed that expressing her frustration with on-label compliance 
limitations to patients facilitated a sense of a “shared experience” that reinforced her 
bond with them.  She put it this way, “I think [my inability to speak off-label] validates 
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the trust because they know I care, they know that I’m a little frustrated or 
unhappy…because we’re sharing that experience together…that strengthens the bonds 
and rapport more so than it harms.” 
Janelle, a telephonic educator for patients with rare conditions, even went as far as 
to offer to reach out to patients’ HCPs directly regarding off-label questions. She shared 
how this served as a gesture of trust for those patients who were uneasy asking questions 
to their HCP.  She explained it this way, “I say, ‘You’re welcome if you want to go into 
your next appointment and say, “You should call the nurse advocate on the phone.” I’m 
happy to chat with them, explain anything they would want.’ I feel like it’s an extra 
added benefit.” 
 Losing trust.  Though educators understood the benefits and necessity of a strong 
trust bond with patients, they also recognized the impact when trust was lost or never 
acquired.  Bonnie, an educator for many different disease types put it succinctly, “There’s 
just no way that you could get somebody to recognize what’s in their way and how they 
can take the first steps to try to change that or overcome that if you don’t have that trust.”  
She went on to elaborate that, in her role as a telephonic educator, a loss of trust will 
curtail patient communication and impede the progress toward overcoming barriers.  She 
stated, “If you don’t have trust, there’s not any way to help people when they have 
barriers, concerns, or they’re upset…I mean, why would you tell people your challenges 
about your health and life, especially if you don’t know that person.” 
Penny, an educator for patients with neurodegenerative and neurological 
conditions, noted that trust losses run the risk of impacting patients’ ability to absorb 
knowledge and develop the skills necessary to self-manage their condition.  She 
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lamented, “You can educate on materials, but if they don’t trust you, do you think it’s 
going to resonate in their lives? Are they going to absorb what you’re teaching and really 
practice and benefit from it if there’s no trust?”  Janelle, an educator for patients with rare 
diseases, associated a patient’s lack of trust in her to also mean a loss of credibility.  She 
believed this could put the patient at risk for not properly managing their disease or 
causing them to revert to negative emotions.  She explained,  
If I don’t seem credible and I don’t seem like I know what I’m talking about, 
they’re going to lose all trust and resort back to a feeling of worry, despair, 
potentially hopelessness. If I don’t sound competent, if I don’t appear confident, if 
I don’t seem like...to know what I’m talking about.  So, I feel like trust is a huge 
thing for them to be able to transfer that trust into confidence in themselves, to 
take on that understanding of things.  
 The clinical educators were keenly aware of the actions or situations that would 
put trust at risk.  For instance, Olivia noted the potential damage to trust that could arise 
if educators ignore expectations of proper follow-through and time management.  She 
explained how these factors were particularly important for her population of patients 
who suffered from a terminal neurodegenerative condition and were physically and 
emotionally reliant on her.  She described it this way, “I think you can lose [trust] and can 
disappoint people if you don’t follow up, if you don’t follow through…you’re not going 
to feel a lot of love for me. Especially in this disease [where] the only outcome is death.”  
Deandra, a telephonic educator for rare diseases, explained that an educator’s lack of 
preparedness or familiarity with the therapy on which they are educating can also 
extinguish a trust bond.  She reflected, “When a nurse goes into a home and…says to the 
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patient, ‘Well, I’ve never done this before but we’ll figure this out. We’ll get this done.’  
That patient’s trust and confidence in this nurse has just been shot to hell.”  Nadine, an 
educator for patients with chronic autoimmune diseases, felt that privacy losses could 
negatively impact the trust relationship, even when the loss occurs within the patient’s 
family.  She explained it this way, “If the patient told you something and wanted to keep 
it private. But when the spouse walks in, you blurt it out, you just shot any chance of that 
patient confiding in you. That shoots trust right out the window.”  Nadine’s beliefs 
illustrate the concept of loss of trust credit points (Petronio, 2002), which are figurative 
points that can increase or decrease based on educators’ privacy actions, and underscores 
the intertwined nature of the constructs of trust and privacy.  The next theme explores this 
relationship between trust and privacy and examines how educators manage disclosed 
information from patients through privacy rule decision criteria. 
Disclosure Rules and Privacy Management 
Theme 6: Educators managed the information disclosed to them by patients using 
routinized rules based on core privacy rule decision criteria as well as changing rules 
based on catalyst privacy rule decision criteria. 
Educators recognized that patients’ willingness to disclose private health 
information was predicated on a strong trust-based relationship.  They also understood 
that the nature of their role as an HCP predisposed them to a level of trust that, for the 
most part, allowed for such disclosures to happen with little resistance or skepticism.  Not 
surprisingly, when educators were asked during their interviews to reflect on the meaning 
of the concept of privacy in the pharmaceutical clinical educator role, they rarely spoke 
about it in the context of communicating information about themselves to patients or 
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others.  Instead, one of the ways educators addressed the topic was by explaining their 
perceptions for how patients disclosed disease and therapy information to family, friends, 
and others—views educators accumulated from their conversations and observations with 
patients.  They noted that patients’ behaviors varied, with some being open toward 
talking about their condition while others kept that information guarded and protected.  
Those descriptions highlighted educators’ interpretations of how patients established 
varying levels of boundary permeability (Petronio, 2002).  Educators also provided 
examples of the way influencing factors impacted the decisions patients would make 
about information disclosures.  These examples were illustrative of CPM’s two categories 
of privacy rule decision criteria, core criteria and catalyst criteria.  The former describes 
criteria that is stable and works in the background, while the latter explains criteria that 
fluctuates based on situational triggers (Petronio, 2002; 2013). 
The other way educators addressed the concept of privacy was by describing 
disclosure expectations placed upon them by different groups including patients, 
government, and themselves.  Educators recognized that, as recipients of patients’ private 
information, patients had expectations regarding how educators managed that 
information.  Additionally, educators also placed expectations upon themselves about 
when, where, why, how, and to whom patients’ information was shared.   However, while 
educators were co-owners of patients’ private information, they engaged in little 
boundary coordination with those patients.  In CPM theory, boundary coordination is 
when the information owner (i.e. the patient) and the recipient of that information (i.e. the 
educator) coordinate decision rules regarding disclosure boundaries (Petronio, 2002).  
Those rules determine such things as how private information is used or shared as well as 
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to whom and when it can be shared.  While little privacy coordination occurred, 
educators still used and followed a set of routinized rules based on core privacy rule 
decision criteria as well as adapted to changing rules using catalyst privacy rule decision 
criteria. 
This theme examines clinical educators’ understanding of the concepts of trust 
and disclosure within their definition of privacy.  This examination begins with an 
explanation of how the trust relationships established between patients and educators 
were foundational to educators’ and patients’ privacy management behaviors. Next, 
educators’ descriptions of how patients’ managed privacy disclosures with their family, 
friends, and others are provided.  Included with those descriptions are interpretations of 
why those patient stories are representative of the CPM constructs of boundary 
permeability and core and catalyst privacy decision criteria.  The insights educators 
gleaned from patients’ disclosure behaviors served to influence educators’ own beliefs 
about privacy management and the clinical educator role.  Lastly, the routinized and 
changing privacy rules educators used, along with their respective core and catalyst 
decision criteria, are discussed within the context of three influential parameters—
professional ethics, political/legal ecological factors, and insights from patients’ privacy 
management behaviors. 
Trust and privacy management.  Trust serves as a foundation for managing 
privacy disclosures across all forms of interpersonal engagements.  The educator-patient 
relationship is no exception given the nature of information that is disclosed by the 
patient to the educator and the role the educator serves in patients’ disease self-
management.  In Petronio and Sargent’s (2011) explanation of the stakeholder confidant 
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role, a concept discussed later in this chapter, the authors outline why healthcare 
professionals tend to be afforded trust easily by patients.  They note that patients give 
guardianship of their information to HCPs because it is predicated on both the functional 
need to receive healthcare as well as a perceived level of trust.  Such an assertion is 
supportive of educators’ previously noted belief that their clinical credentials predisposed 
them to a level of trust not provided to other professions.  As noted earlier, Petronio 
(2002) refers to this predisposition of trust as “trust credit points.”  For instance, 
violations of patients’ disclosure rules can lower the number of credits which, in turn, 
may decrease the amount of boundary permeability in the educator-patient relationship. 
 Educators fully believed that patients’ expectations of privacy were directly 
associated with the nature of the trust relationship that was established between them.  As 
Penny, an educator for patients with a terminal neurodegenerative condition, stated, “I 
think they go hand in hand. It’s one of the components of trust, privacy.” Many educators 
felt that patients’ willingness to disclose private information was predicated on a strong 
trust bond established at the start of their engagements.  Karl, a diabetes educators, held 
such beliefs when he stated, “ If you were able to develop the trust at the beginning, then 
[patients] might be more willing to give you that information versus if you didn’t develop 
the trust then it’s probably likely they won’t give it to you.”  Nadine, an educator for 
patients with chronic autoimmune conditions, supported this contention when discussing 
her telephonic patients, whom she spoke with over the course of multiple weeks.  She 
stated, “But then after they warm up to you, and you’re on to your next call. You do form 
a relationship, and they start to trust you and open up to you.”  Hanna, a diabetes and 
osteoporosis educator, reflected on her earlier experiences of working in the field and 
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charting patient disclosures as part of their medical history.  She explained the 
importance to the trust relationship of reassuring a patient that all disclosures are held in 
confidence, regardless if they are relevant to the patient’s clinical need.  She stated,   
The patient needs to know relevant things to their visit may find their way into a 
note chart. But if something is disclosed has no bearing on that, they need to feel 
confident that, should they tell you something in confidence, it would be held that 
way.  
Later in her conversation, Nadine explained that part of her role as a trusted 
confidant is also being able to read the verbal and nonverbal cues that indicate why a 
patient may cease disclosure.  She described what she might do to maintain trust if it 
were clear that a patient’s disclosures were jeopardized by the presence of a family 
member with whom the patient was not comfortable having in the room.  She stated, 
“Maybe that patient doesn’t want their husband to hear what they’re saying—you take 
those verbal and nonverbal cues from the patient…I’d change the subject, so privacy was 
kept. That plays a big role in trust, it all goes together.”  Penny articulated similar beliefs 
about the relationship between trust and privacy as it pertained to navigating disclosures 
within a patient’s family dynamics.  In her example though, a patient’s wife was 
disclosing information about her husband that she wanted Penny to hold in confidence.  
Penny believed she was equally obliged to honor the confidentiality of the caregiver’s 
request in order to preserve the trusting relationship among all three parties.   She shared, 
“I was talking to a caregiver and she said, ‘I wanted to talk because my husband’s really 
overwhelmed.’ So, my relationship with that caregiver is different than my relationship 
with the patient. But then trust is important, privacy is important.” Earlier in her 
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interview, Penny had also expressed that it was important for educators to view these 
constructs beyond their context in government-related privacy protection mandates such 
as the Health Insurance Portability and Accountability Act (HIPAA).  She used the 
metaphor of “building a bridge” to express how assurances of privacy strengthens trust.  
She reflected, “It’s important because it’s part of HIPAA. Also, if I tell them that 
everything we talk about remains confidential, between you and I, and of course, with 
your physician too…just by saying that helps build that bridge towards trust.” 
Educators strove to protect the privacy of the information disclosed to them by 
patients because doing so was foundational to maintaining trust.  Additionally, educators 
recognized that such confidentiality was not only an expectation the patient had for them; 
it was also an expectation that patients had toward others.  The next section examines 
educators’ interpretations of the beliefs and privacy rules that guided their patients’ 
personal and public disease disclosures. 
 Educators’ interpretations of patients’ privacy management.  Throughout 
their interviews, educators offered stories and assessments of how patients managed their 
disease information with others.  Such actions would later influence educators’ own 
beliefs about privacy management. The examples are indicative of multiple constructs 
within the CPM theory framework.  For instance, one such interpreted concept was 
boundary permeability, the notion that an individual establishes disclosure boundaries in 
figurative degrees of thickness (Petronio, 2002).  Educators also described situations and 
experiences that were illustrative of patients’ use of privacy rule decision criteria to 
manage the way they shared health information with family, friends, and others.  Some 
patient examples were representative of core decision criteria, such as cultural 
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expectations and personality characteristics, which are defined as stable criteria that tend 
to operate in the background. Others aligned to CPM’s constructs of catalyst decision 
criteria, which are circumstance-based criteria that can trigger a change to pre-established 
privacy rules.  Examples of these criteria, interpreted from educators’ descriptions, 
include motivational goals and risk-benefit goals (Petronio, 2002; 2016) .   
Educators recognized that each patient was unique in the way they would allocate 
varying degrees of access to others regarding information about their condition and 
therapies.  Such descriptions were akin to CPM’s concept of boundary permeability in 
which thin boundaries represented a high level of comfort toward sharing private 
information to others, whereas thick boundaries represented a high desire to protect that 
information (Petronio, 2016; Petronio, 2002).  Reba, a diabetes educator, described such 
a phenomenon when she shared,  
There are some people who, with diabetes for instance, they don’t want anyone to 
know they have it, and they want to keep it very personal, private, and 
confidential. Sometimes even to hide it from immediate family members. Then 
there are other patients who, they don’t care if the whole world knows that they 
have a chronic health condition like diabetes. For some…it’s just, ‘This is me, and 
this is the way I deal with life.’ So, I usually saw both extremes. 
Cora, an educator for numerous chronic conditions, maintained a similar understanding, 
even going as far to express that confidentiality protection—however that was defined by 
the individual—was a patient right.  She stated, “Confidentiality is a big thing because 
that’s a patient right. They have their information protected, and not everyone wants 
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everyone to know they have diabetes. Some are open with it and it’s part of their life, 
others don’t want that.”  
 Educators respected and felt obligated to protect the level of boundary 
permeability each patient established for their personal and public disclosures.  However, 
educators still had their own beliefs and opinions regarding the benefits and drawbacks of 
how patients managed privacy.  For instance, Reba noted that there was a risk to her 
diabetes patients who established thick disclosure boundaries with coworkers, 
particularly if a patient experienced side effects related to their medication.  She 
explained that a hypoglycemic event could be misconstrued as poor mental health or 
drunkenness and thereby damage the patient’s reputation.  She shared, “Hypoglycemia 
can be a serious thing if it happens in the workplace. If you wanna keep your diabetes 
very private, then coworkers may think the worst…thinking they’re drunk if they have a 
serious low blood sugar, or they’re psychologically unfit.”  She went on to express her 
belief that patients’ with low tolerances for public disclosures related to their disease are 
at risk of unintended consequences.  She said, “So, it definitely makes a difference in 
how the person with diabetes relates to the rest of their environment, depending on 
whether they want their diabetes to be public or private.”  Reba’s statement demonstrates 
an interpretation of the potential outcome that could arise from a patient’s insufficient 
risk-benefit ratio calculation, one of CPMs catalyst decision criteria (Petronio, 2002; 
2016). 
Educators also understood the importance of never making assumptions about the 
types of privacy boundaries patients may have established with others, particularly as it 
related to a patient’s family.  As Iris, an educator for chronic autoimmune diseases, noted, 
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“Believe it or not, a lot of people don’t tell their spouses or their families or their kids 
what’s going on with them. They consider that that is their private information.”  
Whitney, another diabetes educator, shared an example of privacy protections taken to an 
extreme.  She described the excessive measures one of her patients took to keep anyone, 
including his spouse, from knowing he had diabetes.  She shared, “I’ve one guy that 
brings his meter in a bag because he doesn’t want anybody to know. His wife doesn’t 
know he’s diabetic. It’s ‘close the door’ when you’re talking to him. I can’t say out loud 
he has diabetes.”  Like her peers, Whitney respected that patient’s right to manage his 
disease disclosure in a way in which he was comfortable.  Her description of her patient’s 
disclosure behavior demonstrate the influence of an individual’s personality 
characteristics, one of CPM’s core criteria of privacy rule decision making (Petronio, 
2016; Petronio, 2002).  In fact, that patient’s extreme measures of privacy protection 
would support Petronio’s (2002) contention that individuals with high-Machiavellian 
personality characteristics (i.e. holding cynical views of human nature and internalized 
manipulative personality traits) are low disclosers of information. 
 Vivian, a diabetes educator, discussed a belief that patients’ disclosure tolerability 
can be culturally influenced.  Such an understanding is illustrative of CPM’s cultural 
expectations, another of the core criteria for privacy rule decision making (Petronio, 
2002; Petronio, 2016).  She explained how, in her own personal experiences, she had 
knowledge of the general medical histories of her immediate and extended family.  
However, she was surprised when documenting family medical histories for some of her 
African American patients with diabetes, to frequently hear the response “I don’t know. 
We never talk about that kind of stuff.”  From those interactions, she came to believe that 
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a patient’s cultural experiences influence the disclosure dynamics within a family.  She 
shared, “It’s a whole new concept for me. I just didn’t understand, but then I find out that 
in the African American population that, clearly that’s not something they share. 
Sometimes, even the husband doesn’t know what illnesses the wife has.” Studies in the 
literature would support her view that African-Americans are less likely to know their 
family medical history (Lin et al., 2018; Murff et al., 2005).  Vivian went on to explain 
how that newfound knowledge helped her adjust her approach when engaging patients in 
private conversations, particularly if others were in the room.  She said, “I always ask, 
‘I’m with the diabetes team, is now a good time, or you want me to come back a little bit 
later?’ Especially when there’s people in the room, even if it’s family.”   
Not all educators though spoke of thick boundaries and guarded disclosures.  
Tabitha, a diabetes educator, provided an example of how motivational goals, one of 
CPM’s catalyst criteria for privacy rule decision making, can change patients’ boundary 
permeability (Petronio, 2016; Petronio, 2002).  She reflected on her experience of 
soliciting patients whom she helped overcome disease obstacles, to become advocates for 
others she taught.  She explained, “Once they mastered it, they were pretty proud of 
themselves and willing to share if I asked them, ‘Would you be willing to come and 
speak at one of my classes?’ Nobody ever said no.”  Tabitha hypothesized those patients’ 
willingness to be forthcoming about their diabetes was motivated by inherent altruistic 
tendencies possessed by all people along with a sense of comradery that emerges from 
helping others successfully navigate the shared experience of a disease.  She posited, 
“Once people are comfortable with something, and they think they can help because, 
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we’re basically kind, good people, I believe that. When you feel you can offer something 
because of the experience you’ve gone through, you’re willing to do that.”  
 The insights educators gathered from witnessing how patients navigated 
disclosures with others, influenced the educators’ own beliefs about privacy management 
in their role.  The next section examines the application of those beliefs in the 
communication actions educators would take with patients. 
 Educators’ privacy management of patient information.  Educators managed 
their patients’ private information in the same way their patients did, using rule decision 
criteria.  Like their patients’ rules, the decision criteria were grouped into two types, core 
criteria and catalyst criteria. As CPM theory explains, most core criteria are 
representative of routinized properties.  Routinized rules develop when an individual 
adopts rule criteria that become stable and promote “routine” privacy behaviors over 
long-term use.  Conversely, changing rules, as the name implies, are rules that are apt to 
change because of a triggered catalyst rule criterion (Petronio, 2002; 2016).  For the 
purposes of this study, routinized and changing rule properties were identified within 
three types of parameters—privacy rules that arose from educators’ professional ethics, 
rules that were generated by educators’ adherence to political/legal context factors, and 
rules that were created based on the insights educators’ gathered from the way their 
patients’ managed privacy.  For the most part, the rules that were influenced by an 
educators professional ethics or political/legal context factors tended to be routinized; 
both parameters were stable and were abided to prior to their role as a pharmaceutical-
sponsored educator.   
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Professional ethics and regulations.  Many of the rules the pharmaceutical-
sponsored clinical educators established for managing their patients’ disclosures were 
adopted from the privacy expectations that guided them when they worked in the field.  
Gabi, an educator for chronic autoimmune conditions, explained such behavior when 
discussing the sharing of patient information with others.  She summarized it this way, “I 
wouldn’t share with anyone about the patient or their home. Just like you would for a 
patient in the hospital or clinic, you wouldn’t share that information with anyone else.”  
Gabi equated the privacy rules she followed in her pharmaceutical educator role to be the 
same as the ones she would adhere to in her previous clinical roles.  Such equivalences 
were a common interpretation of proper patient privacy management among many 
educators, including Cora, also an autoimmune disease educator.  Cora stated, “When 
you’re one-on-one, all that information is kept confidential, and you respect the patient 
just as you do in any other aspect of healthcare. That’s private information, and if they 
want to share that information, it’s up to them.”  
 Cora’s use of the phrases “you respect the patient” and “if they want to share that 
information, it’s up to them” highlights that it is her deference to patient autonomy that 
drives the privacy rules she maintains about disclosure.  For Cora and Gabi, proper 
management of disclosed information is a professional obligation, rooted in the ethics 
that orient them as healthcare providers. Later in her interview, Cora reinforced this 
notion when she stated, “I guess in healthcare, we try to encourage people, but yet we 
have to be very careful because...It’s ultimately up to them, and we have to protect their 
wishes and protect their privacy and respect that.”  Iris, an educator for multiple chronic 
conditions, held a similar attitude and referenced how respecting privacy extended to the 
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conversations about patients she had with her professional colleagues.  She maintained, 
“You definitely don’t want to reveal to anyone, even speaking with my other nurse 
friends, I never reveal names if I’m telling stories …but privacy, you truly have to respect 
what information patients want to keep to themselves.” 
 While educators’ professional ethics served as a compass that provided direction 
for how, when, and to whom to disclose information, those same ethics could also push 
them to breach privacy if a patient’s safety was at risk.  For instance, as noted in Chapter 
4, both Iris and Antonia shared dilemmas they faced when a patient and a caregiver 
disclosed suicidal intent.  Both noted that, in those instances, their professional and legal 
responsibility as a healthcare provider is to get immediate help for that individual 
regardless of privacy expectations.  As Antonia acknowledged about her suicidal 
caregiver situation, “But some things we are, as healthcare professionals, required to 
divulge.”  Janelle, an educator for patients with rare diseases, also admitted that this was 
the exception to the disclosure rules created to protect patient autonomy.  She stated, “If 
they say something that’d give me pause, I’d be ‘Well, this is why we shouldn’t do 
that’...The thing is, if any HCP hears something that could be harmful, we’ve a duty to 
advise them to speak with the doctor.”  These examples demonstrate how a situational 
condition (i.e. suicidal ideation) could serve as a catalyst criterion that would trigger 
changes to educators’ ethically based routinized rules regarding disclosure. 
Political/legal factors.  As noted in Chapter 4, political/legal ecological factors, 
manifested in government and industry-imposed compliance regulations, influenced the 
communication dynamics between educators and patients.  Not surprisingly, some of 
these factors evolved into routinized rules that guided educators’ management of patient 
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disclosures.  However, unlike professional ethics rule decisions that arose from 
educators’ internalized beliefs about respect for patient autonomy, political/legal rule 
decisions originated from external forces.  These forces included federal policies such as 
HIPAA, pharmaceutical anti-kickback legislation such as the Sunshine Act, and 
government guardrails that dictated the type of contact between pharmaceutical industry 
representatives and patients.  Together, these factors encouraged educators to create and 
abide to privacy management rules that carried the weight of the law behind them.  Karl, 
a diabetes educator, articulated this understanding when he stated, “[Privacy] plays a 
huge role. We know the rules that we have to protect privacy. You want to protect 
personal health information. There’s HIPAA, there’s the Sunshine Act. There are a lot of 
laws to protect privacy.” In fact, as Karl went on to acknowledge, in some instances, 
educators’ necessity to strictly adhere to these rules could even be disadvantageous to a 
patient’s disclosure wishes.  He put it this way, “It can be to the advantage or 
disadvantage to the patient. For example, the patient is supposed to get a special 
medication and they want you to call the pharmacy for them. You can’t call because it’s a 
privacy issue.” 
  As Karl pointed out, political/legal factors limited who could legally receive 
patient-disclosed information from educators.  While certain brand networks allowed 
pharmaceutical sales representatives to consult with doctor offices regarding patient 
enrollment in clinical educator programs, educators were forbidden from disclosing any 
patient information back to the sales representative.  As Felicia, an osteoporosis educator 
noted, “I’m HIPAA Compliant. I can discuss patients with the physician and nurses. I 
cannot share names or personal information with the rep.  If there’s any issues, I’ve got to 
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be the one that’s communicating that with the office.”   Martin, a diabetes educator, 
explained though that political/legal-based disclosure rules were not unique to the 
pharmaceutical educator role.  Many of them are the same privacy guidelines he is 
required to follow as a clinician working in a hospital or physician’s office.  He shared an 
example from his experience when working as a pediatric educator and receiving 
disclosure requests from teachers.  He said, “Something we deal with was a teacher 
calling to learn how to care for a child. With HIPPA, you wouldn’t discuss that.  It’d be 
‘Let’s get the parents, and you come in with [them].’ Privacy changed how we deliver 
education.” 
 Martin’s statement of “Privacy changed how we deliver education” was indicative 
of how political/legal factors, such as HIPAA, influenced patient privacy management 
across the entire healthcare industry.  Martin and the other educators all had years of 
experience working within government and health industry-imposed privacy regulations 
during their prior tenure as field-based clinicians and educators.  Hence, these type of 
privacy rules were routinized by educators and understood to be applied uniformly across 
all patients. 
 Though many of the political/legal factors that influenced educators’ privacy 
disclosures with patients were carry-overs from their prior work in the field, some 
influences were unique to the pharmaceutical clinical educator role.  Gabi, an educator 
for osteoporosis and chronic autoimmune conditions, noted that some patients had 
concerns about whether their health information was shared with the pharmaceutical 
companies she represented.  She handled this situation by explaining to patients that she 
worked independent of the medication’s manufacturer.  She said, “I also usually 
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emphasize that I don’t work for the pharmaceutical company, that I’m a third party, so 
that they don’t think the pharmaceutical company has their information. I do bring that 
up.”  Lois, a telephonic educator for chronic autoimmune conditions, highlighted that 
same concern.  She reassured patients that, legally, she was not allowed to provide her 
sponsoring companies with patients’ health information.   She stated, “But also, from the 
pharma end of it, if they ask, ‘Will this information be shared?’, then I have to reassure 
them what the guidelines and regulations are that I work with, so they understand that it’s 
a privacy matter.” 
 Interestingly, some educators had qualifying—even self-contradictory—beliefs 
about patients’ perceptions of privacy rules and regulations.  For instance, Lois continued 
by describing how part of her role’s privacy management responsibilities was fielding 
inquiries and educating patients about the policies that were in place regarding 
pharmaceutical-related privacy matters.  This was something she did not experience in 
her prior position working in a physician’s office.  She explained, “[Patients] wanna 
know if it’s going to get on the Internet and they’re gonna start getting marketing calls, 
those things. How I knew who they were, how did I learn about them? I didn’t have that 
at the office practice.”  However, Lois later offered insights that qualified, while patients 
do have some privacy concerns, they worry about them less than what the industry 
perceives them to be.  She stated, “I honestly think we are forced to make privacy a huge 
thing. But I often times feel like it’s not as big of a deal to the patient as it’s made out to 
be by all the rules and regulations.”   
Bonnie, an educator for diabetes and chronic autoimmune conditions, noted some 
similar contradictory concerns from her patients when she stated, “People want to know 
 181 
who we are if it’s a phone call, who are you calling with, who are you representing? They 
want to clarify who they’re talking to.”  However, Bonnie latter clarified that in general, 
patients seemed less concern with privacy matters then the industry’s perception.  She 
posited, “People don’t seem to be concerned with ‘What are you doing with my 
information? Where does that go?’ That’s something we have the responsibility to 
manage and protect. But I don’t feel it’s part of their awareness and everyday 
consciousness.” 
Insights created from patients’ privacy experiences.  As noted previously, one 
thing educators learned during their prior clinical field experiences was that patients had 
varying views regarding privacy, particularly as it related to family.  That insight did not 
change for their pharmaceutical educator role and therefore necessitated the use of 
routinized privacy rules when dealing with familial situations.  For instance, Antonia, an 
educator for patients with a terminal neurodegenerative condition, reiterated the earlier 
notion, learned from the field, that educators should never make assumptions about 
patients’ expectations regarding the disclosure of information to family members.  She 
shared,  “I don’t think we should assume a patient wants family members in, I’d like to 
include them, but when you’re educating a patient, you have to make sure they do want 
their family members present, because they may not.”  Gabi, an educator for patients with 
chronic autoimmune diseases shared the use of a similar privacy rule for her telephonic 
patients.  She stated, “I’m really careful if a husband or wife answers the phone not to say 
what the medication’s for. Because I don’t know if they’ve discussed that with their 
partner.” 
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 Telephonic programs did present other privacy issues around which educators 
needed to navigate.  Bonnie, a telephonic educator for multiple disease types, discussed 
how the ubiquity of cell phones often presented privacy challenges when contacting 
patients.  She explained, “Most people have a cell phone, they could be at the grocery 
store, they could be at work or in a noisy environment or they could be very distracted. I 
do think that privacy can impact the conversation.”  Nadine, a telephonic educator for 
chronic autoimmune disease, pointed out the difficulty of securing patients’ trust on the 
first outbound call she makes to them.  She highlighted the privacy impact of patients’ 
skepticism toward speaking with someone from an unrecognizable phone number who is 
asking personal questions.  She reflected, “At first, they think that you’re a scammer 
trying to get their information…during the first call you’re asking a lot of questions about 
their date of birth, address, their family members’ names.  So, they’re reluctant to answer 
anything for you.” She explained that she was able to overcome the skepticism through 
trust messaging and reassurances of her healthcare credentials and program intent.  As 
she explained though, this would often take multiple calls to accomplish.  She said, “It 
usually isn’t until the second call that they feel comfortable enough to talk…But after 
they warm up to you and you’re on to your next call, you form a relationship, and they 
start to trust you and open up.” 
 Educators who delivered group-based programs had unique privacy issues with 
which they needed to contend.  Multiple educators who delivered product or disease 
programs using this format spoke of its challenges.  Some also shared the routinized 
privacy rules they used to address those issues.  Vivian, a diabetes educator who served 
rural communities, spoke of the drawbacks of group programs for patients in tight-knit 
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small communities where lack of anonymity could be problematic.   She explained, 
“Some people were hesitant, didn’t want to share…Sometimes it was in small towns, so 
people know each other. They didn’t want to know that the neighbor did or didn’t do 
something correctly. It was a little awkward at some places.”   Ursula, a diabetes 
educator, noted similar concerns while highlighting how a one-on-one setting was more 
opportune for personal disclosures.  She stated, “I think people need to feel like they can 
tell you things, and probably in a one-to-one setting more things are going to come out 
than in a group setting, but still you have to protect people’s privacy.”   Cora, who had 
experience delivering programs via interactive webinars, felt that approach was more 
conducive to patients’ disclosure than group programs simply due to the one-way visual 
nature of the technology.  She explained, “When we did the webinars, people were most 
candid and open because they could see us but we couldn’t see them. Whereas when you 
sat in the classroom or one-on-one, those types of personal questions really didn’t come 
into play.” 
  Reba had spent part of her career working for a network in which patients could 
attend multiple group diabetes programs as part of a series focusing on different disease-
related topics.  She found that, in those instances, most patients tended to become 
comfortable with sharing personal information the further along they went in the series.  
However, she also clarified that this was not the case for all patients.  She described, 
“I’ve had patients that it’s taken weeks, a number of visits, to establish a rapport that they 
would feel comfortable telling me personal circumstances that impact their diabetes 
management. There are some patients that you may never get.”  While Reba shared her 
beliefs that patients’ discomfort with sharing was not uncommon, she also pointed out 
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there were those individuals who were at the other end of the continuum.  She explained, 
“Then I’ve had patients who really try to domineer the situation and you have to cut them 
back and say, ‘Let’s move on and give other people an opportunity to interact.’  So, you 
usually have both extremes in a group.”  
 Whitney, a diabetes educator, reinforced her peers’ beliefs that the dynamics of 
the group classes can make disclosure intimidating for some patients.  However, she also 
believed that non-disclosing patients still benefited from group programs because many 
would feel empowered to speak with her after the program.  She stated, “I really think 
they get more out of group classes, because they feed off that [information]. There’s 
sometimes in classes, people will ask you things after the fact that they didn’t want to 
bring up with the group.”   
 Educators understood they walked a fine line when it came to expectations of 
receiving personal disclosures from patients in group settings.  They believed there was a 
therapeutic value of having patients actively participating in discussions about the shared 
experience of their disease.  However, they also felt obligated to respect the desired 
privacy of patients who were not comfortable with disclosing.  One way Deandra, an 
educator for rare diseases, handled this dilemma was by soliciting input through a gentle 
invitation for stories.  She explained, “You invite people to share their stories, to share 
treatments they’re on. But you don’t force it. You put a general question out there. 
‘Would anybody like to share what treatment they’re on or what it was like getting 
diagnosed?’”  Reba offered a similar invitation to participants during her group sessions 
while also impressing upon the group the mandate to keep any disclosed information 
confidential.  She explained it this way, “We said… ‘Anything we talked about was 
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confidential, it didn’t leave the room.’ …I tried to introduce early on the importance of 
privacy.  And, that patients can learn from each other, so anyone who has a question 
should feel free.” 
Educators’ privacy management behaviors were managed using routinized rules 
based on core privacy rule decision criteria as well as changing rules based on catalyst 
privacy rule decision criteria.  However, these rules were also influenced by the type of 
confidant relationship patients created with educators.  The next theme addresses three of 
these confidant role types and examines how educators’ co-construction of those roles 
impacted disclosure dynamics. 
Clinical Educators as Confidants 
Theme 7:  Educators managed multiple types of confidant roles with patients 
including stakeholder, deliberate, and reluctant.  
 CPM theory asserts that recipients of disclosed information co-create various 
types of confidant roles with the discloser to include deliberate, inferential, reluctant, and 
stakeholder (Petronio, 2002; Petronio & Sargent, 2011).  These roles are flexible and 
situationally based as an individual’s confidant status can fluctuate based on the context 
or content of the disclosed information.  Additionally, the privacy rules that are generated 
between the discloser and the recipient also vary among confidant types. The deliberate 
confidant is an individual, such as a counselor, therapist, or coach, who receives private 
information because it is solicited.  The inferential confidant is someone who expects to 
give or receive disclosure because of the nature of the relationship, such as a wife to her 
husband or a child to their parent.  The reluctant confidant is someone who receives 
private information, intentionally or inadvertently, without an expectation for such.  An 
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example of this role is a passenger on a plane  to whom a stranger discloses information 
(Petronio, 2002).  Lastly, in the domain of healthcare services, there are those who 
operate as stakeholder confidants.  These are individuals, such as doctors, nurses, and 
other patient-facing health professionals who, by nature of their healthcare role, receive 
patients’ private health information (Petronio & Sargent, 2011). 
 Data from this study suggested that pharmaceutical-sponsored clinical educators 
represented three of the four confidant roles—stakeholder, deliberate, and reluctant.  This 
theme further defines those three confidant roles within the context of the educator-
patient relationship.  This includes an explanation that helps delineate the stakeholder and 
deliberate confidant role as they relate to the clinical educators in this study.  The 
stakeholder confidant role is explored first, followed by the deliberate confidant role.  
The section ends with findings regarding the reluctant confidant role. 
Clinical educators as stakeholder confidants.  For the purposes of this study, an 
educator’s role as a stakeholder confidant is examined in the context of an individual who 
solicits and receives patients’ health information as a function of their clinical credentials 
and/or perception of them by patients as a de facto HCP (Petronio & Sargent, 2011).  
This clarification is provided to avoid confusion with the deliberate confidant role that is 
described later in this chapter.  A stakeholder confidant is an individual who becomes a 
co-owner of patient’s personal health information because they are a stakeholder in the 
patient’s care (Petronio & Sargent, 2011).  As such, this type of confidant is expected to 
manage and protect that information out of a responsibility to patients and a professional 
obligation to their field (Brann & Mattson, 2004). The pharmaceutical-sponsored clinical 
educator has a unique role though, in that they are not part of the patient’s formal 
 187 
healthcare team; rather the educator is tangential to the team.  However, like a traditional 
HCP member, the clinical educators for this study were often afforded access to patients’ 
private health information when it was disclosed to them by patients or when it was 
provided as health data during the enrollment process.  Unlike a member of the formal 
healthcare team though, the historical data accessible by clinical educators was limited; 
rarely would an educator possess a complete medical history.  Hence, this proved to be a 
challenge for educators who sought to deliver customized educational engagements.  
Still, because the educator was able to establish a therapeutic relationship based on the 
necessity of helping patients manage their disease, patients typically perceived educators 
as de facto guardians of information.  
Felicia, an osteoporosis educator, noted that while patients may not completely 
understand her role, she still served them in a manner that was representative of 
stakeholder confidant characteristics.  She attributed this phenomenon to the trust patients 
placed in her nursing credentials as well as the trust patients afforded her because she was 
viewed as an extension of the physician.  She shared, “Not everyone understands, they 
know I’m a nurse, and I’m coming to teach them. And I’ve got their information from 
their doctor. So, he must trust me if he gave me their information. So, kind of opens up 
the communication.”  The concept of clinical educators as “extensions of the physician” 
was similarly described by Yvonne, a diabetes educator.  She explained that patients 
sometimes viewed her this way, especially when they had complaints about other staff 
who worked in the office.  She stated, “I’ve had people complain about the person at the 
front desk—never a problem with the doctor but complain about the person at the front 
desk because they know I’m an extension of the doctor.” Bonnie, an educator for 
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numerous disease states, believed that generational views of the patient-provider 
relationship was a factor in why older patients often perceived her as a stakeholder 
confidant.  She felt that that population tended to have a more paternalistic interpretation 
of physicians and members of their healthcare team.  Hence, as an extension of the 
physician, she took on stakeholder confidant responsibilities.  She noted “That 
[paternalistic approach] works for some people a lot, especially the older population. In 
that case, an educator might continue that role and try to just follow through.” 
 Educators felt they were automatically imbued with stakeholder confidant status 
because of their credentials and their tangential relationship to physicians.  However, 
there were two other reasons why they achieved this type of confidant status—the way 
they defined expectations of themselves to patients, and the ease with which they were 
accessible for communication.  For instance, Antonia, an educator for patients with a 
terminal neurodegenerative condition, would explain her responsibilities to patients in a 
way that acknowledged her connection to a pharmaceutical company while also implying 
she is a de facto member of the healthcare team.  She put it this way, “I let [patients] 
know they can call me about pretty much anything, but I explain that I work with [drug 
name].  Anything around my drug, you can call me about. But I end up navigating a lot of 
general stuff.”  Yvonne, similarly acknowledged to patients that her role and her 
responsibilities extended beyond the drug company for whom she works.  She made sure 
patients understood that she is first and foremost a healthcare provider.  She would say to 
them during engagements, “Keep in mind, [pharmaceutical company] signs my 
paycheck. With that in mind, when this job is long gone, I’ll still be a diabetes educator. 
Our product may not be the best. I’m totally prepared to tell you that.”  
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Janelle, an educator for patients with rare diseases, shared how she would 
frequently serve as a surrogate for patients’ physicians simply because she was more 
easily accessible via the phone.  However, she explained that often times the objective of 
the call was simply for her to serve as an outlet to which patients could vent disease 
frustrations.   She noted, “People get upset because either their doctor isn’t taking them 
seriously or isn’t calling them back because they’re really high needs.  They end up 
calling us because we’ll answer the phone, and they just need to vent.”  Lois, a telephonic 
educator for chronic autoimmune conditions had similar beliefs.  She stated, “It’s more 
convenient for them to reach us than to get someone at the doctor’s office to return calls 
or get answers. We pick up the phone or respond to voicemail within a quick timeframe. 
So, they call us first.”  Lois went on to clarify that, given the compliance guardrails she 
was required to follow, she oftentimes had to refer patients back to their physicians’ 
offices anyway to have questions and concerns fully addressed.  She noted, “I’ll get calls 
from patients asking what their dosing schedule is supposed to be. I can tell them what it 
is for in the FDA guidelines, but I have to refer them to their doctor’s office to confirm 
that.” 
Petronio and Sargent (2011) explained that one of the reasons patients established 
stakeholder relationships was because of their need to disclose emotions about their 
medical state.  In other words, patients trusted that HCPs would help manage the range of 
emotions that were related to the disease journey.  When patients perceived they could 
trust the educator, disclosure came more easily.  Quinn, a diabetes and osteoporosis 
educator, summarized this notion succinctly when she stated, “I believe it’s the trust 
thing. I don’t know why that happens. I can only speak for myself, but I have patients that 
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will pour their whole life out to me while I’m sitting there with them.”  Educators 
understood though that disclosures were still predicated on establishing the sort of 
trusting relationship that was genuine and comfortable.  Otherwise, as Ursula, a diabetes 
educator noted, patients could present a façade of confidence that masks hidden anxiety.  
She explained, “You really had to gain somebody’s trust to start with, so they share 
things with you and didn’t just ‘yes’ you. You know? ‘Yes, yes’ and meanwhile in their 
head they’re going ‘No, no. there’s no way I’m doing that.’” Nadine, who managed other 
educators, admitted that engaging patients in discussions beyond what was outlined in the 
script guides helped provoked disclosures because it reinforced trust.  She stated, “Even 
the seasoned nurses will not always talk about the topics on the scripts. They’ll have 
general conversations…But that’s the part of forming that relationship and that trust with 
a patient and letting them talk about what’s pressing to them.” 
 Felicia found that once that trust was firmly established, deliberate disclosures 
from patients could even occur long after an engagement.  She shared an example of a 
patient who contacted her months after a training session to provide an osteoporosis 
status update.  She shared, “There has to be trust that develops over phone calls for them 
to welcome me into their home. I had a patient call me that I haven’t seen in a year to let 
me know her bone density result.”   
Additionally, patients confided in educators in a stakeholder way because the trust 
bond between them created a safe and comfortable environment for sharing.  In fact, 
many educators highlighted how their engagements frequently functioned as a type of 
social outlet for patients.  Janelle noted this was the case for her rare disease patients who 
often felt isolated by having a disease to which few others could relate.  She explained, 
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“For the rare disease that I’m currently working with, they disclose a lot. They will tell 
you anything and everything...I feel like they just are constantly looking for an outlet, so 
they will say anything and everything.”  Hanna described this same sort of openness 
toward sharing from her osteoporosis patients, many of whom were widows who simply 
enjoyed her company.  She reflected, “Two thirds of the patients I visited have been 
widows.  So, it’s their social outlet…I love my ladies. I have a fabulous time.  If I don’t 
get ‘Come back for dinner if you’re in the area,’ I’ve done something wrong.”  Like 
Hanna, Quinn also found that a subset of her older patients was lonely and therefore 
viewed her programs as an opportunity to engage with someone conversationally.  Hence, 
they disclosed freely.  In fact, Quinn acknowledged that some of those engagements 
eventually blossomed into friendships.  She shared, “A lot of them are still my friends. I 
still talk to them. And some of them don’t have anyone to talk to.  You walk into the 
home, and you’re all they’ve talked to in the last week or two.”  Quinn continued by 
stating that she believed such connectedness with patients reinforced the notion that her 
role was to be an advocate for them.  She said, “But they get to where they know you’re 
an advocate for them and when they feel like you’re there for them, that makes a big 
difference.” 
 Educators’ ability to offer a venue for social outlet benefitted other patients in 
addition to those who were lonely or suffered from rare conditions.  Nadine, a telephonic 
educator for chronic autoimmune conditions, described how she often functioned as an 
empathetic ear for patients frustrated with unsympathetic family members who did not 
understand the disease journey.  She explained, “You’ve got somebody that’s supportive, 
that you can talk to about barriers. Or maybe you don’t want to burden your family 
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anymore…It’s refreshing for the patient to have somebody that’s not a family member 
and understands what they’re feeling.”  In fact, Nadine found her ability to serve as a 
deliberate confidant in those instances to be as rewarding for her as they were for her 
patients.  She said, “It’s rewarding to hear them say, ‘I appreciate you calling. I’m feeling 
better because of what you told me. I’ve a new outlook on life because of this.’ For me, 
the reward is leaving somebody better than you found them.” 
Clinical educators as deliberate confidants.  A deliberate confidant is an 
individual who purposefully solicits and receives personal information as a means for 
providing coaching and counseling (Petronio, 2002). Unlike the stakeholder confidant, 
the deliberate confidant role expands beyond the medical context to include any 
individual who actively solicits and/or receives disclosed information for the purpose of 
advising, coaching, or counseling (Petronio, 2002).  As evident in this study’s data, the 
clinical educator role frequently involved the exchange of information to coach and 
counsel the patient in ways not just related to clinical outcomes or therapeutic 
advancements.  Additionally, educators were able to establish solid, trustworthy 
relationships with patients that nurtured unfettered disclosures for reasons beyond their 
clinical credentials or perceptions that they functioned as surrogate HCPs.  For these 
reasons, pharmaceutical-sponsored clinical educators served as deliberate confidants as 
well as stakeholder confidants.  This section examines how educators functioned as 
deliberate confidants.  Specially, two provisions are explored that exemplify why 
educators were able to take on the deliberate confidant role.  These include the provision 
of access and time and the provision of reciprocating self-disclosures. 
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Educators spoke frequently of their role in soliciting, receiving, and managing 
personal and sensitive disclosures.  In fact, the disclosed information typically went 
beyond the clinical components of the disease journey.  Educators used words like 
“sensitive” to express the qualitative nature of the engagement and the connectedness that 
arose from their deliberate confidant status.  Bonnie, an educator for numerous chronic 
conditions reflected on the nature of sensitivity in her patient experiences.  She said, “I 
mean it’s sensitive information, it’s your health, it’s very personal. I just think that maybe 
we’re a little bit more aware of, that we do that.  So, privacy, it definitely impacts the 
conversation…It’s sensitive because it’s just so personal.”  Tabitha highlighted how 
educating patients on self-injection often created an intimate environment because she 
was asking patients to expose parts of their body to her.  She stated, “When you’re 
teaching somebody, especially the one-on-one patients, that relationship becomes 
intimate very quickly. I mean we’re teaching them how to inject and they’re lifting up 
their shirts and we’re telling them, ‘It’s okay, you’re gonna do great.’” 
Educators believed that, because they established an environment that valued the 
private and intimate nature of patients’ personal disclosures, patients were more likely to 
divulge sensitive health information.  Antonia, an educator for a terminal 
neurodegenerative condition, put it this way, “So, in a clinic setting or in a home setting, 
typically you can give privacy, but I often have patients tell me things in confidence that 
they would not say if somebody else were present.”  In fact, educators often created such 
a safe and comfortable setting for disclosure that patients would sometimes disclose 
personal health-related information they had not even shared with their physician.  Cora, 
an educator for many different conditions, shared one such example.  She stated, 
 194 
[Patients] would ask some pretty personal questions. But I think they felt like that 
was an open forum, and a lot of them just...they were personal in nature like 
erectile dysfunction. They hadn’t talked to their doctor about it. I came against 
that all the time because it’s like they’re embarrassed to talk to their doctor about 
it...It’s like they almost just needed someone to say, “It’s okay to talk about it.” I 
think that brought them a lot of relief.  
Providing access and time.  Ease of access was a factor that allowed educators to 
take on the deliberate confidant role.   Bonnie, a telephonic educator for multiple 
conditions, believed that her ability to provide time to listen was one of the reasons 
patients disclosed that amount and type of personal information she frequently received.  
She stated, “One of the things I say is, ‘If you sit down in a patient’s room for three 
minutes, you’ll be shocked what they will tell you.’ …But I feel people will tell us 
anything if we give them the opportunity.”  Hanna echoed this belief explaining how her 
in-home patient education experiences often included receiving information that, though 
not always clinically relevant, provided an overall snapshot of the patient’s life.  She 
attributed this phenomenon to the fact that she gives patients her time.  She stated,  “I let 
them know my time belongs to them…We’ve gotten to the point where we’ve laughed, 
been offered something to eat, met the dog, husband, found out they love Santa Fe…As 
you have that discourse, you find out so much.”   
After sharing numerous examples of the ease by which patients disclosed 
voluminous amounts of personal information, Felicia, an osteoporosis educator, was 
asked why her patients seemed so willing to divulge their life stories to her.  She 
attributed their actions to simply the fact that she was there to sit and listen.  She stated, 
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“I sit and listen. The other day, I got up and I had to hug the woman because she started 
crying, telling me about the death of her daughter. I don’t know, I sit and listen.”  Xoe, a 
diabetes educator, articulated a similar idea.  She felt that the type of disclosure 
relationships she created by giving patients her time allowed her to gain more accurate 
insights toward clinically relevant behaviors such as medication non-adherence.  She 
explained,  
I’m amazed at what patients tell the physician, and then what they tell us when we 
have an hour with them.  You say, “Well, tell me why your blood sugars are out 
of control. What's going on in your life?” Maybe you found out that they had an 
extra bill, and they had to get the car fixed, so they didn't pick up their medicine. 
It’s not that they’re non-compliant, it’s that life got in the way.  
Ursula, a diabetes educator, believed that the time she invested with patients was not only 
rewarding to them, it also brought her a sense of meaning and professional fulfillment.  
She reflected, “You know, you get to close a door and yeah, you’re really busy, but for 
that hour or whatever time you’re spending with the patient, there’s nothing else going 
on. It’s just you and that patient. And it’s so special.” 
Educators who delivered engagements in patients’ homes felt that setting was 
another unique element of their role that afforded them both time and an opportunity to 
establish the type of relationships more indicative of the deliberate confidant.  Felicia, an 
osteoporosis educator, reflected on this notion when she stated, “I have a different 
relationship because I’ve been in their home. I’ve met family members, their pets, I’ve 
heard their story. It’s different from the doctor’s office and he’s in and out quickly, where 
I’ve actually been in their home.”  Gabi, who had also provided chronic disease education 
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in the home, felt the nature of that environment as a comfortable and safe space allowed 
her to better establish the type of personal connection inherent in the deliberate confidant 
role.  She shared, “It’s a huge bonus to go into the patient home and sit with them. It’s a 
great value add because they feel comfortable and I think they feel safer with the 
treatment. Just knowing, having that personal touch with them.” 
 Expectations for reciprocation.  One hallmark of the deliberate confidant role 
noted by Petronio (2002) includes an expectation of reciprocating disclosures.  She points 
outs that, in the instance of the therapist-patient relationship, this may sometimes prove 
problematic as therapists might alter their communication strategies if they believe 
patients have reciprocating expectations.  During the interviews, few educators spoke of 
patients having expectations to receive personal information from them as a condition of 
the engagement.  In fact, Nadine, a telephonic educator for chronic autoimmune 
conditions, was the only participant who provided a detailed example of such a request.  
She described, “I've had one or two cases, they were men, where they wanted me to share 
my information. They’d say, ‘You called and asked me all these questions. Now I want to 
ask you questions and you're not gonna tell me?’”  Nadine went on to explain how she 
was able to navigate around the request by deferring to her network’s compliance policy 
that stipulated educators were not permitted to share personal information with patients.  
She described the way she responded when asked by a patient for her last name, “But as 
far as my information, I will just tell them that we are told that we're not to give our last 
name.”  Nadine appreciated this policy as she felt it was necessary to protect her and her 
identity.  However, her actions also support Petronio’s contention that reciprocity 
expectations can alter the communication dynamics between a therapist and patient.  
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Nadine, who lived in the Midwest, exemplified this notion when she stated, “One 
gentleman, I told him that I lived in Georgia because he was really creepy…just not 
something that I'm comfortable with…I put a note in the chart, and just kind of let 
everybody know not to talk to him.” 
 Aside from Nadine, only two other educators, Martin and Hanna, discussed the 
concept of reciprocating disclosures.  However, both spoke of it in the context of 
proactive actions necessary for furthering patient engagement as opposed to reactive 
measures provoked from patient requests.  Martin was a diabetes educator who also had 
Type 1 diabetes for most of his life.  He believed that his disclosure of his condition to 
the patients he taught improved their level of interaction and understanding.  In fact, he 
admitted to conducting his own informal comparative experiment in group education 
classes in which he assessed patients’ responses to not receiving or receiving that 
personal disclosure.  The latter approach was more successful.  He explained it this way, 
“I did my own personal experiment where I’d start a class and not tell them and then give 
a class and tell them right up front I’ve got diabetes. I’d see a totally different level of 
interaction, alertness, understanding.”  Martin went on to explain that because he became 
known by the diabetes community in his local area as someone who shared their disease, 
newly diagnosed patients would often request to be in his classes.  He stated, “I’ve had 
patients tell me, ‘I want you because you have diabetes, and the other ones don’t.’”  In 
Martin’s view, patients saw value in the opportunity to learn about diabetes self-
management from someone with that shared experience.   
However, Martin also pointed out that patients were sometimes surprised by his 
response to their self-management disclosures.  Though he was empathetic to the 
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challenges of diabetes, Martin was often unsympathetic to self-pity or unreasonable 
excuses for improper or non-adherent behaviors, having overcome his own challenges 
with the condition.  He shared, “The doctor I worked with didn’t have diabetes. I’d tell 
[patients], ‘He’s probably a lot more sympathetic, pampering-petting than me. I’ve lived 
through a life of going to college, getting three degrees, with diabetes. I know it can be 
done.’”  
 Hanna, an educator for both diabetes and osteoporosis, also spoke at length about 
the notion of reciprocating disclosures.  She shared Martin’s view that proactive personal 
admissions of health struggles can motivate patients to be more active with discussing 
disease self-management behaviors.  She provided the example of how she would share 
her own struggles of sticking to a diet when discussing that topic with her diabetes 
patients.  She stated, “If you’re talking about changing dietary patterns, it’s more 
humanizing to say, ‘I know this is difficult. I’ve had issues with this myself.’ In the sense 
that, you’re not perfect, and it’s not one of those ‘Do as I say…’”  Hanna believed that 
these sorts of self-disclosures served a purpose as they helped assure patients she was 
non-judgmental in her interpretation of their journey.  She put it this way, “I think 
something else that, once again, feeds into that is that self-disclosure as the educator. 
That patient needs to know that you are non-judgmental, and a lot of times that will come 
through with some self-disclosure.” 
 Hanna’s insightfulness toward the purpose and potential of her personal 
disclosures had been prevalent throughout her interview.  She had expressed earlier a 
belief that impactful disclosures needed to occur with appropriate timing during the 
engagement.  She felt that her delivery of a self-disclosure was contingent upon receiving 
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an invitation for it from the patient.  That invitation could only come after a patient had 
the opportunity to share their story and their experience of the disease journey.  She 
reflected,  
I have learned over 30 years of doing all this that everybody has a story, and they 
have to tell their story first. Not only does it give you the background that you 
need, but they need to tell you. I mean, it is an absolute necessity that they tell you 
their story. I don’t know what to say that accounts for that, but I just witnessed it 
so frequent. Then, once they get their story told, it’s almost as though you are then 
being given permission to disclose some things about yourself, which is another 
one of those bricks for the foundation for building that rapport.  
Clinical educators as reluctant confidants.  A reluctant confidant is defined as 
someone who is disclosed information without an expectation or need for that disclosure.  
For instance, an individual who randomly receives private unexpected information from a 
stranger is a reluctant confidant (Petronio, 2000).  Petronio also points out though that a 
deliberate confidant can become a reluctant confidant when they are provided more 
information than they want or need to know.  The educators for this study shared 
numerous examples of experiences that are representative of a reluctant confidant role.   
In fact, for educators who delivered multiple touchpoint programs, those situations were 
quite common.  One reason for this phenomenon is that, as trust builds throughout the 
intervention relationship, so does the potential for the patient to reveal personal 
disclosures unrelated to the therapeutic goals of the program.  The remainder of this 
theme examines educators experiences as reluctant confidant and includes descriptions of 
strategies they used to manage or deflect unwanted or irrelevant disclosures. 
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 As evident throughout the interviews, educators felt they were frequently on the 
receiving end of extraneous and irrelevant information disclosed by patients.   Deandra, 
who provided in-home education for patients with chronic conditions and rare diseases, 
summarized this phenomenon this way, “When you’re sitting in their home with them for 
a couple of hours and you’re doing this every week for a couple of weeks, yeah, you can 
get into some really interesting conversations.”  Gabi, another in-home educator for 
multiple disease types, went as far as to admit that the disclosures were sometimes so 
unusual or surreal, they seemed contrived.  Though she did not provide any specific 
examples, she jokingly explained, “I sometimes wonder when I go into a home, I’m like, 
‘Am I on Candid Camera or something?’ Sometimes I’m like ‘Is this real? I can’t believe 
it, are they testing me?’” Later in her interview, Deandra went on to rationalize that, 
regardless of the information that was disclosed, she felt it was her duty to listen.  She 
believed that receiving extraneous information had a purpose, if for no other reason than 
serving as a type of therapeutic release for the patient.  She stated, “You put your eyeballs 
back in your head and sit and let them tell you because they obviously feel comfortable 
and there’s a reason they’re telling you. It’s usually a therapeutic thing for them to be 
able to tell somebody.”  Antonia found this interpretation also relevant for her terminal 
neurodegenerative disease patients.  She understood that the despairing nature of their 
condition could often lead them to haphazardly share information with little relevance to 
their therapy.  She stated, “Patients that are terminal are desperate and they’re desperate 
for someone to understand them. And for someone too, this is a very rare disease. And 
they’ll tell you things that you would never chart.” 
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 Felicia was an educator who joyfully shared numerous stories and anecdotes 
about her experiences as a reluctant confidant.  She delivered training for an osteoporosis 
medication in an area of the country known for having an affluent population of retired 
and widowed women.  She affectionately referred to her patients as “my little old ladies” 
and took great pleasure in engaging them in conversations during her product training 
sessions.  She felt that many of her patients equally enjoyed her company as they would 
freely disclose information about themselves.  She put it this way, “Oh, God. Well, most 
of the patients, if I could stay there for hours, they would tell me their entire life story.”  
She continued by offering examples of the various non-therapy-related topics patients 
would broach and how those conversations have even given way to invitations to join 
them for social outings.  She shared “I’ve heard about children’s death, divorce, cheating 
husband, woman followed her husband to the car dealership and caught him with this 
girl. It’s amazing! I’ve been invited to go for drinks with a group of 75-year-old women 
looking for men.”   Felicia later admitted that, while such socially enriching experiences 
made her job enjoyable, they also made it challenging from a time management 
perspective.  She noted, “My first osteoporosis patient was a two-hour visit.  She told me 
about her husband, the divorce, the girlfriend, the this, the that. I walked out going, ‘I’m 
not going to get any work done if every visit is like this.’”  
 Petronio (2002) explained that professions such as nurses fall into a subset of 
reluctant confidants she referred to as occupational confidants.  These are individuals 
who are frequently disclosed extraneous or unsolicited information as a result of their 
occupation.  Other examples include bartenders and hair stylists.   She states that, while 
many of these individuals tend to recognize their occupation predisposes them to 
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receiving unwanted information, they still use strategies to curtail or deflect that sort of 
information.  Such was the case with clinical educators.  In fact, a few educators shared 
the tactics they used to mitigate or control unwanted disclosures when placed in a 
reluctant confidant role.  Hanna, a diabetes and osteoporosis educator, believed that 
educators should be careful in not dismissing or ignoring disclosed extraneous 
information.  She felt it was important to accept and listen to all of what the patient was 
sharing, as not doing so was a discredit to the patient.  She stated, “To be dismissive of 
them, and/or to not give them your time, I think is a discredit, not only to being a 
provider, but I think it’s also very insulting.” 
 Other educators, however, felt there were tactful ways to address a derailed 
conversation without endangering trust or appearing dismissive.  Gabi, an educator for 
multiple disease types, explained that her approach is a gentle redirection back to the 
topic at hand, what she referred to as “bringing them back onboard”.  She put it this way, 
“You just roll with it, if it’s not pertinent to their training…I bring them back to what we 
were there to discuss. It’s just experience...talking with patients, you just bring them back 
onboard.”  Nadine, an educator for patients with chronic autoimmune diseases, offered a 
similar strategy, noting how redirecting the conversation can sometimes require creative 
nuancing.  She shared, “You got to find balance between allowing the patient to talk 
about what they want to talk about, but also redirecting the focus of the task at hand. You 
got to be creative and know when it’s safe to break.”  
 One educator, Olivia, believed that in some instances, an educator may need to 
simply shut down unwanted disclosures if they become a distraction or seem 
disingenuous to the goal of the engagement.  She shared an example of a patient who 
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disclosed repeatedly that she was using recreational marijuana while taking the drug on 
which Olivia was training.  The patient continued to broach the topic to the point Olivia 
felt the patient was simply trying to goad a disapproving reaction from her.  She 
explained that she eventually put a hard stop to the situation by stating the following to 
the patient, “I’m not going to comment on that as a nursing professional.  Our package 
insert doesn’t speak to using marijuana with this medication, and I’m done talking about 
this.’  Sometimes you just have to put it out on Front Street.” 
Summary of Findings 
Educators viewed trust as foundational to their relationships with patients.  It was 
necessary for soliciting the types and quality of disclosures that enabled them to 
effectively coach patients to behavior changes.  When discussing the concept of trust in 
their role, many educators interpreted its meaning within the context of rapport.  Some 
believed the terms to be synonymous while others felt one was predicated upon the other.  
Regardless, most educators believed they benefited from a predisposed high level of trust 
automatically imbued to them by patients because of their healthcare credentials. 
Educators shared that it was important to establish trust at the start of their 
relationship by reassuring patients they had their best interest at heart.  Some educators 
even felt it appropriate to disclose personal anecdotes related to their role.  Once trust was 
established, educators engaged in strategies to maintain it, especially for patients enrolled 
in multiple engagement programs.  Some educators noted how the mere fact they were 
accessible and available to provide time for coaching was a trust-strengthening factor; 
physician inaccessibility was a common criticism of patients. Giving patients their time 
and an attentive ear also included allowing patients the opportunity to share their story 
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and their disease journey—a concept educators noted as an effective trust-strengthening 
tactic. Along with accessibility, educators noted that it was important to present a 
demeanor of honesty along with a non-judgmental attitude.  Educators placed a high 
value on maintaining trust as they recognized the potential devastating impact of a trust 
loss on their credibility and on patient outcomes.  They believed a disruption of trust 
could stymie comprehension and impede achievement of disease self-management goals.  
When asked during their interviews how they interpreted the concept of privacy 
within the context of their role, educators often shared thoughts about the way their 
patient disclosed health information to families, friends, and others.  According to the 
educators, these disclosure strategies were diverse with some patients not even sharing 
their disease diagnosis with spouses or other immediate family members.  The other way 
educators addressed the notion of privacy was through descriptions of the disclosure 
expectations placed upon them by patients and by themselves.  In all these cases, 
educators highlighted a range of privacy rules used by themselves and patients to manage 
when, where, why, how, and to whom information was shared.  These rules fell into two 
CPM privacy rules management categories, routinized and changing.  The routinized 
rules were dictated by stable, non-changing criteria called core criteria while changing 
rules were dynamic, situationally based and managed by catalyst rule criteria. 
The routinized and changing rules educators used to manage their own disclosure 
behaviors regarding patient information were examined within the context of three 
influential parameters.  The first parameter was professional ethics which described how 
educators adopted privacy management strategies based on the ethics that oriented them 
during their experiences working as a field clinician.  The second parameter was the 
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political/legal ecological context.  This construct examined how compliance and 
regulatory factors described in Chapter 4 were influential in the development of the 
routinized rules used for managing patients’ private information.  The final parameter 
was insights garnered from patients’ privacy management behaviors.   The knowledge 
educators gained from their observations of the way patients managed privacy with 
family, friends, and others, influenced the core and catalyst criteria educators used for 
developing and utilizing privacy rules. 
Patients’ expectations of the way their disclosures were managed by educators 
were dependent on the type of confidant role they co-constructed with those educators.  
For this study, three CPM confidant roles—stakeholder, deliberate, and reluctant—were 
relevant.  Patients often freely disclosed information to educators because they saw the 
educators as a stakeholder confidant in their care.  As such, patients understood 
disclosure was necessary to receive care.  Patients also trusted the educators would 
manage their private health information because of the professional and ethical 
obligations inherent to their field. 
Clinical educators undertook a deliberate confidant role meaning that patients 
expected to disclose information to educators because of the educators’ roles as coaches 
and counselors.  In return, educators recognized that they needed to make certain 
provisions for patients.  One provision was trust; patients needed to feel they could trust 
their educator.  Next, educators needed to provide patients with an outlet for sharing as 
well as access and time.  Finally, a few educators noted the appropriateness of providing 
reciprocating self-disclosures.  This included self-disclosures that were reactive and in 
response to patient requests as well as proactive measures used to motivate and reassure. 
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Educators frequently assumed a role of a reluctant confidant—an individual who 
receives disclosures without an expectation for such.  As most of the educators in this 
study delivered programs that included multiple engagements with each patient, the 
educators were often on the receiving end of extraneous or irrelevant information.  While 
such disclosures possessed the potential to derail the educator-patient dynamic, most 
educators were able to mitigate impact through deflection strategies. 
The next chapter will discuss what these findings mean within the context of the 
two theoretical frameworks as well as the implications they have for the policies and 
regulations that manage the way educators communicate with patients.  That chapter will 
also include an explanation of the limitations of this study as well as opportunities for 
future studies that can address those limitations. 
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Chapter 6: Discussion 
In this chapter, I discuss the conclusions and implications of the findings outlined 
in the previous two chapters.  The goal of this chapter is to understand how the identified 
themes are supportive of, and operate within, the two theoretical frameworks that guided 
and extended the study.  Those frameworks are the ecological model of communication 
in the medical encounter (Street, 2003) and communication privacy management (CPM) 
theory (Petronio, 2002).  The chapter is organized by sections corresponding to each of 
the seven themes identified in the Findings chapters.  Each section explores conclusions 
that can be made about the theme as it related to the theoretical framework/s.  The 
practical implications of those conclusions then follow.  The chapter ends with an 
explanation of limitations of the study as well as potential areas and ideas for future 
research.  A short narrative of final thoughts closes the chapter and the study. 
Conclusions and Implications of Themes 1 and 2 
Theme 1 states, “Political/legal contexts factors, manifested in pharmaceutical 
industries’ compliance regulations, greatly influenced clinical educators’ communication 
with patients.” Theme 2 states, “The influence of ecological factors, particularly within 
the political/legal context, would frequently force educators to experience ethical 
dilemmas.”   
Conclusions of theme 1. Educators were keenly aware of the unique legal 
implications of their job and how their responsibilities exposed them to liabilities not 
experienced by most healthcare providers (HCPs) or other roles within the 
pharmaceutical industry.  The looming threat of legal repercussions resulting from their 
actions served as a highly influential, if not the most influential, ecological factor in 
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determining the way they engaged with their patients.  One educator’s quip of “Not only 
do we practice medicine, but we practice law” captured that realization succinctly.  
Educators spoke repeatedly of the litigiously minded nature of their employers. In fact, 
some educators believed the pressure to remain constantly vigilant to the industry’s legal 
parameters and regulatory expectations went as far as to spawn feelings of paranoia.  
Other educators were more sympathetic to the industry’s intense focus on liability 
protection by focusing culpability on the aggressive government regulators who oversaw 
them.  For instance, one educator’s comparison of the U.S. Food and Drug 
Administration (FDA) to “vipers” who would attack any company not perceived to be 
towing the compliance line was emblematic of that view.   Regardless, educators 
understood that the political/legal ecological factors inherent to their role had high-stakes 
monetary implications in the form of government fines and court settlements. 
Unfortunately, the legal ramifications related to the clinical educator role had a heavy 
impact on the communication dynamics between patients and educators.  The remainder 
of this section examines such conclusions and implications.  
Educators recognized that government agencies create compliance regulations to 
protect the public’s health and ensure the safe and accurate distribution and promotion of 
prescription medication.  Additionally, educators understood that, for their employers, 
compliance regulations served first and foremost as a means for managing the liability 
risks inherent to their industry.  Still, for most of the interviewed educators, the influence 
of political/legal context factors, such as compliance regulations, functioned as a type of 
communication constraint and thereby, also a source of frustration. This study identified 
three types of compliance regulations that served as the primary factors of 
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communication influence— adverse event (AE) reporting, staying on-label, and fair-
balance presentation.   
 Many of the conclusions and implications that arise from these three influences 
are reflective of assertions noted in Street’s (2003) ecological model.  For instance, he 
hypothesized that the impact of health system regulations and managed care policies (two 
organizational context factors), coupled with the fear of litigation imposed by health 
insurers, forced some physicians to use a more cautious or guarded style of conversation 
with their patients.  Further, that physician-centered communication style functioned in a 
manner that Street considered a predispositional influence.  Predispositional influences, 
along with cognitive-affective influences, are the two categories of interpersonal contexts 
that operate in the center of Street’s ecological model and are inherent to both patients 
and HCPs.  Interpersonal context factors, such as communication styles, are often 
outcomes that result from the influence of other ecological factors such as age, gender, or 
personal finances as well as internalized attributes such as personality or self-efficacy 
perceptions.    
Emanuel and Emanuel’s four models of physician-patient relationship (1992) 
provides further perspective on the nature of communication styles as it relates to Street’s 
(2003) ecological model.  The authors identified four models of interpersonal health 
communication processes that have frequently been applied within the context of shared 
medical decision making.  Though Emanuel and Emanuel focused on the physician role, 
the constructs of model type and shared decision making has been studied with other 
types of HCPs, including nurses (Friesen-Storms et al., 2015; Stacey et al., 2008).  While 
Emanuel and Emanuel identify four models, only two are relevant to the present study.  
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In the paternalistic model, the physician emphasizes the patient’s well-being over the 
patient’s need for autonomy and thereby determines for the patient what is in their best 
interest.  The physician does this because of their belief that that patient’s values are the 
same as their own and therefore do not need to be solicited from the patient.  Since this 
model engenders the HCP as the decision maker, it would not be reflective of the 
pharmaceutical clinical educator role given that educators are legally prohibited from 
providing medical advice, yet alone making medical decisions.  The informative model, 
which the authors note is akin to Rotor and Hall’s (1992) consumerism model, is the 
inverse of the paternalistic model.  Here, the patient’s values are clearly defined and 
articulated, and there is no need or place for the provider’s values.  The patient is simply 
in need of the facts from the physician, who takes on the role of a technical advisor. The 
third model is identified as the interpretive model which posits that the role of the HCP is 
to provide technical information to patients as well as to elucidate values regarding 
proposed therapies and medical decisions.  Ultimately though, the patient still maintains 
autonomy for decision making and determines whose values will guide treatment.  The 
interpretive model is different from Emanuel and Emanuel’s fourth model, the 
deliberative model.  For this model, the HCP not only empowers the patient with both 
technical knowledge and values, he or she also helps the patient make medical decisions.  
Like the paternalistic model, the deliberative model would be outside of the 
pharmaceutical clinical educator scope   as educators cannot provide any sort of medical 
advice or clinical assistance.  
 When observed within the context of the role of the pharmaceutical-sponsored 
clinical educator, two of these models become relevant, the informative and the 
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interpretive.  For the most part, the interview data suggested that most clinical educators 
idealized a deliberative model, particularly as a communication approach for their clinical 
field experiences.  However, given their recognition of their limitations for providing 
medical advice, educators strove to utilize an interpretive style of communication.  
Emanuel and Emanuel (1992) equated the HCP’s role in this model as a counselor or 
advisor whose purpose is to assist a patient in identifying and articulating his or her 
values regarding the management of their health.  Educators frequent refrain of “meeting 
the patient where they are at” was, among many articulated strategies, indicative of how 
theirs views were supportive of the interpretive model.  Educators saw themselves as 
coaches, counselors, and advisors. 
 Interestingly though, while most educators endeavored to engage patients using a 
communication style aligned to tenets of the interpretive model many of them found 
themselves forced to adopt an approach reflective of the informative model.  As Emanuel 
and Emanuel (1992) note, this communication style is characterized by HCPs whose 
purpose is simply to deliver information about the disease state, treatment options, and 
related risks without any imposition of values; they described an HCP in this model as a 
technical advisor.  Educators’ attitudes were such that this was the preferred model of 
pharmaceutical companies and government regulators, given the industry’s stringent 
focus on liability protection.   Even more so, the nature of the compliance regulations 
themselves provoked a level of influence that many educators felt left little option for a 
communication style other than the informative one.  Hence, educators’ beliefs provide 
validation for Street’s (2003) assertion that organizational context factors, such as 
managed care systems, force physicians to adopt a communication approach that limits 
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patient engagement.  The following section interprets how the political/legal context 
factor of adverse event reporting, staying on-label, and fair-balance presentation 
functioned in a comparable manner and similarly created limitations and barriers for 
educators’ preferred communication style. 
Interpretation of the adverse events factor.  Unlike pharmaceutical sales 
representatives who may receive an AE report from a physician, educators are unique in 
the industry because their role predisposes them to receiving a high volume of AE reports 
directly from the primary source, the patient.  However, unlike their prior positions as 
field clinicians in which AE reporting was voluntary, the pharmaceutical educator role 
mandates they capture and report any side effect or reaction that could be perceived to be 
an adverse event.  This proved problematic for educators who noted that collecting AE 
data from patients was a time-consuming endeavor given the required scope and detail of 
requested information. Ultimately, AE documentation stole minutes from the already 
limited amount of time educators were afforded to engage the patient in education and 
behavior change management conversations.   
In general, the current AE documentation process required by the FDA which 
places a mandatory collection onus on drug manufacturers, has been described as taxing 
and inefficient (Moore et al., 2015; Silverman, 2016; Thomas, 2015). This is because, 
apart from clinical educators, most company-based reports originate from secondary 
sources, such as sales representatives receiving information about an incident during a 
physician’s office visit.  Hence, the information provided by the industry to the FDA is 
often limited or incomplete (Moore et al., 2015). Adding to the issue is that the FDA 
rarely receives reports directly from patients.  Criticisms leveraged at the FDA have also 
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suggested that field-based clinicians, who are voluntary reporters, are more likely to 
possess the type of comprehensive information about new or previously unreported AEs 
that produce the most accurate safety data (Moore et al., 2015).  As multiple educators 
from this study noted, many of the AEs they collect are already known side effects or 
reactions, yet they must still report each instance.  This requirement can directly impact 
communication dynamics.  Additionally, educators described how the use of common 
clinical conversation starters such as “How are you doing today?” were discouraged as 
they could facilitate a response that includes a reportable event, even if it seems unrelated 
to the medication.  
My own experience developing program materials and telephonic call guides 
would validate how the industry’s desire for mitigating AE reports impacted educators’ 
communication approaches.  During a meeting with one of my pharmaceutical client’s 
Medical Legal Regulatory (MLR) team, an internal division responsible for reviewing 
educational and public-facing media and materials for medical accuracy and regulatory 
compliance, a draft program guide was being evaluated for approval for use.  Members of 
the MLR team requested that I remove a line at the start of an instructional guide for 
educators that directed them to greet the patient with, what I assumed at the time to be an 
innocuous statement such as “How are you doing today?”  The rationale for the removal, 
as stated by the MLR team, was that such a statement could trigger the type of 
disclosures that, even if unlikely to be related to the use of the medication, would be 
considered reportable AEs.  This example illustrates how a common trust-building 
greeting used frequently in field-based clinical encounters was subject to veto in a 
pharmaceutical-sponsored education engagement.  Hence, a universal strategy that 
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educators could use to help build trust was stymied.  Additionally, from a theoretical 
perspective, the industry’s aversion toward the use of conversational pleasantries out of 
fear for prompting AEs is revealing of its preference for an informative style of 
interpersonal communication (Emanuel & Emanuel, 1992). Unfortunately, though, such 
behavior by pharmaceutical companies may inadvertently prevent educators from 
engaging with patients in a communication style to which they value and are most 
accustomed.  
AE disclosures can be problematic to the educator-patient relationship in other 
ways.  Though AE reports submitted to the FDA by pharmaceutical companies are 
generally not considered admissible in civil litigation cases (Beck, 2010), other 
documents or notes written by educators about patients and their health could be 
considered discoverable evidence.  Hence, this is the reason why most pharmaceutical 
companies have a policy against educators keeping notes about their patients, such as the 
regulation described by an educator in Chapter 4.  The primary concern is that, if an 
educator records any information that could be perceived as an adverse event but then 
does not report that information through proper FDA channels, the company could face 
legal repercussions and the AE information could potentially be included as evidence in 
civil court cases.   
The detrimental influences related to AE reporting requirements should not be 
misconstrued as an argument against the necessity for educators to properly solicit and 
collect them.   In fact, there is a theoretical precedent that illustrates why actively 
encouraging a patient to disclose treatment status, including unforeseen reactions, is 
supportive of better long-term health outcomes (Cegala, 2011).   However, the industry 
 215 
needs to understand that such patient disclosures are more likely to happen when an 
educator embraces a type of communication style that encourages a shared values 
approach.  Cegala found that communication styles that promote collaboration in the 
medical encounter (i.e. characteristics of the interpretive and deliberative model), tend to 
result in patients reporting more detailed information about their disease and therapy 
responses.  As he goes on to point out, this is important as studies have shown that up to 
80% of decisions an HCP makes about diagnosis and treatment is based on the 
information patients disclose about their condition, with the remaining information 
coming from laboratory tests and other assessment measures (Frederikson, 1995; 
Peterson et al., 1992).  Though educators are not able to make medical decisions based on 
AE reports, they do have a responsibility to ensure their patients’ physicians are made 
aware of AEs.  Hence, educators who engage with patients in a coaching or counseling 
capacity, as opposed to acting as merely a purveyor of technical information, will be 
more likely to receive AEs which, once shared with the physician, may result in a better 
and more precise treatment for the patient. 
Educators raised legitimate concerns regarding the burdensome nature of 
excessive and unnecessary AE reporting that can adversely impact their programs’ 
intended clinical and behavioral outcomes.  When the documentation process becomes so 
onerous it shortens the time educators can spend engaging patients in fruitful 
conversations, patient comprehension of information can suffer.  When educators are 
advised to avoid using empathy-building communication pleasantries for fear of sparking 
an AE, trust bonds can be weakened.  When educators are denied the ability to document 
the type of patient information that allows them to nurture meaningful and tailored 
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conversations, disease journey navigation becomes more difficult.  While the legal and 
liability rationales for AE reporting are apparent, their unintended consequences need to 
be given greater consideration by the industry and regulators lest they undermine the 
ability to fully protect patients. 
Interpretation of the staying on-label factor.  Like AE reporting, educators 
understood the rationale for maintaining on-label compliance though noting that it often 
adversely influenced their communication with patients.  While program scripts and 
instructional guides provided the roadmaps for delivering consistent-with-label content, 
patients who posed off-label questions created challenges.  Of notable frustration were 
those situations in which educators knew the answer to an off-label question but were 
obligated to defer the patient back to their physician or to another resource.  This was one 
area in which some educators highlighted a clear disadvantage of the pharmaceutical 
educator role compared to their field clinician role—where engaging in off-label 
discussions was typically permissible.   
In addition to inconveniencing the patient, educators believed that this 
requirement left patients skeptical of educators’ capabilities or would force patients to 
question the legitimacy of their role.  Even more so, educators seemed most concerned 
that their inability to address off-label questions could have repercussion for patients’ 
comprehension of information.  As discussed in the findings, concerns with staying on-
label were not always related to questions posed reactively by patients. Physicians can 
prescribe a drug for a different indication or dosing regimen than what is stated in the 
prescribing information (PI).  Both instances are considered “off-label uses” (U.S. Food 
& Drug Administration, 2019).  As such, this introduces a unique communication 
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challenge as educators must train those patients using language and materials containing 
content that does not address, or potentially conflicts with, the information or statements 
provided by the physician.  Adding to that challenge is that, because of the requirement to 
stay on-label, educators cannot adjust the delivery of the content to account for such 
differences nor address patient questions regarding those conflicts beyond deferring the 
inquiry back to the prescriber.  Should a patient ask whether their off-label dosing 
regimen changes the likelihood or severity of side-effects, an educator, whose academic 
training or prior field experiences may have provided them the knowledge to accurately 
address the question, would still need to defer the patient back to their physician for the 
answer. 
 Educators are expected to stay on-label because, like mandatory AE reporting, 
regulators consider such actions necessary to safeguard patients and the industry sees it as 
another layer of liability protection.  As multiple educators pointed out though, many 
patients quickly establish strong trust and communication bonds by virtue of an 
educator’s nursing credentials and the fact educators are more likely to spend the sort of 
time engaging patients in the types of meaningful conversations that are absent in 
physician encounters.  Additionally, as educators also noted, some patients are 
intimidated with raising questions with their physician that could be perceived by the 
physician as a challenge to his or her authority or expertise.  Hence, when an educator 
defers an off-label question to which they know the answer, trust bonds can be eroded.  
Secondly, patients are at risk of never receiving the information if they are uncomfortable 
discussing the topic with their doctor.  Together, these two outcomes have the potential to 
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adversely impact patients’ understanding of the rationale or benefits of treatment and 
subsequently hamper their ability to properly self-manage their disease. 
 An educator’s off-label response is typically a reactive issue.  For the most part, 
such problems arise only after a patient asks a question or poses a concern that requires 
the educator to reply.  An interesting paradox is that those educators who adopt a 
communication style in the spirit of the interpretative model are at higher risk for 
receiving off-label questions than those educators who embrace a style characteristic of 
the informative model.  As Street (2003) and Cegala (2011) made clear, HCPs who 
employ a collaborative communication style tend to receive a higher degree of 
participation from patients, including receiving more thoughtful and relevant questions.  
At the same time, when an educator defers off-label questions back to a patient’s HCP, a 
perception of dismissiveness may erode trust and thereby stymie a collaborative 
environment.  Fortunately, as will be discussed later in this chapter, educators utilized 
other communication strategies to moderate the impact of off-label deferring and 
therefore, safeguarded trust bonds. 
 Interpretation of the fair-balance presentation factor.  Multiple educators 
euphemistically summarized the concept of fair-balance presentation as the requirement 
to give patients “the good, the bad, and the ugly,” an acknowledgement of their mandate 
to address difficult topics such as black box warnings and other side effects in addition to 
a product’s efficacy and benefits.  Interestingly, educators did not begrudge their 
obligation to share risks and potential consequences of a medication.  In fact, they viewed 
doing so as a requisite strategy necessary to ensure patient autonomy, a concept discussed 
later in this chapter.  For most of the educators, their primary criticism of this factor was 
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how it manifested itself via overly structured program expectations and inflexible 
materials and instructional processes.  Many pharmaceutical companies sought to control 
the fair-balance message, and ensure liability protection, by producing call scripts, 
instructor guides, and presentation media that left little to no option for customization to 
specific patient needs or learning situations.    
  Not surprisingly, educators tended to focus their ire on these types of programs, 
expressing that their inflexibility devalued educators’ clinical and communication skills.  
While the logic for highly structured programs mirrored the rationales for AE reporting 
and staying on-label (i.e., patient safety and legal protection), they similarly had 
unintended consequences with the potential to undermine their primary intent.  One 
concern articulated by numerous educators was that rigid program delivery requirements 
could not account for the diversity of health literacy levels, comprehension skills, or 
language barriers of an entire patient population.  Hence, large segments of the intended 
audience would not comprehend the programs if presented as expected.  Not only did 
program inflexibility prevent educators from adapting the word choice or language style 
to a patient’s perceived literacy level, some noted that it impeded their ability to evenly 
properly assess whether a patient was understanding, or being engaged by, the content. 
 While educators did not speak of this issue in socio-ecological parlance, they did 
interpret it within the primary constructs of Street’s (2003) ecological model.  For 
example, ecological scholars contend patients’ communication capability and style are 
uniquely related to the context factors that define their personal characteristics (i.e. highly 
educated patients tend to ask more questions than their less educated counterparts, more 
worried patients articulate more concerns)  (Cegala, 2011; Street et al., 2005, 2012).  
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Educators similarly recognized this relationship and, as most were proponents of an 
interpretive style of interpersonal communication, they sought to engage patients in ways 
that aligned to their educational and affective levels.  In other words, educators 
understood that when they can adapt their language and delivery tactics to patients’ 
preferred learning styles and literacy levels, not only were patients more likely to 
comprehend the program content, they are also more likely to engage in active 
participation behaviors such as asking questions and setting health goals.  Additionally, 
as studies on communication competence would note, compliance regulations could 
actually function to constrain an educator’s communication skills (Spitzberg & Cupach, 
1989).  Therefore, educators become a less competent communicator and potentially less 
likely to utilize share decision-making strategies  
A few educators hypothesized that part of the problem with stringent and 
inflexible programs was that they were designed by the pharmaceutical companies’ 
marketing teams instead of professionals with a background and expertise in health 
literacy, adult learning principles, and patient education.  One educator’s rhetorical 
question of “Do you want an architect or a chef to design your kitchen?” captured the 
essence of the belief that the manufacturers of a drug are not necessarily the best entities 
to design the approach for teaching patients how to use it.  Given my responsibilities as a 
program designer and content developer for VMS, I can provide relevant insight for this 
topic.  While I cannot attest to how other patient support services’ companies approached 
development, the process for creating clinical educator programming and materials at 
VMS was typically a collaborative effort between the client’s brand management team 
and VMS’ creative services and account management divisions.   I worked within VMS’ 
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creative services department. Another frequent contributor was the client’s agency of 
record (AOR), which is a third-party marketing or advertising firm responsible for 
developing and managing the client’s entire brand strategy, marketing and media 
artifacts, and promotional efforts.   
Program development responsibilities were outlined as part of the contractual 
agreements between VMS and the client.  However, the scope of influence among the 
three entities—VMS, the client, and the AOR—related to program design and 
development varied based on budgets, existing materials and resources, and the client’s 
oversight tolerance and risk aversion levels.  In my experience, those clients with an 
existing suite of patient support resources, along with a need for vigilant oversight and a 
high aversion to risk, tended to result in the types of highly structured, rigid programs 
that educators found most troublesome.  On the other hand, those clients without existing 
patient support resources, or with little risk aversion and less need to engage in oversight, 
would result in programming that provided greater flexibility and freedom in the way it 
was delivered.  Like the educators though, my program design strategies and content 
structure were ultimately accountable to the same compliance regulations and protocols 
within which they were required to work.  Ideas I proposed for leveraging educators’ 
communication skills more effectively, or tactics I sought to utilize to provide educators 
greater autonomy in content delivery, were often denied and removed during the MLR 
approval process.  Hence, in many cases, the issue was not that the “architects” were not 
consulted for a best design, it was that the best design was not approved. 
Like the educators in this study, my own personal belief regarding patient-
educator interpersonal communication styles centered on approaches that promoted a 
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sharing of values and a high level of mutual engagement.  In essence, my view was 
supportive of the interpretive model (Emanuel & Emanuel, 1992).  Hence, whenever 
possible, I would incorporate in program design and delivery methodologies those 
educational tactics and engagement strategies that nurtured that style of communication.  
As Street (2003) concluded, patients and providers each have the potential to exert 
considerable influence over the behavior of the other.  Therefore, both must cooperate 
and coordinate their responses to create a coherent and successful exchange.  As the 
instructional designer, my idealized goal was to develop a program framework that 
fostered a balanced level of influence, while still staying within the compliance 
framework required by the client and regulatory agencies.  Yet, as many educators 
surmised, such was a task that is easier said than done.  I empathized with their concerns 
that highly scripted and inflexible programs forced them into the role of a “technical 
advisor”, a characterization of the informative model.  I understood that their frustration 
extended beyond how those programs devalued their professional expertise.  For most 
educators, their concern was far less personal. 
Educators warned that two serious implications of these types of programs were 
that they had the potential to exacerbate treatment failures and they could encourage 
patients to drop out before the program completed.  Treatment failure was not predicted 
to be a direct effect of inflexible programs, but rather was the outcome from a progressive 
series of breakdowns.  Treatment failure happened because the patient was not adherent 
to taking the medication as prescribed.  Non-adherence was a result of them not 
understanding the information about the medication, which was a consequence of them 
not receiving the information in way that aligned to their comprehension level and 
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literacy skills.  Thus, educators were reiterating many of the concerns noted in the 
literature about adherence issues (Briot et al., 2009; Hammond, 1995; Shu et al., 2009). 
Secondly, some educators felt that highly scripted programs forced them into an 
unnatural presentation and linguistic style that was perceived by patients as contrived or 
insincere.  As a result, patients who were enrolled in programs with multiple 
engagements would simply stop attending midway through. 
Conclusions of theme 2.  Like the participant sample for this study, most of the 
healthcare professionals who provide pharmaceutical-sponsored clinical education come 
from nursing, a profession to which patients and the public offer high levels of respect.  
In fact, nurses are repeatedly ranked at the very top of annual public opinion surveys of 
the nation’s most trustworthy careers, placing higher than physicians and pharmacists, 
because they are viewed as honest, of moral character, and committed to high ethical 
standards (Brenan, 2018; Reinhart, 2020; A. Stone, 2019).  The participants for this study 
were aware of the sense of trust imbued upon them and often referenced it as a 
foundation of their professional and philosophical orientation. Throughout their 
interviews, they frequently articulated the high expectations by which they held 
themselves for maintaining that trust, even though their clinical educator role was outside 
of direct patient care. 
Trust was fundamental to the educators’ role from the perspective of the 
ecological model as well.  In fact, Street (2003) provided insights that match the beliefs 
articulated by many educators.  One insight was that an HCP’s predispositional 
influences (i.e. their communication style and performance) have a direct bearing on level 
of trust given to the HCP by the patient.  In the context of this study, that meant that 
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patients were more inclined to actively participate in an educator program in a manner 
that is characteristic of the interpretive model when there were high levels of trust. 
Street (2003) continued by a describing the interrelated nature of trust, ecological 
factors, and the larger healthcare system—a relationship relevant to this study as well.  
As he explained, one drawback to the ecological influence of managed care programs is 
that trust in the entire healthcare industry itself can be put at risk.  This happens when 
there is discontinuity of care caused by an employer changing health plans and thereby 
forcing a patient to sever a relationship with an established physician.  When an 
established bond is forcibly broken between patient and physician by the healthcare 
system, a patient’s trust in that system can abate until the patient establishes a new bond 
with a new physician.  
Not surprisingly, the pharmaceutical industry was keen in its understanding that 
hiring highly trusted professionals was in their best interest for that same reason.  By 
employing primarily nurses as clinical educators, pharmaceutical companies, an industry 
increasingly distrusted among the public (Bulik, 2018; Harris Poll, 2017; J. McCarthy, 
2019), have capitalized on the profession’s implied trustworthiness. Interviewed 
educators overwhelming stated they felt trusted by their patients.  However, this was 
despite many educators believing their role has been increasingly handicapped and 
devalued by overly restrictive and counterproductive compliance regulations.  In turn, 
that devaluation forced them to adopt interpersonal communication styles akin to that of a 
technical advisor. 
This belief that their role is perceived by the industry as simply an information 
transmission conduit between two entities, the pharmaceutical company and the patient, 
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has similarly been noted in studies of other healthcare professionals, specifically medical 
interpreters (Hsieh, 2008).  Those studies explored how medical interpreters, physicians, 
and other HCPs recognized medical interpreters as a utilitarian conduit role that was to be 
“robotic” and non-thinking.  In essence, the primary function of the profession is to 
neutrally and faithfully convey information between the patient and HCP without 
influencing the content or dynamic between them (Hsieh et al., 2010; Hsieh & Kramer, 
2012).  Outcomes from those studies can inform the implications for this one.  For 
example, in one study, a passive and utilitarian perception of the interpreter role by HCPs 
was noted to create interpersonal and ethical dilemmas with the power to compromise 
patient care because they pitted the needs of the patient against the needs of the provider 
(Hsieh & Kramer, 2012).  Such ethical dilemmas are explored next. 
Interpretation of ethical principles.  One of the key takeaways from Theme 1 
was that the influence of political/legal context factors, manifested in compliance 
regulations, often conflicted with educators’ professional ethics and sense of duty to their 
patients.  Additionally, many educators felt morally bound to do whatever was necessary 
to avoid breaching the trust they established with patients.  For some educators, these 
attitudes prevailed over their obligation to deliver a compliant educational engagement.  
Hence, those educators chose to engage in purposeful non-compliant behaviors. In 
Chapter 4, three educators were profiled for being the most forthcoming in their 
disclosures of such actions.  However, other educators intimated that they too had 
broached compliance protocols in the past or were amenable to doing so if an appropriate 
situation required it.   While these educators engaged in different types of non-compliant 
actions, their rationales for doing so all centered on a deep-seeded moral and ethical 
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obligations that placed patient needs over employer expectations.  In fact, educators 
frequently found themselves contending with internal struggles such as, “What do I do 
ethically? Where is my first responsibility? Is it to this patient or to this drug company?”   
Educators often addressed such questions within the framework of three medical ethics 
foundational to most HCPs’ professional orientation—respect for autonomy, beneficence, 
and non-malfeasance (Beauchamp & Childress, 2013).   
Medical ethics are critical factors for the patient-HCP communication dynamic.  
In fact, Duggan and Street (2015) contend that this relationship has been instrumental for 
society’s fundamental shift from the biomedical model of medicine, which focused on 
disease pathology and a paternalistic communication style, toward a relationship-centered 
model. They noted, “Relationship-centered care values the individual characteristics and 
concerns of patients…and places moral value on the formation and maintenance of 
genuine provider-patient relationships” (p. 245). 
Not surprisingly, the relationship between ethics and the patient-HCP 
communication dynamic has been interpreted within the context of multiple interpersonal 
health communication frameworks.  However, in most communication models that 
explore this relationship, the medical ethic of respect for patient autonomy is often the 
singular or primary focus.  For instance, Street (2003) explained that physician’s respect 
for patient autonomy was often impeded by the physicians’ obligations to the managed 
care system to which they were part.  Such systems fell under Street’s definition of an 
organizational context.  Additionally, Emanuel and Emanuel’s four models of the 
physician-patient relationship (1992) characterized the physician-patient relationship not 
as a power dynamic, but as a conflict between the ethical principle of autonomy and 
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health, as well as between the values of the patient and the values of the provider.  Other 
studies have examined dialectal tensions—opposing needs that appear mutually exclusive 
but must be met simultaneously—that are created from patients and HCPs contrasting 
needs for autonomy and connectedness (Jameson, 2004).    For instance, Brown and 
Levinson’s politeness theory (1987) has been used to demonstrate how physicians, 
nurses, and patients are able to navigate through the autonomy-connection dialectic and 
create stronger collaborations (Jameson, 2004).   The dialectal tension created between 
the opposing needs of ethical principles and the promotion of medication adherence, have 
similarly been explored within the context of nurse-patient interpersonal communication 
(Hess, 1996). 
The remainder of this section will outline how the influence of the political/legal 
context factors, which were manifested as compliance regulations, created ethical 
tensions for clinical educators and challenged the way they coached and counseled 
patients to behavior change. The practical implications of this relationship between ethics 
and educator-patient interpersonal communication are large and significant to the 
industry and clinical educator programs.  As such, many of those ramifications will be 
addressed at the end of this section and again at the conclusion of the chapter in the 
section on future studies.  However, understanding the practical implications requires 
some analysis of this relationship from a theoretical perspective as well.  As noted above, 
Street’s (2003) ecological model provides some perspective regarding the association 
between medical ethics and the HCP-patient communication dynamic. Scholars have 
used other interpersonal communication frameworks though to further conceptualize this 
relationship, some of which will be explored below.   
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Ethical principles have long been viewed as a guiding force in patient education 
because of the educator’s unique ability to influence an individual’s learning, decision 
making, and consequent behaviors regarding their health (Clarke, 1993).   Additionally, 
these principles are engrained as hallmarks of the nursing profession starting with nurse 
training programs (Tuckett, 2000).   An ethical nurse is viewed as a moral agent who 
understands that being virtuous is not just expressed through her beliefs about how she 
should act, but also in her beliefs about how she should be.  In other words, an ethical 
nurse is a state of character or orientation that serves to guide decisions that are right and 
good (Tuckett, 2000).   Hence, it is not surprising that the clinical educators in this study, 
most of whom were nurses, placed such high value in honoring ethical principles such as 
autonomy, beneficence, and non-malfeasance.  Though educators did not utilize those 
specific terms during interviews, the verbiage and descriptions they provided embraced 
their spirit. 
 For instance, the necessity for respecting and nurturing patients’ autonomy was a 
prominent construct articulated throughout the interviews.  One educator talked about the 
concept using the term “control,” as in “You have to let people know they have some 
modicum of control over what's happening to them” while others referred to it using 
gerunds of “empower”.  Scholars support the synonymous interpretation of autonomy and 
empowerment that exists within the realm of patient education.  Some studies have even 
suggested the two words can be used interchangeably since “the action for autonomy lies 
in its power base” (Clarke, 1993, p. 535).  Reach (2013) believed that patient education in 
chronic care is contingent on empowerment, or catalyzed patient autonomy, particularly 
in the way that it helps patients account for their own and their HCP’s concerns and 
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desires.  Additionally, he felt patient education provides the vehicle by which patients can 
knowledgably choose between their own and their HCP’s preferences.  He noted, “Patient 
education is the empowering process that in chronic care not only provides information to 
the patients but also leads them to an interpretation of their own preferences and a 
deliberation between their, and the HCP’s, preferences” (p. 20).   
Many educators had beliefs about promoting autonomy, or empowerment, that 
would be reflective of Emanuel and Emanuel’s (1992) interpretive model of physician-
patient relationship.  For example, educators’ intense support of the ideal of patient-
centricity would align to the concept of the interpretive model as they felt responsible for 
helping patients recognize and leverage their role as “the center of the healthcare team.”  
For these educators, patient autonomy meant nurturing a patient’s self-agency.  Such an 
interpretation is reinforced by studies that have examined the concept of a patient-centric 
communication style as a type of predispositional influence.  Those studies demonstrated 
that a patient-centric approach leads to better patient participation in a healthcare 
engagement (Cegala, 2011; Street et al., 2005).   
Hence, educators in this study believed they had a unique moral imperative to 
their role.  Though they were not part of a patient’s primary healthcare team, they 
believed they were still responsible for helping patients assert their autonomy to that team 
while also teaching patients how to better communicate with their HCPs.  Scholars such 
as Clarke (1993) would support such an interpretation.  She posited that part of the 
autonomy-boosting role of the health educator is assisting patients in the development of 
their own decision-making and assertive skills required for self-development.  
Additionally, ecological perspective studies have shown that patients who receive 
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communication skills education and support are more likely to increase their level of 
participation in medical encounters with physicians (e.g. Cegala, 2011). Thus, by 
teaching patients how to better communicate with their doctors, educators saw 
themselves as resources that were helping patients meet broader health goals.  
Additionally, as Street et al. (2012) asserted, “identifying, clarifying and taking into 
account a patient's preferences for care is good clinical practice because it honors ethical 
principles of respect and autonomy” (p. 173).   
Educators were also experienced in understanding and navigating the ethical 
antinomy that frequently presents itself when the principle of autonomy conflicts with 
other principles, such as beneficence.   Some scholars understand this to be an ethical 
paradox; the desire to do good for the patient is at odds with the desire to ensure 
autonomy (Reach, 2013; Tuckett, 2000).  In such cases, the ethical nurse recognizes that 
patient autonomy takes precedent.  As Clarke (1993) explained, respect for autonomy is 
inclusive of the right of a patient to not comply with given instructions, or as one 
educator surmised, “Whatever they decide, I'm good with it. It's their life, it's their 
diabetes.”  Such a statement could easily be construed as representative of Emanuel and 
Emanuel’s (1992) informative model or Rotor and Hall’s (1992) consumerism model, 
both of which assert that the patient’s values are clearly defined and articulated, and 
therefore, there is no need or place for the HCP’s values.  In these instances, patient 
autonomy dominates the interpersonal relationship.  While some educators may have 
supported an informative model belief, the data suggested such attitudes were in the 
minority.   
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As the literature also points out, patient and HCP preference for these differing 
communication styles—informative, interpretative, deliberative—are rarely static and 
often change as patients progress through varying phases of the disease journey (Street et 
al., 2012).  Therefore, regardless as to whether educators’ and patients’ communication 
actions and behaviors were indicative of the informative model or the interpretive model, 
educators still believed that a patient’s right for autonomy in decision making was 
sacrosanct.  Yet, such sanctity did not always absolve educators of feelings of moral 
ambiguity as evident by anecdotes in which they felt obligated to place autonomy over 
beneficence.  As one educator had stated after a patient decided to continue taking a 
medication despite the educator’s warning that doing so was unadvised as it was 
contraindicated to her other therapies, “It made me feel really uncomfortable, but I had to 
respect her decision.” 
 Like autonomy, the ethical principles of beneficence and non-malfeasance 
functioned as a balance for the formidable influence of political/legal context factors that 
manifested themselves as compliance regulations.  These two principles are understood to 
be harmonious constructs, often referred to as the principles of goodness and rightness; 
beneficence is defined as engaging in an act in order to benefit another, while non-
malfeasance is defined as refraining from acting in a way that could inflict harm (Tuckett, 
2000).  For example, one educator’s embracing of the Buddhist concept of loving 
kindness— “Going in where the patient is and being able to truly have their interest at 
heart”—signified how beneficence was a philosophical framework for how she, and 
many other educators, viewed the educator-patient relationship.  Further, it engendered 
ethics scholars’ belief that the dynamic of the nurse-patient relationship functions in such 
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a way to nurture the type of beneficence that could not exist outside of that relationship 
(Tuckett, 2000).   
 Within patient education, beneficence is safeguarded when the patient is fully 
informed and understands treatment information and its implications (Clarke, 1993).  
Educators recognized that, while the industry’s frequent inflexibility toward adapting a 
presentation to a patient’s specific learning needs was problematic, such compliance 
factors served to facilitate beneficence.  Euphemisms such as “not sugar-coating things” 
and “giving them the good, the bad, and the ugly” further illustrated that educators 
conceptualized fair-balance presentation as an action of beneficence.   
 The findings also showed that, on occasion, the clinical educators’ commitment to 
non-malfeasance was tested when it conflicted with perceived beneficence.  While 
Tuckett (2000) noted that, when faced with a situation in which non-maleficence and 
beneficence come into conflict, non-maleficence should guide the decision, educators still 
struggled to resolved such dilemmas.  One educator’s moral deliberation regarding a 
perceived inverted risk/benefit ratio for patients prescribed a drug on which she provided 
education embodied that moral conflict.  Other educators had noted that their 
commitment to non-malfeasance was tested when there was a conflicting sense of duty to 
a patients’ HCPs and the perceived necessity to not contradict those HCPs.  Such 
conflicts exemplified how the influence of political/legal context factors forced educators 
into ethical situations in which they had to choose between competing loyalties.   The 
next section explores the interpretations of the three types of dual loyalty described in 
Chapter 4 and their relationship to the role of the clinical educator and the industry that 
employs them. 
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Interpretation of dual loyalty dilemmas.  An ethical dilemma is defined as “a 
situation of a moral nature that requires a choice between two or more unsatisfactory or 
unacceptable options” (Gallagher, 1999).  Additionally, the literature also uses varying 
terms to describe the divided sense of loyalty an individual faces when having to address 
the needs of two opposing entities.  This includes dual loyalties (Beentjes et al., 2016; 
Gágyor et al., 2018; La Puma & Schiedermayer, 1989) conflicting loyalties (Lagerwey, 
2010; Russell, 2012; Trandel-Korenchuk & Trandel-Korenchuk, 1982), and divided 
loyalties (Tabak, 1994; Weingarten et al., 2010).  Navigating dual loyalty situations was 
likely not a new challenge for clinical educators as studies have shown nurses often face 
ethical quandaries when working in the field (Beentjes et al., 2016; Gágyor et al., 2018; 
Russell, 2012).  Still, as evident from their anecdotes, educators’ frequent experiences of 
moral distress regarding these conflicts are supportive of studies that assert such 
dilemmas can impede autonomous nursing practice and patient advocacy (Russell, 2012). 
 When sharing stories and beliefs of ethical dilemmas, educators spoke most 
frequently of the conflicts that arose between their patients and the industry that 
employed them.  Common educator criticisms included a perception that companies were 
more concerned with program volume than program quality as well as the concern 
regarding the industry’s inflexible attitude toward adapting programs to specific patient 
learning needs.  In both instances, educators felt the industry’s actions were shortsighted 
and contradictory to their programs’ goals.  However, educators also felt somewhat 
powerless to do anything about it, as evident by one educator who rhetorically asked, “Do 
I just stand there like a puppet and recite what the regulations tell me to say and walk 
away?”  Situations such as this are not uncommon for nurses as they have a historical 
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precedent in the clinical setting.  Both Thompson (1982) and Trandel-Korenchuk and 
Trandel-Korenchuk, (1982) asserted that nurses have frequently been unsupported or 
even thwarted in their ability to practice their profession by the very institutions 
responsible for patient care.  Thompson placed blame for this disparity on the way the 
healthcare industry, at that time, had embraced a utilitarianism philosophy summarized 
by the phrase “the greatest good for the greatest number.”  As she pointed out, this can 
lead to ethical dilemmas for nurses whose principle concern is often with each individual 
patient currently under their charge.  Not surprisingly, many of the clinical educators had 
concerns about the industry’s perception of patients as a commodity, a belief that seemed 
to support Thompson’s views. 
Clinical educators in this study also found themselves occasionally at odds with 
the healthcare providers whose patients they educated.  Some educators shared anecdotes 
of being caught as a mediator between a patient and their HCP or in situations in which 
they needed to, begrudgingly, defend a physician’s actions or attitudes out of sense of 
professional courtesy.    As Russell (2012) noted, the expectation of  “nurses as 
mediators” between patients and physicians or patients and their families was common in 
the clinical setting.  Therefore, such situations arising in the pharmaceutical clinical 
educator role is not surprising.  Additionally, Thompson (1982) explained how, within 
the clinical setting, nurses typically feel obliged to support the physician, given his or her 
role as captain of the healthcare team, even if they feel a sense of sympathy or loyalty to 
the patients under their care.   
As educators frequently educated patients in the presence of family members, 
they often encountered situations in which the expectations of the two diverged.  Russell 
 235 
(2012) explained that these conflicts can be tricky, especially when a nurse plays a part in 
an end-of-life situation or when a patient is unable to speak for themselves.  All four of 
the educators who served on the network for patients with a terminal neurodegenerative 
condition spoke of the relationships they developed with families throughout the course 
of that year-long program and the challenges it posed.  One educator’s example of her 
need to mediate a discussion between a patient and her sister regarding the use of a 
feeding tube during the latter progression of the disease was one such example.  That 
situation was illustrative of studies that found nurses were often conflicted between their 
duty to preserve a patient’s autonomy and trust while simultaneously respecting the 
family member’s need to properly care for the patient once the severity of the disease 
progressed to the point the patient could no longer self-manage (Beentjes et al., 2016). 
These dilemmas are illustrative of Street’s (2003) contention that the manner in 
which interpersonal communication happens between a patient and HCP is not simply the 
outcome of a single ecological context or an individual factor.  Factors within the 
political/legal context—such as staying on-label, fair-balance presentation, and AE 
reporting—certainly presented educators with communication challenges to which there 
were no precedents to draw upon from their prior field clinician roles.  Hence, for many 
of the dual loyalty dilemmas they faced, they could not reflect upon how they handled 
such an experience when working in a hospital or doctor’s office.  However, as noted 
earlier, Street’s model is unique among other ecological perspective frameworks in that it 
narrows its focus to the engagements between patients and HCPs within the context of 
the medical encounter.  As such, Street emphasizes the role of predispositional and 
cognitive/affective factors within the interpersonal context as having a greater weight of 
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influence in that communication dynamic. Because of this, educators struggled when the 
industry-centric value of “compliant behaviors are ethical behaviors” conflicted with the 
patient-centric values of autonomy and empowerment.  They were challenged when 
emotionally driven factors, such as fear of legal repercussions or a necessity for 
allegiance to their fellow healthcare providers, forced them to consider alternatives to the 
messages they truly wanted to deliver to patients.  Lastly, they grappled with whether 
they could compromise their preference for an interpretive communication style for 
employers who viewed their role as primarily a technical advisor or information conduit.   
Implications of themes 1 and 2.  Educators’ commitment to ethical principles 
and their challenges for overcoming ethical dilemmas have implications for the industry 
and the policies that regulate them.  Pharmaceutical companies need to recognize that for 
many of their clinical educators, including their most valued, experienced, and respected 
ones, the question of whether to be compliant is not a legal or policy matter.  It is a moral 
and ethical issue.  Despite liability concerns, policy directives, and compliance training 
programs, there will be educators who will engage in purposeful non-compliant 
behaviors, regardless of consequences, because they believe them to be the more ethical 
options and the ones necessary to avoid a breach of trust.  One educator made such a 
belief entirely clear when she referred to an expectation to teach what she believed to be 
an unsterile self-injection technique by declaring “That’s nuts! You know what? Fine me! 
Do whatever, fire me!” While this pronouncement may have bordered on the hyperbolic, 
it demonstrated in no uncertain terms that her commitment to the principle of non-
malfeasance superseded any compliance obligation expected by her employer.   
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Interestingly, educators’ passionate defiance of compliance protocols and their 
ongoing challenges in resolving ethical dilemmas presents a unique quandary for the 
pharmaceutical companies who hire them.  If the industry wants to continue to benefit 
from the hiring of nurses and other highly trusted healthcare professionals for their 
clinical educator roles, they need to accept the ethical dilemmas those educators will 
continue to face given the current regulatory environment in which educators navigate.  
The companies’ only other option is to hire non-clinicians, who, given the overly 
structured and scripted nature of some programs, could still deliver much of the content.  
Additionally, non-clinicians might be less likely to struggle with conflicts of professional 
ethics and therefore also be less likely to engage in purposeful non-compliant behavior 
that result from those conflicts.  Unfortunately, though, non-clinicians lack the imbued 
trustworthiness associated with the nursing credentials that educators, and the industry, 
believe are necessary for most effectively coaching to appropriate disease self-
management skills.   
However, as the industry continues to embrace the use of credentialed clinicians 
for program delivery, it will need to do more than simply recognize and accept the moral 
tensions that exist in the clinical educator role if they wish to curtail the non-compliant 
behaviors that result from these tensions.  To begin, pharmaceutical and patient services 
companies should address the moral and ethical stresses that permeate the clinical 
educator role starting with training and onboarding programs that acknowledge their 
existence and present strategies for addressing them. 
As an insider to this industry, my experience has been that such trainings are 
largely absent in the industry. During my six years working as an instructional designer 
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and trainer for clinical educator services, I can state that, as far as VMS training 
programs, topics related to the moral implications and potential ethical conflicts that may 
arise as part of the clinical educator experience did not exist.   In fact, when educators did 
receive structured information about ethical practices in the pharmaceutical industry, it 
was often only part of a mandatory training required by a Corporate Integrity Agreement 
(CIA) imposed on the pharmaceutical client by the U.S. Department of Health & Human 
Services’ Office of Inspector General.  A CIA is a punitive measure levied against 
pharmaceutical companies or other healthcare organizations who violate federal 
healthcare laws (U.S. Office of Inspector General, 2015). In addition to potential fines, 
corrective actions, and other scrutiny measures, most CIAs typically mandate that 
company employees and their agents receive training related to drug marketing and 
promotion annually for five years (U.S. Office of Inspector General, 2015). During my 
time at VMS, three separate pharmaceutical clients were under CIAs.  As such, most 
VMS employees, including all educators for those client brands, were required to 
complete the computer-based CIA training.  These training modules, as well as other 
VMS compliance training programs that were required of clinical educators, framed the 
ethics message within the principle of “compliant behaviors are ethical behaviors”.  
Rarely, if ever, were contradictory ethical expectations inherent to the clinical educator 
role addressed in any VMS training program or policy documents to which I was privy.  
No VMS formalized training program during my tenure acknowledged that educators 
may experience moral dilemmas in which the ethical expectations of their employer 
conflicted with the ethical expectations of their profession.   
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While I can only speak definitively of the company for which I worked, I would 
postulate that such trainings are absent in most other companies that provide patient 
support services for pharmaceuticals.  The reason for this belief is based on multiple 
rationales.  First, any training program that addressed topics of ethical conflicts resulting 
from compliant behaviors could be perceived to contradict the industry’s generally 
accepted principle that “compliant behaviors are ethical behaviors”.  In fact, patient 
services companies like VMS may be hesitant to even propose such trainings to their 
pharmaceutical clients.  Doing so may be misinterpreted by the client as an indication 
that the patient services company hired poorly trained or sub-standard educators.  
Additionally, approval of such training programs by the client’s MLR team could prove 
to be difficult, particularly if a client is under a CIA.  Regarding the second rationale, all 
but two educators had prior experiences as a clinical educator working directly for a 
pharmaceutical company or for a VMS competitor.  At no point during the interviews did 
any of these educators disclose having received such training in a prior position.   
Lastly, companies will need to do more than develop strategies and training 
protocols that address those professional and ethical orientations.  This should include 
working with regulators to create the type of policies that address those situations that 
force educators into ethical deliberations and potential breaches of trust.   Regulators and 
the industry will need to look closely at the way they embrace and promote the 
philosophical orientation of “compliant behaviors are ethical behaviors.”  This maxim 
functions primarily as a legal endorsement for compliant actions designed to protect the 
populace from dubious promotional tactics such as white coat marketing, kickback 
schemes, and off-label product promotion.  However, it fails to truly account for 
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expectations of autonomy, beneficence, and non-malfeasance, for which we also hold 
clinical educators responsible.  
Conclusions and Implications of Theme 3 
Theme 3 states, “A sixth context, the disease and treatment context, not 
previously identified in the ecological model literature, emerged from the interviews as 
having significant influence in the conversation dynamics between the educator and 
patient.”   
 Conclusions of theme 3. Every educator discussed factors that influenced the 
communication dynamic with patients that were supportive of the ecological model 
(Street, 2003).  Chapter 4 focused on educators’ interpretation of the compliance and 
regulatory factors that manifested themselves as part of the political/legal context.  
However, educators described factors that aligned to Street’s (2003) other contexts—
cultural, media, and organizational—throughout the data.  Additionally, they had 
provided insights that were supportive of the everyday talk interpersonal context 
described by Head and Bute (2017).  Together, these factors are demonstrative of the core 
paradigm of ecological perspectives, which is the belief that behaviors and 
communication exchanges cannot be separated from the environmental and policy 
contexts in which they occur (Sallis et al., 2008).  Street (2003) noted that within his 
model, these influencing factors happen simultaneously at multiple levels to include 
interpersonal, intrapersonal, organizational, community, and public policy.   
This theoretically based explanation of Street’s ecological model served to inform 
the rationale for a proposed modification to that model.  However, as noted in Chapter 4, 
there were ecological factors that could not be accounted for by those contexts already 
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identified in the literature.  Hence, this facilitated the need for an additional context—the 
disease and treatment ecological context—which is the thrust of this section.  The 
argument for this new context is further catalyzed by the unique nature of my researcher 
role in this project and the way that role precipitated the interpretation of the interview 
data. 
 As discussed in Chapter 3 Methods, my role as a VMS employee and the 
experiences I acquired there as a program designer and trainer, provided me with a 
unique perspective toward this study and the way I interpreted the data.  In addition to 
creating the program curricula, instructional guides, call scripts, and resource materials 
used by the brand networks, my VMS responsibilities also included a heavy focus on 
insights research related to a range of different disease types, their associated patient 
journeys, and the role of HCPs in helping patients navigate those journeys. Much of this 
research included collecting and reviewing qualitative studies published in the medical 
and social sciences academic literature.  Other referenced sources included data garnered 
from patient profile dossiers written by clients’ market research firms, as well as 
information gleaned from websites and resources published by patient advocacy groups, 
government health agencies, and HCP professional organizations.  I synthesized this 
collected information into summary reports that I later used in developing program 
instructional methods and assessment measures.  Additionally, this information was also 
utilized by VMS’ business development personnel as a resource for creating customized 
sales pitches and business proposals.   
These experiences provided me with a generalized knowledge of the physical, 
emotional, and social experiences of patients afflicted with various diseases and the way 
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those journeys influenced the interpersonal engagements patients had with their HCPs.  
More so, these experiences helped nurture a robust understanding of the complex 
interplay of ecological factors illustrative of Street’s (2003) model.  Finally, the training 
approaches I would use when onboarding educators to a program network often included 
lively discussions during which educators would disclose personal and professional 
experiences of patients’ disease journeys.  Thus, those conversations further affirmed and 
reinforced many of the beliefs and attitudes that I developed about the nature of disease 
and its impact on patients and HCPs.  Such awareness would prove useful as I immersed 
myself in the data for this study. 
During the data analysis process, I noticed insights and stories that, though they 
were clearly indicative of ecological phenomena that were influencing the educator-
patient communication dynamic, did not seem to fit within the definition for any of the 
four socio-political context factors identified by Street (2003).  Additionally, they were 
not supportive of factors associated with the everyday interpersonal context presented by 
Head and Bute (2017).  For instance, some educators claimed that patients’ perceptions 
of a product’s lack of efficacy could directly impede their willingness to engage in on-
going educational conversations.  However, none of the ecological contexts defined in the 
literature would seem to account for the influence of treatment side effects, which include 
therapeutic failures, on the communication exchanges between the clinical educator and 
the patient.  Similarly, multiple educators shared anecdotes of how they would 
spontaneously adjust their interaction approach to account for patients who showed up to 
a training and disclosed a comorbid condition. Yet, the influence of disease comorbidities 
would not fit within the definition of any of the existing ecological contexts.  Thirdly, 
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educators who taught patients to self-inject often spoke of the need to adapt their 
communication approaches to account for the varying complexities of different injection 
devices. Like the prior examples, treatment administration modalities were not factors 
that would fit within any of the aforementioned ecological contexts.  Together, these, and 
the other examples noted in Chapter 4 Findings, present a gap in Street’s original 
ecological model of communication in medical encounters that is also not accounted for 
by additions to that model, such as the one suggested by Head and Bute.  Additionally, 
these examples do not function as predispositional influences as they are not 
representative of communication styles or individual self-concepts. They also are not 
representative of cognitive-affective influences as they are not related to strategic, 
attributional, or relational considerations.   
The remainder of this section examines this group of factors that emerged from 
the data and share a commonality of influence related to the presence of disease and how 
it is treated.  For this study, it has been titled the disease and treatment context.  The 
Chapter 4 Findings discussed different factors that comprise it.  One such factor was 
disease side effects.  Educators shared multiple examples of how the symptoms or 
indicators of a disease influenced the way they communicated with patients.  One 
example was the challenges that arose when patients stricken with a progressive and 
terminal neurodegenerative disease lost their verbal functions.  Educators also 
highlighted how the asymptomatic nature of diseases like osteoporosis or the early stages 
of diabetes, posed communication challenges; patients seemed less likely to be motivated 
to accept treatment for a condition for which there were no perceivable symptoms.  A 
patient’s prior or current experiences with treatment side effects also posed interpersonal 
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issues.  Educators shared multiple examples of how they acted as adherence barriers.  
Additionally, a few educators pointed out that discussions of a medication’s potential side 
effects required a different educational approach when the patient was pregnant or 
planning on becoming pregnant.  The presence of disease-related comorbidities or 
disabilities functioned as ecological factors within this context.  Educators shared various 
examples of how both physical comorbid conditions, such as hypertension or stroke 
damage, as well as mental health comorbidities, such as depression, would often require 
them to adapt their style of engagement or educational tactics.  Similarly, educators 
explained how they would frequently need to spontaneously adjust their teaching 
strategies for patients with disabilities, such as vision problems or dexterity issues, that 
were often unknown to them prior to the start of a program.  Treatment administration 
modalities served as another factor that influenced communication behaviors between 
educators and patients.  Many educators focused on how the real or perceived complexity 
of administration devices such as syringes, autoinjectors, and infusion pumps required 
them to utilize a different instructional and conversational approach than if they were 
educating a patient on an oral medication. 
The remaining disease and treatment context factor that was explored in Chapter 4 
was disease type.  Educators provided robust data regarding this factor and how it 
influenced their role and the way they engaged with patients.   The Chapter 2 Literature 
Review provided examples of studies that have used Street’s (2003) model for 
interpreting ecological factors within specific diseases, particularly chronic conditions 
such as diabetes, asthma, HIV, dementia, cardiovascular disease, and chronic pain (Fisher 
et al., 2005; Hruschak & Cochran, 2017; McKenzie et al., 2012; Mudd-Martin et al., 
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2014; Rose & Garwick, 2003; Tan et al., 2014).  Yet, the data from this study suggests 
that the type of disease was itself an influencing factor in the way educators choose to 
engage patients in conversations and education. Insights, beliefs, and anecdotes provided 
by educators demonstrated that they engaged in different communication approaches 
when speaking with a patient afflicted with a rare disease with few treatment options 
compared to those diagnosed with a common condition, such as diabetes or psoriasis, to 
which there are many medications.  Phrases such as “they need more high-touch” and 
“there’s a lot of therapeutic listening that goes in with those patients” served as exemplars 
of the communication challenges that distinguished rare disease patients from their 
common disease counterparts.  Similarly, educators broached discussions with a patient 
experiencing a terminal neurodegenerative disease differently than the way they would 
approach a manageable chronic condition such as osteoporosis.  As one educator had 
suggested about the difference with her terminal patients over her chronic disease 
patients, “The conversation becomes deeper.”   
Of course, none of these disease and treatment context factors operated in 
isolation.  As ecological scholars point out, there is not just one single ecological factor 
that determines the full scope of influence between a patient and an HCP in the medical 
encounter.  Rather, multiple ecological and interpersonal factors function simultaneously 
at multiple levels within communication engagements (Street, 2003; Street et al., 2005).  
Such interplay became evident when interpreting how disease and treatment context 
factors functioned within interpersonal influences.  For instance, as educators engaged 
themselves in discussions or shared anecdotes of patient’s disease journeys, they would 
often do so in a way that did not divorce the emotional experience of the disease from its 
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physical or technical aspects.  In fact, at times it seemed as if the emotional journey was a 
synonymous or parallel experience of the disease journey.  Street (2003) accounts for the 
role of emotions in the ecological model by explaining that they are a cognitive-affective 
influence that function as a mediator within interpersonal communication.  In this study, 
patient emotions such as fear, anxiety, denial, and even shame frequently operated in 
conjunction with disease and treatment context factors.  
For instance, educators who worked with osteoporosis patients described 
situations that exemplified the interaction of the emotion of denial with the context factor 
of disease side effects.  They expressed how the asymptomatic nature of osteoporosis, 
when coupled with an inability to accept the disease and its relationship to the aging 
process, created a need for a communication approach that focuses on acceptance.  One 
osteoporosis educator’s statement had captured this thusly, “It's a silent disease. They 
don't believe they have it. And they don't want to start the treatment because that's 
admitting you're getting old because osteoporosis is seen as an old lady disease. I think it 
hinders their acceptance.” 
Implications of theme 3. Just as the addition of the everyday interpersonal 
context suggested by Head and Bute (2017) did not fundamentally change the core 
framework of Street’s (2003) ecological model, neither would adding a disease and 
treatment context.  In fact, as Head and Bute pointed out, an extension to the model not 
only provides a venue for new areas for research, it allows researchers to better interpret 
their findings within the framework of the larger model.    
The participants for this study were pharmaceutical-sponsored clinical educators, 
and as such, the disease and treatment context is highly relevant to their role and 
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responsibilities.  Moreover, it is the types of therapies for which these educators provide 
services that makes this context so significant for them.  All the educators interviewed for 
this study educated patients on biologics or other medications that required parenteral 
(i.e. non-digestive system route) administration.  Such medications typically require a 
different learning curve for mastering the administration process than education for an 
oral therapy.  However, these medications do not tend to distinguish themselves from 
their oral prescription counterparts regarding their level of risk for adverse events.   In 
general, parenteral administration typically does not account for either an increase or 
decrease in the overall prevalence or severity of side effects compared to oral 
medications.  These drugs do though tend to have worse adherence rates than those taken 
orally because of the financial, emotional, and psychosocial stresses associated with them 
that function as barriers to self-care (Brixner et al., 2019; Lorenzi et al., 2011).  Hence, 
any HCP charged with managing patients prescribed these types of medications, or the 
scholars who study this phenomenon, should find that this context provides a means for 
interpreting and better understanding the relationship between a patient’s disease journey 
and their parenteral therapies. Additionally, scholars can view the clinical educator 
experience as one more context that supports the relationship between clinician 
communication and adherence (Duggan & Thompson, 2011). 
Still, medication administration modality is not the only mitigating factor for 
consideration of this context.  The data clearly revealed that the type of disease—chronic, 
rare, or terminal—served as a highly influential force in the way educators interacted 
with patients.  Hence, this context is not just pertinent for those HCPs who prescribe 
biologics or other parenteral medications.  It is particularly relevant to those non-
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specializing HCPs who treat or manage patients with a diversity of disease types.  This 
would include those who work in primary care, internal medicine, gerontology, or 
pediatrics.  For instance, a primary care physician will still have on-going interactions 
with a patient who also sees a rheumatologist and has been prescribed a biologic for 
rheumatoid arthritis.  A pediatrician may still provide general healthcare services for a 
pre-adolescent who also sees an immunologist and is self-infusing a medication to treat 
the rare condition of primary immunodeficiency.  Many general practitioners in rural 
areas are often the sole source of care and the primary provider of in-office infusion 
services for patients afflicted with the terminal neurodegenerative disease noted in this 
study.  Such patients are often physically or financially unable to travel to far-off cities to 
have their specialty medication infused by a specialist.  The interpersonal communication 
skills of the doctors and support clinicians in all these situations can benefit from a robust 
understanding of the nature of the disease context and its influence on patients’ 
willingness to actively engage in their own care.  
Conclusions and Implications of Theme 4 
Theme 4 states, “Educators employed communication strategies to navigate 
within the political/legal and disease and treatment context ecological factors.” 
 Conclusions of theme 4. As evident from the findings noted in Chapter 4, the 
impact of the political/legal context and the disease and treatment context was such that 
the factors within these contexts often functioned as barriers toward fruitful interpersonal 
engagements between educators and patients.  Subsequently, those barriers had the power 
to manifest themselves as adherence and self-management failures.  Educators spoke at 
length of their frustration with compliance regulations and the way they adversely 
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influenced their engagements with patients.  They also shared insights about how 
treatment side effects, disease comorbidities, parenteral medication administration 
modalities, and other factors of the disease and treatment context created communication 
and instructional challenges that were often difficult to overcome.  Still, the educators 
persisted in their role as they felt they had the knowledge, experience, and requisite 
skillset to help patients navigate through many of these barriers.  The remainder of this 
section explores those skills, strategies, and tactics educators utilized to address the 
challenges raised in Themes 1, 2, and 3. 
One facet of this study that I found enjoyable, and that worked toward my benefit, 
was that the individuals I interviewed were subject matter experts in the area of patient-
provider interpersonal communication.  All educators reflected on their robust personal 
experiences with interpersonal communication as foundational to their understanding of 
how to effectively engage patients.  However, many of them also referenced specific 
university courses or formal post-graduate classes in patient-provider communication that 
were part of a credentialing or professional development program.  Others referred to 
communication training sessions they received through workshops, certificate programs, 
or as part of an employer’s onboarding process.   
Not surprisingly, communication is recognized as a foundational skill for the 
nursing profession as evident from Standard 9 of the American Nurses Association’s 
(ANA) Nursing Scope and Standards of Practice which states, “The registered nurse 
communicates effectively in all areas of practice” (American Nurses Association, 2015, 
p. 71).  Three competencies within that standard are especially relevant to the focus of 
this study.  These are: (1) the registered nurse incorporates appropriate alternative 
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strategies to communicate effectively with healthcare consumers who have visual, 
speech, language, or communication difficulties; (2) the registered nurse assesses 
communication ability, health literacy, resources, and preferences of healthcare 
consumers to inform the interprofessional team and others; and (3) the registered nurse 
uses communication styles and methods that demonstrate caring, respect, deep listening, 
authenticity, and trust (American Nurses Association, 2015, p. 71). 
 The educators’ recognition of the value of communication as an essential skill 
was evident throughout the interviews and focus groups.   Many of the educators spoke of 
the relationship between communication and clinical outcomes at a level indicative of 
advanced scholarship in the matter.  They shared anecdotes and personal experiences that 
showed they not only internalized the ANA communication standard and its associated 
competencies, but understood their proper application in the field and in the industry.   
 Educators used multiple communication strategies to address the difficulties 
posed by the compliance factors of fair-balance presentation, staying on-label, and 
adverse event reporting that were inherent to the political/legal context.  A few educators 
indicated that they felt the best strategies were the pragmatic ones.  In other words, these 
educators believed the best course of action was simply to stick to the rules—i.e. strict 
adherence to program materials and guides, no deviation from call scripts, and direct and 
unqualified deferrals back to the HCP when off-label questions arose.  Some of the 
educators who advocated this viewpoint may have done so because they had internalized 
the pharmaceutical principle of “compliant behaviors are ethical behaviors.”  Therefore, 
they placed the greatest value on industry-centric strategies because they believed doing 
so was necessary to maintain a sense of ethical centeredness.  This rationale was 
 251 
exemplified by educators’ strategy for addressing fair-balance presentation, which they 
described with euphemisms such as “not sugar-coating it” or “giving them the good, the 
bad, and the ugly.”  As noted earlier, educators saw this approach as a moral imperative 
because it reinforced their commitment toward ensuring patient autonomy. 
 Of interesting note though is that educators who adopted a “stick to the rules” 
predispositional influence may have done so out of a belief that they were upholding their 
ethical principles.  However, the industry-centric nature of that kind of presentation 
would most likely result in a communication style illustrative of the informative model 
(Emanuel & Emanuel, 1992), something few educators seemed to espouse.  As evident 
from the interview responses though, the other likely reason why some of them were 
supportive of a stick to the rules approach was purely out of a need for self-preservation.  
Educators feared putting themselves at legal or disciplinary risk by engaging in any 
strategy that bordered on, or was perceived to border on, the non-compliant. As Street 
(2003) explained, emotional factors, such as fear, that make up the cognitive-affective 
context can greatly influence how an HCP engages with patients interpersonally.  So, 
though educators who valued an absolute and pragmatic approach to program delivery 
may have believed they were doing so out of a moral obligation for ensuring autonomy, 
their true rationale may have originated from their own emotional orientation. 
Regardless, most educators shared ideas and examples of tactics and strategies 
that, in their view, allowed them to effectively navigate through compliance-related 
limitations.  They did this while keeping within “the letter of the law,” or as one 
educator’s euphemism of “almost compliant” would imply, at least the spirit of the law.  
In many ways, educators’ efforts to employ solutions for overcoming compliance-driven 
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communication problems were emblematic of their commitment to both an interpretive 
model of interpersonal communication (Emanuel & Emanuel, 1992) as well as the ANA 
Communication Standard’s (2015) competency of “The registered nurse incorporates 
appropriate alternative strategies to communicate effectively with healthcare consumers 
who have visual, speech, language, or communication difficulties” (p. 71).  Educators 
recognized that it was their responsibility to uphold the spirit of this standard by finding 
solutions for compliance-related communication issues.   
For instance, educators occasionally trained patients who may have been 
prescribed an off-label dosage of their medication or instructed by their physician to 
administer it in a different manner than outlined in the prescribing information.  
Educators shared examples of nonverbal gestures or linguistics tactics, such as voice 
inflections or key-word emphases, to help alleviate confusion that arose when a 
physician’s instructions contradicted the materials they used during instruction.  This was 
an important strategy since educators were not allowed to deviate from those materials 
but still needed patients to understand the importance of following their physician’s 
recommendations.   
 Educators were also keenly aware of the risk to trust bonds that could arise when 
they were required to defer off-label questions back to patients’ HCPs.  This threat was 
why so many of them offered detailed strategies beyond just an unqualified statement of 
“You need to talk to your doctor about that.”  One simple yet effective tactic was to 
provide patients the rationale for why a question could not be addressed.  Educators noted 
that patients were mostly accepting of that pronouncement if they were also made aware 
that there was a legal or policy reason for it.  Additionally, educators would explain to 
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patients that, because they lacked access to full medical histories, any attempt to address 
an off-label question could be unsafe and unethical.  Other educators chose to enlist a 
proactive approach to this strategy by informing patients at the start of the engagement of 
their limitations for addressing certain questions.  Some educators believed trust bonds 
could be unaffected if they acknowledged the validity of a patient’s question and then 
sought out the motivation for it.   
Educators also employed tactics that actively engaged the patient in the solution.  
For instance, a few educators thought it was helpful to have patients write down 
questions that could not be addressed, so the patient could then share them with the 
physician during their next visit.  Educators recognized that some patients have had bad 
experiences in which they did not receive a return call from their HCP office after leaving 
a message that included questions for the physician to address.  In those instances, 
educators would often defer the patient to their company’s medical information line that 
employed clinicians with the authority to address a broader range of topics.  Lastly, 
educators understood that a segment of their population was intimidated by asking their 
physician questions.  For those situations, educators explained that they would take on 
the role of an intermediary by offering to pose the question to the physician on the 
patient’s behalf.    
According to assertions offered by Street (2003), educators use of these different 
strategies would serve as evidence of their desire to embrace interpersonal 
communication in a way that upheld the spirit of the interpretive model (Emanuel & 
Emanuel, 1992).  He claimed, “A provider who shows interest in what the patient is 
saying and solicits opinions or questions is in effect legitimizing the patient's 
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involvement as well as creating opportunities and expectations for the patient to elaborate 
on issues of concern” (p. 70).  As discussed earlier, this notion of “legitimizing the 
patient’s involvement” reinforces the responsibility educators felt for helping patients 
assert their autonomy to the formal healthcare team—a team to which they were not part.  
Educators who took on the role of an intermediary between the patient and their provider 
felt empowered to do so not just because of an ethical obligation.  They took such action 
as it was driven by a predispositional influence that valued patient centricity as 
fundamental to interpersonal communication.   
Educators handled other issues in ways that are emblematic of the ecological 
model.  One challenge faced by educators when presented with an AE was how to 
simultaneously encourage the patient to share the information with their HCP while not 
inciting alarm.  Interestingly, multiple educators suggested that the best way to handle the 
situation was to use the AE as a teachable moment to help patients understand concepts 
like comorbidities, the risk/benefit analysis their physician performs before prescribing a 
medication, and how some, but not all, side effects are captured as part of a drug’s 
clinical trial process.  As with off-label questions, some educators also served as 
intermediaries to physicians by assisting the patient in disclosing the AE.  Telephonic 
educators also recognized the challenges posed by a reported AE, particularly if it was 
the type of side effect that required a visual inspection.  Educators would often impress 
an urgency with patients to have such reactions immediately examined by their HCP, or 
if warranted, emergency services.  Once again, these strategies demonstrated how 
educators engaged patients in a manner that nurtured their confidence, thus reinforcing 
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studies that asserted such actions can lead to greater levels of participation from patients 
in future healthcare exchanges (Cegala, 2011; Street, 2003; Street et al., 2005). 
 Lastly, when educators shared how they addressed disease and treatment factors 
that were functioning as communication and behavioral barriers, their answers were 
indicative of the ANA Communication Standard’s (2015) competency of “The registered 
nurse uses communication styles and methods that demonstrate caring, respect, deep 
listening, authenticity, and trust” (p. 71).  Of the three competencies noted, this one 
directly addresses the importance of communication style.  Even more so, not only does it 
recognize the significance of style, it offers specific values that define an ideal version of 
it; the first four—caring, respect, deep listening, authenticity—often serving as mediators 
of the final one, trust.  Hence, clinical educators who used communication strategies that 
were indicative of the values of this ANA Communication competency, would also be 
likely to support a philosophical orientation that aligned to the interpretive or deliberative 
models of interpersonal engagement. 
For instance, some educators spoke about the ways they tried to find a type of 
“connectedness” with the patient, or a means for the patient to feel like they were in a 
partnership with the educator.  For some, that meant using inclusive pronouns such as 
“we” or “us.”  Educators had also stressed the importance of recognizing the uniqueness 
of the disease experience for each patient as well as the importance of avoiding making 
assumptions about experiences with prior treatments.  When addressing side effects and 
treatment administration barriers, educator sought to correct common misconceptions that 
were often related to topics such as insulin failure, device needle size, and injection pain.  
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Additionally, educators frequently embraced the use of administration demonstrations via 
practice devices or online videos. 
Implications of theme 4. The strategies educators used acted as a counterbalance 
to the potential deleterious effects that were possible from the political/legal and disease 
and treatment context factors that functioned as communication and behavioral barriers.   
Educators acutely understood that these barriers possessed the capability to extinguish 
medication adherence and sabotage proper disease self-management behaviors.  They 
also recognized that, unlike in their field clinician roles, there were more and different 
limitations in the way they could address those challenges. 
Interestingly though, educators still drew from their knowledge and experiences 
as field clinicians to assist them in their efforts.  During their interviews, educators were 
asked to identify patient communication best-practices they learned during their prior 
experiences working in the field that were important to their pharmaceutical educator 
role.  Some of their responses included common-sense communication tactics such as 
making eye contact, being an active listener, making sure to account for body language 
presentations, and providing consistent and on-going verbal encouragement and support.  
They also stressed the importance of gathering a historical understanding of patients’ 
experiences at the start of any engagement as well as the necessity for maintaining an on-
going balanced assessment of both the patient’s comprehension, as well as the 
communication dynamic.  This included continuously reflecting on the type of linguistics 
they used and how they were delivering information.  One educator referred to this as 
part of “the art of nursing” though such skills are also characteristic of the ANA 
Communication Standard’s (2015) competency of, “The registered nurse assesses 
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communication ability, health literacy, resources, and preferences of healthcare 
consumers to inform the interprofessional team and others” (p. 71). 
The main implication that can be synthesized from such evidence is that the role 
of the pharmaceutical clinical educator is best served by clinicians who have had broad 
and varied experiences providing patient education in the field.   Currently, most 
pharmaceutical companies who provide patient education services, along with the patient 
support services companies like VMS who are contracted to run them, have followed 
such a model by utilizing highly skilled field-experienced clinicians.  However, like most 
industries, pharmaceutical companies are always seeking to control costs.  Using 
seasoned and credentialed clinicians is far less affordable than hiring non-clinicians.  
Given how some educator programs are highly scripted and provide little room for 
customization, a cost-controlling pharmaceutical executive might lean toward the non-
clinician option if they perceive a lack of necessity for clinical expertise.  However, as 
apparent from the findings of this study, the value and skills field-experienced 
credentialed clinicians bring to their role is why educators can effectively overcome the 
shortcomings associated with scripted programs.  That same experience is also why they 
can successfully navigate through many of the other barriers posed by political/legal and 
disease and treatment context factors. 
Conclusions and Implications of Theme 5  
Theme 5 states, “Educators believed they needed to establish and maintain trust 
throughout the engagement process for them to successfully solicit meaningful patient 
disclosures.”   
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 Conclusions of theme 5. A core commonality that runs throughout the findings 
of Chapters 4 and 5 is the notion of trust.  The concept is a core construct within the 
context of Street’s (2003) ecological model of communication in medical encounters as 
well as in Petronio’s (2002) communication privacy management (CPM) theory.  In 
Chapter 4, educators conceptualized trust in relation to each of the three compliance 
factors that served as predominant influences on the educator-patient relationship.  
Educators expressed the importance of not sugarcoating information as part of their 
responsibility for fair-balance presentation, lest they lose trust.  They recognized the 
necessity of utilizing nuanced communication strategies to avoid the erosion of trust 
when required to defer a patient’s off-label question.  They also leveraged established 
trust by ensuring a reported AE did not unduly alarm a patient while simultaneously 
impressing upon that patient the importance of informing his or her HCP.   
 Trust is foundational to the framework of CPM theory (Petronio, 2002).  Studies 
that have examine the application of CPM theory within the context of healthcare have 
asserted its value for understanding the way patients and HCPs manage private 
information (Hammonds & Ribarsky, 2018; Petronio et al., 1996; Petronio & Sargent, 
2011).  Just as educators understood the importance of strong trust-bonds for navigating 
compliance barriers, they also recognized its necessity for helping patients feel 
comfortable and confident when sharing private information.   
 An interesting notion that had propagated throughout some of the interviews was 
that educators, by nature of their role and status as nurses, benefited from a high level of 
imbued trust that was not afforded to other professions, including other professionals in 
healthcare.  Though some educators disagreed with such a belief stating that trust could 
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only be earned, those that did support the concept of assumed trust based the idea on a 
popular annual opinion poll.  Nurses have been ranked as the most honest and most 
ethical profession every year but one between 2000 and 2020 by Gallup’s annual public 
opinion poll on the topic (Brenan, 2018; Reinhart, 2020).  Popular consumer media and 
nursing’s professional organizations have often reframed the “most honest and ethical” 
message to be synonymous with “most trusted” (McCarthy, 2019; Stone, 2019).  Of 
course, whether the small subset of the general populace who participate in 
pharmaceutical-sponsored clinical educator programs hold similar beliefs about the 
trustworthiness of their educator is beyond the scope of this study.  Still, the perception 
by many of the educators was that they enter their educational and coaching engagements 
with a beneficial amount of trust already instilled in them by their patients.  Accordingly, 
they believe that predisposed trust worked toward their advantage when soliciting 
information from patients.    
 Educators’ belief that patients automatically instilled trust in them, and therefore 
willingly disclosed information, was interpreted within the context of the opinion polls 
that characterized the profession as honest and ethical.  However, the CPM literature 
would suggest other interpretations for educators’ perceptions of assumed trust.  One 
relevant explanation is Petronio’s (2002) concept of “trust credit points.” These are 
figurative increments of trust given to an information recipient from the discloser that can 
increase or decrease based on how the recipient manages the disclosed information.  If 
the recipient breaks negotiated privacy rules, he or she loses points and must engage in 
actions or a renegotiation of rules in order to restore them.  In the context of this study, 
educators perceived patients as providing them with many points at the start of their 
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engagements.  If educators maintain their expectations and obligations for patient 
privacy, they held on to those points. 
Another possible explanation discussed in the CPM literature is that patients’ 
willingness to automatically instill trust was the result of the patients’ functional need to 
receive healthcare (Petronio et al., 2012).  In other words, patients trusted educators and 
were willing to disclose information to them because they knew that, in exchange, the 
educators would assist them with their healthcare needs.  This is the main premise of the 
stakeholder confidant role noted in the CPM literature (Petronio & Sargent, 2011) and 
described in Chapter 5.  It is discussed in greater detail later in this chapter. 
 Still, there was a sense among some educators that trust was not inherent and 
therefore they still needed to earn it—or at least earn more trust than what was 
automatically assumed.  Additionally, once trust was received, it had to be maintained in 
order to facilitate an on-going exchange of information.  When establishing trust, 
educators spoke of strategies that leveraged their empathetic nature, such as assuring 
patients at the beginning of the program that they understood their challenges and had 
their best interests at heart.  Another shared strategy educators used for making a personal 
connection was to start engagements with a disclosure of personal information about 
themselves.  This tactic could be considered a characteristic of Petronio’s (2002) concept 
of the deliberate confidant.  That role is one in which a recipient, who has actively 
solicited private information from another for coaching or counseling purpose, may 
reciprocate by sharing their own personal information out of an obligation toward trust.  
This confidant role is also discussed in greater detail later in this chapter. 
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 Educators described many different ideas and strategies for maintaining trust once 
it was established.  For instance, some expressed that their ability to spend quality time 
engaging patients in discussions of their health helped to sustain trust, especially given 
that some patients’ adverse attitudes about the amount of time their HCP affords them.  
One educator noted in Chapter 5 that she strengthens trust by sharing her frustration with 
patients regarding her inability to speak to off-label topics.  She had stated, “They know I 
care, they know that I’m a little frustrated or unhappy…because we’re sharing that 
experience together…that strengthens the bonds and rapport more so than it harms.”  This 
was an interesting insight that highlights the relationship that exists between Street’s 
(2003) ecological model and CPM theory.  It demonstrates that, for both disclosers and 
recipients, the ability to establish the sort of trust that can facilitate the sharing of private 
information does not occur in isolation of ecological and interpersonal influences.   
Though the educators worked diligently to maintain trust, they also recognized 
that loss or erosion of trust was possible.  Such loss could be precipitated by what 
Petronio (2002) referred to as boundary turbulence.  This is when an unintended or 
purposeful breach of negotiated privacy rules by the recipient forces the discloser to 
change the thickness of boundary permeability and/or renegotiate the privacy rules.  
Educators sought to avoid boundary turbulence and loss of trust as they believed these 
could impede patients’ comprehension and hinder achievement of disease self-
management goals. 
Implications of theme 5.  Educators may have had varying beliefs about whether 
trust was imbued, earned, or situationally dependent.  However, all seemed to coalesce 
around the idea that it was a value that needed to be constantly nurtured and maintained 
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throughout the tenure of their engagements with patients.  Multiple educators had used 
the phrase “open and honest communication” to describe their preferred strategy for 
maintaining trust when soliciting and receiving private information.  Others utilized 
similar terms such as “being upfront” or “being transparent.”  In fact, educators 
understood such transparency to be a requisite for ensuring patient autonomy, as noted in 
their reference to giving patients “the good, the bad, and the ugly,” that was part of their 
obligation for fair-balance presentation.  Yet, there is incongruity between their support 
for open and honest communication as a strategy for facilitating disclosures and the 
reality of compliance regulations that inhibit them from sharing “unapproved” 
information regarding diseases and/or treatments.  So, while educators may value or 
strive for complete transparency and an open and honest approach for communication, 
their ability to deliver full, unfettered information, ideas, and opinions is an idealistic 
goal, but not a realistic one. 
This realization has implications for educators’ interpretation of trust as well as 
for how they set the tone of their engagements with patients.  Educators should avoid the 
use of messaging or the setting of expectations that implies they will be completely open 
and forthcoming in their communication with patients.  In reality, their ability to address 
all of the questions or information requested by patients is not possible.  Hence, an 
educator who tells a patient they will always be “completely open and honest” stands a 
greater risk for damage to trust bonds when deferring an off-label question than the 
educator who set qualified expectations about their limitations for information sharing.   
As many educators had pointed out, any erosion of trust can severely impact patients’ 
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willingness to disclose the type of health information they need to properly educate and 
counsel. 
Conclusions and Implications of Theme 6 
Theme 6 states, “Educators managed the information disclosed to them by 
patients using routinized rules based on core privacy rule decision criteria as well as 
changing rules based on catalyst privacy rule decision criteria.”   
Conclusions of theme 6.  When educators were asked a general question during 
the interviews about the role of privacy in patient education, they answered from two 
different perspectives, their own and the patients’.  Arguably, the best way to truly 
understand patients’ interpretation of privacy is to gather that data directly from them, 
something that was outside the scope of this study.  Still, the educators were able to 
ascertain a unique understanding of patients’ conceptions of privacy based on the 
educators’ observations and experiences engaging with them.  As noted in the Chapter 5, 
educators did understand that their patients utilized privacy rule decision criteria to 
manage how they shared health information with family, friends, and others.  However, 
educators did not use the CPM terminology associated with privacy rule decision 
criteria—i.e. boundary permeability, core decision criteria, catalyst decision criteria, 
routinized rules, and changing rules— to explain their views during interviews (Petronio, 
2002; Petronio, 2013).  Still, educators shared multiple stories and anecdotes that 
exemplify the spirit of privacy rule decision criteria and privacy rule decision making as 
interpreted from patients’ perspectives. 
 For example, one exemplary anecdote noted in Chapter 5 demonstrated the 
process by which an educator was able to interpret the concept of cultural values—a 
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CPM criteria for privacy rules decision making—that was supportive of assertions found 
in the literature.  Cultural applications of CPM have been the subject of many studies in 
the literature (Petronio, 2013), including those that have focused on the health 
experiences of the African American community (Dillon & Basu, 2019; Gaskins et al., 
2012; Hovick et al., 2015).  In the current study, an educator who was white had shared 
how, in her own personal experiences, family medical histories were known and willingly 
shared among immediate family members and other close relatives.  However, she went 
on to assert that that was frequently not the case for many of the African American 
diabetes patients with whom she worked.  She cited examples of spouses or adult 
children of parents not being aware of their family member’s current treatments and 
disease management requirements, as it was not communicated between them.  She had 
shared how those experiences led her to believe that that type of interfamilial 
communication dynamic was culturally related.   
Studies from the literature would back up her hypothesis.  Lin et al. (2018) found 
that, when compared to their white counterparts, African American diabetes patients were 
more likely to have uneven distribution of family medical history knowledge (i.e. one 
informant knowing and the other not knowing).  The study also found that African 
American family dyads (i.e. husband/wife, parent/child) had fewer reciprocating health 
communication ties than white family dyads.  Studies in the genetic counseling literature 
would support the educator’s contention as well, although with the caveat that other 
social determinants within a race, such as education level and socioeconomic status, 
could scale the influence of interfamilial communication (Ashida et al., 2012; Thompson 
et al., 2013). 
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 This was one example of how educators’ interpretations of patient behaviors were 
representative of CPM’s privacy rule decision principles, but it was not the only one.  
Educators explained that patients often used varying degrees of boundary permeability.  
They shared stories of patients exhibiting different tolerances for disease disclosures to 
families and others.  Interestingly, the educators framed those interpretations within the 
context of professional ethics, maintaining that each patient had “the right” (i.e. 
autonomy) to determine privacy boundaries.  Therefore, if a patient desired to not 
disclose a diagnosis or treatment to their spouse, the educator was obliged to respect that 
decision.  Such predicaments parallel findings by Petronio and Sargent (2011) who had 
found that hospital nurses struggled with similar dilemmas that weighed privacy against 
standards of professional ethics. 
Interestingly, while many educators cited examples in which respect for patient 
autonomy equated to limiting or constraining the sharing of personal health information, 
others had provided instances of a contrary phenomenon.  A few educators cited 
examples of patients who, because they had experienced successes with disease 
management, were motivated to share their disease stories with newly diagnosed 
individuals that participated in the educators’ group education classes.  Such instances 
would exemplify the process by which motivational goals, a CPM catalyst criterion for 
privacy rule management, leads to changing rules (Petronio, 2002). 
 Like their patients, educators relied on privacy rule decision criteria to manage 
patients’ private information.  These criteria included the core criteria, which resulted in 
routinized rules, and catalyst criteria, which produced changing rules.  Routinized rules 
are stable and promote routine privacy management behaviors.  Conversely, changing 
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rules are flexible and result from triggered catalyst rule criteria based on situations, 
motivations, and emotions (Petronio, 2002; Petronio, 2013).  Chapter 5 examined 
educators’ privacy rule decision criteria, both core and catalyst, within three parameters: 
professional ethics, political/legal context factors, and insights educators gathered from 
their observations of the way patients’ managed privacy. 
 Nurses’ ethics as a factor for understanding privacy management decision has 
been examined in studies both within and outside the CPM framework.  For instance, 
Kim, et al. (2017) noted that nurses perception of how well they managed patient privacy 
protection was higher than their actual management performance.  They attributed this 
phenomenon to how nurses’ strong desire for honoring patient autonomy created a false 
perception of actual practice.  Suzuki, et al. (2015) found that, when making privacy 
decisions, nurses would place weighted value judgements on the patients’ right to 
autonomy based on the nature of situation.  If a situation was life-threatening, nurses’ 
respect for patient autonomy would come secondary when deciding to whom to make 
disclosures.  When interpreted within the framework of CPM theory, the ethical 
principles that guided educators’ decisions regarding their compliant (or non-compliant) 
actions were the same ones that were also foundational to the routinized rules educators 
used when managing private information while working in the field.  Many of the 
routinized rules from the clinical field followed educators to their pharmaceutical role as 
did the ethical principles on which they were built.  When discussing patient privacy 
management, educators’ responses were most reflective of the ethical principle of respect 
for autonomy.  This was not surprising since many educators tended to give deference to 
this principle when it conflicted with others such as beneficence and non-malfeasance.   
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Petronio, et al. (2012) accounted for this deference noting that, from a CPM perspective 
of the HCP-patient relationship, “managing privacy means navigating between the need 
for autonomy and the need for connectedness” (p. 41).  Educators strove for 
connectedness with their patients that was best accomplished through thin privacy 
boundaries that facilitated rich and unfettered disclosures.  Yet, educators’ reverence for 
patient autonomy also meant they respected the wishes of patients who chose thick 
privacy boundaries.  Hence, much like their compliance-related dilemmas, educators’ 
decisions related to privacy management also proved ethically challenging. 
 The ethical principles parameter that helped guide educators’ privacy rule 
decisions originated from their prior experiences as field clinicians working in hospitals, 
clinics, and physician offices.  The second parameter, political/legal context factors, 
commenced from those experiences as well and therefore exemplify an intersection of 
Street’s (2003) ecological model and CPM theory (Petronio, 2002).   When asked to 
interpret the nature of privacy in their pharmaceutical role, many educators referred to the 
influence of their years of experience working as field clinicians under various kinds of 
government and healthcare industry-imposed privacy regulations.  One outcome of 
working under government policies in hospitals and physicians’ offices was that 
educators developed routinized privacy rules that they uniformly applied to all patients.    
When educators discussed privacy regulations, some referenced specific policies 
or legislation—most frequently HIPAA, the Health Insurance Portability and 
Accountability Act—while others spoke of them in a more generalized nature.  This was 
not surprising as Petronio and Sargent (2011) pointed out that, along with a code of 
ethics, regulations and legislation such as HIPAA often serve to define nurses’ 
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parameters of patient confidentiality.  Those educators who did specifically mention 
HIPAA tended to be well-versed in its applications.  This was most likely a result of how 
HIPAA is often interpreted by nurses as the hallmark legislation related to the protection 
of individuals’ health information (Erickson & Millar, 2005).  That understanding is 
predicated on the HIPAA Privacy Rule, the federal regulation that set the standards by 
which individually identifiable health information is electronically transmitted among 
stakeholder entities (U.S. Department of Health and Human Services, 2015).  When 
employed by a hospital, clinic, or physician’s office, a clinical educators’ role would fall 
under the HIPAA designation of a “covered entity,” meaning they are legally bound to 
the privacy obligations outlined in the HIPAA Privacy Rule.  As an employee or 
contractor for a pharmaceutical company or patient support services company though, 
educators fall outside the official designation of covered entity.  Instead they would be 
recognized as the HIPAA designation of a “business associate” of covered entities, as 
they receive identifiable health information from covered entities.  In that regard, 
educators are still expected to abide by the HIPAA Privacy Rule (U.S. Department of 
Health and Human Services, 2009).   
 The concrete and unambiguous nature of federal privacy laws such as HIPAA 
functioned as core criteria for the routinized rules that educators applied across their 
career paths.  Additionally, the ethical principles that guided their profession’s moral 
compass were similarly unyielding and thereby also functioned as core criteria for 
routinized privacy rules (Petronio & Sargent, 2011).  The third parameter though that 
provided a framework for privacy rule decision criteria was the insights educators 
garnered from their observations of how patients managed their private information with 
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others.  In other words, educators would develop privacy rules for patient interactions 
based on what they observed about the way patients managed privacy rules with families, 
friends, acquaintances, and others.  As such, this parameter tended to be more represented 
by catalyst criteria and changing rules. 
 The prior case of the educator who noticed differences in interfamilial 
communication with her African American patients serves as an exemplar of this 
phenomenon.   According to this educator, because of cultural expectations inherent 
within that community, black patients were less likely than white patients to know or 
disclose family medical histories among close family members.  That cultural expectation 
functioned as a core privacy decision criterion for patients who were part of that 
community.  The educator later went on to explain that she eventually started adjusting 
her communication approach when working with African American patients and/or 
family members because of her observations.  Her decision to adjust her privacy rule was 
provoked by the situational condition of the presence of family members when training 
African American patients.  Thus, her actions are exemplary of CPM’s assertion that 
situational conditions can function as catalyst criteria for privacy rule changes (Petronio 
& Durham, 2008; Petronio, 2013).  
 Educators shared other examples of situational conditions that were indicative of 
catalyst criteria that prompted privacy rules changes.  For instance, telephonic educators 
explained that they would occasionally need to spontaneously adjust their conversational 
style and approach when they perceived that the patient they had on a call was in a 
physical setting that lacked privacy, such as a store or busy office.  Additionally, 
educators explained that the privacy rules they established with patients were frequently 
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adjusted based on patients’ attitudes or tolerances for using that communication modality 
for health engagement purposes.  Patients who had little or no prior experience with 
telephonic education often displayed skepticism toward educators’ intentions, especially 
during the first call.  As Petronio (2002) points out, emotions, such as skepticism or 
distrust, can also function as catalyst criteria that force recipients of information to adjust 
their privacy management behaviors.  Other emotions, such as the embarrassment related 
to disease stigma, similarly served as privacy management rule catalysts, particularly in 
the group education classes that some of the educators led.  Educators shared how the 
presence of a range of emotions within each class, from acceptance to ambivalence to 
shame, could prove challenging when trying to manage privacy expectations of every 
member of the group.  According to the educators, some patients found the offering and 
receipt of personal disclosures regarding disease journey experiences to be therapeutic 
while other patients preferred simply listening and avoided making any contributions to 
discussions.   
Implications of theme 6.  Many of the everyday decisions clinical educators 
make about patient privacy are driven by policies and structures outside of their control.  
These include federal government acts such as the HIPAA Privacy Rule as well as 
industry policies such as those rooted in liability protection purposes.  For instance, one 
example mentioned in Chapter 4 is the expectation that educators should not keep 
handwritten notes regarding their patients.  Such laws and regulations function as 
routinized rules that leave little room for wavering.  However, much like the impact of 
compliance regulations on educators’ ability to customize programs, these rules have 
ethical implications for privacy.  As noted earlier in this chapter, educators are not trained 
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on navigating the relationship between their ethical orientations and the privacy rules that 
can impact their communication approaches and patterns with patients.  A case in point is 
the educator who adjusted her privacy communication behavior for her African American 
patients.  She did so because of her belief that cultural expectations, inherent to that 
community, influenced the way they disclosed family medical histories among family 
members.  For her, adjusting her approach was an ethical choice grounded in her core 
decision criteria even though the situation itself (i.e. the presence of family members) 
functioned as a changing rule.  She believed adapting her privacy management practice 
was ethically necessary to protect the patient’s autonomy.  However, that choice may 
have also violated her network’s compliance regulations, which stipulated she should not 
make unapproved changes to her program delivery methods.   
As noted previously, educators receive little training or guidance for resolving the 
tensions that are created when professional ethics conflict with practice expectations.  
Such conflicts, as they relate to patient privacy, is no exception.  Educators receive 
formal training on the practical tenets of laws and regulations like HIPAA, but rarely on 
their moral or philosophical impact.  This is something that should be addressed through 
structured training and professional development programs given the influence of 
professional ethics on the clinical educator role.  
Conclusions and Implications of Theme 7 
Theme 7 states, “Educators managed multiple types of confidant roles with 
patients including stakeholder, deliberate, and reluctant.   
 Conclusions of theme 7.  CPM theory identifies multiple types of confidant roles 
for representing the nature of relationships between a discloser of information and the 
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recipient.  Three of them were identified in Chapter 5 as relevant to this study—the 
stakeholder confidant, the deliberate confidant, and the reluctant confidant.  The 
remainder of this section will examine how those roles were interpreted in relation to the 
Chapter 5 findings as well as the implications for the pharmaceutical clinical educator 
profession. 
 Interpretation of the stakeholder confidant role.  Unlike the other types of 
confidant roles which have been interpreted across many different domains, the 
stakeholder confidant has been examined in the literature primarily as it relates to 
physicians and nurses in the healthcare context (Helft & Petronio, 2007; Petronio & 
Sargent, 2011).  As the name implies, the stakeholder confidant status develops because 
the HCP functions as a stakeholder in the patient’s care.  However, the role as addressed 
here is more limited than what is described in other studies that have explored its 
meaning in the context of clinicians in the field.  Still, key assertions from the literature 
are relevant to the experiences of educators in this study.   
 Petronio and Sargent (2011) noted that the privacy boundaries that are inherent to 
the stakeholder confidant roles are co-created by the nurse and patient for two reasons, 
“because of patients’ emotional needs to disclose feelings about a medical state and to tell 
the nurse private medical information to receive health care” (p. 256).  The latter reason 
noted in that statement was touched upon earlier as a potential rationale for why 
educators were automatically imbued with a high degree of trust from patients.  Patients 
gave educators trust credit points because, in return, the educator would assist them in 
learning how to administer medication and manage their disease.  Petronio (2002) used 
the term trust credit points to explain a predisposition of trust provided to a recipient of 
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information from the discloser.  Hence, the stakeholder confidant role could be 
understood as a role that includes imbued trust.  This interpretation was evident in one 
educator’s comment, who said, “They know I’m a nurse, and I’m coming to teach them. 
And I’ve got their information from their doctor. So, he must trust me if he gave me their 
information. So, kind of opens up the communication.”  The educator’s statement points 
to three factors that highlight characteristics of the stakeholder role: (a) a reference to her 
purpose of providing health services, (i.e. “I’m coming to teach them”), (b) her 
acknowledgement that her credentials as a nurse carry weight for receiving predisposed 
trust, and (c) her reference to the physician, another stakeholder confidant, and how his 
trust in her helps affirm a patient’s willingness to accept her as a stakeholder as well.   
Educators perceived themselves to be trusted by patients as stakeholder 
confidants.  Educators also knew that patients saw them as a resource for accessing 
healthcare information—a criterion of the stakeholder confidant’s role.  In fact, as some 
educators were quick to point out, patients often turned to them for additional disease 
information and services that would typically be the purview of the physician or his/her 
office staff.  A few educators had surmised that this phenomenon happened because 
educators were viewed as more accessible and were therefore, prioritized over a 
physician for questions or concerns.   
 The second reason, according to Petronio and Sargent (2011), why educators were 
able to co-create a stakeholder confidant role with patients was because there was an 
emotional need by patients to disclose feelings about their disease.  Responses from 
educators as to why patients were so freely able to disclose information to them was 
because of the trust that was vested in the educators.  Trust not only functioned as an 
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incentive for driving patients’ disclosure of disease experience information, it also 
functioned as a vector by which patients could engage in emotional disclosures related to 
their journey.  For instance, many of the osteoporosis educators hypothesized that their 
one-on-one training sessions offered their older, widowed patients a respite from 
loneliness.  Hence, it was not unusual for those patients to share long and detailed disease 
and life narratives that far exceeded the information educators required to perform their 
training.  As one educator suggested, “It’s their social outlet.”  Other educators noted that 
providing an empathetic ear was as much an expectation and valued component of their 
role as their clinical expertise, particularly for those patients who had grown frustrated 
with the loss of support and sympathy from friends and family members.   
 Interpretation of the deliberate confidant role.  Educators also served as a 
deliberate confidant for patients.  This meant they purposefully solicited and received 
personal information as a means for coaching and counseling (Petronio, 2002).  As 
pointed out in Chapter 5, the deliberate confidant role has been interpreted in studies 
beyond just healthcare and medicine.  However, the concept of the deliberate confidant is 
relevant to this study because it accounted for two provisions, the provision of access and 
time, and the provision of reciprocating disclosures. 
 One of the reasons educators were indicative of the deliberate confidant role was 
because they could provide the type of access and time that was necessary for soliciting 
and receiving thoughtful and meaningful disclosures.  This was important because lack of 
access and time were variables that educators mentioned as objects of criticism from 
patients regarding their HCPs.   Educators found immense value in their ability to provide 
the sort of opportunities that nurtured disclosure. In fact, many educators suggested that 
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the value of an unrushed and thoughtful engagement could not be underestimated for its 
ability to understand and promote better therapeutic and behavioral outcomes, 
particularly related to adherence.  
 The stories and anecdotes from educators who provided education program in 
patients’ homes, similarly reinforced the connection of access and time as foundational to 
the deliberate confidant role.  Educators noted that those situations provided for a more 
personal connection with patients because of the comfort and safety afforded by the home 
environment.  In turn, that connection cultivated a higher sense of trust and thin boundary 
permeability, as evident by one educator who stated, “I have a different relationship 
because I’ve been in their home.” 
 Chapter 5 also noted that a hallmark of the deliberate confidant role is the 
expectation of reciprocity of information (Petronio, 2002).  The rationale for such action 
is often referred to as the norm for reciprocity which is a term that describes the 
phenomenon by which an individual who receives information from discloser feels 
obligated to reciprocate with a matching personal disclosure (Bradac et al., 1978).  
However, some CPM literature maintains that this norm could prove problematic for the 
deliberate confidant in a healthcare context; an HCP who reciprocates with personal 
disclosures to a patient can create an awkward situation for both parties.  Specifically, 
that literature has asserted that, unless an HCP’s reciprocating disclosure is contextually 
or therapeutically relevant, it should be avoided as it can actually impede the ability for 
an HCP to secure and maintain a requisite trust bond with patients (Petronio, 2002; 
Petronio et al., 2012).   The findings from Chapter 5 suggested that educators believed 
that, for the most part, patients had few expectations for reciprocating personal 
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disclosures.  For those few educators who did broach the topic, their responses 
demonstrated alignment with the assertions noted by Petronio as they tried to avoid 
giving patients personal information about themselves.  
 Other educators’ actions though were representative of Petronio’s qualifier of 
“unless an HCP’s reciprocating disclosure is contextually or therapeutically relevant.”  
For example, the proactive self-disclosures of two educators noted in Chapter 5 
illustrated the exceptions to the “no reciprocating self-disclosures” rule.   Both educators 
shared stories of how they divulged personal anecdotes to patients regarding their own 
struggles with disease and health issues.  One educator explained that he would tell his 
patients with diabetes that he also suffered from the Type 1 form of the disease because 
in doing so, he would “see a totally different level of interaction, alertness, 
understanding.”  Similarly, the other educator alluded to the way that her proactive 
disclosure of her own issues with weight management benefited her patients who were 
also coping with the problem.  
 Interpretation of the reluctant confidant role.  Educators shared numerous 
anecdotes and narratives evident of the reluctant confidant role.  As Petronio (2002) 
pointed out, this is an individual who receives private information from a discloser 
without an expectation for that information.  Additionally, she also points out that an 
HCP who functions as a deliberate or stakeholder confidant can take on a reluctant 
confidant role when patients disclose information not relevant to their health or the 
therapeutic context (Petronio & Sargent, 2011).  As nurses, clinical educators fell under a 
subset of reluctant confidants describe by Petronio (2002) as occupational confidants.  
These are individuals who receive unsolicited or extraneous information as a result of 
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their occupation.  Regardless of the terminology given to the role, in instances of 
unwanted disclosures, the HCP was left to determine how to manage that extraneous 
information within the already established privacy rules.   
 Many of the educators in this study accepted that the disclosure of superfluous 
and irrelevant information was a byproduct of their role, thus reinforcing their status as 
occupational confidants (Petronio, 2002).  They took it in stride and even made light of 
some of the peculiar personal narratives patients had provided.  Educators who worked 
mostly with elderly individuals, such as those who educated on the osteoporosis 
medication, hypothesized these sorts of disclosures happen frequently because their 
patients were lonely.  Hence their reluctant confidant role was co-created from a need for 
social engagements.  Conversely, one of the educators who provided education for 
terminal neurodegenerative disease patients postulated such disclosures served a 
therapeutic function. 
 Earlier in this chapter, three types of ethical dilemmas were discussed in relation 
to the influence of political/legal context factors that manifested themselves as 
compliance regulations.  Two of those ethical dilemmas, patients versus their families 
and patients versus their HCPs, can be viewed in the context of the reluctant stakeholder 
role.  Many of the examples from those two types of dilemmas were situations in which a 
patient disclosed to an educator information about family members or HCPs.  If the 
educators were to have revealed that information to those HCPs or family members, they 
would be at high risk for damaging the boundary permeability they had with the patient.  
More so, that disclosure could also harm the boundary permeability between the patient 
and his/her family and HCP.  Petronio and Sargent (2011) conceded this type of 
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emotional and moral distress in their study of nurses who frequently functioned as 
reluctant confidants.  However, just as Petronio and Sargent acknowledged that the 
nurses in their study developed various strategies to address such dilemmas, so too did 
the educators in this project.  One tactic mentioned by educators was the “just roll with 
it” tactic.  These educators believed that it was important to not be dismissive of the 
disclosure of extraneous information while using subtle verbal prompts to get the patient 
back on track.  Others though stressed that in some instances, irrelevant narratives could 
be counterproductive and therefore, a “cut it off” approach was warranted. 
Implications of theme 7.  Pharmaceutical-sponsored clinical educators are 
partners in a unique, paradoxical relationship with patients.  Educators are simultaneously 
a member within, and an outsider to, each patients’ healthcare team.  They are an 
“insider” in that they assume a role and legitimize a perception by patients as an investor 
in their care.  This is because educators provided the type of information and educational 
services that become integral for patients’ adherence to therapy as well as for the 
development of confidence and skills necessary to properly self-manage a disease.  
Additionally, educators actively solicit, receive, and document personal health 
information from their patients that is used to support and nurture the achievement of 
broader health and treatment goals.  Conversely, as an outsider to a patient’s “formal” 
healthcare team, educators are not allowed to provide medical advice, are limited in their 
ability to address certain topics related to the disease or treatment, and cannot access, or 
even be privy to, a complete medical history.  Such barriers can therefore impede 
educators’ ability to deliver the sort of tailored information that is possible when working 
in the field. 
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 Educators’ ability to co-construct different confidant roles speaks to theirs, and 
their patients’, perceptions of them as both insiders and outsiders to the healthcare team.  
As a stakeholder confidant, they serve mostly as an insider and therefore should continue 
to abide to the same privacy structures and behaviors they utilized in their field 
experiences.  Based on the responses of most educators in this study, that is already part 
of their common privacy management practices.  However, while many educators 
approached that role with an assumption of imbued trust, they should continue to be 
vigilant to the limitations that may carry.  As many educators also pointed out, regardless 
as to whether trust is initially earned or automatically instilled, it can always be lost.  
Therefore, efforts should always be undertaken to assure trust is maintained.  Trust 
maintenance is a core component of the other two roles, especially given that these roles 
tend to exist more in the outsider realm.  When patients engage educators as a deliberate 
or reluctant confidant, they do so because they view the educator as providing the sort of 
time, access, and unwavering ear for disclosure that is not available from their HCP.  As 
such, educators must be sure to set proper expectations with patients as to how those 
disclosures will be kept private.  Yet, they also need to simultaneously impress upon the 
patient the necessity to share disclosed concerns with their HCP.   
Limitation and Future Studies   
 Limitations. The clinical educators for this study were all selected from a 
recruitment pool provided by one patient support services company, VMS BioMarketing.  
While most of those interviewed also had experiences working as clinical educators for 
VMS competitors or directly with a pharmaceutical company, the VMS commonality did 
serve as a limiting factor.  One way it impacted the study was because of my relationship 
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with the company; I was a VMS employee at the time interviews were conducted.  Even 
though multiple efforts were taken to assure participants that their confidentiality would 
be protected, educators may have been apprehensive in providing candid responses to me, 
particularly those educators employed or under contract with VMS at that time.  Even 
those participants who were no longer employed or under contract with VMS may have 
felt some reluctance to be fully forthcoming, lest they assume word would get back to 
VMS and hurt future job prospects.     
Another drawback of this study was that some educators limited their responses in 
a way that was only representative of their VMS experiences, even though they were 
asked to reflect on the totality of their career as a pharmaceutical-sponsored clinical 
educator.  Had I the ability to interview clinical educators with no prior or current 
affiliation with VMS, I would have been able to isolate and interpret the data beyond that 
company’s context.  This would have generated some insight as to whether the identified 
themes were salient and relevant to educators regardless of employer.  While my role as 
an “insider” to this study’s phenomena of interest proved beneficial on many fronts, these 
two study weaknesses are examples of the way that role limited collection and analysis of 
data.  
 The medium by which data was collected was also a limiting factor.  Many of the 
telephonic educators spoke of the difficulty in not being able to view their patients’ body 
language when conversing with them—a skill they had mastered and found helpful for 
properly assessing patients when working in their field roles.  This was true for this study 
as well.  As all participant data was collected telephonically, I was unable to observe the 
sort of facial and kinesthetic cues that would have indicated instances of excitement, 
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boredom, annoyance, etc. during the interview.  Hence, while I was able to rely on some 
verbal and linguistic cues regarding an educator’s emotional state, and adjust my line of 
questioning appropriately, I was not able to account for emotions that manifested 
themselves via body language and facial expressions.   
 Future studies.   A frequently articulated and debated concept that emerged from 
the data was the notion of imbued trust, the idea that educators were automatically 
instilled with a high level of trust based on their HCP credentials.  Future studies could 
explore if educators’ perceptions of that construct, as outlined in this study, align in other 
situations.  This could include examining clinical educators’ concept of imbued trust as a 
study, in and of itself, that is more broadscale and which incorporates survey data from a 
larger population of educators.  Along that same line, there is opportunity to explore the 
question as to whether and how nurses would approach their communication 
engagements differently if they felt they did not have a high level of trust already imbued 
in them. 
Predisposed trust should also be explored from the patient perspective in which a 
research focus is understanding how those who engage with clinical educators develop 
trust relationships.  Such studies could be approached from a qualitative perspective that 
relies on interview data, such as this one, as a means for developing rich understandings 
regarding the nature of the patient-educator experience.  However, a broadscale 
quantitative or mixed methods approach could also examine the imbued trust 
phenomenon across large populations to examine the phenomenon within or between 
demographic, therapeutic, or other ecological factors.  
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 As noted in Chapter 3, an intent for this study was to examine the research 
questions beyond the domain of a specific program delivery modality, disease state, 
medication administration method, or educator employment type using a maximum 
variation sampling strategy.  Hence the findings and conclusions that emerged have 
interpreted the communication experiences of pharmaceutical-sponsored clinical 
educators with broad thematic strokes.  On-going research could now examine educators’ 
experiences within the context of one of the specified domains above.  For instance, how 
do themes that emerge from a study of just diabetes clinical educators align to the ones 
identified in the study?  Does a study that includes only telephonic clinical educators 
draw similar conclusions as this one?  Are the implications the same for educators who 
have only provided education on self-infusion medications the same as those noted for 
the broader range of educators here?  Additionally, there are even more opportunities for 
studies that explore how clinical educators engage within different patient demographic 
factors.  This would include studies that examine the educator-patient relationship within 
the context of a specific characteristics such as gender, race, socioeconomic status, 
geography, education, or health literacy level. 
 Lastly, the clinical educator is just one of multiple stakeholders related to the field 
of pharmaceutical education and coaching.  This study examined their views strictly in 
reference to the patients they served.  However, future studies could also examine the 
communication experiences and relationships educators have with the HCPs with whom 
they also serve, as well as their relationship with the members of the industry who 
employ and support their efforts.  
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Final Thoughts 
Prior to my position working for VMS, I had no concept of who a 
pharmaceutical-sponsored clinical educator was, yet alone what one did.  Like many, I 
am fortunate in that I have not required their services.  Over the last six-plus years 
though, I have gained an appreciation for the unique role they satisfy in an increasingly 
complex healthcare system.  Their relationship with patients as both insiders and 
outsiders to the formal care team serves as a benefit and a challenge.  I surmise that most 
educators find the position to be a suitable means for fulfilling the altruistic tendencies 
that drove them to a life of service and care for others.  In many ways, the types of 
connections they develop with patients are as genuine and rewarding as the ones they 
created when working in hospitals and physicians’ offices—for some, even more so.   
CPM scholars provide a rationale for how and why patients were quick to 
establish a strong personal bond with HCPs like clinical educators; patients had an 
emotional need to disclose feelings and understood that doing so was required to receive 
health services (Petronio & Sargent, 2011).  However, a relevant assertion that can be 
made is that the educators felt as equally a strong need as their patients for establishing an 
emotional connection, particularly for those educators who served in a fulltime capacity.  
The lives of such educators often imitated that of a traveling salesperson, spending long 
hours in the car, punctuated with short interpersonal exchanges with strangers before 
heading out on the road to their next stop.  Similarly, most telephonic educators worked 
from home, devoid of personal contact with both patients and their fellow healthcare 
professionals.  Hence, the isolation that is inherent to their jobs, along with the altruistic 
and empathetic predisposition common among HCPs, could explain why so many of 
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them believed their responsibilities extended beyond purveying information.  Some 
educators were as emotionally invested in their patients as their patients were invested in 
them.  As one educator stated, “For me, that's the reward, is leaving somebody better than 
you found them.” 
Unfortunately, such statements are typically not part of the narrative that makes 
the headlines or captures the attention of government regulators as it relates to the 
services provided by clinical educators.  As these sorts of programs increase in 
popularity, so too does the scrutiny of educators’ responsibilities and expectations.  Issues 
of white coat marketing will continue to pose a concern by those inside and outside the 
industry.  However, though the educators I interviewed struggled with many of the rules 
that governed their duties, their perspectives were not indicative of the way those 
compliance regulations impacted their companies’ bottom lines.  The educators who 
engaged in compliance violations always did so from a professional and ethical 
obligation, not a financial one.  Such a moral compass should be held up as an exemplar 
for an industry that struggles with maintaining the public’s trust. 
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Chapter 7: Appendices 
Appendix A  
Recruitment and Participation Communication 
Interview Recruitment Email (email #1) 
Subject: BE A PART OF A CLINICAL EDUCATOR RESEARCH STUDY! 
VMS is excited to announce we are assisting Indiana University Purdue 
University Indianapolis (IUPUI) in a research study of the experiences of clinical 
educators who deliver education and coaching services to patients on behalf of 
pharmaceutical and biotech companies.  VMS has agreed to provide IUPUI researchers 
with access to their current and former educators and is encouraging educators to 
participate.  As there is little research that has examined the experiences of healthcare 
professionals like you who provide these types of services, this study may offer valuable 
information and insights.   
Participation is voluntary and is completely independent of your VMS-related 
responsibilities.  Therefore, your involvement will be completely confidential.  
If you would like to participate or would like more information, simply send 
an email stating so to [email address] by [date].   Use the phrase “Clinical Educator 
Study” in the subject line. 
DO NOT REPLY TO THIS EMAIL. 
Thank you, 
Tim Barshinger 
PhD Candidate IUPUI 
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Follow-up to Interview Recruitment Email (email #2) 
Thank you for your interest in participating in this research project.  I want to 
provide you with some additional information to assist in your decision-making process.  
My name is Tim Barshinger and I am a PhD candidate in Health Communication at 
Indiana University Purdue University Indianapolis (IUPUI).  This study will provide the 
data for my dissertation project.  I also work for VMS as an instructional designer in the 
Creative Services Department.   
As was shared in the initial email, this study is completely voluntary and will be 
independent of any client work you do for VMS.  You will not be compensated for 
participating.  If you are selected to be interviewed, your involvement will be kept 
confidential and I will only share the data collected from you with my research team at 
IUPUI.  You will also be given a pseudonym that will be used for data tracking, analysis, 
and reporting.  Additional information about confidentiality protection is included in the 
attached Study Information Sheet (SIS).  Please review the SIS carefully as it also 
describes in greater detail the study’s purpose and potential risks.  This project has been 
approved by the Indiana University Institutional Review Board (IRB).   
Participation involves three components: 
• Filling out and returning the attached participant information form.  This 
should only take a few minutes.  This form is to help in the selection of 
participants and to guide some of the questions that will be asked during the 
interview.  Non-identifying information from the form may also be used as part of 
data analysis and reporting. If you are not selected to be interviewed, this form 
will be destroyed. 
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• A single, one-on-one interview with me.  This interview should last no more 
than 45-60 minutes and will be conducted telephonically, via web-conference, or 
if possible, face-to-face.  The interview will be audio recorded and transcribed. 
• Attending and contributing to at least one, but no more than two, focus 
group discussions approximately 1-3 months after the initial interview.  
These meetings should last no more than 60-90 minutes and will also be audio 
recorded and transcribed. 
I am interested in interviewing a broad range of clinical educators from different 
backgrounds, client networks, disease states, and program delivery modalities.  
Therefore, not everyone who expresses an interest may be selected to participate.  I am 
also only interviewing educators who have provided pharmaceutical-sponsored education 
and/or coaching to patients at some point in their career.  If you have only ever provided 
pharmaceutical-sponsored education to healthcare providers, I will not be able to 
interview you.   
Additionally, I am wanting to interview educators who are comfortable speaking 
about how they navigate within compliance guidelines while educating patients.  This 
would include talking with educators who may have experienced adverse event reports 
from patients, those who may have had to respond to questions or concerns not addressed 
within the scope of a product label, and/or those who may have been asked for personal 
opinions or for elaborations on a product’s risks and benefits.  I am also seeking 
educators who are comfortable discussing how different types of patient demographics, 
lifestyle factors, and health behaviors influence communication.  Finally, I am seeking 
educators willing to reflect on and discuss the concept of “privacy” as it relates to 
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information shared by patients.  Once again, your identity and responses will NOT be 
provided to anyone other than the IUPUI researchers. Both the researchers and VMS 
understand that participants will need to be candid and honest with the information they 
share. 
The next steps: 
• Carefully review the attached Study Information Sheet (SIS) 
• Fill out the attached participant information form 
• Email the completed information form back to me within one week 
Once I have received your form, I will contact you and inform you whether you will 
be interviewed and, if so, to schedule a time to conduct it.  
If you have any questions, please don’t hesitate to contact me via phone or email.  If 
you decide that you would not like to participate, please respond to this email indicating 
such. 
Thanks so much! 
Tim Barshinger 
 
Follow-up to Interview Recruitment Email (email #2-ALTERNATE VERSION) 
Hey (name): 
Thank you for your interest in participating in this research project.  I want to 
provide you with some additional information to assist in your decision-making process.  
In addition to working at VMS, I am also a PhD candidate in Health Communication at 
Indiana University Purdue University Indianapolis (IUPUI).  This study will provide the 
data for my dissertation project.   As I shared in the initial email, this study is completely 
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voluntary and will be independent of any client work you do for VMS.  Additionally, as 
this is an unfunded project, I am unable to compensate you for participating.  The 
primary data collected for this project will be from interviews and focus groups meetings 
with a representative group of Clinical Educators. 
If you are selected to be interviewed, your involvement will be kept confidential 
and I will only share the data collected from you with my research team at IUPUI.  You 
will also be given a pseudonym that will be used for data tracking, analysis, and 
reporting.  Additional information about confidentiality protection is included in the 
attached Study Information Sheet (SIS).  Please review the SIS carefully as it also 
describes in greater detail the study’s purpose and potential risks.  This project has been 
approved by the Indiana University Institutional Review Board (IRB).  
Participation involves three components: 
• Filling out and returning the attached participant information form.  This 
should only take a few minutes.  This form is to help in the selection of 
participants and to guide some of the questions that will be asked during the 
interview.  Non-identifying information from the form may also be used as part of 
data analysis and reporting. If you are not selected to be interviewed, this form 
will be destroyed. 
• A single, one-on-one interview with me.  This interview should last no more 
than 45-60 minutes and will be conducted telephonically, via web-conference, or 
if possible, face-to-face.  The interview will be audio recorded and transcribed. 
• Attending and contributing to at least one, but no more than two, focus 
group discussions approximately 1-3 months after the initial interview.  
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These meetings should last no more than 60-90 minutes and will also be audio 
recorded and transcribed. 
I am interested in interviewing a broad range of clinical educators from different 
backgrounds, client networks, disease states, and program delivery modalities.  
Therefore, not everyone who expresses an interest may be selected to participate.  I am 
also only interviewing educators who have provided pharmaceutical-sponsored education 
and/or coaching to patients at some point in their career.  If you have only ever provided 
pharmaceutical-sponsored education to healthcare providers, I will not be able to 
interview you.  
Additionally, I am wanting to interview educators who are comfortable speaking 
about how they navigate within compliance guidelines while educating patients.  This 
would include talking with educators who may have experienced adverse event reports 
from patients, those who may have had to respond to questions or concerns not addressed 
within the scope of a product label, and/or those who may have been asked for personal 
opinions or for elaborations on a product’s risks and benefits.  I am also seeking 
educators who are comfortable discussing how different types of patient demographics, 
lifestyle factors, and health behaviors influence communication.  Finally, I am seeking 
educators willing to reflect on and discuss the concept of “privacy” as it relates to 
information shared by patients.  Once again, your identity and responses will NOT be 
provided to anyone other than the IUPUI researchers. Both the researchers and VMS 
understand that participants will need to be candid and honest with the information they 
share. (See the attached VMS Letter of Support) 
The next steps: 
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• Carefully review the attached Study Information Sheet (SIS) 
• Fill out the attached participant information form 
• Email the completed information form back to me within one week 
Once I have received your form, I will contact you and inform you whether you will 
be interviewed and, if so, to schedule a time to conduct it. 
If you have any questions, please don’t hesitate to contact me via phone or email.  If 
you decide that you would not like to participate, please respond to this email indicating 
such. 
Thanks so much! 
Tim Barshinger   
 
Focus Group Invitation Email (email #3) 
Subject: CLINICAL EDUCATOR RESEARCH STUDY FOLLOW-UP FOCUS 
GROUP 
Hope you are doing well.  And thank you again for participating in this research 
study on the communication experience of pharmaceutical-sponsored clinical educators. 
As I had shared during the interview, I am reaching out to you again regarding the second 
part of this study.  I would like to have you participate in a [telephonic/web-conference] 
focus group discussion with other clinical educators who were interviewed.  This 
discussion will serve as a strategy referred to as “member checking” which is a technique 
by which study participants are asked to review and reflect on some of the initial findings 
noted by the researchers.   I have attached a summary document of those findings that 
will guide our discussion.  Please review it prior to attending.  To accommodate 
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everyone’s schedule, I am offering multiple sessions as noted below.  Please respond to 
this email indicating ALL the sessions you could be available to attend by [date].  
This will help me create similar-sized groups.  You will only be scheduled for one 
session. 
Yours and the other participants’ confidentiality remains an imperative.  
Therefore, during the discussion I will refer to everyone using their pseudonym and 
request that you do the same.  If you recognize the identity of another participant, I ask 
that you not divulge that information to anyone else.  I have also attached the Study 
Information Sheet (SIS) that was emailed to you at the start of this project and outlines 
the purpose, benefits, and risks of this study. 
• Your pseudonym is [name]. 
• The date/time options for focus group sessions are the following: [date/time list] 
Once I have received the responses indicating everyone’s availability, I will email 
you with your scheduled date and time along with instructions for connecting to the 
discussion. 
If you have any questions, please don’t hesitate to contact me via phone or email.   
Thanks so much! 
Tim Barshinger   
 
Phone/Voicemail Message for Responders to Initial Email  
This is Tim Barshinger.  I’m calling as you responded to my email about 
participating in the research study on clinical educators.  First, I want to share my 
excitement for your interest in participating.  Just some information about me.  I’m a PhD 
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candidate in Health Communication at Indiana University and this study will provide the 
data for my dissertation.  So I’m very appreciative of those folks who volunteer their time 
to help me with this.  I also work for VMS as an Instructional Designer. 
I just wanted to share some quick points about the study.  First, the study includes 
three parts.  The first is filling out a very short form about your background as a clinical 
educator.  The second is participating in a telephone interview with me that will last 
about 45-60 minutes.  The third part is participating in a telephonic focus group with 
other interviewees a few month a few months after the initial interview. 
I’ll be sending you an email today that explains this and more in greater detail.  
The email also will have three attachments.  The first is the Indiana University Study 
Information Sheet which describes the purpose and guidelines of the study, its potential 
risks and contact information.  The second is a letter of support from VMS BioMarketing 
(not commissioned).  The third is the Participant Information form which is the 
background survey form I’ll need you to complete and send back to me if you are 
interested in participating.  If you can get that form back to me ASAP, I’d greatly 
appreciate it. 
If you decide you would not like to participate, that is absolutely fine.  I’d just ask 
if you would call or email me to let me know. 
If you have any questions, don’t hesitate to contact me.   And once again, thank 
you so much for your interest.  I’m looking forward to speaking with you. 
Tim 
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Appendix B 
Study Information Sheet 
INDIANA UNIVERSITY STUDY INFORMATION SHEET FOR 
 
Interpretations of Communication Experiences of  
Pharmaceutical-Sponsored Clinical Educators 
 
 
You are invited to participate in a research study of how pharmaceutical-sponsored clinical 
educators communicate with, and interpret, their experiences with patients. You were selected as 
a possible subject because of your role as a current or former pharmaceutical-sponsored clinical 
educator. We ask that you read this form and ask any questions you may have before agreeing to 
be in the study.  
 
The study is being conducted by Timothy Barshinger and Dr. Jennifer Bute of Indiana 
University Purdue University Indianapolis’ Department of Communication Studies. Timothy is 
also an employee of VMS BioMarketing. 
 
STUDY PURPOSE 
 
The purpose of this study is to gain insight as to how pharmaceutical-sponsored clinical 
educators—individuals who provide medication and disease education on behalf of 
pharmaceutical companies—communicate with patients. This study may help the 
pharmaceutical industry understand how regulatory requirements can influence patients’ 
adherence goals.  It may also assist the industry by identifying weaknesses of the 
pharmaceutical-sponsored clinical educator model and providing recommendations to address 
them. Finally, this study may be valuable to the policy makers who create the guardrails that 
regulate these programs.   
 
PROCEDURES FOR THE STUDY: 
 
If you agree to be in the study, you will do the following things: 
 
A. You will fill out a short participant information form. This should only take a few 
minutes.  This form is to help in the selection of participants and to guide some of the 
questions that will be asked during the interview.  Non-identifying information from the 
form may also be used as part of data analysis and reporting. If you are not selected to 
be interviewed, this form will be destroyed. 
B. You will participate in a one-on-one interview with a researcher that will last 
approximately 45-60 minutes.  Your interview may be conducted face-to-face, 
telephonically, or via web-conference.  All interviews will be audio recorded and then 
transcribed.  Timothy and/or a professional transcription service will complete the 
transcriptions.  If a service is use, Timothy will review the transcriptions for accuracy 
and remove identifiable information prior to analysis.  The interview will occur in late 
2018 or early 2019.  The purpose of the interview is to gather background information, 
discuss experiences with patient interventions, and explore conversation dynamics as 
well as provide you an opportunity to offer insights and recommendations regarding 
education programs.     
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C. You will also participate in at least one, but no more than two, focus group discussions 
with other interviewed participants. The first focus group will occur within the first four 
months of 2019 and will be conducted telephonically or via a web-conference.  It will 
last approximately 60-90 minutes and will be audio recorded and transcribed. The 
purpose of the first focus group is to have you review and reflect on of some of the 
initial findings noted by the researchers.  If the focus groups’ interpretations are 
discordant to the findings and extensive reanalysis of the data occurs, then you may be 
asked to participate in a second focus group meeting a few months later. 
 
RISKS AND BENEFITS 
 
A risk of participating in this research is being uncomfortable answering questions posed during 
the interview questions and during the focus group meeting/s.  
 
There is also a risk of loss of confidentiality.  
 
You are not expected to directly benefit from participating in this research.  However, the 
analysis of the data collected from you may be used to help inform and guide other patient 
educator programs, including those of your employer or contracting organization.  
 
CONFIDENTIALITY 
 
Efforts will be made to keep your personal information confidential.  We cannot guarantee 
absolute confidentiality.  Your personal information may be disclosed if required by law.  Your 
identity will be held in confidence in reports in which the study may be published and databases 
in which results may be stored.  Tape and/or video recordings of interviews will only be 
accessible to the researchers and will be destroyed within one year following the completion of 
the study.  
 
Organizations that may inspect and/or copy your research records for quality assurance and data 
analysis include groups such as the study investigators and their research associates, the Indiana 
University Institutional Review Board or its designees, and (as allowed by law) state or federal 
agencies, specifically the Office for Human Research Protections (OHRP). 
 
PAYMENT 
 
You will not receive payment for taking part in this study. 
 
 
CONTACTS FOR QUESTIONS OR PROBLEMS 
 
For questions about the study, contact the researcher Jennifer Bute at (###) ###-#### or Timothy 
Barshinger at (###) ###-####.  
 
For questions about your rights as a research participant or to discuss problems, complaints or 
concerns about a research study, or to obtain information, or offer input, contact the IU Human 
Subjects Office at (###) ###-#### or (###) ###-####. 
 
VOLUNTARY NATURE OF STUDY 
 
Taking part in this study is voluntary.  You may choose not to take part or may leave the study at 
any time.  Leaving the study will not result in any penalty or loss of benefits to which you are 
entitled.  Your decision whether or not to participate in this study will not affect your current or 
future relations with VMS BioMarketing.  
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Appendix E 
Interview Guides 
Interview Guide 
Note:  Indented questions will serve as additional “prompts” that will only be used 
when/if needing to probe for more detailed information.  
1. Before we begin, I first need to verify that you are not currently engaged in any 
sort of legal dispute or action related to patient and/or healthcare provider 
education services with VMS Biomarketing, or a pharmaceutical company, 
biotech company, or any company that offers similar services as VMS. 
2. Briefly summarize your background as a health professional (timeline). 
3. Reflect back on your training, tell me what you recall about learning HOW to 
communicate with patients?  
a. Did you take any structured courses, seminars, or workshops about 
patient-provider communication?  
b. Compare your training on clinical skills with training on 
interpersonal/communication skills. 
c. How would you compare the importance of clinical skills with the 
importance of interpersonal & communication skills for nursing? 
4. Tell me about your previous experience teaching and/or coaching patients when 
you worked in the field (e.g. doctor’s office, hospital, pharmacy, etc)? 
a. How did you come about working for these programs? 
b. How were those engagements initiated? 
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c. What conversations were stressful, challenging, or uncomfortable to have 
with patients? 
d. What strategies did you use to overcome or lessen that stress and anxiety? 
5. Tell me about any organizational structures or guardrails that guided or directed 
the training and coaching conversations you had with patients. 
6. As you talk with patients, you often gain insights into their lives.  Does this 
knowledge ever impact or change how you talk with them or deliver the education 
program?  How so? 
7. What role does “trust” play in patient education? 
8. What role does “privacy” play in patient education 
9. The rest of the questions are going to be in regard to your experiences delivering 
patient education that has been sponsored by on conducted on behalf of a 
pharmaceutical or biotech company.  Tell me about the programs for which you 
provide service? (VMS and non-VMS related) 
a. Tell me about the materials and resources that you use. 
b. Tell me about the system you use to capture data. 
10. What parts of the program excite you the most? 
11. What parts of the program frustrate you the most? 
12. Let’s talk about HOW you talk with patients during these programs.  Tell me 
about the way you determine what to say to patients and how to say it. 
13. Tell me about the role or nature of compliance regulations in your programs? 
14. Do compliance regulations make your job harder?  How so?  (Presented with an 
off-label question) 
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15. Tell me what an adverse event, or a reportable event, is and how it affects 
communication or patient education? 
16. Let’s revisit the concept of “trust” we talked about earlier.  Tell me about the 
nature of this concept “trust” as it relates to how you deliver a pharmaceutical-
sponsored program. 
17. Let’s revisit the concept of “privacy” we talked about earlier. Tell me about the 
nature of this concept “privacy” as it relates to how you deliver a pharmaceutical-
sponsored program. 
18. If you had a respected colleague from the field who has a similar background and 
great passion toward patient education tell you s/he was thinking about becoming 
a pharmaceutical educator, what would you say to them? 
19. I had an educator, when answering that question, explain to me that when she first 
told her colleagues that she was taking a job as a pharmaceutical educator, they 
said to her “So you’re going to the dark side”.  Have you experienced anything 
similar?  Why do you think they said that?  How did/would you respond then?  
How about now?   
20. What changes or recommendations would you offer to VMS and/or the 
pharmaceutical companies you work with? 
OPTIONAL 
21. Throughout the program, you have asked patients to set goals, tell me more about 
those goals and how you help the patient determine suitable ones. 
a. How do patients react when asked to create goals? 
b. How do you respond to those reactions? 
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22. How do you go about getting a patient to enroll in the programs? 
a. What do you believe are some the reasons patients choose to enroll in the 
Program? 
b. What do you believe are some of the reasons patients choose not to enroll? 
c. Do you feel you have a sense at the start of the first conversation whether 
or not a patient will enroll?   
23.  [For programs involving a self-injected biologic] The medication you discuss 
with patients is a self-injectable biologic.  Self-administering an injectable on a 
regular basis would seem stressful or anxiety-producing for some patients.   Tell 
me what verbal cues you listen for to help you identify whether a patient has 
anxiety about self-injecting. 
a. What communication strategies have you found to be most helpful when 
speaking with a patient you perceive to be anxious about self-injecting? 
b. Tell me how the script guides help and/or hinder your ability to have these 
conversations. 
24. Tell me if you ever feel like you know a patient is going to benefit or succeed 
with a program?  What are the indicators?  (Feel free to provide examples) 
a. Why do you think they will benefit or succeed? 
b. What qualities or characteristics do they possess that make you believe 
this? 
25. Tell me if you ever feel like you know a patient is NOT going to benefit or 
succeed with a program?  What are the indicators?  (Feel free to provide 
examples) 
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a. Why do you think they won’t benefit or succeed? 
b. What qualities or characteristics do they possess that make you believe 
this? 
26. Take a moment to reflect on the conversations you have had so far with those two 
patients.  In what ways is your conversation different between them? 
a. How might have you use different words or phrases? 
b. How might have you clarified, elaborated, or probed with each? 
c. How might have their language or responses influenced your words and 
actions? 
27. Compare the conversations you have with the program patients to patients in your 
other positions. 
a. In what ways are they similar? 
b. In what ways are they different? 
c. Do you feel program conversations are easier, harder, or no different than 
other types of patient conversations?  Explain why. 
28. The primary goal for your programs is to provide information and support for 
patients that encourages them to stay on their medication.  Would you agree with 
that?  Are there other goals and how do they compare to the one I mentioned? 
a. How do the script guides support you for reaching those goals? 
b. How do the script guides hinder you in reaching those goals? 
a. Would you prefer more structure, less structure, or no change to the 
scripts?  Why? 
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29. Do you feel program conversations are easier, harder, or no different than other 
types of patient conversations? 
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Interview Guide-2nd Wave 
Note:  Indented questions will serve as additional “prompts” that will only be used 
when/if needing to probe for more detailed information.  
1. Before we begin, I first need to verify that you are not currently engaged in any 
sort of legal dispute or action related to patient and/or healthcare provider 
education services with VMS Biomarketing, or a pharmaceutical company, 
biotech company, or any company that offers similar services as VMS. 
2. Briefly summarize your background as a health professional (timeline). 
3. Tell me how you would interpret the term “authentic nursing” (or “authentic 
healthcare providing” for non-RNs).   
4. Reflect back on your training, tell me what you recall about learning HOW to 
communicate with patients?  
5. Tell me about your previous experience teaching and/or coaching patients when 
you worked in the field (e.g. doctor’s office, hospital, pharmacy, etc)? 
6. As you talk with patients, you often gain insights into their lives.  Does this 
knowledge ever impact or change how you talk with them or deliver the education 
program?  How so? 
7. What role does “trust” play in patient education? 
8. What role does “privacy” play in patient education 
9. The rest of the questions are going to be in regard to your experiences delivering 
patient education that has been sponsored by on conducted on behalf of a 
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pharmaceutical or biotech company.  Tell me about the programs for which you 
provide service? (VMS and non-VMS related) 
10. What parts of the program excite you the most? 
11. What parts of the program frustrate you the most? 
12. Tell me about the role or nature of compliance regulations in your programs? 
13. Do compliance regulations make your job harder?  How so?  (Presented with an 
off-label question) 
14. Tell me some of the strategies, or tactics, you use to navigate through or around 
compliance regulations. 
15. Tell me what an adverse event, or a reportable event, is and how it affects 
communication or patient education? 
16. Let’s revisit the concept of “trust” we talked about earlier.  Tell me about the 
nature of this concept “trust” as it relates to how you deliver a pharmaceutical-
sponsored program. 
17. Let’s revisit the concept of “privacy” we talked about earlier. Tell me about the 
nature of this concept “privacy” as it relates to how you deliver a pharmaceutical-
sponsored program. 
18. Have you ever been in a situation or had a feeling like you were caught between 
your loyalty to a patient and your loyalty to the pharma company?  How about 
between the patient and his/her HCP or family member? 
19. At the beginning of our conversation, I asked you to explain the concept of 
“authentic nursing” Do you consider what you do as a pharma-sponsored clinical 
educator to fit within that definition? 
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20. Do the patients you work for consider what you do to be authentic nursing?  The 
HCPs you work with?  The pharmaceutical company/clinical educator services 
provider (i.e. VMS)? 
21. If you had a respected colleague from the field who has a similar background and 
great passion toward patient education tell you s/he was thinking about becoming 
a pharmaceutical educator, what would you say to them? 
22. I had an educator, when answering that question, explain to me that when she first 
told her colleagues that she was taking a job as a pharmaceutical educator, they 
said to her “So you’re going to the dark side”.  Have you experienced anything 
similar?  Why do you think they said that?  How did/would you respond then?  
How about now?   
23. What changes or recommendations would you offer to VMS and/or the 
pharmaceutical companies you work with? 
OPTIONAL 
24. Throughout the program, you have asked patients to set goals, tell me more about 
those goals and how you help the patient determine suitable ones. 
c. How do patients react when asked to create goals? 
d. How do you respond to those reactions? 
25. How do you go about getting a patient to enroll in the programs? 
d. What do you believe are some the reasons patients choose to enroll in the 
Program? 
e. What do you believe are some of the reasons patients choose not to enroll? 
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f. Do you feel you have a sense at the start of the first conversation whether 
or not a patient will enroll?   
26.  [For programs involving a self-injected biologic] The medication you discuss 
with patients is a self-injectable biologic.  Self-administering an injectable on a 
regular basis would seem stressful or anxiety-producing for some patients.   Tell 
me what verbal cues you listen for to help you identify whether a patient has 
anxiety about self-injecting. 
c. What communication strategies have you found to be most helpful when 
speaking with a patient you perceive to be anxious about self-injecting? 
d. Tell me how the script guides help and/or hinder your ability to have these 
conversations. 
27. Tell me if you ever feel like you know a patient is going to benefit or succeed 
with a program?  What are the indicators?  (Feel free to provide examples) 
a. Why do you think they will benefit or succeed? 
b. What qualities or characteristics do they possess that make you believe 
this? 
28. Tell me if you ever feel like you know a patient is NOT going to benefit or 
succeed with a program?  What are the indicators?  (Feel free to provide 
examples) 
a. Why do you think they won’t benefit or succeed? 
b. What qualities or characteristics do they possess that make you believe 
this? 
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29. Take a moment to reflect on the conversations you have had so far with those two 
patients.  In what ways is your conversation different between them? 
a. How might have you use different words or phrases? 
b. How might have you clarified, elaborated, or probed with each? 
c. How might have their language or responses influenced your words and 
actions? 
30. Compare the conversations you have with the program patients to patients in your 
other positions. 
a. In what ways are they similar? 
b. In what ways are they different? 
c. Do you feel program conversations are easier, harder, or no different than 
other types of patient conversations?  Explain why. 
31. The primary goal for your programs is to provide information and support for 
patients that encourages them to stay on their medication.  Would you agree with 
that?  Are there other goals and how do they compare to the one I mentioned? 
c. How do the script guides support you for reaching those goals? 
d. How do the script guides hinder you in reaching those goals? 
b. Would you prefer more structure, less structure, or no change to the 
scripts?  Why? 
32. Do you feel program conversations are easier, harder, or no different than other 
types of patient conversations? 
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Appendix F 
Interview Guides 
Focus Group Discussion Guide 
Interpretations of Communication Experiences of Pharmaceutical-Sponsored 
Clinical Educators 
Abstract: This study explores the communication experiences of clinicians who 
provide patient education and coaching services on behalf of a pharmaceutical sponsor.  
I am investigating how these clinical educators interpret their role and how they navigate 
a medical encounter within the domain of three regulatory drivers—on-label compliance, 
fair-balance presentation, and adverse event reporting.  I am using the ecological model 
of communication in medical encounters and the theory of Communication Privacy 
Management (CPM) as the lenses for designing the study and interpreting the data.  
Specifically, I am investigating how the three regulatory drivers function as a type of 
organizational context within the ecological model and thereby influences the 
conversation dynamics between clinical educators and patients.  Additionally, I am 
exploring the concept of the clinical educator experience within the context of three CPM 
confidant roles—deliberate confidant, stakeholder confidant, and reluctant confidant.  
Finally, I am examining how the regulatory drivers may impact the boundary 
permeability of the patient-educator relationship. Outcomes from this study will provide 
insight as to how pharmaceutical-sponsored clinical educators communicate with 
patients.  As more pharmaceutical companies enlist the assistance of clinical educators 
for patient education services, and a growing number of patients are utilizing them to 
receive health information and make healthcare decisions, studies such as this one are 
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necessary. This study will assist the pharmaceutical industry in understanding that the 
regulatory requirements that function as ecological drivers for these programs can 
influence the programs’ adherence goals.  Additionally, this study will help the industry 
by identifying other weaknesses of the pharmaceutical-sponsored clinical educator model 
and provide recommendations to address them.   
Research Questions 
RQ1: How do ecological factors, such as regulatory requirements, function within 
pharmaceutical-sponsored clinical educators’ communication with patients? 
RQ2:  How do those ecological factors influence the way pharmaceutical-sponsored 
clinical educators establish and manage communication privacy boundaries with 
patients? 
About the Interview Process 
A total of twenty-six clinical educators were interviewed for this study in two 
waves.  The first wave of seventeen interviews took place in January and February.  The 
second wave of nine interviews occurred in May and June.  Transcripts from the first 
wave were coded in March and April.  This preliminary analysis led to emergent ideas 
and themes that were further refined or explored in the second wave.  Therefore, some 
interview questions were changed, added, or omitted for the second wave.   
About the Participants 
All twenty-six clinical educators were recruited from VMS’ rosters of current and 
former employees and contractors.  A few of the twenty-six educators served at one point 
as both an employee and a contractor.  In addition, most educators had current or 
previous experience in a pharmaceutical-sponsored clinical educator role beyond VMS.  
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Some educators even had prior experiences working for pharmaceutical companies as a 
sales rep or in other roles.  All interviewed educators had prior field-based clinical 
healthcare experience such as working in a hospital, clinic, or physician’s office.  The 
majority of clinical educator’s delivered programs that included multiple engagements or 
sessions with patients (face-to-face or telephonically) though a few noted their 
pharmaceutical educator experiences consisted primarily of a single intervention (i.e. 
“one and done”).  Some other statistics about the group: 
• All but two participants were female 
• Two had delivered programs in Spanish.  Everyone had delivered programs in 
English 
• Educators were geographically diverse with 9 from the Midwest, 6 from the 
Southeast, 3 from the Northeast, 3 from the Southwest, 3 from the West Coast, 
and 2 from the Mountain West 
• Half of participants were in the age range of 46-60, 8 were over 60, and 5 were 
30-45 
• 22 were RNs, 2 were RDs, 2 were NPs, 2 were MScNs, 1 was MEd, 1 was LN, 1 
was MPH, and 11 were CDEs 
• 12 had between 3-5 years’ experience delivering pharma programs, 8 had over 10 
years, and 6 had 6-10 years 
• 23 had experience providing pharma-sponsored education for a self-injectable 
syringe and/or pen, 10 for orally-administered drugs, 9 for self-infusion drugs, 
and 12 for HCP-administered 
 312 
• 15 educators had experience providing pharma-sponsored education for T2 
diabetes, 12 educators for T1 diabetes, 11 educators for osteoporosis and 
psoriasis, 10 educators for psoriatic arthritis, 9 educators for ankylosing 
spondylitis, 6 educators for Crohn’s disease and rheumatoid arthritis, 5 educators 
for ulcerative colitis, 4 educators for hyperlipidemia, ALS, and primary 
immunodeficiency, 3 educators for MS.   
About the Theories 
Ecological Model of Communication in the Medical Encounter 
This model explains how ecological factors influence the nature and scope of 
interpersonal patient-provider dialogue within a medical encounter. Proponents of this 
model typically segment these factors into four contexts of socio-political and 
demographic factors that impact both the patient and the HCP and the way their 
interactions unfold.  The culture context is comprised of factors such as race, gender, 
ethnicity, religion, geography, education, socioeconomic status, and family dynamics.  
The media context includes factors such mass media exposure as well as access to, and 
use of, the Internet and telemedicine.  The organizational context includes the influence 
of structures such as managed cared, the medical services available, and the standards of 
care that drive those services.  The political-legal context is inclusive of factors that are 
tied to governments’ influence is healthcare such as the Affordable Care Act (ACA), 
HIPAA, government-funded healthcare programs (e.g. Medicare, Medicaid), malpractice 
litigation, and patients’ bill of rights.   
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Communication Privacy Management (CPM) Theory 
CPM asserts that individuals believe they maintain ownership over their private 
information and the way others can access it.  Individuals develop their own set of 
privacy rules as the means for maintaining control and management of the information.  
These rules manifest themselves in figurative boundaries that vary in terms of thickness.  
“Thickness” is a metaphor akin to the concept of boundary permeability that describes 
the degree of trust an individual is willing to provide to another person regarding the type 
and amount of disclosed information.  Thick boundaries are considered impermeable as 
they represent high levels of restriction to information while thin boundaries are viewed 
as permeable with fewer constraints.  However, CPM theory goes on to state that once 
information is disclosed to another person, that information in now co-owned with the 
recipient.  The recipient and discloser may then establish the privacy rules regarding the 
sharing of that information.  The recipient is responsible for abiding to those privacy 
rules.  If the recipient violates those rules, whether purposefully or because of 
miscommunication or misinterpretation, privacy turbulence occurs.  When this happens, 
boundary permeability between the discloser and recipient might change and new privacy 
rules might be established.  CPM notes that recipients of private information are often 
assigned one of four types of confidant roles by the discloser, three of which are relevant 
to this study—deliberate, reluctant, and stakeholder. 
• Deliberate confidant: an individual who is disclosed private information because 
it is actively solicited, such as in the case of a counseling, therapy, or education 
• Reluctant confidant: an individual who receives private information, intentionally 
or inadvertently, but did not have an expectation for such 
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• Stakeholder confidant: an individual, such as doctors, nurses, and other patient-
facing health professional who, by nature of their healthcare role, receive patients’ 
private health information 
 
Discussion Guide for Emerging Themes 
Theme 1: Clinical educator interpretation of their role identity is rooted in their 
experiences.  
Insights 
As all educators had prior field experience, the pharmaceutical-sponsored clinical 
educator role was defined in relationship to that field role. 
While all educators identified themselves within the construct of “pharmaceutical-
sponsored clinical educator,” there were variant interpretations of that role based on such 
factors as patients’ disease journey-type (e.g. terminal disease vs. chronic), 
communication modality (e.g. all telephonic), shared disease experiences, and prior 
experience as a pharma sales rep.  
 
Theme 2: While educators were mostly consistent in their interpretation of the concept of 
“authentic nursing” or “authentic healthcare providing”, there was wide discrepancy as to 
whether they felt their role as a pharmaceutical-sponsored clinical educator would fall 
within that interpretation.  
Insights 
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“Authentic” was typically discussed within a context of providing hands-on 
clinical care, open communication, exhibiting the characteristics of empathy and respect, 
and creating a relationship built on trust. 
Educators who felt they were not practicing “authentic nursing” or “authentic 
healthcare providing” pointed to such factors as their inability to provide clinical care or 
offer medical advice, a lack of access to patient medical records, the impact of 
compliance regulations (e.g. unable to address off-label questions), or a limited number 
of opportunities to engage the patient (e.g. “one and done”) 
While there was inconsistency among educators in the way they viewed the 
authenticity of their role, most educators felt that patients and some HCPs perceived the 
pharmaceutical-sponsored clinical educator to be an authentic healthcare provider.   
There was also inconsistency among educators as to whether the pharmaceutical 
industry, particularly sales reps, viewed them as authentic healthcare providers. 
What is your view of “authentic nursing”/ “authentic healthcare providing” as it 
relates to the pharmaceutical-sponsored clinical educator role?    Why is this a relevant 
question to be asking? 
 
Theme 3: The four contexts of ecological factors—culture, media, organizational, and 
political-legal—influence how a clinical educator communicates with patients. 
Insights 
Educators most-frequently identified culture context factors—age, race, religion, 
gender, geography, SES, language, education, and family/community dynamics—as they 
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were related to the patient.  The exception to this was “age” which was also identified as 
being influential as it related to the educator. 
Within the media context, educators identified influential factors such as health 
literacy and media literacy as well as patients’ experiences using telephonic and on-line 
communication resources. 
Within the organizational context, educators overwhelmingly noted that health 
insurance navigation and related medication access bureaucracy impacted communication 
and education. 
The political-legal context was discussed within the domain of government and 
industry-imposed compliance regulations related to factors such as on-label compliance, 
fair-balance presentation, and adverse event reporting. 
There was discrepancy as to whether compliance regulations made the clinical 
educator job more difficult.  What are your views?  Is the answer to this question found 
on a strict dichotomy (“yes” or “no”) or as notches on a continuum?    Is it situationally 
related? 
 
Theme 4: A fifth context, not previously identified in the ecological model literature, 
emerged from the interviews as having significant influence in the conversation dynamics 
between the educator and patient.  This is the disease context.  
Insights 
Throughout the interviews, educators frequently referenced how the nature of the 
disease itself and/or its treatments and therapies were highly influential in how they 
would communicate with and educate a patient. 
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The types of factors educators identified that could fit within a disease context 
include: chronic or terminal prognosis, disease side effects, treatment side effects, 
pregnancy status (as it related to disease or treatment side effects), drug administration 
modality (e.g. oral, self-injectable, etc.), prevalence of disability or comorbidity, and 
where the patient was on their disease journey. 
 
Theme 5: When educating patients, educators accommodate many, but not all, ecological 
factors as they have multiple context-specific strategies they use.  Within the political-
legal context, they have learned how to compliantly navigate within regulatory structures 
through “nuanced” communication tactics. 
Insights 
A common tactic for addressing compliance-related factors was “deferment”—
typically redirecting those patient questions or concerns they felt they were not allowed 
to answer, back to the patient’s HCP.  
While educators noted that deferment could sometimes frustrate patients, most 
educators used communication strategies to help abate that frustration.   
A development of “rapport” and “trust” was frequently described as a necessary 
precursor for navigating patients through ecological factors that served as barriers to 
disease management. 
 
Theme 6: The nature of the clinical educator role, such as the impact of compliance 
regulations on communication, occasionally forced educators to experience ethical 
dilemmas.   
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Insights 
A sense of “dual loyalty”—a conflicting loyalty to the patient to provide the best 
care possible and to the sponsoring pharmaceutical company to deliver a compliant 
program—was noted as a challenging aspect of the clinical educator role. 
Some educators explained that patients sometimes view clinical educators as a 
surrogate for their physician and will even disclose frustration or negative information 
about the physician and their office staff.  Educators also noted that physicians have even 
provided information to patients that would be incorrect or inconsistent with the product 
label.  This can create a tension among the physician, patient, and clinical educator 
relationships. 
While educators understand the rationale for “scripted” programs, many regarded 
them to be overly scripted and therefore a hindrance and a source of frustration.  Is going 
off script ever “ok”, such as in a situation in which a patient is inattentive or not grasping 
the concepts as they are presented?  Do you think pharmaceutical companies give tacit 
approval for this?    
 
Theme 7: When discussing how patient disclose private information, educators described 
patient behaviors indicative of all three types of confidant roles—deliberate, reluctant, 
and stakeholder.  However, educators tended to use descriptors and language more 
aligned to a deliberate confidant role, as opposed to a stakeholder confidant role, to 
define their communication relationships with patients. 
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Insights 
Earning trust was noted to be one of the most (if not, the most) important factor 
necessary for establishing a confidant relationship with a patient.   
Some educators felt that a public perception of nurses as a trust-worthy profession 
helped initially imbue them with a level of trust necessary to outweigh any negative 
perceptions related to their affiliation with the pharmaceutical industry. 
The concept of “meeting the patient where they are at” was a frequent refrain in 
the interviews.  What does this mean as it relates to confidant roles?  Is it always possible 
in the pharmaceutical-sponsored clinical educator role?   
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Appendix G 
Codebook 
First-level Codes 
# CODE LONG NAME/S DEFINITION RELATED CODES 
1 Abandon Abandon/s Refers to a Pt quitting or 
discontinuing participating in 
CE services or programs 
Accessible, Adherence, Barrier, Distrust, 
DrugScrutiny, Fail, Fear, PtEcon, Safety, Stress, 
Unprep,  
2 AboveBey Above and Beyond Describes or refers to CE or 
HCP efforts that go beyond 
the usual 
Balance, CDE, CERole, Connect, DiffMaker, 
EngagePts, Excites, Holistic, LovePts, PtShoes, 
Satisfaction, Support, Workaround,  
3 Accept Accept/s/ance Related to Pt accepting an 
explanation or information 
provided by CE or HCP 
Adherence, AgeImpact, Connect, DisDefine, 
EngagePts, Goals, Motivator, Protect,  PtEcon, 
Respect, SavingFace, SelfManage, TrustEarned, 
TrustHCP, TrustRelate, Validate, 
4 Accessible Accessible/ility Related to ability for Pt to 
access education, medication 
or health services 
Abandon, Adherence, BehavChng, Boundaries, 
Connect, Enroll, HealthInfo, Holistic, InfoSeek, 
Insurance, LangLit, Navigate, ProgBene, 
Support,  
5 Accountable Accountable Describes or refers to holding 
Pt or CE accountable for their 
actions 
Adherence, Goals, HCPRelate, Liability, 
Metric, RelateDyna, SelfAdvocate, 
SelfManage, TrustEarned,  
6 Adherence Adherence Refers to adherence or ability 
to follow therapy regimens 
prescribed by HCP 
Abandon, Accept, Accessible, Accountable, 
AgeImpact, Barrier, BehavChng, Behavior, 
Fail, Fear, Frustration, Goals, Inject, Insurance, 
LangLit, Motivator, Navigate, PtEcon, PtKnow, 
PtSavvy, SelfManage, SideEffect, Strategies, 
Stress, Support,  
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7 AE Adverse Event/s Refers to an adverse event 
within the context of 
compliance regulations 
Barrier, Comorbid, CompRegs, Death, 
DrugAdmin, DrugScrutiny, FairBal, Inject, 
Liability, OnLabel, PharmaTrust, Protect, 
Report, Safety, SideEffect, Undocumented,  
8 AgeImpact Age Impact Describes or refers to how a 
Pt's age influences or impacts 
their behavior or education 
Accept, Adherence,  AssessPts, Barrier, 
BehavChng, Behavior, CommSkills, Connect, 
Counsel, Culture, DiscCE, DrugAdmin, EdFam, 
EngagePts, ExpLimit, FamCare, FamDyna, 
Holistic, LangLit, ModImpact, PersEx, 
PtKnow, PtSavvy, RelateDyna, SelfAdvocate, 
SelfManage, Support, Tailoring, Misconcept,  
9 AgeValue Age Value CE explaining the value, or 
drawback, of their age in 
education 
CDE, CERole, CommSkills, Counsel, Empathy, 
ExpLimit, FldVPharm, PersEx, ProfDev, 
Rapport, RelateDyna,  
10 AssessPts Assessing/ment of 
Patients 
Refers to or describes manner 
in which CE assesses a patient 
for education 
AgeImpact, Barrier, CERole, Counsel, Data, 
Holistic, LangLit, Metric, Misconcept, PtKnow, 
Strategies, Tailoring, Validate,  
11 Authentic Authentic/ity Related to or demonstrating an 
"authentic" interpretation of 
nursing and/or healtcare 
 
12 AutoImm Auto Immune Disease/s Related to auto immune 
diseases or conditions  
CERole, ChronDis, Comorbid, DisDefine, 
DisState, DrugAdmin, HIV,  Infusion, RareDis, 
TermDis,  
13 Autonomy Autonomy/ous Describes or refers to patient 
autonomy 
 
14 Balance Balance/s/ing/ed Refers to CE instance or 
expectation to balance 
competing needs of Pt and 
HCP 
AboveBey, CEIndep, EngagePts, FairBal, 
FldVPharm, LovePts, OpenComm, PersEx, 
PrivManage, ProtoBreach, RelateDyna, 
SavingFace, TrustDef, TrustRelate,  
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15 Barrier Barrier/s Describes or refers to those 
things that impede education 
for Pt or CE 
Abandon, Accessible, Adherence, AE, 
AgeImpact, AssessPts, BehavChng, Culture, 
Depress, DiscBarr, Distrust, ExpLimit, Fail, 
Fear, Frustration, Goals, Insurance, LangLit, 
Misconcept, Motivator, NoVoice, PtEcon, 
SavingFace, SelfManage, Stress, Support,  
TrustSac, Unprep, 
16 BehavChng Behavior Change/s Describes or refers to the 
process of changing Pt 
behavior 
Adherence, AgeImpact, Barrier, Behavior, 
EngagePts, Goals, InfoSeek, Misconcept, 
Motivator, Navigate, PersEx, PtKnow, PtLeads, 
PtSavvy, Satisfaction, SelfManage, Strategies,  
17 Behavior Behavior/s Describes or refers to 
behaviors within the the 
context of Pt disease or 
education 
Adherence, AgeImpact, BehavChng, Rapport, 
SavingFace, SelfAdvocate, SelfManage, Stress, 
TrustSac,  
18 Boundaries Boundaries Related to a CE or Pt setting 
guidelines or guardrails 
related to education 
Accessible, CompRegs, FairBal, HCPFeedback, 
OnLabel, OpenComm, PrivManage, Protect, 
RelateDyna, Respect, Script, Security, 
Sensitive, TrngProc, Unethical, UninhibDisc,  
19 Cardiac Cardiac Related to the heart, heart 
disease, or cardiac care 
CERole, ChronDis, Comorbid, Death, 
DisDefine, DisState, DrugAdmin, RareDis, 
TermDis,  
20 CDE Certified Diabetes 
Educator 
Describes or refers to a 
certified diabetes educator 
AboveBey, AgeValue, CEBenefit, CEIndep, 
CERole, Diabetes, Dietitian, FldVPharm, 
PharmaRep, ProfDev,  
21 CEBenefit Clinical Educator 
Benefit/s 
Refers to a benefit of being a 
CE 
CDE, CEIndep, CERole, DiffMaker, 
EngagePts, Excites, LovePts, Motivator, 
ProgBene, Respect, Satisfaction, Teach,  
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22 CEIndep Clinical Educator/s 
Independence 
Related to CE demonstrating 
independence from influence 
of HCP or Pharma Co. 
Balance, CDE, CEBenefit, CERole, FairBal, 
FldVPharm, HCPFeedback, NoVoice, 
PharmaTrust, PrivBreach, PrivManage, 
ProgReco, Protect, TrustBreach, TrustRelate,  
23 CERole Clinical Educator/s 
Role/s 
Refers to a CE describing, 
defining, or interpreting their 
role or the things they do 
AboveBey, AgeValue, AssessPts, AutoImm, 
Balance, Cardiac, CDE, CEBenefit, CEIndep, 
Counsel, Demo, DiffMaker, DiscCE, Empathy, 
EngagePts, ExpLimit, FairBal, Holistic, ICU, 
Inject, LovePts, Motivator, Notekeeping, 
Oncology, Osteo, PersEx, PrivRole, ProfDev, 
ProgReco, Protect, Teach, TeleEd, TrustRelate,   
24 ChronDis Chronic Disease/s Refers to a chronic disease AutoImm, Cardiac, Comorbid, Diabetes, 
DisDefine, DisState, HIV, Neuro, Oncology, 
Osteo, Parkinsons, RareDis, SideEffect, 
TermDis,  
25 CommInhibit Communication 
Inhibit/s/ion 
Related to communication that 
is inhibited 
CommSkills, CompExcess, CompImpact, 
CompRegs, Defer, DiscBarr, DiscCE, 
DiscFacil, Distrust, LangLit, Liability, 
Misconcept, OpenComm, PrivBreach, 
Sensitive, Support, TrustBreach, UninhibDisc,  
26 CommSkills Communication Skill/s Highlights, explains or defines 
a communication skill relevant 
to Pt. education 
AgeImpact, AgeValue, CommInhibit, Connect, 
Counsel, Defer, DiscFacil, Empathy, 
EngagePts, FairBal, FTF, LangLit, ModImpact, 
Notekeeping, OnLabel, OpenComm, 
PrivManage, ProfDev, Rapport, RelateDyna, 
Strategies, Support, Tailoring, Teach, TrngProc, 
TrustRelate, WebEd, 
27 Community Community/ies Describes or refers to a Pt's 
community or how that 
community impacts Pt 
education 
Culture, EdFam, FamDyna, PersEx, PrivFam, 
Support,  
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28 Comorbid Comorbidity/ies Describes or refers to health 
conditions other than disease 
of interest 
AE, AutoImm, Cardiac, ChronDis, Depress, 
Diabetes, DisState, ICU, Oncology, Osteo, 
Parkinsons,  
29 CompExcess Compliance 
Excess/es/iveness 
Related to instance or 
interpretation of compliance 
regs being excessive 
CommInhibit, CompImpact, Defer, Distrust, 
DrugScrutiny, Frustration, Liability, OnLabel, 
PharmaTrust, PharmaOps, PrivBreach, 
PrivManage, Protect, Report, Safety, TeleLimit, 
TrustBreach, Undocumented,  
30 CompImpact Compliance 
Impact/s/ing 
Describes or refers to how 
compliance regs have a (+ or -
-) effect or impact 
CommInhibit, CompExcess, CompRegs, Defer, 
Distrust, FairBal, Frustration, Liability, 
OnLabel, PharmaTrust, PharmaOps, 
PrivManage, Protect, Report, Safety, Sensitive, 
Stress, TrngProc, TrustBreach,  
31 CompRegs Compliance 
Regulation/s 
Describes or refers to 
compliance regulations 
AE, Boundaries, CommInhibit, CompExcess, 
CompImpact, Consent, FairBal, Liability, 
OnLabel, Metric, Notekeeping, PharmaOps, 
PrivManage, Protect, Report, Security, 
SideEffect, TrngProc, Workaround,  
32 Connect Connect/s/ion/ed Refers to CE and Pt making 
an relationship connections 
AboveBey, Accept, Accessible, AgeImpact, 
CommSkills, DiffMaker, DiscCE, Empathy, 
FTF, HandlingLoss, Holistic, HCPRelate, 
LangLit, LovePts, OpenComm, Rapport, 
RelateDyna, Respect, SelfManage, Support, 
TrustDef, TrustEarned, TrustRelate, 
UninhibDisc, Validate,   
33 Consent Consent/s/ing Refers to obtaining or 
honoring Pt consent as it 
relates to a CE, HCP, or ed. 
Program 
CompRegs, Counsel, EngagePts, HCPConsent, 
Inject, LangLit, Liability, PharmaOps, 
PrivBreach, PrivManage, Protect, ProtoBreach, 
SelfManage, TrustPriv,  
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34 Consistency Consistency/ies Related to maintaining 
consistency as related to the Pt 
education process 
FairBal, Metric, Rapport, Script, SelfManage, 
TrngProc, Unprep,  
35 Counsel Counsel/s Related to the process or 
manner in which an CE or 
HCP counsels a Pt. 
AgeImpact, AgeValue, AssessPts, CEBenefit, 
CERole, CommSkills, Consent, DrugAdmin, 
EngagePts, FamCare, FTF, Holistic, Inject, 
LangLit, Navigate, PtLeads, PtShoes, Rapport, 
RelateDyna, Respect, SelfManage, Support, 
Tailoring, TeleEd, TrngProc, TrustRelate, 
Validate,  
36 Culture Culture/s/al Related to the role or impact 
of culture on Pt education 
AgeImpact, Barrier, Community, Distrust, 
EdFam, FamCare, HealthInfo, LangLit, 
Misconcept, PharmaTrust, PrivRole, PtShoes, 
Rapport, Respect, Sensitive, Support, Tailoring, 
TrustRelate, Workaround,  
37 Data Data Refers to Pt data or 
information that is gathered by 
the CE or HCP 
AssessPts, Enroll, Goals, HealthInfo, Materials, 
Metric, Notekeeping, Report, Satisfaction, 
Undocumented,  
38 Death Death Related to experiences or 
references of death 
AE, Cardiac, Depress, Desperate, DisState, 
Fear, HandlingLoss, ICU, Oncology, RareDis, 
Suicide, TermDis,  
39 Defer Defer/s/ment/ments Related to the manner in 
which a CE must defer a Pt to 
their HCP for info. 
CommInhibit, CommSkills, CompExcess, 
CompImpact, DiscCE, Distrust, Frustration, 
Navigate, OnLabel, PharmaTrust, PharmaOps, 
SavingFace, Strategies, TrustSac, Workaround,  
40 Demo Demonstration/s Related to a CE performing a 
demonstration or patient 
giving return demo 
CERole, DrugAdmin, EngagePts, FTF, 
Infusion, Inject, Materials, PtKnow, PtLeads, 
Strategies, TrngProc,  
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41 Depress Depression/Depressing Refers to descriptions or 
actions of Pt related to 
depression 
Barrier, Comorbid, Death, Desperate, 
DisDefine, Fail, Fear, HandlingLoss, NoVoice, 
SideEffect, Stress, Suicide, TermDis,  
42 Desperate Desperate Related to a sense of 
desperation from the patient or 
CE 
Death, Depress, Fear, Frustration, 
HandlingLoss, Manipulating, PtEcon, RareDis, 
Stress, Suicide, TermDis, Unprep,  
43 Diabetes Diabetes Describes or refers to diabetes CDE, ChronDis, Comorbid, DisState,  
44 Dietitian Dietitian Related to the role or 
profession of dietitian or 
dietitics  
CDE, PersEx, ProfDev,  
45 DiffMaker Difference Maker Describes or refers to when or 
how a CE making a difference 
or wanting to make one 
AboveBey, CEBenefit, CERole, Connect, 
Empathy, EngagePts, Excites, Goals, Holistic, 
LovePts, NoVoice, ProgBene, RelateDyna, 
Satisfaction, Support, TrustRelate,  
46 DiscBarr Disclosure Barrier/s Describes or refers to barriers 
or factors that inhibit 
disclosures by Pts 
Barrier, CommInhibit, DiscCE, DiscFacil, 
Distrust, FamDyna, Fear, Frustration, 
HCPRelate, LangLit, Misconcept, ModImpact, 
NoVoice, PharmaTrust, PrivBreach, PrivSet, 
ProtoBreach, Rapport, RelateDyna, SavingFace, 
Sensitive, Support, TeleLimit, TelePriv, 
TrustBreach, TrustPriv, TrustRelate,  
47 DiscCE Discloses/ing/ure to 
Clinical Educator 
Describes or refers to 
how/when a Pt (or family) 
discloses private information 
to CE 
AgeImpact, CERole, CommInhibit, Connect, 
Defer, DiscBarr, DiscFacil, EngagePts, 
FamCare, FamDyna, FTF, Holistic, LangLit, 
Misconcept, PrivManage, PrivRole, PtLeads, 
Rapport, TrustEarned, TrustPriv, TrustRelate, 
UninhibDisc,  
48 DiscFacil Disclosure Facilitator/s Describes or refers to things 
factors that facilitate or 
encourage disclosures by Pts 
CommInhibit, CommSkills, DiscBarr, DiscCE, 
EngagePts, Goals, Holistic, LangLit, LovePts, 
Motivator, OpenComm, PrivSet, PtSavvy, 
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Rapport, RelateDyna, Support, TelePriv, 
TrustEarned, TrustPriv, TrustRelate, 
UninhibDisc,  
49 DisState Disease State Refers to information or 
education related to a Pt's 
disease  
AutoImm, Cardiac, ChronDis, Comorbid, 
Death, Diabetes, DisDefine, HealthInfo, HIV, 
ICU, Neuro, Oncology, Osteo, Parkinsons, 
PtKnow, RareDis, TermDis,  
50 DisDefine Disease Define/s/ed/ing Refers to notion that Pts' 
diseases defines who they are 
Accept, AutoImm, Cardiac, ChronDis, Depress, 
DisState, Empathy, Fear, HIV, LangLit, 
NoVoice, Oncology, Osteo, PersEx, PtKnow, 
PtShoes, Rapport, RareDis, SavingFace, Stress, 
TermDis, Validate,  
51 Distrust Distrust/s/ing Describes or refers to instance 
or sense of distrust 
Abandon, Barrier, CommInhibit, CompExcess, 
CompImpact, Culture, Defer, DiscBarr, 
DrugScrutiny, Fear, Frustration, HCPRelate, 
Misconcept, Manipulating, PharmaTrust, 
PrivBreach, ProtoBreach, RelateDyna, 
SelfManage, Sensitive, Stress, TrustBreach, 
Unethical,  
52 DrugAdmin Drug Administration/s Describes or refers to the 
process of administering a 
drug to a Pt. 
AE, AgeImpact, AutoImm, Cardiac, Counsel, 
Demo, DrugScrutiny, FairBal, ICU, Infusion, 
InHome, Inject, Materials, Misconcept, 
Oncology, OnLabel, Osteo, PharmaCo, 
PharmaOps, PharmaRep, Safety, Stress, 
TrngProc, Unprep,  
53 DrugScrutiny Drug Scrutiny Related to scrutiny of a drug 
by an HCP, CE or Pt. 
Abandon, AE, CompExcess, Distrust, 
DrugAdmin, HCPRelate, Infusion, Inject, 
PharmaCo, PharmaTrust, Pregnant, Safety, 
SideEffect, TrustBreach, TrustHCP, 
TrustRelate,  
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54 EdFam Education of Family Related to the education of a 
patient's family, caregivers, 
etc. 
AgeImpact, Community, Culture, FamCare, 
FamDyna, InHome, Navigate, PrivFam, 
PrivSet, Support, Tailoring, TrngProc, TrngSet,  
55 Efficacy Efficacy/ies Describes or is related to the 
efficacy or benefits of 
treatment 
 
56 Empathy Empathy Describes or is related to the 
showing of empathy by the 
CE or Pt 
AgeValue, CERole, CommSkills, Connect, 
DiffMaker, DisDefine, EngagePts, FamCare, 
HandlingLoss, HCPRelate, Holistic, LovePts, 
Motivator, PtShoes, Rapport, RelateDyna, 
SavingFace, Sensitive, Support, TrustDef, 
TrustEarned, TrustHCP, TrustRelate,  
57 EngagePts Engaging Patient/s Refers to or describes manner 
in which patients are engaged 
in education 
AboveBey, Accept, AgeImpact, Balance, 
BehavChng, CEBenefit, CERole, CommSkills, 
Consent, Counsel, Demo, DiffMaker, DiscCE, 
DiscFacil, Empathy, FTF, Goals, HCPEngage, 
HCPRelate, Holistic, LangLit, ModImpact, 
OpenComm, PrivManage, PtKnow, PtLeads, 
Rapport, RelateDyna, Respect, Satisfaction, 
SelfManage, Strategies, TrngProc, TrustDef, 
TrustEarned, TrustRelate,  
58 Enroll Enroll/s/ing/ment Related to the process of 
getting Pts enrolled in a 
pharma education 
service/program 
Accessible, Data, HCPConsent, Inject, 
Notekeeping, PtEcon, TrngProc, 
Undocumented,  
59 EthDilemma Ethical Dilemma/s Refers to an ethical dilemma 
faced by CE related to Pt care 
 
60 Excites Excite/s/ing/ed Describes or refers to things 
that are, or may, excite a CE 
about his/her role 
AboveBey, CEBenefit, DiscBarr, Goals, 
LovePts, PersEx, Satisfaction,  
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61 ExpLimit Experience Limitation/s Describes or refers to CE or 
HCP being limited in ability 
because of lack of experience 
AgeImpact, AgeValue, Barrier, CERole, 
PersEx, ProfDev, Teach, TrustRelate, Unprep,  
62 Fail Fail/s/ure/ures Refers to Pt or CE inability to 
accomplish task or goal 
related to health 
Abandon, Adherence, Barrier, Depress, Fear, 
Frustration, Manipulating, NoVoice, PtKnow, 
SelfManage, Stress, TeleLimit, Unprep,  
63 FairBal Fair Balance Related to requirement that 
CE must present balance of 
efficacy and risk in education 
AE, Balance, Boundaries, CEIndep, CERole, 
CommSkills, CompImpact, CompRegs, 
Consistency, DrugAdmin, FldVPharm, 
Frustration, LangLit, Liability, Materials, 
OnLabel, PharmaOps, PharmaOps, Report, 
Safety, Script, SideEffect, Strategies, TrngProc,  
64 FamCare Family Care/ing Describes or refers to the 
manner in which a CE cares 
for the family as well as Pt. 
AgeImpact, Community, Counsel, Culture, 
DiscCE, EdFam, Empathy, FamDyna, InHome, 
LangLit, Navigate, Pregnant, PrivFam, PrivSet, 
PtKnow, RelateDyna, Strategies, Support, 
TrngProc, TrngSet, TrustEarned,  
65 FamDyna Family Dynamic/s Describes or refers to how 
family dynamics impact or 
come into play in education 
AgeImpact, DiscBarr, DiscCE, EdFam, 
FamCare, Fear, Frustration, HandlingLoss, 
InHome, LangLit, Misconcept, Motivator, 
Pregnant, PrivSet, PtEcon, PtShoes, 
RelateDyna, SavingFace, SelfAdvocate, 
SelfManage, Stress, UninhibDisc,  
66 Fear Fear/s Related to role or impact of 
fear on Pt or CE 
Abandon, Adherence, Barrier, Death, Depress, 
Desperate, DiscBarr, DisDefine, Distrust, Fail, 
FamDyna, Frustration, Misconcept, NoVoice, 
Pregnant, PrivBreach, Safety, Sensitive, Stress, 
Suicide, TermDis, TrustBreach, Validate,  
67 FldVPharm Field Versus Pharma Comparison of CE 
experiences or education 
AgeValue, Balance, CDE, CEIndep, FairBal, 
OnLabel, PharmaCo, PharmaOps, PrivRole, 
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delivery in the field versus as 
pharma rep 
ProgBene, ProgReco, Rapport, RelateDyna, 
Tailoring, TrngSet,  
68 Frustration Frustration/s Related to CE or Pt's 
frustration with drug or 
education process 
Adherence, Barrier, CompExcess, CompImpact, 
Defer, Desperate, DiscBarr, Distrust, Fail, 
FamDyna, Insurance, Misconcept, 
PharmaTrust, PtEcon, Stress, TeleLimit, 
TrustBreach, Unethical, Unprep,  
69 FTF Face-to-Face Describes or refers to Pt 
education programs delivered 
live and in-person  
CommSkills, Connect, Counsel, Demo, 
DiscCE, EngagePts, ModImpact, PrivSet, 
TeleEd, TimeImpact, TrngSet, WebEd,  
70 Goals Goals Describes or refers to goals or 
goal setting by the Pt or CE 
Accept, Accountable, Adherence, Barrier, 
BehavChng, Data, DiffMaker, DiscFacil, 
EngagePts, Excites, Fear, Holistic, InfoSeek, 
Metric, Navigate, ProfDev, PtSavvy, 
SelfAdvocate, SelfManage, Strategies, Support, 
Tailoring, TrngProc, TrustRelate, Workaround,  
71 HandlingLoss Handling Loss Related to references or 
descriptions by CE of how 
they handle Pt death 
Connect, Death, Depress, Desperate, Empathy, 
FamDyna, LovePts, Navigate, OpenComm, 
RelateDyna, Strategies, Support, TermDis, 
Validate,  
72 HCPConsent Healthcare Provider 
Consent 
Refers to when or how an 
HCP provides a consent or 
permission to a Pt or CE 
Consent, Enroll, HCPEngage, HCPFeedback, 
HCPRelate, PrivManage, RelateDyna, 
TrustHCP,  
73 HCPEngage Healthcare Provider/s 
Engagement/s 
Related to how a CE engages 
or interacts with an HCP 
EngagePts, HCPConsent, HCPFeedback, 
HCPRelate, OpenComm, RelateDyna, Respect, 
Support, TimeImpact, TrustHCP,  
74 HCPFeedbac
k 
Healthcare Provider 
Feedback 
Related to CE providing 
feedback to an HCP regarding 
a Pt. 
Boundaries, CEIndep, HCPConsent, 
HCPEngage, HCPRelate, PrivManage, 
PrivRole, Protect, RelateDyna, Report, 
Satisfaction, TrustHCP,  
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75 HCPRelate Healthcare Provider/s 
Relationship/s 
Describes or refers to 
relationships created between 
Pts and HCPs or CEs and 
HCPs 
Accountable, Connect, DiscBarr, Distrust, 
DrugScrutiny, Empathy, EngagePts, 
HCPConsent, HCPEngage, HCPFeedback, 
Holistic, OpenComm, PrivManage, Rapport, 
RelateDyna, Satisfaction, Support, TrustHCP,  
76 HealthInfo Health Information Related to the sources for, use 
of, or search for health 
information by Pt 
Accessible, Culture, Data, DisState, FairBal, 
InfoSeek, LangLit, Materials, Misconcept, 
PtKnow, Security, Strategies, Support,  
77 HIV HIV Related to HIV/AIDS AutoImm, ChronDis, DisState, DisDefine, 
TermDis,  
78 Holistic Holistic Refers to a holistic approach 
as related to patient care 
AboveBey, Accessible, AgeImpact, AssessPts, 
CERole, Connect, Counsel, DiffMaker, 
DiscCE, DiscFacil, Empathy, EngagePts, Goals, 
HCPRelate, InfoSeek, LovePts, Motivator, 
Navigate, OpenComm, PtKnow, Rapport, 
RelateDyna, Respect, Strategies, Support, 
Tailoring, TrngProc, TrustRelate, UninhibDisc, 
Unprep,  
79 ICU Intensive Care Unit Related to experiences or 
work in the ICU 
CERole, Comorbid, Death, DisState, 
DrugAdmin, TermDis,  
80 InfoSeek Information Seeking Describes or refers to 
information seeking processes 
or behaviors by Pts or CEs 
Accessible, BehavChng, Goals, HealthInfo, 
Holistic, LangLit, Misconcept, Navigate, 
OpenComm, PtKnow, PtSavvy, Security, 
SelfAdvocate, SelfManage, Tailoring, 
TimeImpact, Unprep,  
81 Infusion Infusion/s Referencing or related to 
giving/receiving an infusion or 
the infusion process 
AutoImm, Demo, DrugAdmin, DrugScrutiny, 
InHome, Inject, PharmaCo, RareDis, TermDis,  
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82 InHome In-home Refers to education or 
engagement that occur in the 
patient's home 
DrugAdmin, EdFam, FamCare, FamDyna, 
Infusion, Inject, PrivSet, Tailoring, TrngSet,  
83 Inject Injection/Injection 
Training/s 
Related to the process or 
occurrence of an injection or 
injection training 
Adherence, AE, CERole, Consent, Counsel, 
Demo, DrugAdmin, DrugScrutiny, Enroll, Fear, 
Infusion, InHome, Misconcept, OnLabel, 
PharmaCo, SelfManage, Strategies, Stress,  
84 Insurance Insurance/s Related to health insurance 
companies or their policies, 
procedures, or actions 
Accessible, Adherence, Barrier, Frustration, 
Protect, PtEcon, Stress,  
85 LangLit Language and Literacy Describes or refers to the 
relationship among language, 
literacy, and education 
Accessible, Adherence, AgeImpact, AssessPts, 
Barrier, CommInhibit, CommSkills, Connect, 
Consent, Counsel, Culture, DiscBarr, DiscCE, 
DiscFacil, DisDefine, EngagePts, FairBal, 
FamCare, FamDyna, HealthInfo, Holistic, 
InfoSeek, Misconcept, ModImpact, Navigate, 
NoVoice, OpenComm, PrivManage, PtKnow, 
PtLeads, PtSavvy, Rapport, RelateDyna, 
SelfAdvocate, Support, Teach, TrustHCP, 
UninhibDisc,  
86 Liability Liability/ies Describes or refers to a 
professional or legal liability 
for the CE or HCP 
Accountable, AE, CommInhibit, CompExcess, 
CompImpact, CompRegs, Consent, FairBal, 
Manipulating, Notekeeping, OnLabel, 
PrivBreach, ProtoBreach, Safety, 
Undocumented, Unethical, Workaround,  
87 LovePts Love Patients Related to examples or 
experiences of CE loving their 
work with Pts 
AboveBey, Balance, CEBenefit, CERole, 
Connect, DiffMaker, DiscFacil, Empathy, 
Excites, HandlingLoss, Holistic, PersEx, 
PtShoes, RelateDyna, Respect, Satisfaction, 
TrustEarned, TrustRelate,  
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88 MalePersp Male Perspective/s Describes or refers to 
experiences or perspectives of 
male CEs 
 
89 Manipulating Manipulating Refers to manipulating or 
deceitful behaviors 
Desperate, Distrust, Fail, Liability, Misconcept, 
PharmaTrust, TrustBreach, Unethical,  
90 Materials Materials Refers to physical or 
electronic resource and 
materials used in patient ed. 
Data, Demo, DrugAdmin, FairBal, HealthInfo, 
InfoSeek, Metric, OnLabel, Script, Strategies, 
Tailoring, TrngProc,  
91 Metric Metric/s Related to metrics or 
assessments for measuring 
success or impact of Pt 
education 
Accountable, AssessPts, CompRegs, 
Consistency, Data, Goals, Materials, 
ModImpact, ProgReco, PtKnow, Strategies, 
TrngProc,  
92 Misconcept Misconception/s Related to a Pt's health 
misconception and the impact 
on education or disease  
AssessPts, Barrier, BehavChng, CommInhibit, 
Culture, DiscBarr, DiscCE, Distrust, 
DrugAdmin, FamDyna, Fear, Frustration, 
Frustration, InfoSeek, Inject, LangLit, 
Manipulating, NoVoice, PersEx, PtKnow, 
SelfManage, Stress, Unprep, AgeImpact,  
93 ModImpact Modality/ies Impact Describes or refers to impact 
on Pt education related to 
communication modality 
AgeImpact, CommSkills, DiscBarr, EngagePts, 
FTF, LangLit, Metric, ProtoBreach, Script, 
Tailoring, TeleEd, TeleLimit, TelePriv, 
TimeImpact, TrngProc, WebEd, Workaround,  
94 Motivator Motivator/s Related to factors or things 
that are motivate or are 
motivating for a Pt or CE 
Accept, Adherence, Barrier, BehavChng, 
CEBenefit, CERole, DiscFacil, Empathy, 
FamDyna, Holistic, OpenComm, Pregnant, 
ProgBene, PtEcon, PtSavvy, RelateDyna, 
Respect, Satisfaction, SelfManage, Strategies, 
Support, TrustEarned, TrustRelate, Validate,  
95 MS Multiple Sclerosis Related to Multiple Sclerosis 
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96 Navigate Navigate/s/ion/ing Describes or refers to how a Pt 
navigates through their disease 
or the health system 
Accessible, Adherence, BehavChng, Counsel, 
Defer, EdFam, FamCare, Goals, HandlingLoss, 
Holistic, InfoSeek, LangLit, OnLabel, PersEx, 
PrivManage, PtLeads, PtSavvy, SelfAdvocate, 
Support, TrngProc, TrustRelate, Workaround,  
97 Neuro Neurology/Neurologist/
s 
Related to neurologist or 
neurology field 
ChronDis, DisState, Parkinsons, RareDis, 
TermDis,  
98 NonEng Non-English Speaking Describes or refers to non-
English speaking Pts and their 
education 
 
99 NonVerbal Non-Verbal Describes or refers to non-
verbal language related to Pt 
education 
 
100 Notekeeping Notekeeping Refers to CE documentation 
of Pt information 
CERole, CommSkills, CompRegs, Data, Enroll, 
Liability, Report, Strategies, Undocumented,  
101 NoVoice No Voice Refers to the notion that the 
patient has no voice (or no 
say) in their healthcare 
Barrier, CEIndep, Depress, DiffMaker, 
DiscBarr, DisDefine, Fail, Fear, LangLit, 
PrivBreach, PrivRole, RelateDyna,  
102 Oncology Oncology/ist Related to oncology, cancer, 
or cancer care 
CERole, ChronDis, Comorbid, Death, 
DisDefine, DisState, DrugAdmin, Misconcept, 
RareDis, SideEffect, TermDis,  
103 OnLabel On-label Describes or refers to a CE's 
requirement to remain on-
label  
AE, Boundaries, CommSkills, CompExcess, 
CompImpact, CompRegs, Defer, DrugAdmin, 
FairBal, FldVPharm, Inject, Liability, 
Materials, Navigate, PharmaCo, PharmaOps, 
Protect, ProtoBreach, Script, SideEffect, 
TrngProc, Workaround,  
104 OpenComm Open Communication Related to a desire for, 
example of, or definition for 
unfettered communication 
Balance, Boundaries, CommInhibit, 
CommSkills, Connect, DiscFacil, EngagePts, 
HandlingLoss, HCPEngage, HCPRelate, 
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Holistic, InfoSeek, LangLit, Motivator, 
PrivManage, Rapport, Respect, SelfManage, 
TimeImpact, UninhibDisc,  
105 Osteo Osteoporosis Describes or refers to 
osteoporosis 
CERole, ChronDis, Comorbid, DisDefine, 
DisState, DrugAdmin, RareDis,  
106 Palliative Palliative Describes or refers to 
palliative or end-of-life care 
 
107 Parkinsons Parkinson's Disease Related to Parkinson's Disease ChronDis, Comorbid, DisState, Neuro, 
TermDis,  
108 PersEx Personal Experience/s A personal experience that 
impacted or influenced a CE 
or Pt. 
AgeImpact, AgeValue, Balance, BehavChng, 
CERole, Community, DisDefine, Dietitian, 
Excites, ExpLimit, LovePts, Misconcept, 
Navigate, Pregnant, ProfDev, ProgReco, 
PtKnow, PtShoes, Rapport, TrustRelate, 
Validate,  
109 PharmaCo Pharmaceutical 
Company/ies 
Describes or relates to a 
pharmaceutical company 
DrugAdmin, FldVPharm, Infusion, Inject, 
OnLabel, PharmaTrust, PharmaOps, 
PharmaRep, ProgReco, Teach,  
110 PharmaTrust Pharmaceutical 
Trust/s/ing Distrust 
Related to a Pt or HCP 
feelings of trust or distrust of 
pharma companies 
AE, CEIndep, CompExcess, CompImpact, 
Culture, Defer, DiscBarr, Distrust, 
DrugScrutiny, Frustration, Manipulating, 
PharmaCo, PharmaOps, PharmaRep, 
PrivBreach, Safety, SideEffect, TrustBreach, 
Unethical,  
111 PharmaOps Pharmaceutical 
Operation/s 
Describes or refers to 
operational processes or 
procedures of a pharma 
company 
CompExcess, CompImpact, CompRegs, 
Connect, Defer, DrugAdmin, DrugScrutiny, 
FairBal, FldVPharm, OnLabel, PharmaCo, 
PharmaTrust, PharmaRep, ProgReco, Report, 
TrngProc,  
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112 PharmaRep Pharmaceutical 
Representative/s 
Referencing or related to a 
pharma rep 
CDE, DrugAdmin, PharmaCo, PharmaOps, 
PharmaTrust,  
113 Pregnant Pregnant/ancy Related to pregnancy and it's 
impact in education or use of a 
therapy 
DrugScrutiny, FamCare, FamDyna, Fear, 
Motivator, PersEx, Stress,  
114 PrivBreach Privacy Breach/es/ing Describes or refers to 
occurrence (or potential for) 
privacy breach between Pt & 
CE 
CEIndep, CommInhibit, CompExcess, Consent, 
DiscBarr, Distrust, Fear, Liability, NoVoice, 
PharmaTrust, PrivManage, ProtoBreach, 
TrustBreach, TrustSac, Unethical,  
115 PrivFam Privacy Family Refers to privacy concerns or 
management with Pt family 
involvement 
Community, EdFam, FamCare, PrivManage, 
PrivSet, PtLeads,  
116 PrivManage Privacy Management Describes or refers to 
strategies or processes for 
managing privacy 
Balance, Boundaries, CEIndep, CommSkills, 
CompExcess, CompImpact, CompRegs, 
Consent, DiscCE, EngagePts, HCPConsent, 
HCPFeedback, HCPRelate, LangLit, Navigate, 
OpenComm, PrivBreach, PrivFam, PrivRole, 
PrivSet, RelateDyna, Security, SelfManage, 
Sensitive, Strategies, TelePriv, TrustBreach, 
TrustEarned, TrustPriv,  
117 PrivRole Privacy Role/s Describes or refers to the role 
privacy plays in Pt education 
CERole, Culture, DiscCE, FldVPharm, 
HCPFeedback, NoVoice, PrivManage, PrivSet, 
Protect, Security, Sensitive, TrustPriv,  
118 PrivSet Privacy Setting/s Refers to impact or role of a 
physical setting on privacy 
concerns or management 
DiscBarr, DiscFacil, EdFam, FamCare, 
FamDyna, FTF, InHome, PrivFam, 
PrivManage, PrivRole, TeleEd, TelePriv, 
TrngSet,  
119 ProfDev Professional 
Development 
Describes or refers to a CE's 
professional development 
opportunities or experiences 
AgeValue, CDE, CERole, CommSkills, 
Dietitian, ExpLimit, Goals, PersEx, Tailoring, 
Teach, Workaround,  
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120 ProgBene Program Benefit Describes or refers to a benefit 
of Pt education program. 
Accessible, CEBenefit, DiffMaker, FldVPharm, 
Motivator, ProgReco, PtKnow, PtLeads, 
PtSavvy, SelfAdvocate, SelfManage, Support, 
TrustEarned, Validate, Workaround,  
121 ProgReco Program 
Recommendation/s 
Describes or refers to CEs' 
recommendations  to improve 
Pt or HCP  programs  
CEIndep, CERole, FldVPharm, Metric, PersEx, 
PharmaCo, PharmaOps, ProgBene, Satisfaction, 
TrngProc,  
122 Protect Protect/s/ing/ion/ed Refers to action or process a 
CE takes to protect a Pt 
AboveBey, AE, Boundaries, CEIndep, CERole, 
CompExcess, CompImpact, CompRegs, 
Consent, FairBal, HCPFeedback, Insurance, 
OnLabel, PrivRole, Report, Safety, Security, 
TrustEarned, Workaround,  
123 ProtoBreach Protocol Breach/es/ing Describes or refers to a breach 
of protocol or process related 
to Pt education 
Balance, Consent, DiscBarr, Distrust, Liability, 
ModImpact, OnLabel, PrivBreach, TeleLimit, 
TrustBreach, TrustSac,  
124 PtEcon Patient/s Economics Describes or refers to the role 
or impact of a patient's 
personal finances  
Abandon, Accept, Adherence, Barrier, 
Desperate, Enroll, FamDyna, Frustration, 
Insurance, Motivator, PtSavvy, SelfManage, 
Stress, Support,  
125 PtKnow Patient/s Knowledge Refers to existing or necessary 
Pt knowledge related to their 
disease or therapy 
Adherence, AgeImpact, AssessPts, BehavChng, 
Demo, DisDefine, DisState, EngagePts, Fail, 
FamCare, FamDyna, HealthInfo, Holistic, 
InfoSeek, LangLit, Metric, Misconcept, PersEx, 
ProgBene, PtSavvy, Satisfaction, SelfManage, 
Validate,  
126 PtLeads Patient Lead/s/ing Describes or refers to example 
or instance of Pt taking the 
lead in their care or educ. 
BehavChng, Counsel, Demo, DiscCE, 
EngagePts, LangLit, Navigate, PrivFam, 
ProgBene, PtSavvy, RelateDyna, SavingFace, 
SelfAdvocate, SelfManage, Support, Tailoring,  
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127 PtSavvy Patient/s Savvy/iness Related to Pt's ability to 
navigate or understand 
complexity of health info or 
processes 
Adherence, AgeImpact, BehavChng, DiscFacil, 
Goals, InfoSeek, LangLit, Motivator, Navigate, 
ProgBene, PtEcon, PtKnow, PtLeads, 
SavingFace, SelfAdvocate, SelfManage,  
128 PtShoes Patient Shoes Refering to a CE putting 
themselves in their patients' 
shoes to gain understanding 
AboveBey, Counsel, Culture, DisDefine, 
Empathy, FamDyna, LovePts, PersEx, Rapport, 
RelateDyna, Respect, Strategies, TrustDef, 
Validate,  
129 Rapport Rapport Describes or refers to 
relationship rapport between 
Pt and CE or Pt and HCP 
AgeValue, Behavior, CommSkills, Connect, 
Consistency, Counsel, Culture, DiscBarr, 
DiscCE, DiscFacil, DisDefine, Empathy, 
EngagePts, FldVPharm, HCPRelate, Holistic, 
OpenComm, PersEx, PtShoes, RelateDyna, 
Respect, Satisfaction, SelfManage, TrustDef, 
TrustEarned, TrustRelate,  
130 RareDis Rare Disease/s Refers to a rare disease AutoImm, Cardiac, ChronDis, Death, 
Desperate, DisDefine, DisState, Infusion, 
LangLit, Neuro, Oncology, Osteo, TermDis,  
131 RelateDyna Relationship Dynamic/s Describes or refers to 
relationship dynamics 
between CE and Pt or CE and 
HCP 
Accountable, AgeImpact, AgeValue, Balance, 
Boundaries, CommSkills, Connect, Counsel, 
DiffMaker, DiscBarr, DiscFacil, Distrust, 
Empathy, EngagePts, FamCare, FamDyna, 
FldVPharm, HandlingLoss, HCPConsent, 
HCPEngage, HCPFeedback, HCPRelate, 
Holistic, LangLit, LovePts, Motivator, 
NoVoice, PrivManage, PtLeads, PtShoes, 
Rapport, Respect, Satisfaction, Support, 
TrustDef, TrustRelate,  
132 Report Report/s/ing Refers to a CE or HCP need to 
create or deliver a reportable 
event 
AE, CompExcess, CompImpact, CompRegs, 
Data, FairBal, HCPFeedback, LovePts, 
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Notekeeping, PharmaOps, Protect, Safety, 
SideEffect, Suicide, Undocumented,  
133 Respect Respect/s/ing/ed Describes instances or 
examples that demonstrate 
respect among CEs, Pts, and 
HCPs 
Accept, Boundaries, CEBenefit, Connect, 
Counsel, Culture, EngagePts, HCPEngage, 
Holistic, Motivator, OpenComm, PtShoes, 
Rapport, RelateDyna, TrustDef, TrustHCP, 
TrustRelate, Validate,  
134 Safety Safety Refers to a CE describing a 
situation or event in which Pt 
safety is at risk 
Abandon, AE, CompExcess, CompImpact, 
DrugAdmin, DrugScrutiny, FairBal, Fear, 
Liability, PharmaTrust, Protect, Report, 
SideEffect, Stress, Suicide, Unethical, Unprep,  
135 Satisfaction Satisfaction Refers to Pts or HCPs 
satisfaction with the services 
or programs provided by a CE 
AboveBey, BehavChng, Data, DiffMaker, 
EngagePts, Excites, HCPFeedback, HCPRelate, 
LovePts, Motivator, ProgReco, PtKnow, 
Rapport, RelateDyna, SelfManage, Support, 
Tailoring, TrustEarned, TrustRelate,  
136 SavingFace Saving Face Describes or refers to how a 
CE or Pt attempts to save face 
Accept, Balance, Barrier, Behavior, Defer, 
DiscBarr, DisDefine, Empathy, FamDyna, 
PtLeads, PtSavvy, SelfAdvocate, TrustSac, 
Unprep, Workaround,  
137 Script Script/s Related to scripts or scripting 
of program utilized by CE 
within Pt education programs 
Boundaries, Consistency, FairBal, OnLabel, 
Materials, ModImpact, Strategies, Tailoring, 
TeleEd, TeleLimit, TrngProc, WebEd,  
138 Security Security Refers to manner in which CE 
protects or secures Pt 
information 
Boundaries, CompRegs, HealthInfo, InfoSeek, 
PrivManage, PrivRole, Protect, Sensitive, 
Strategies,  
139 SelfAdvocate Self Advocate/s/ing/y Refers to process or manner in 
which a Pt must advocate for 
him/herself 
Accountable, AgeImpact, Behavior, FamDyna, 
Goals, InfoSeek, LangLit, Navigate, ProgBene, 
PtLeads, PtSavvy, SavingFace, SelfManage, 
Support, TrustEarned, TrustRelate,  
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140 SelfManage Self Manage/s/ing/ment Refers to process or manner in 
which a Pt self-manages their 
health 
Accept, Accountable, Adherence, AgeImpact, 
Barrier, BehavChng, Behavior, Connect, 
Consent, Consistency, Counsel, Distrust, 
EngagePts, Fail, FamDyna, Goals, InfoSeek, 
Inject, LangLit, Misconcept, Motivator, 
OpenComm, PrivManage, ProgBene, PtEcon, 
PtKnow, PtLeads, PtSavvy, Rapport, 
Satisfaction, SelfAdvocate, Strategies, Support, 
TrustHCP, TrustRelate, Validate, Workaround,  
141 Sensitive Sensitive/ity/ities Describes or refers to 
sensitivities as related to 
privacy, information or 
communication 
Boundaries, CommInhibit, CompImpact, 
Culture, DiscBarr, Distrust, Empathy, Fear, 
PrivManage, PrivRole, Security, TelePriv, 
Undocumented,  
142 SideEffect Side Effect/s Refers to a current or potential 
side effect 
Adherence, AE, ChronDis, CompRegs, 
Depress, DrugAdmin, FairBal, Oncology, 
OnLabel, PharmaTrust, Report, Safety, Stress,  
143 Strategies Strategies Describes or refers to 
strategies or techniques used 
in education 
Adherence, AssessPts, BehavChng, 
CommSkills, Defer, Demo, EngagePts, Fail, 
FairBal, Goals, HandlingLoss, HealthInfo, 
Holistic, Inject, Materials, Metric, Motivator, 
Notekeeping, PrivManage, PtShoes, Script, 
Security, SelfManage, Support, Tailoring, 
Validate, Workaround,  
144 Stress Stress Refers to a Pt or CE feeling 
stressed or impacted by a 
stressful situation 
Abandon, Adherence, Barrier, Behavior, 
CompImpact, Depress, Desperate, DisDefine, 
Distrust, DrugAdmin, Fail, FamDyna, Fear, 
Frustration, Inject, Insurance, Misconcept, 
Pregnant, PtEcon, Safety, SideEffect, 
TimeImpact, TrustBreach, Unprep,  
145 Suicide Suicide/s Referencing suicide or 
suicidal ideation 
Death, Depress, Desperate, Fear, Report, 
Safety,  
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146 Support Support System/s Describes or refers to a Pt's 
personal support systems or 
resources 
AboveBey, Accessible, Adherence, AgeImpact, 
Barrier, CommInhibit, CommSkills, 
Community, Connect, Counsel, Culture, 
DiffMaker, DiscFacil, EdFam, Empathy, 
FamCare, Goals, HandlingLoss, HCPEngage, 
HCPRelate, HealthInfo, Holistic, LangLit, 
Motivator, Navigate, ProgBene, PtEcon, 
PtLeads, RelateDyna, Satisfaction, 
SelfAdvocate, SelfManage, Strategies, 
TrustDef, TrustHCP, TrustRelate,  
147 Tailoring Tailoring Describes or refers to 
customization of patient 
education  
AgeImpact, AssessPts, CommSkills, Counsel, 
Culture, EdFam, FldVPharm, Goals, Holistic, 
InfoSeek, InHome, Materials, ModImpact, 
ProfDev, PtLeads, Satisfaction, Script, 
Strategies, TimeImpact, TrngProc, TrngSet, 
Workaround,  
148 Teach Teach/er/es/ing Describes or refers to being a 
teacher or teaching HCPs in 
formal education settings 
CEBenefit, CERole, CommSkills, ExpLimit, 
LangLit, PersEx, ProfDev,  
149 TeleEd Telephonic Education Related to CE education 
provided telephonically 
CERole, Counsel, FTF, ModImpact, PrivSet, 
Script, TeleLimit, TelePriv, TrngSet, WebEd,  
150 TeleLimit Telephonic Limitation/s Describes or refers to 
limitations that are related to 
telephonic education 
CompExcess, DiscBarr, Fail, Frustration, 
ModImpact, ProtoBreach, Script, TeleEd, 
TelePriv, WebEd,  
151 TelePriv Telephonic Privacy Describes or refers to issues of 
privacy related to telephonic 
Pt education 
DiscBarr, DiscFacil, ModImpact, PrivManage, 
PrivSet, Sensitive, TeleEd, TeleLimit, 
TrustPriv, WebEd,  
152 TermDis Terminal Disease/s Refers to a terminal disease AutoImm, Cardiac, ChronDis, Death, Depress, 
Desperate, DisDefine, DisState, Fear, 
HandlingLoss, FairBal, ICU, Infusion, Neuro, 
Oncology, Parkinsons, RareDis,  
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153 TimeImpact Time Impact Describes how time, or lack of 
time, impacts or influences 
education 
FTF, HCPEngage, InfoSeek, ModImpact, 
OpenComm, Stress, Tailoring, TrngProc, 
Unprep,  
154 TrngProc Training 
Process/Training 
Protocol 
Descriptions or explanations 
of the training process, 
protocols or their components 
Boundaries, CommSkills, CompImpact, 
CompRegs, Consistency, Counsel, Demo, 
DrugAdmin, EdFam, EngagePts, Enroll, 
FairBal, FamCare, Goals, Holistic, Materials, 
Metric, ModImpact, Navigate, OnLabel, 
PharmaOps, ProgReco, Script, Tailoring, 
TimeImpact, TrngSet, WebEd,  
155 TrngSet Training Setting/s Describes or refers to the 
physical location where CE 
trains Pts. 
EdFam, FamCare, FldVPharm, FTF, InHome, 
PrivSet, Tailoring, TeleEd, TrngProc, WebEd,  
156 TrustBreach Trust Breach/es/ing Refers to situation or 
experience in which trust has, 
or is at risk, of being breached 
CEIndep, CommInhibit, CompExcess, 
CompImpact, DiscBarr, Distrust, DrugScrutiny, 
Fear, Frustration, Manipulating, PharmaTrust, 
PrivBreach, PrivManage, ProtoBreach, Stress, 
TrustDef, TrustRelate, Unethical,  
157 TrustDef Trust Defined/Trust 
Definition 
Refers to when a CE or Pt 
describes or defines the 
concept of trust 
Balance, Connect, Empathy, EngagePts, 
PtShoes, Rapport, RelateDyna, Respect, 
Support, TrustBreach, TrustEarned, TrustHCP, 
TrustPriv, TrustRelate, TrustSac,  
158 TrustEarned Trust Earned Describes or refers to the 
process of earning (or losing) 
trust 
Accept, Accountable, Connect, DiscCE, 
DiscFacil, Empathy, EngagePts, Fail, LovePts, 
Motivator, PrivManage, ProgBene, Protect, 
Rapport, Satisfaction, SelfAdvocate, TrustDef, 
TrustHCP, TrustPriv, TrustRelate, TrustSac, 
Validate,  
159 TrustHCP Trust/s Healthcare 
Provider/s 
Related to an expectations or 
instance of trust of Pt or CE 
toward HCP 
Accept, DrugScrutiny, Empathy, HCPConsent, 
HCPEngage, HCPFeedback, HCPRelate, 
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LangLit, Respect, SelfManage, Support, 
TrustDef, TrustEarned, TrustRelate,  
160 TrustPriv Trust Privacy Refers to notion that privacy 
between Pt and CE is related 
to trust 
Consent, DiscBarr, DiscCE, DiscFacil, 
PrivManage, PrivRole, TelePriv, TrustDef, 
TrustEarned, TrustRelate,  
161 TrustRelate Trust Relate/Trust 
Relationship 
Describes or refers to the role 
of trust in the CE/Pt 
relationship 
Accept, Balance, CEIndep, CERole, 
CommSkills, Connect, Counsel, Culture, 
DiffMaker, DiscBarr, DiscCE, DiscFacil, 
DrugScrutiny, Empathy, EngagePts, ExpLimit, 
Goals, Holistic, LovePts, Motivator, Navigate, 
PersEx, Rapport, RelateDyna, Respect, 
Satisfaction, SelfAdvocate, SelfManage, 
Support, TrustBreach, TrustDef, TrustEarned, 
TrustHCP, TrustPriv, TrustSac,  
162 TrustSac Trust Sacrifice/d/Trust 
Sacrificing 
Describes or refers to when a 
sacrifice is required to build 
trust between CE & Pt. 
Barrier, Behavior, Defer, PrivBreach, 
ProtoBreach, SavingFace, TrustDef, 
TrustEarned, TrustRelate, Workaround,  
163 Undoc Undocumented Related to purposefully not 
making, or the inability to 
make, documentation 
AE, CompExcess, Data, Enroll, Liability, 
Notekeeping, Report, Sensitive, Unethical,  
164 Unethical Unethical Related to action or 
communication by CE or HCP 
that violates ethics 
Boundaries, Distrust, Frustration, Liability, 
Manipulating, PharmaTrust, PrivBreach, Safety, 
TrustBreach, Undocumented,  
165 UninhibDisc Uninhibited 
Disclosure/s 
Refers to a disclosures from 
Pts provided with little or no 
inhibitions 
Boundaries, CommInhibit, Connect, DiscCE, 
DiscFacil, FamDyna, Holistic, LangLit, 
OpenComm,  
166 Unprep Unprepared Refers to patient not receiving 
suitable education to self-
manage 
Barrier, Consistency, Desperate, DrugAdmin, 
ExpLimit, Fail, Frustration, Holistic, InfoSeek, 
Misconcept, Safety, SavingFace, Stress, 
TimeImpact,  
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167 Validate Validate/s Related to CE or HCP 
reaffirming or validating Pt 
beliefs, fears, barriers, et. 
Accept, AssessPts, Connect, Counsel, 
DisDefine, Fear, HandlingLoss, Motivator, 
PersEx, ProgBene, PtKnow, PtShoes, Respect, 
SelfManage, Strategies, TrustSac,  
168 WebEd Web Education/ing Describes or refers to Pt 
education delivered over the 
web 
CommSkills, FTF, ModImpact, Script, TeleEd, 
TeleLimit, TelePriv, TrngProc, TrngSet,  
169 Workaround Workaround/s Refers to manner in which CE 
works around a regulation or 
barrier 
AboveBey, CompRegs, Culture, Defer, Goals, 
Liability, ModImpact, Navigate, OnLabel, 
ProfDev, ProgBene, Protect, SavingFace, 
SelfManage, Strategies, Tailoring, TrustSac,  
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Second-level Codes 
PARENT GROUP LONG NAME SHORT NAME DEFINITION     
ROLE PERCEPTION   ROLEPERC How a clinical educator perceives 
their role within the healthcare field  
Field Role defined RPFieldDef CE's perception of their role when 
working in the field (non-pharma)  
Pharma Role defined RPPharmDef CE's perception of their role when 
working on behalf of pharma or 
biotech  
Field vs Pharma RPFldVPharm CE comparing their field role to their 
pharma role  
Surrogate 
HCP/Conciliator 
RPSurrogate CE's perception of them serving as a 
surrogate clinician for Pt's HCP  
A Fellow patient RPFellowPt CE perception of their role while 
experiencing same/similar disease as 
the Pts they engage with  
Terminal Disease CE 
role  
RPTermDis CE's perception of their role working 
on behalf of pharma for terminal 
disease  
Telephonic CE role RPTelephonic CE's perception of their role as a 
telephonic educator     
AUTHENTIC NURSING   AUTHNURS Perceptions of [how, why, why 
don’t] pharma-sponsored CE's 
practice authentic nursing  
CE sees self ANCESelf Related to [how, why, why don’t] CEs 
consider themselves to practice 
authentic nursing 
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Patient sees CE ANPtCE Related to [how, why, why don’t] 
patients consider CEs to practice 
authentic nursing as interpreted by the 
CE  
Family sees CE ANFamCE Related to [how, why, why don’t] 
patients' families consider CEs to 
practice authentic nursing as 
interpreted by the CE  
HCP sees CE ANHcpCE Related to [how, why, why don’t] 
HCPs consider CEs to practice 
authentic nursing as interpreted by the 
CE  
Pharma sees CE ANPharmCE Related to [how, why, why don’t] 
Pharma Co's consider CEs to practice 
authentic nursing as interpreted by the 
CE     
CPM CONFIDANT ROLES TO PTs   CPMROLEPT A CE fulfilling a confidant role to 
Pts as defined by CPM  
Deliberate RolePTDelib Exemplifies a CE fulfilling a deliberate 
confidant role to Pts as defined by 
CPM  
Reluctant RolePTReluct Exemplifies a CE fulfilling a reluctant 
confidant role to Pts as defined by 
CPM  
Stakeholder RolePTStake Exemplifies a CE fulfilling a 
stakeholder confidant role to Pts as 
defined by CPM     
CPM CONFIDANT ROLES TO 
HCPs 
  CPMROLEHCP A CE fulfilling a confidant role to 
HCPs as defined by CPM 
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Deliberate RoleHCPDelib Exemplifies a CE fulfilling a deliberate 
confidant role to HCPs as defined by 
CPM  
Stakeholder RoleHCPStake Exemplifies a CE fulfilling a 
stakeholder confidant role to HCPs as 
defined by CPM     
DUAL LOYALTY   DUALLOYAL A CE is caught between their loyalty 
to their patient and loyalty to other 
related stakeholders  
Ethical Dilemma DLEthDil Exemplifies a CE's perception of being 
caught in an ethical dilemma  
Patient vs Pharma DLPtVPharm Exemplifies a CE's dual loyalty 
conflict between their Pt and their 
Pharma Co  
Patient vs HCP DLPtVHcp Exemplifies a CE's dual loyalty 
conflict between their Pt and the Pt's 
HCP  
Patient vs 
Family/caregiver 
DLPtVFam Exemplifies a CE's dual loyalty 
conflict between their Pt and the Pt's 
family     
FUNCTION OF TRUST   TRUST Related to the the role or function of 
trust in the CE relationship w/ Pts, 
HCPs, family, or Pharma Co  
Defining trust TRUSTDefine CE's interpretation of what trust is as it 
relates to their relationship w/ Pts, 
HCPs, family, or Pharma Co 
  
 
3
4
8
 
 
Earning trust TRUSTEarn CE's interpretation of how trust is 
earned as it relates to their relationship 
w/ Pts, HCPs, family, or Pharma Co  
Breaching trust TRUSTBreach CE's interpretation of how trust is 
breached as it relates to their 
relationship w/ Pts, HCPs, family, or 
Pharma Co     
NUANCED COMMUNICATION   NUANCED CE using a communication strategy 
or nuancing their language to 
overcome a communication barrier  
Defer to HCP NUDefer Exemplifies the CE deferring a patient 
to their HCP for additional help or 
information  
Off-label NUOffLabel Exemplifies a CE using nuanced 
communication to deal with off-label 
information requests  
Fair Balance NUFairBal Exemplifies a CE using nuanced 
communication to present fair balanced 
information  
Adverse Event NUAdverse Exemplifies a CE using nuanced 
communication to handle adverse 
event reports  
Liability protection NULiability Exemplifies a CE relating nuanced 
communication to legal issues or 
liability protection  
Navigating regulations NUNavigate Exemplifies a CE relating nuanced 
communication to navigating 
compliance regulations 
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Telephonic navigation NUTelephonic Exemplifies a CE using nuanced 
communication to overcome 
telephonic limitations  
Disease/treatment 
barriers 
NUBarriers Exemplifies a CE using nuanced 
communication to overcome a disease 
or treatment barrier     
PRIVACY MANAGEMENT   PRIVMGMT Related to the the role or manner in 
which privacy is mangaged in the 
CE relationship w/ Pts, HCPs, 
family, or Pharma Co  
Defining privacy PMDefine CE's interpretation of what privacy is 
as it relates to their relationship w/ Pts, 
HCPs, family, or Pharma Co  
Protecting privacy PMProtect CE's interpretation of how privacy is 
protected as it relates to their 
relationship w/ Pts, HCPs, family, or 
Pharma Co  
Breaching privacy PMBreach CE's interpretation of how privacy is 
breached as it relates to their 
relationship w/ Pts, HCPs, family, or 
Pharma Co     
ECOLOGICAL: CULTURAL   ECOCULT Describes or is related to the cultural 
context of the ecological model  in 
the CE relationship w/ Pts  
Religion CULTReligion Exemplifies religion as an influencing 
factor in the CE relationship w/ Pts  
Race/Ethnicity CULTRace  Exemplifies race or ethnicity as an 
influencing factor in the CE 
relationship w/ Pts 
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Age CULTAge Exemplifies age as an influencing 
factor in the CE relationship w/ Pts  
Gender CULTGender Exemplifies gender as an influencing 
factor in the CE relationship w/ Pts  
SES CULTEcon Exemplifies socioeconomic status as 
an influencing factor in the CE 
relationship w/ Pts  
Language CULTLang Exemplifies language/non-English 
fluency status as an influencing factor 
in the CE relationship w/ Pts  
Education CULTEduc Exemplifies educaation level as an 
influencing factor in the CE 
relationship w/ Pts     
ECOLOGICAL: MEDIA   ECOMEDIA Describes or is related to the media 
context of the ecological model  in 
the CE relationship w/ Pts  
Education & Health 
Literacy 
MEDIALit Exemplifies education and/or health 
literacy as an influencing factor in the 
CE relationship w/ Pts  
Telephonic & web comm MEDIATele Exemplifies use of telephone or web-
conferencing as an influencing factor 
in the CE relationship w/ Pts     
ECOLOGICAL: 
ORGANIZATIONAL 
  ECOORG Describes or is related to the 
organizational context of the 
ecological model  in the CE 
relationship w/ Pts 
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Insurance ORGInsur Exemplifies health insurance as an 
influencing factor in the CE 
relationship w/ Pts  
Health system 
bureaucracy  
ORGBureau Exemplifies health sytem bureauocracy 
as an influencing factor in the CE 
relationship w/ Pts     
ECOLOGICAL:LEGAL/POLITICA
L 
  ECOLEGAL Describes or is related to the 
legal/political context of the 
ecological model  in the CE 
relationship w/ Pts  
Compliance regs 
(general) 
LEGALCompReg Exemplifies the general nature of 
compliance regulations as an 
influencing factor in the CE 
relationship w/ Pts  
On label LEGALOnLab Exemplifies the necessity of 
maintaining on-label compliance as an 
influencing factor in the CE 
relationship w/ Pts  
Fair Balance LEGALFairBal Exemplifies the necessity of fair 
balance presentation as an influencing 
factor in the CE relationship w/ Pts  
AE reporting LEGALAdverse Exemplifies the necessity of adverse 
event reporting as an influencing factor 
in the CE relationship w/ Pts     
ECOLOGICAL: EVERYDAY 
TALK 
  ECOET Describes or is related to the 
everyday talk of the ecological model  
in the CE relationship w/ Pts 
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Family dynamics ETFamDyna Exemplifies a Pt's family dynamics as 
an influencing factor in the CE 
relationship w/ Pts  
Community dynamics ETCommunity Exemplifies a Pt's community 
dynamics as an influencing factor in 
the CE relationship w/ Pts     
DISEASE CONTEXT   DISCONTEXT Describes or is related to the role or 
impact of the disease  in the CE 
communication relationship w/ Pts  
Chronic vs Terminal DCChronVTerm Exemplifies a disease's chronic or 
terminal status as an influencing factor 
in the CE relationship w/ Pts  
Disease Side Effects DCDisSideEff Exemplifies a disease's symptoms or 
side effects as an influencing factor in 
the CE relationship w/ Pts  
Treatment Side Effects DCTreatSideEff Exemplifies a disease treatment's side 
effects as an influencing factor in the 
CE relationship w/ Pts  
Pregnancy DCPreg Exemplifies a Pt's pregnancy or 
motherhood status as an influencing 
factor in the CE relationship w/ Pts  
Drug Admin Modality DCAdmMod Exemplifies a disease treatment's 
administration modality as an 
influencing factor in the CE 
relationship w/ Pts  
Disabilities/Comorbiditie
s 
DCDisCo Exemplifies a Pt's disability or 
comorbid conditions as an influencing 
factor in the CE relationship w/ Pts 
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Disease Journey DCJourney Exemplifies where the patient is in 
their disease journey as an influencing 
factor in the CE relationship w/ Pts 
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